TW202128610A - 醫藥調配物 - Google Patents
醫藥調配物 Download PDFInfo
- Publication number
- TW202128610A TW202128610A TW109136022A TW109136022A TW202128610A TW 202128610 A TW202128610 A TW 202128610A TW 109136022 A TW109136022 A TW 109136022A TW 109136022 A TW109136022 A TW 109136022A TW 202128610 A TW202128610 A TW 202128610A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- particle size
- size distribution
- niclosamide
- crystal
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000002245 particle Substances 0.000 claims abstract description 272
- 229960001920 niclosamide Drugs 0.000 claims abstract description 232
- 238000009826 distribution Methods 0.000 claims abstract description 189
- 239000013078 crystal Substances 0.000 claims abstract description 138
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical class OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims abstract description 138
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 150000003839 salts Chemical class 0.000 claims abstract description 64
- 239000000126 substance Substances 0.000 claims abstract description 57
- 239000002552 dosage form Substances 0.000 claims abstract description 34
- -1 niclosamide compound Chemical class 0.000 claims description 451
- 150000001875 compounds Chemical class 0.000 claims description 251
- 239000002253 acid Substances 0.000 claims description 71
- 239000003814 drug Substances 0.000 claims description 52
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 35
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 34
- 230000002829 reductive effect Effects 0.000 claims description 33
- LOCWBQIWHWIRGN-UHFFFAOYSA-N 2-chloro-4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1Cl LOCWBQIWHWIRGN-UHFFFAOYSA-N 0.000 claims description 29
- NKBASRXWGAGQDP-UHFFFAOYSA-N 5-chlorosalicylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1O NKBASRXWGAGQDP-UHFFFAOYSA-N 0.000 claims description 22
- 206010009887 colitis Diseases 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 230000002496 gastric effect Effects 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 16
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 16
- 229960004436 budesonide Drugs 0.000 claims description 16
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 14
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 208000011231 Crohn disease Diseases 0.000 claims description 13
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
- 230000001363 autoimmune Effects 0.000 claims description 12
- 210000001072 colon Anatomy 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 102000015617 Janus Kinases Human genes 0.000 claims description 11
- 108010024121 Janus Kinases Proteins 0.000 claims description 11
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 10
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 claims description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 10
- 102000015774 TYK2 Kinase Human genes 0.000 claims description 9
- 108010010057 TYK2 Kinase Proteins 0.000 claims description 9
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 9
- 229960004963 mesalazine Drugs 0.000 claims description 9
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 229940092705 beclomethasone Drugs 0.000 claims description 8
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 8
- 150000003904 phospholipids Chemical group 0.000 claims description 8
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 claims description 7
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 claims description 7
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 7
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 7
- 239000004012 Tofacitinib Substances 0.000 claims description 7
- 229940010849 brepocitinib Drugs 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 229940018036 ritlecitinib Drugs 0.000 claims description 7
- 229960001350 tofacitinib Drugs 0.000 claims description 7
- DADAEARVGOQWHV-OSYLJGHBSA-N CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 Chemical compound CC1=CC(NC2=NC(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)=C3C=CC=NC3=C2)=NN1 DADAEARVGOQWHV-OSYLJGHBSA-N 0.000 claims description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 6
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 6
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 5
- 108010041012 Integrin alpha4 Proteins 0.000 claims description 5
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims description 5
- 101700026522 SMAD7 Proteins 0.000 claims description 5
- 108010009978 Tec protein-tyrosine kinase Proteins 0.000 claims description 5
- 102000002689 Toll-like receptor Human genes 0.000 claims description 5
- 108020000411 Toll-like receptor Proteins 0.000 claims description 5
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 5
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 210000001815 ascending colon Anatomy 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 210000004921 distal colon Anatomy 0.000 claims description 5
- 230000000642 iatrogenic effect Effects 0.000 claims description 5
- 108010044426 integrins Proteins 0.000 claims description 5
- 102000006495 integrins Human genes 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 210000003384 transverse colon Anatomy 0.000 claims description 5
- KSELABKNBIUMGG-YGBAREPYSA-N (2z,3ar,4r,5r,6as)-3,3-difluoro-4-[(e,3r,4r)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2h-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3ah-cyclopenta[b]furan-5-ol Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1(F)F)/C=C/[C@@H](O)[C@H](C)C=2C=C(C)C=CC=2)\C1=C/CCCC=1N=NNN=1 KSELABKNBIUMGG-YGBAREPYSA-N 0.000 claims description 4
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 claims description 4
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 claims description 4
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 claims description 4
- BZZKEPGENYLQSC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical group C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NN(C=N1)C)OC BZZKEPGENYLQSC-FIBGUPNXSA-N 0.000 claims description 4
- VFGSKBLZRDRHOI-ZAGPDIDGSA-N 6-[[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]amino]-8-chloro-4-(2,2-dimethylpropylamino)quinoline-3-carbonitrile Chemical compound C12(CC(C1)C2)N1N=NC(=C1)[C@H](C1=C2C=CN(C(C2=CC=C1)=O)C)NC=1C=C2C(=C(C=NC2=C(C=1)Cl)C#N)NCC(C)(C)C VFGSKBLZRDRHOI-ZAGPDIDGSA-N 0.000 claims description 4
- 229940124282 BMS-986165 Drugs 0.000 claims description 4
- XPLZTJWZDBFWDE-OYOVHJISSA-N CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N Chemical compound CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N XPLZTJWZDBFWDE-OYOVHJISSA-N 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 229940124281 PF-06826647 Drugs 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 229950008141 ozanimod Drugs 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- IXYNFLOLUBKHQU-FZCWJHTDSA-N [(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl] hydrogen phosphate Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O IXYNFLOLUBKHQU-FZCWJHTDSA-N 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 229960001164 apremilast Drugs 0.000 claims description 3
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 229950001404 cobitolimod Drugs 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 claims description 3
- 230000007115 recruitment Effects 0.000 claims description 3
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical group C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 claims description 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 2
- 108010072524 BKT140 Proteins 0.000 claims description 2
- 229940125565 BMS-986016 Drugs 0.000 claims description 2
- 102100025429 Butyrophilin-like protein 2 Human genes 0.000 claims description 2
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 claims description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 2
- 102000007563 Galectins Human genes 0.000 claims description 2
- 108010046569 Galectins Proteins 0.000 claims description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 2
- 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 claims description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 claims description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 2
- 101150069255 KLRC1 gene Proteins 0.000 claims description 2
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 claims description 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102000002111 Neuropilin Human genes 0.000 claims description 2
- 108050009450 Neuropilin Proteins 0.000 claims description 2
- 101150012848 PVR gene Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims description 2
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950007843 bavituximab Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 229950004647 emactuzumab Drugs 0.000 claims description 2
- 229940069604 etrasimod Drugs 0.000 claims description 2
- 229950006663 filgotinib Drugs 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229950000456 galunisertib Drugs 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229950011263 lirilumab Drugs 0.000 claims description 2
- JJVZSYKFCOBILL-MKMRYRNGSA-N motixafortide Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccc(F)cc1 JJVZSYKFCOBILL-MKMRYRNGSA-N 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 108010048507 poliovirus receptor Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 229950007213 spartalizumab Drugs 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229950010095 ulocuplumab Drugs 0.000 claims description 2
- 229950000088 upadacitinib Drugs 0.000 claims description 2
- 229950005972 urelumab Drugs 0.000 claims description 2
- 229950001067 varlilumab Drugs 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 3
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 101710092458 Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 230000005496 eutectics Effects 0.000 claims 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- YQKBOUPIOWUMTE-NRFANRHFSA-N (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoic acid Chemical compound N([C@@H](CC1=CC=C(C=C1)N1C(=O)N(C)C2=CC=C(C=C2C1=O)N(C)C)C(O)=O)C(=O)C1=C(Cl)C=CC=C1Cl YQKBOUPIOWUMTE-NRFANRHFSA-N 0.000 claims 1
- 102000002627 4-1BB Ligand Human genes 0.000 claims 1
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 108010017533 Butyrophilins Proteins 0.000 claims 1
- 102000004555 Butyrophilins Human genes 0.000 claims 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 claims 1
- 108010008701 Mucin-3 Proteins 0.000 claims 1
- 102000007295 Mucin-3 Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 230000010799 Receptor Interactions Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 229950003024 carotegrast Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- ABASMUXUCSQFKC-PKEKLUKKSA-N mongersen Chemical compound CC1=CN([C@H]2C[C@H](OP(=S)(O)OC[C@H]3O[C@H](C[C@@H]3OP(=S)(O)OC[C@H]4O[C@H](C[C@@H]4OP(=S)(O)OC[C@H]5O[C@H](C[C@@H]5OP(=S)(O)OC[C@H]6O[C@H](C[C@@H]6OP(=S)(O)OC[C@H]7O[C@H](C[C@@H]7O)N8C=CC(=NC8=O)N)n9cnc%10C(=O)NC(=Nc9%10)N)n%11cnc%12c(N)ncnc%11%12)N%13C=CC(=NC%13=O)N)n%14cnc%15C(=O)NC(=Nc%14%15)N)[C@@H](COP(=S)(O)O[C@H]%16C[C@@H](O[C@@H]%16COP(=S)(O)O[C@H]%17C[C@@H](O[C@@H]%17COP(=S)(O)O[C@H]%18C[C@@H](O[C@@H]%18COP(=S)(O)O[C@H]%19C[C@@H](O[C@@H]%19COP(=S)(O)O[C@H]%20C[C@@H](O[C@@H]%20COP(=S)(O)O[C@H]%21C[C@@H](O[C@@H]%21COP(=S)(O)O[C@H]%22C[C@@H](O[C@@H]%22COP(=S)(O)O[C@H]%23C[C@@H](O[C@@H]%23COP(=S)(O)O[C@H]%24C[C@@H](O[C@@H]%24COP(=S)(O)O[C@H]%25C[C@@H](O[C@@H]%25COP(=S)(O)O[C@H]%26C[C@@H](O[C@@H]%26COP(=S)(O)O[C@H]%27C[C@@H](O[C@@H]%27COP(=S)(O)O[C@H]%28C[C@@H](O[C@@H]%28COP(=S)(O)O[C@H]%29C[C@@H](O[C@@H]%29COP(=S)(O)O[C@H]%30C[C@@H](O[C@@H]%30CO)n%31cnc%32C(=O)NC(=Nc%31%32)N)N%33C=C(C)C(=O)NC%33=O)N%34C=C(C)C(=NC%34=O)N)n%35cnc%36C(=O)NC(=Nc%35%36)N)N%37C=CC(=NC%37=O)N)N%38C=CC(=NC%38=O)N)N%39C=CC(=NC%39=O)N)N%40C=CC(=NC%40=O)N)N%41C=C(C)C(=O)NC%41=O)N%42C=C(C)C(=O)NC%42=O)N%43C=CC(=NC%43=O)N)N%44C=C(C)C(=O)NC%44=O)N%45C=CC(=NC%45=O)N)N%46C=CC(=NC%46=O)N)N%47C=CC(=NC%47=O)N)O2)C(=O)N=C1N ABASMUXUCSQFKC-PKEKLUKKSA-N 0.000 claims 1
- 229950002917 mongersen Drugs 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 31
- 229940124597 therapeutic agent Drugs 0.000 description 32
- 238000011282 treatment Methods 0.000 description 24
- 239000011734 sodium Substances 0.000 description 18
- 229910052708 sodium Inorganic materials 0.000 description 18
- 229940083542 sodium Drugs 0.000 description 18
- 235000015424 sodium Nutrition 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 16
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 15
- 239000003246 corticosteroid Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 229960001334 corticosteroids Drugs 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 150000005829 chemical entities Chemical class 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 229960000598 infliximab Drugs 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 229960005069 calcium Drugs 0.000 description 9
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 9
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 8
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 8
- 229910052797 bismuth Inorganic materials 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 229960002568 ethinylestradiol Drugs 0.000 description 8
- 229960001571 loperamide Drugs 0.000 description 8
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 8
- 229960001428 mercaptopurine Drugs 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229960001940 sulfasalazine Drugs 0.000 description 8
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 8
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 8
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 7
- 229960002170 azathioprine Drugs 0.000 description 7
- 229950000210 beclometasone dipropionate Drugs 0.000 description 7
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 229960004914 vedolizumab Drugs 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 5
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229960000396 atropine Drugs 0.000 description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 229940081733 cetearyl alcohol Drugs 0.000 description 5
- 229960004106 citric acid Drugs 0.000 description 5
- 229960002227 clindamycin Drugs 0.000 description 5
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 5
- 229960003276 erythromycin Drugs 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 150000002576 ketones Chemical group 0.000 description 5
- 229960000448 lactic acid Drugs 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 229960000278 theophylline Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 4
- 241000242722 Cestoda Species 0.000 description 4
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 4
- 101710116149 Histone acetyltransferase KAT5 Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960002903 benzyl benzoate Drugs 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- 229960001803 cetirizine Drugs 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229960003405 ciprofloxacin Drugs 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 4
- 229960003324 clavulanic acid Drugs 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 4
- 229960000452 diethylstilbestrol Drugs 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229960003376 levofloxacin Drugs 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 235000001055 magnesium Nutrition 0.000 description 4
- 229940091250 magnesium supplement Drugs 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 229940041669 mercury Drugs 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 239000010452 phosphate Chemical group 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 4
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
- XPRDUGXOWVXZLL-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C(O)=O)=CC=2)=C1 XPRDUGXOWVXZLL-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- XEEPVFFWNATEGX-PSUQFXNXSA-N Egonine Chemical class CO[C@H]1CC2N(C)C[C@H](O)[C@@]2(C=C1)C1=C(CO)C=C2OCOC2=C1 XEEPVFFWNATEGX-PSUQFXNXSA-N 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
- 239000005770 Eugenol Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 229920001100 Polydextrose Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000009470 Theobroma cacao Nutrition 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 229940022682 acetone Drugs 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229960002964 adalimumab Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 229940011037 anethole Drugs 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 229960000981 artemether Drugs 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 229960002274 atenolol Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960001716 benzalkonium Drugs 0.000 description 3
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 3
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 3
- 239000012965 benzophenone Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 3
- 229960002781 bisoprolol Drugs 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229960000623 carbamazepine Drugs 0.000 description 3
- 229960000484 ceftazidime Drugs 0.000 description 3
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 3
- 229940106164 cephalexin Drugs 0.000 description 3
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 3
- 229940090100 cimzia Drugs 0.000 description 3
- 229940001468 citrate Drugs 0.000 description 3
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 3
- 229960004022 clotrimazole Drugs 0.000 description 3
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 3
- 229960004976 desogestrel Drugs 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001912 dicoumarol Drugs 0.000 description 3
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 3
- 229960003520 diphenidol Drugs 0.000 description 3
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 3
- 229960004192 diphenoxylate Drugs 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 229940031098 ethanolamine Drugs 0.000 description 3
- 229960002217 eugenol Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 229960002491 ibudilast Drugs 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 229940124589 immunosuppressive drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 229960003350 isoniazid Drugs 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
- 229960000681 leflunomide Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 229940099690 malic acid Drugs 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 229960002510 mandelic acid Drugs 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 3
- 238000010951 particle size reduction Methods 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960005385 proguanil Drugs 0.000 description 3
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229960003010 sodium sulfate Drugs 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 235000019832 sodium triphosphate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003433 thalidomide Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- LJOQGZACKSYWCH-LHHVKLHASA-N (s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=C(OC)C=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-LHHVKLHASA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- QBWLKDFBINPHFT-UHFFFAOYSA-L 1,3,2$l^{2}-benzodioxabismin-4-one;hydrate Chemical compound O.C1=CC=C2C(=O)O[Bi]OC2=C1 QBWLKDFBINPHFT-UHFFFAOYSA-L 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- ZSSOUAIRYPTMIN-UHFFFAOYSA-N 1-aminothioxanthen-9-one Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N ZSSOUAIRYPTMIN-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- DQTMTQZSOJMZSF-UHFFFAOYSA-N 3-pentadecylcatechol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
- XYCDHXSQODHSLG-UHFFFAOYSA-N 4-chloro-2-[(2-chloro-4-nitrophenyl)carbamoyl]phenolate;2-hydroxyethylazanium Chemical compound NCCO.OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl XYCDHXSQODHSLG-UHFFFAOYSA-N 0.000 description 2
- LTSOENFXCPOCHG-GQCTYLIASA-N 4-chloro-6-[[(e)-3-oxobut-1-enyl]amino]-1-n-prop-2-enylbenzene-1,3-disulfonamide Chemical compound CC(=O)\C=C\NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(=O)(=O)NCC=C LTSOENFXCPOCHG-GQCTYLIASA-N 0.000 description 2
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N 6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 description 2
- NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 239000005711 Benzoic acid Chemical class 0.000 description 2
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 2
- 235000012035 Boswellia serrata Nutrition 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- ZOWKQQIGQBVKSV-BZLLESMPSA-N Cascarillin Chemical compound C=1([C@H](O)C[C@@]2([C@@H]3[C@@]([C@@]([C@H](O)CC3)(C)O)(C)C[C@H]([C@H]2C)OC(C)=O)C=O)C=COC=1 ZOWKQQIGQBVKSV-BZLLESMPSA-N 0.000 description 2
- GZVVOAJUBYETCL-UHFFFAOYSA-N Cascarillin Natural products CC1C(OC(C)=O)CC(C(C(O)CC2)(C)O)(C)C2C1(C(O1)O)CC1C=1C=COC=1 GZVVOAJUBYETCL-UHFFFAOYSA-N 0.000 description 2
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IPOBOOXFSRWSHL-UHFFFAOYSA-N Cibenzoline Chemical compound C=1C=CC=CC=1C1(C=2C=CC=CC=2)CC1C1=NCCN1 IPOBOOXFSRWSHL-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 241001137876 Diphyllobothrium Species 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- MWAYRGBWOVHDDZ-UHFFFAOYSA-N Ethyl vanillate Chemical compound CCOC(=O)C1=CC=C(O)C(OC)=C1 MWAYRGBWOVHDDZ-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- LJOQGZACKSYWCH-AFHBHXEDSA-N Hydroquinidine Natural products C1=C(OC)C=C2C([C@@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-AFHBHXEDSA-N 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000008986 Janus Human genes 0.000 description 2
- 108050000950 Janus Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- XYQRXRFVKUPBQN-UHFFFAOYSA-L Sodium carbonate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]C([O-])=O XYQRXRFVKUPBQN-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 2
- 229960004047 acamprosate Drugs 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
- 229960004607 alfuzosin Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- ZMJWRJKGPUDEOX-LMXUULCNSA-A alicaforsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 ZMJWRJKGPUDEOX-LMXUULCNSA-A 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 229950007019 ambuside Drugs 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229950003588 axetil Drugs 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 229950011260 betanaphthol Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 2
- 229940036358 bismuth subcarbonate Drugs 0.000 description 2
- 229960000782 bismuth subsalicylate Drugs 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 description 2
- 229960001242 cefotiam Drugs 0.000 description 2
- 229960001668 cefuroxime Drugs 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004757 cibenzoline Drugs 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 2
- 229950001647 clometacin Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- 229960003077 cycloserine Drugs 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229960002615 dalfopristin Drugs 0.000 description 2
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 2
- 108700028430 dalfopristin Proteins 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 2
- 229960003309 dienogest Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 229960002032 dihydroergocryptine Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 229960003933 dorzolamide Drugs 0.000 description 2
- 229960001393 dosulepin Drugs 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 229960001104 droxidopa Drugs 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 229960001348 estriol Drugs 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 229940009626 etidronate Drugs 0.000 description 2
- 229960005387 etofylline Drugs 0.000 description 2
- 229960004979 fampridine Drugs 0.000 description 2
- 229960000379 faropenem Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- 229960004273 floxacillin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003469 flumetasone Drugs 0.000 description 2
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- 229960001048 fluorometholone Drugs 0.000 description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 229960000308 fosfomycin Drugs 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- LAWKVNVCUPIOMG-HWWYPGLISA-N gardimycin Chemical compound C1=CC=C2C(C[C@H](C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@H](CC)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(O)=O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](C)NC(=O)[C@@H](CC)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)N)[C@@H](C)CC)C(C)C)=CNC2=C1 LAWKVNVCUPIOMG-HWWYPGLISA-N 0.000 description 2
- 108010070411 gardimycin Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 229960003480 gemeprost Drugs 0.000 description 2
- KYBOHGVERHWSSV-VNIVIJDLSA-N gemeprost Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-VNIVIJDLSA-N 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229960005352 gestodene Drugs 0.000 description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 229940096898 glyceryl palmitate Drugs 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001915 hexamidine Drugs 0.000 description 2
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 2
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 2
- 229960003258 hexylresorcinol Drugs 0.000 description 2
- 229960001872 hidrosmin Drugs 0.000 description 2
- XYFLWVOTXWXNAM-WTNNCJBMSA-N hidrosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OCCO)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 XYFLWVOTXWXNAM-WTNNCJBMSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 229960000811 hydroquinidine Drugs 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 2
- 229950006971 incadronic acid Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000077 insect repellent Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 229960001888 ipratropium Drugs 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 description 2
- 229950003165 lanicemine Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 2
- 229960004577 laquinimod Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 229950008204 levosalbutamol Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- MHPZZZZLAQGTHT-UHFFFAOYSA-N mebrofenin Chemical class CC1=CC(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1Br MHPZZZZLAQGTHT-UHFFFAOYSA-N 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229950009792 mirikizumab Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 2
- 229950005421 olprinone Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 229960003540 oxyquinoline Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229950009297 pivoxil Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229940095050 propylene Drugs 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- 229950007943 risankizumab Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- 229940001593 sodium carbonate Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940018038 sodium carbonate decahydrate Drugs 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940100515 sorbitan Drugs 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Chemical class 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 description 2
- 108010073046 teduglutide Proteins 0.000 description 2
- 229960002444 teduglutide Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 229940045136 urea Drugs 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 229950002148 vatelizumab Drugs 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000012711 vitamin K3 Nutrition 0.000 description 2
- 239000011652 vitamin K3 Substances 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- NGZXDRGWBULKFA-NSOVKSMOSA-N (+)-Bebeerine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-NSOVKSMOSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- 229940099368 (+/-)- limonene Drugs 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- VANQPTNYODZMFL-UHFFFAOYSA-N (1-chloro-1,3-dinitrooxypropan-2-yl) nitrate Chemical compound ClC(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] VANQPTNYODZMFL-UHFFFAOYSA-N 0.000 description 1
- YXBQLONCIPUQKO-UJPOAAIJSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol Chemical compound O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 YXBQLONCIPUQKO-UJPOAAIJSA-N 0.000 description 1
- XNMVAVGXJZFTEH-BUYFANAVSA-N (1r,2s,4r)-4,7,7-trimethyl-3-oxobicyclo[2.2.1]heptane-2-carboxylic acid Chemical compound C1C[C@@]2(C)C(=O)[C@@H](C(O)=O)[C@@H]1C2(C)C XNMVAVGXJZFTEH-BUYFANAVSA-N 0.000 description 1
- JKFZMIQMKFWJAY-RQJQXFIZSA-N (1r,3s,5z)-5-[(2e)-2-[(3as,7as)-1-[(2r)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C JKFZMIQMKFWJAY-RQJQXFIZSA-N 0.000 description 1
- AXMKZEOEXSKFJI-XSSZXYGBSA-N (1s,2r,4r)-2-hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1C[C@@]2(C)C(=O)[C@H](O)[C@@H]1C2(C)C AXMKZEOEXSKFJI-XSSZXYGBSA-N 0.000 description 1
- NJQADTYRAYFBJN-FWWHASMVSA-N (1s,2s,4r)-2-bromo-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1C[C@@]2(C)C(=O)[C@@H](Br)[C@@H]1C2(C)C NJQADTYRAYFBJN-FWWHASMVSA-N 0.000 description 1
- UXFVRWPSABSGRQ-AFWJMSMISA-N (1s,3r,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-1,3-diol Chemical compound C1C=C2C[C@@H](O)C[C@H](O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 UXFVRWPSABSGRQ-AFWJMSMISA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- GBNXMEVVZBZIAC-SLPGGIOYSA-N (2R,3R,4R,5S)-6-hydrazinylidenehexane-1,2,3,4,5-pentol Chemical compound NN=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GBNXMEVVZBZIAC-SLPGGIOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- AERYWTWBOYIUJS-GCCVQAHUSA-N (2S)-3-[4-[(Z)-C-aminocarbonohydrazonoyl]phenyl]-N-cyclopentyl-N-methyl-2-(naphthalen-2-ylsulfonylamino)propanamide (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CN(C1CCCC1)C(=O)[C@H](Cc1ccc(cc1)C(\N)=N\N)NS(=O)(=O)c1ccc2ccccc2c1 AERYWTWBOYIUJS-GCCVQAHUSA-N 0.000 description 1
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LQIPDFIUPOYMPR-BKYURJJWSA-N (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide Chemical compound O1[C@@H]([C@@H](O)CO)[C@H](NC(=O)CNC(=O)/C=C/C=C/CCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1NC=N2 LQIPDFIUPOYMPR-BKYURJJWSA-N 0.000 description 1
- JMPZTWDLOGTBPM-OUQSKUGOSA-N (2e,4e,6e)-7-(3,5-ditert-butylphenyl)-3-methylocta-2,4,6-trienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 JMPZTWDLOGTBPM-OUQSKUGOSA-N 0.000 description 1
- ZJMMJMHTXLTBFW-REOHCLBHSA-N (2r)-2-(carboxyamino)-3-sulfanylpropanoic acid Chemical compound OC(=O)N[C@@H](CS)C(O)=O ZJMMJMHTXLTBFW-REOHCLBHSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WNDUPUMWHYAJOR-SADXPQEKSA-K (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WNDUPUMWHYAJOR-SADXPQEKSA-K 0.000 description 1
- XJFMHMFFBSOEPR-DNZQAUTHSA-N (2r,3r,4s,5r)-2-[6-amino-2-[(2e)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C(N)=NC=1N\N=C\C1CCCCC1 XJFMHMFFBSOEPR-DNZQAUTHSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FOPALECPEUVCTL-QMMMGPOBSA-N (2s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid Chemical compound CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O FOPALECPEUVCTL-QMMMGPOBSA-N 0.000 description 1
- KZBKRARRXDZOII-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;2-hydroxybenzoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)C1=CC=CC=C1O KZBKRARRXDZOII-ZSCHJXSPSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- YLFZHHDVRSYTKT-NRFANRHFSA-N (2s)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid Chemical compound COC1=CC(COCC)=CC(OC)=C1C(C=C1)=CC=C1C[C@@H](C(O)=O)NC(=O)C1=C(F)C=CC=C1F YLFZHHDVRSYTKT-NRFANRHFSA-N 0.000 description 1
- JMWOGOGGXYCJQC-YYQZADIYSA-N (2s)-2-[[(2s)-2-aminohexanoyl]amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4h-imidazol-4-yl)-1-oxo Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(N)=O)C1C=NC=N1 JMWOGOGGXYCJQC-YYQZADIYSA-N 0.000 description 1
- QCLDSHDOWCMFBV-AWEZNQCLSA-N (2s)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 QCLDSHDOWCMFBV-AWEZNQCLSA-N 0.000 description 1
- QXOPTIPQEVJERB-JQWIXIFHSA-N (2s)-2-[[5-[2-[(6s)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C1=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)SC(CC[C@H]2CC=3C(=O)N=C(N)NC=3NC2)=C1C QXOPTIPQEVJERB-JQWIXIFHSA-N 0.000 description 1
- NAFSYPCVPLWHFY-HNNXBMFYSA-N (2s)-3,3,3-trifluoro-2-hydroxy-2-methyl-n-(5,5,10-trioxo-4h-thieno[3,2-c][1]benzothiepin-9-yl)propanamide Chemical compound FC(F)(F)[C@](O)(C)C(=O)NC1=CC=CC(S(C2)(=O)=O)=C1C(=O)C1=C2C=CS1 NAFSYPCVPLWHFY-HNNXBMFYSA-N 0.000 description 1
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
- NOYZWUQUALADDO-VWLOTQADSA-N (2s)-n-(4-amino-1-methyl-2,6-dioxo-3-phenylpyrimidin-5-yl)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound O=C([C@@]1(C)OC=2C(C)=C(C(=C(C)C=2CC1)O)C)NC(C(N(C)C1=O)=O)=C(N)N1C1=CC=CC=C1 NOYZWUQUALADDO-VWLOTQADSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- YHKWDHMRGAMOKU-YGMDSVBLSA-N (2s,5s,8r,11r,14s)-11-(2-amino-2-oxoethyl)-n-[2-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-8-(3-amino-3-oxopropyl)-5-[(2s)-butan-2-yl]-2-[(4-hydroxyphenyl)methyl]-3,6,9,12,20-pentaoxo-1,4,7,10,13-pentazacycloicosane- Chemical compound N1C(=O)CCCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CC=C(O)C=C1 YHKWDHMRGAMOKU-YGMDSVBLSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- XLPLFRLIWKRQFT-XUJYDZMUSA-N (3,3-dimethyl-2-oxobutyl) (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound CC(C)(C)C(=O)COC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XLPLFRLIWKRQFT-XUJYDZMUSA-N 0.000 description 1
- MBRMDGSBOOLIGQ-QYJZNYBASA-N (3S,5S,6R,7R,8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,6,7-triol Chemical compound C([C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC/C(=C/C)[C@@]2(C)CC1 MBRMDGSBOOLIGQ-QYJZNYBASA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- MFOOVZCXWVAWOV-RUZDIDTESA-N (3r)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid Chemical compound C=1C(C)=CC(C)=C(NC(=O)C[C@H](CC(O)=O)C=2C3=CC=CC=C3C=CC=2)C=1C(=O)N(CC1)CCC21CCCC2 MFOOVZCXWVAWOV-RUZDIDTESA-N 0.000 description 1
- IPRJDKMLMDPMBH-XFULWGLBSA-N (3r)-n-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2C(C2)=C1CN[C@H]2C(=O)NCC1=CC=C(OCO2)C2=C1 IPRJDKMLMDPMBH-XFULWGLBSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- ABNXKGFLZFSILK-MOPGFXCFSA-N (3s)-3-[[(3r)-1-(3-piperidin-4-ylpropanoyl)piperidine-3-carbonyl]amino]-3-pyridin-3-ylpropanoic acid Chemical compound C([C@H](C1)C(=O)N[C@@H](CC(=O)O)C=2C=NC=CC=2)CCN1C(=O)CCC1CCNCC1 ABNXKGFLZFSILK-MOPGFXCFSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-MQHIEMKOSA-N (3s,10r,13e)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)OC([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-MQHIEMKOSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
- LGFJIKSTEFKSNQ-ILWKUFEGSA-N (4R,4aR,7aR,12bS)-11-acetyl-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound C(C)(=O)C1=CC(OC)=C2C=3[C@@]45[C@@H](O2)C(=O)CC[C@H]4[C@@H](CC1=3)N(C)CC5 LGFJIKSTEFKSNQ-ILWKUFEGSA-N 0.000 description 1
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 1
- WRVJTXDJDKITNK-XNGFCKKMSA-N (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-3-[(3s,5s)-5-[(r)-hydroxy-[(3r)-pyrrolidin-3-yl]methyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.C([C@H]1[C@@H](O)[C@H]2NC[C@H](C2)SC=2[C@H](C)[C@@H]3[C@H](C(N3C=2C(O)=O)=O)[C@H](O)C)CNC1 WRVJTXDJDKITNK-XNGFCKKMSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- KZSSWXACMCYLBM-RMWNCEGRSA-N (5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 KZSSWXACMCYLBM-RMWNCEGRSA-N 0.000 description 1
- XZPSYCOYKJRHKE-MRXNPFEDSA-N (5s)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC([N+]([O-])=O)=C(O)C=C2[C@H]1C1=CC=CC2=C1OCC2 XZPSYCOYKJRHKE-MRXNPFEDSA-N 0.000 description 1
- IUHMIOAKWHUFKU-YINIXLNUSA-N (5s,6r,7r)-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-[(2s)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-5h-cyclopenta[b]pyridine-6-carboxylic acid Chemical compound C1([C@H]2[C@@H]([C@H](C3=CC=C(N=C32)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1C[C@H](C)C(O)=O IUHMIOAKWHUFKU-YINIXLNUSA-N 0.000 description 1
- VKSIBVBEGLEBSB-ATVHPVEESA-N (5z)-5-hydroxyimino-6h-benzo[b][1]benzazepine-11-carboxamide Chemical compound C1\C(=N\O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 VKSIBVBEGLEBSB-ATVHPVEESA-N 0.000 description 1
- YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 1
- HKHRWODVCOCCIC-UCZFRPJKSA-N (6s)-3-[[(2-amino-2-oxoethyl)-methylamino]methyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S1C(CN(C)CC(N)=O)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)C21 HKHRWODVCOCCIC-UCZFRPJKSA-N 0.000 description 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
- BSRQHWFOFMAZRL-BODGVHBXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C BSRQHWFOFMAZRL-BODGVHBXSA-N 0.000 description 1
- MCKJPJYRCPANCC-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 MCKJPJYRCPANCC-XLXYOEISSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical group C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FZENGILVLUJGJX-NSCUHMNNSA-N (E)-acetaldehyde oxime Chemical compound C\C=N\O FZENGILVLUJGJX-NSCUHMNNSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- XFDJYSQDBULQSI-QFIPXVFZSA-N (R)-doxapram Chemical compound C([C@H]1CN(C(C1(C=1C=CC=CC=1)C=1C=CC=CC=1)=O)CC)CN1CCOCC1 XFDJYSQDBULQSI-QFIPXVFZSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-INIZCTEOSA-N (S)-fluoxetine Chemical compound O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-INIZCTEOSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- UEJJHQNACJXSKW-VIFPVBQESA-N (S)-thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H]1CCC(=O)NC1=O UEJJHQNACJXSKW-VIFPVBQESA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- NPOMAIJXMCXWGP-UHFFFAOYSA-N (cyanatodisulfanyl) cyanate Chemical compound N#COSSOC#N NPOMAIJXMCXWGP-UHFFFAOYSA-N 0.000 description 1
- KMCRQJMZUHNLKJ-NSCUHMNNSA-N (e)-4-(4-nitrophenyl)but-3-en-2-one Chemical compound CC(=O)\C=C\C1=CC=C([N+]([O-])=O)C=C1 KMCRQJMZUHNLKJ-NSCUHMNNSA-N 0.000 description 1
- IMWCPTKSESEZCL-SPSNFJOYSA-H (e)-but-2-enedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O IMWCPTKSESEZCL-SPSNFJOYSA-H 0.000 description 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 1
- XEPXTKKIWBPAEG-UHFFFAOYSA-N 1,1-dichloropropan-1-ol Chemical compound CCC(O)(Cl)Cl XEPXTKKIWBPAEG-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- ANSIWEGOCFWRSC-UHFFFAOYSA-N 1,2-dimethyl-1h-indene Chemical compound C1=CC=C2C(C)C(C)=CC2=C1 ANSIWEGOCFWRSC-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- KETQAJRQOHHATG-UHFFFAOYSA-N 1,2-naphthoquinone Chemical compound C1=CC=C2C(=O)C(=O)C=CC2=C1 KETQAJRQOHHATG-UHFFFAOYSA-N 0.000 description 1
- 229940105324 1,2-naphthoquinone Drugs 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- WQAQKERCWPUIMH-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CN1C(C)=CC(=O)N1C1=CC=CC=C1 WQAQKERCWPUIMH-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- MPTJIDOGFUQSQH-UHFFFAOYSA-N 1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole Chemical compound C12=CC=CC=C2CCC2=CC(Cl)=CC(Cl)=C2C1N1C=CN=C1 MPTJIDOGFUQSQH-UHFFFAOYSA-N 0.000 description 1
- FXCYGAGBPZQRJE-ZHACJKMWSA-N 1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1,6-heptadien-3-one Chemical compound CC1=CCCC(C)(C)C1\C=C\C(=O)CCC=C FXCYGAGBPZQRJE-ZHACJKMWSA-N 0.000 description 1
- DBDVAKGHPZJLTH-UHFFFAOYSA-N 1-(2-phenylethyl)piperidine Chemical compound C1CCCCN1CCC1=CC=CC=C1 DBDVAKGHPZJLTH-UHFFFAOYSA-N 0.000 description 1
- MRFOLGFFTUGAEB-UHFFFAOYSA-N 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone Chemical compound [O-][N+](=O)C1=C(O)C(O)=CC(C(=O)CC=2C=CC=CC=2)=C1 MRFOLGFFTUGAEB-UHFFFAOYSA-N 0.000 description 1
- SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 1
- SQZCAOHYQSOZCE-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N=C(N)N=C(N)N SQZCAOHYQSOZCE-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KPQFKCWYCKXXIP-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylamino)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(NC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 KPQFKCWYCKXXIP-XLPZGREQSA-N 0.000 description 1
- FMBVHKPWDJQLNO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC(F)=C1 FMBVHKPWDJQLNO-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- MBGVUMXBUGIIBQ-LEWJYISDSA-N 1-[(3r,4r)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one Chemical compound C([C@H]([C@@H](C1)CO)N2C3=CC=CC=C3N(C2=O)CC)CN1CC1CCCCCCC1 MBGVUMXBUGIIBQ-LEWJYISDSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- UDDPPYHULIXFDV-UHFFFAOYSA-N 1-[(6-chloro-2-methoxyacridin-9-yl)amino]-3-(diethylamino)propan-2-ol Chemical compound C1=C(OC)C=C2C(NCC(O)CN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 UDDPPYHULIXFDV-UHFFFAOYSA-N 0.000 description 1
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- JTUQXGZRVLWBCR-UHFFFAOYSA-N 1-[1-[2-(phenylmethyl)phenoxy]propan-2-yl]piperidine Chemical compound C1CCCCN1C(C)COC1=CC=CC=C1CC1=CC=CC=C1 JTUQXGZRVLWBCR-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 1
- USMXIXZBRZZOQH-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;dihydrate;octahydrochloride Chemical compound O.O.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 USMXIXZBRZZOQH-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 description 1
- CGKLGZAQJJODCG-UHFFFAOYSA-N 1-bromo-1-(3-methylbutyl)urea Chemical compound BrN(C(=O)N)CCC(C)C CGKLGZAQJJODCG-UHFFFAOYSA-N 0.000 description 1
- ZAONJNQXCRQBQZ-UHFFFAOYSA-N 1-bromo-1-fluoropropane Chemical compound CCC(F)Br ZAONJNQXCRQBQZ-UHFFFAOYSA-N 0.000 description 1
- WLJXUWKOEVKMGD-UHFFFAOYSA-N 1-chloro-2,3-dihydro-1h-indene Chemical compound C1=CC=C2C(Cl)CCC2=C1 WLJXUWKOEVKMGD-UHFFFAOYSA-N 0.000 description 1
- RPOUGULCGNMIBX-UHFFFAOYSA-N 1-chlorophenazine Chemical compound C1=CC=C2N=C3C(Cl)=CC=CC3=NC2=C1 RPOUGULCGNMIBX-UHFFFAOYSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JMGNVALALWCTLC-UHFFFAOYSA-N 1-fluoro-2-(2-fluoroethenoxy)ethene Chemical compound FC=COC=CF JMGNVALALWCTLC-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- ZYDGCYWJDWIJCS-UHFFFAOYSA-N 1-methoxyphenazine Chemical compound C1=CC=C2N=C3C(OC)=CC=CC3=NC2=C1 ZYDGCYWJDWIJCS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HKGUUZAACYBIID-UHFFFAOYSA-N 1-methylsulfanyldecane Chemical compound CCCCCCCCCCSC HKGUUZAACYBIID-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- BJQHLKABXJIVAM-BGYRXZFFSA-N 1-o-[(2r)-2-ethylhexyl] 2-o-[(2s)-2-ethylhexyl] benzene-1,2-dicarboxylate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@H](CC)CCCC BJQHLKABXJIVAM-BGYRXZFFSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PYFVRMNFLPOIHE-UHFFFAOYSA-N 1-phenylethanone;sodium Chemical compound [Na].CC(=O)C1=CC=CC=C1 PYFVRMNFLPOIHE-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QVEPWCHFXPHWJG-GNAFDRTKSA-N 11-[[(2r)-1-[2-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl]methyl]-6h-benzo[c][1,5]benzoxazepine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CCN1[C@@H](CN2C3=CC=CC=C3OCC3=CC=CC=C32)CCC1 QVEPWCHFXPHWJG-GNAFDRTKSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- IIATUSCNYYSFNW-UHFFFAOYSA-N 12-ethoxy-2,3,8,9-tetramethoxy-5-methylbenzo[c]phenanthridin-5-ium Chemical compound COC1=C(OC)C=C2C(OCC)=CC3=C(C=C(OC)C(OC)=C4)C4=C[N+](C)=C3C2=C1 IIATUSCNYYSFNW-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- BRKWHJOZIGLDPP-UHFFFAOYSA-N 18-hydroxyoctadecyl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OCCCCCCCCCCCCCCCCCCO BRKWHJOZIGLDPP-UHFFFAOYSA-N 0.000 description 1
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
- HTCJGXGLMIWOCW-UHFFFAOYSA-N 1alpha-hydroxycholesterol Natural products C1C=C2CC(O)CC(O)C2(C)C2C1C1CCC(C(C)CCC(=C)C(C)C)C1(C)CC2 HTCJGXGLMIWOCW-UHFFFAOYSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- KDMAKCTXYYDWPM-UHFFFAOYSA-N 2,2-dibutyldecanedioic acid Chemical class CCCCC(CCCC)(C(O)=O)CCCCCCCC(O)=O KDMAKCTXYYDWPM-UHFFFAOYSA-N 0.000 description 1
- ZNOVVAJWYUBFMI-JIFFNSBPSA-N 2,2-dimethylpropanoyloxymethyl (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3r)-5-oxopyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)S[C@H]1CNC(=O)C1 ZNOVVAJWYUBFMI-JIFFNSBPSA-N 0.000 description 1
- YLUSMKAJIQOXPV-UHFFFAOYSA-N 2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine Chemical compound C1CCCC2=C1N=C1CCCC1=C2N YLUSMKAJIQOXPV-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical compound OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- VCSQIXYYZLLGKD-UHFFFAOYSA-N 2,3-diiodoquinoline Chemical compound C1=CC=C2N=C(I)C(I)=CC2=C1 VCSQIXYYZLLGKD-UHFFFAOYSA-N 0.000 description 1
- NAZQXTHWEFCOOX-UHFFFAOYSA-N 2,4-dimethyl-6-prop-2-enyl-7,8-dihydropurino[7,8-a]imidazole-1,3-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N1CCN(CC=C)C1=N2 NAZQXTHWEFCOOX-UHFFFAOYSA-N 0.000 description 1
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical compound OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 description 1
- IUKJNIOSXCPLLP-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid;piperazine Chemical compound C1CNCCN1.C1CNCCN1.C1CNCCN1.C1CNCCN1.C1CNCCN1.C1CNCCN1.C1CNCCN1.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 IUKJNIOSXCPLLP-UHFFFAOYSA-N 0.000 description 1
- WEBILLRFBZTUIX-BTJKTKAUSA-N 2-(1-adamantyl)ethyl 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetate;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OCC(O)CNC(C)C)=CC=C1CC(=O)OCCC1(C2)CC(C3)CC2CC3C1 WEBILLRFBZTUIX-BTJKTKAUSA-N 0.000 description 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
- JHVHEDNLONERHY-UHFFFAOYSA-N 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine Chemical compound CSC1=CC=CC(N(C)C(N)=NC=2C(=CC=C(SC)C=2)Cl)=C1 JHVHEDNLONERHY-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- YCTSCXLOPJCPDH-UHFFFAOYSA-N 2-(3,7-dimethyl-2,6-dioxopurin-1-yl)acetic acid Chemical compound CN1C(=O)N(CC(O)=O)C(=O)C2=C1N=CN2C YCTSCXLOPJCPDH-UHFFFAOYSA-N 0.000 description 1
- FNLNSQHJKVQCBP-UHFFFAOYSA-N 2-(3-sulfanylpropyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CCCS FNLNSQHJKVQCBP-UHFFFAOYSA-N 0.000 description 1
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 description 1
- KOLPMNSDISYEBU-WJOKGBTCSA-N 2-[(3r)-1-(2,2-diethoxyethyl)-3-[(4-methylphenyl)carbamoylamino]-2-oxoindol-3-yl]-n-(4-methylphenyl)acetamide Chemical compound C([C@]1(NC(=O)NC=2C=CC(C)=CC=2)C(=O)N(C2=CC=CC=C21)CC(OCC)OCC)C(=O)NC1=CC=C(C)C=C1 KOLPMNSDISYEBU-WJOKGBTCSA-N 0.000 description 1
- SOLIIYNRSAWTSQ-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 SOLIIYNRSAWTSQ-UHFFFAOYSA-N 0.000 description 1
- CQEOXWCXSBFJMB-UHFFFAOYSA-N 2-[1-[1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl]indol-6-yl]-n-methylacetamide Chemical compound C12=CC(CC(=O)NC)=CC=C2C=CN1C(CC1)CCN1CCC1=CC=CC=C1F CQEOXWCXSBFJMB-UHFFFAOYSA-N 0.000 description 1
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 1
- BCPQOBQIVJZOFL-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OCC(O)=O)C=C2O1 BCPQOBQIVJZOFL-UHFFFAOYSA-N 0.000 description 1
- MELCWEWUZODSIS-UHFFFAOYSA-N 2-[2-(diethylamino)ethoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOCCN(CC)CC MELCWEWUZODSIS-UHFFFAOYSA-N 0.000 description 1
- XNGGRURGYIXOBY-UHFFFAOYSA-N 2-[3-[1-(4-fluorobenzoyl)piperidin-4-yl]phenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC(C2CCN(CC2)C(=O)C=2C=CC(F)=CC=2)=C1 XNGGRURGYIXOBY-UHFFFAOYSA-N 0.000 description 1
- FJNRJBQUOQLUNQ-CYBMUJFWSA-N 2-[3-[[(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]propyl]pyridazin-3-one Chemical compound O=C1C=CC=NN1CCCNC[C@H]1OC2=CC=CC=C2OC1 FJNRJBQUOQLUNQ-CYBMUJFWSA-N 0.000 description 1
- OUEKLNJUMVZULZ-UHFFFAOYSA-N 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-n-[3-(3,4-dimethylphenyl)propyl]acetamide;hydron;chloride Chemical compound Cl.C1=C(OCCN)C(OC)=CC(CC(=O)NCCCC=2C=C(C)C(C)=CC=2)=C1 OUEKLNJUMVZULZ-UHFFFAOYSA-N 0.000 description 1
- WFPIAZLQTJBIFN-BLLMUTORSA-N 2-[4-[(3e)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1CC\C=C/1C2=CC(Cl)=CC=C2SC2=CC=CC=C2\1 WFPIAZLQTJBIFN-BLLMUTORSA-N 0.000 description 1
- KKXPBQQLKHBRDA-DJJJIMSYSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(OCC(O)=O)C=C1 KKXPBQQLKHBRDA-DJJJIMSYSA-N 0.000 description 1
- LYXKFNHUJJDTIA-UHFFFAOYSA-N 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound O=C1C2=CC=CC=C2S(=O)(=O)N1CCCCN(CC1)CCN1C1=CC(Cl)=CC2=C1OCCO2 LYXKFNHUJJDTIA-UHFFFAOYSA-N 0.000 description 1
- BOIPLTNGIAPDBY-UHFFFAOYSA-N 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine Chemical compound C1=CC(Cl)=CC=C1OCCCCCCN=C(NC#N)NC1=CC=NC=C1 BOIPLTNGIAPDBY-UHFFFAOYSA-N 0.000 description 1
- FHEYFIGWYQJVDR-ACJLOTCBSA-N 2-[[3-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1h-indol-7-yl]oxy]acetic acid Chemical compound C1([C@@H](O)CN[C@@H](CC=2C3=CC=CC(OCC(O)=O)=C3NC=2)C)=CC=CC(Cl)=C1 FHEYFIGWYQJVDR-ACJLOTCBSA-N 0.000 description 1
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- SEIRRUDMPNNSCY-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC=N2 SEIRRUDMPNNSCY-UHFFFAOYSA-N 0.000 description 1
- MDKVDJZIHRFUBO-UHFFFAOYSA-N 2-amino-3-benzoyl-4-(2-benzoylphenyl)iminocyclohexa-2,5-dien-1-one Chemical compound C1=CC=C(C=C1)C(=O)C2=CC=CC=C2N=C3C=CC(=O)C(=C3C(=O)C4=CC=CC=C4)N MDKVDJZIHRFUBO-UHFFFAOYSA-N 0.000 description 1
- JLYSZBQNRJVPEP-KGFZYKRKSA-N 2-amino-9-[[(1s,2r)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C[C@]1(CO)C[C@H]1CO JLYSZBQNRJVPEP-KGFZYKRKSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- KWIPUXXIFQQMKN-UHFFFAOYSA-N 2-azaniumyl-3-(4-cyanophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-UHFFFAOYSA-N 0.000 description 1
- BURBNIPKSRJAIQ-UHFFFAOYSA-N 2-azaniumyl-3-[3-(trifluoromethyl)phenyl]propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(C(F)(F)F)=C1 BURBNIPKSRJAIQ-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- ZCXUVYAZINUVJD-RCVQEXLNSA-N 2-deoxy-2-((18)F)fluoro-beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-RCVQEXLNSA-N 0.000 description 1
- BYVQIEDYUFEJJI-UHFFFAOYSA-N 2-ethoxy-6-[2-[(3-ethoxy-2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound C(C)OC1=C(C(C=NCCN=CC=2C(O)=C(C=CC=2)OCC)=CC=C1)O BYVQIEDYUFEJJI-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical compound CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- AJKXDPSHWRTFOZ-UHFFFAOYSA-N 2-ethylhexane-1,6-diol Chemical compound CCC(CO)CCCCO AJKXDPSHWRTFOZ-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- XHKUTQNVGAHLPK-UHFFFAOYSA-N 2-fluorocyclohexa-2,5-diene-1,4-dione Chemical compound FC1=CC(=O)C=CC1=O XHKUTQNVGAHLPK-UHFFFAOYSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- XPQIPNORJZZYPV-UHFFFAOYSA-N 2-hydroxymethylglutaric acid Chemical compound OCC(C(O)=O)CCC(O)=O XPQIPNORJZZYPV-UHFFFAOYSA-N 0.000 description 1
- JZSMZIOJUHECHW-GTJZZHROSA-N 2-hydroxypropyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(C)O JZSMZIOJUHECHW-GTJZZHROSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- VZUKEVFHSPMCSH-UHFFFAOYSA-N 2-nitroethanamine Chemical compound NCC[N+]([O-])=O VZUKEVFHSPMCSH-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LNRYKMIXUDFZHA-UHFFFAOYSA-N 2-phenyl-9h-fluoren-1-ol Chemical compound OC1=C2CC3=CC=CC=C3C2=CC=C1C1=CC=CC=C1 LNRYKMIXUDFZHA-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-O 2-phenylethanaminium Chemical compound [NH3+]CCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-O 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- FBVDVFULNXWYRF-UHFFFAOYSA-N 3-(6-oxo-3h-purin-9-yl)-n-[3-(2-oxopyrrolidin-1-yl)propyl]propanamide Chemical compound C1=NC(C(NC=N2)=O)=C2N1CCC(=O)NCCCN1CCCC1=O FBVDVFULNXWYRF-UHFFFAOYSA-N 0.000 description 1
- VMJQLPNCUPGMNQ-HNNXBMFYSA-N 3-[(2s)-6-hydroxy-2,7,8-trimethyl-3,4-dihydrochromen-2-yl]propanoic acid Chemical compound C1C[C@@](C)(CCC(O)=O)OC2=C(C)C(C)=C(O)C=C21 VMJQLPNCUPGMNQ-HNNXBMFYSA-N 0.000 description 1
- WAWDOEHEAULMGC-UHFFFAOYSA-N 3-[(6-butoxypyridin-3-yl)diazenyl]pyridine-2,6-diamine Chemical compound C1=NC(OCCCC)=CC=C1N=NC1=CC=C(N)N=C1N WAWDOEHEAULMGC-UHFFFAOYSA-N 0.000 description 1
- LZXRQLIIMYJZDA-UETOGOEVSA-N 3-[(r)-[(2s,5r)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-n-(3-fluorophenyl)-n-methylbenzamide Chemical compound C[C@H]1CN(CC=C)[C@H](C)CN1[C@H](C=1C=C(C=CC=1)C(=O)N(C)C=1C=C(F)C=CC=1)C1=CC=CC(O)=C1 LZXRQLIIMYJZDA-UETOGOEVSA-N 0.000 description 1
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
- IHRBZSIEWFFJQW-UHFFFAOYSA-N 3-[2-[4-(3-chloro-2-methylphenyl)piperazin-1-yl]ethyl]-1-(1h-imidazol-5-ylmethyl)-5,6-dimethoxyindazole;dihydrochloride Chemical compound Cl.Cl.N=1N(CC=2N=CNC=2)C=2C=C(OC)C(OC)=CC=2C=1CCN(CC1)CCN1C1=CC=CC(Cl)=C1C IHRBZSIEWFFJQW-UHFFFAOYSA-N 0.000 description 1
- XDJCLCLBSGGNKS-UHFFFAOYSA-N 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole Chemical compound C=1C=CC(C=2C3=CC(=CC=C3NN=2)C=2NN=CN=2)=CC=1OCCN1CCCCC1 XDJCLCLBSGGNKS-UHFFFAOYSA-N 0.000 description 1
- WDTAYDBPNYFWDR-WOJBJXKFSA-N 3-[4-[(3ar,9br)-9-methoxy-3,3a,4,9b-tetrahydro-1h-chromeno[3,4-c]pyrrol-2-yl]butyl]-8-phenyl-1h-pyrazino[1,2]thieno[3,4-b]pyrimidine-2,4-dione Chemical compound C([C@@H]1COC=2C=CC=C(C=2[C@@H]1C1)OC)N1CCCCN(C(C=1SC2=NC=3)=O)C(=O)NC=1C2=NC=3C1=CC=CC=C1 WDTAYDBPNYFWDR-WOJBJXKFSA-N 0.000 description 1
- LZVBMKDVEPGGFK-DQEYMECFSA-N 3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2s,5s)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea Chemical compound COC1=CC([C@H]2O[C@@H](CC2)C=2C=C(OC)C(OC)=C(OC)C=2)=CC(CNC(=O)N(C)O)=C1OCCSC1=CC=C(Cl)C=C1 LZVBMKDVEPGGFK-DQEYMECFSA-N 0.000 description 1
- RTKMFQOHBDVEBC-UHFFFAOYSA-N 3-bromo-3-buten-1-ol Chemical compound OCCC(Br)=C RTKMFQOHBDVEBC-UHFFFAOYSA-N 0.000 description 1
- BEPPRIUEZLYDFH-UHFFFAOYSA-N 3-bromo-3h-indene-1,2-dione Chemical compound C1=CC=C2C(Br)C(=O)C(=O)C2=C1 BEPPRIUEZLYDFH-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- BJAFXUDGNNZFNZ-UHFFFAOYSA-N 3-ethyl-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(CC)=C1C1=CC=CC=C1 BJAFXUDGNNZFNZ-UHFFFAOYSA-N 0.000 description 1
- NUPUDYKEEJNZRG-LBPRGKRZSA-N 3-ethynyl-5-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CN1CCC[C@H]1C1=CN=CC(C#C)=C1 NUPUDYKEEJNZRG-LBPRGKRZSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- TZZGHGKTHXIOMN-UHFFFAOYSA-N 3-trimethoxysilyl-n-(3-trimethoxysilylpropyl)propan-1-amine Chemical compound CO[Si](OC)(OC)CCCNCCC[Si](OC)(OC)OC TZZGHGKTHXIOMN-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FXRYWOJYVGJZLE-UHFFFAOYSA-N 4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine Chemical compound C1=CC=C2C(C)(C)CN[Se]C2=C1 FXRYWOJYVGJZLE-UHFFFAOYSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 description 1
- ABLISKCYCSSHKJ-UHFFFAOYSA-N 4-(4-aminophenyl)-3-iodoaniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1I ABLISKCYCSSHKJ-UHFFFAOYSA-N 0.000 description 1
- LTBKOSQVBVYJKW-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2h-pyridine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(F)=CC=C1C(CC1)=CCN1CCCCN1N=CN=C1 LTBKOSQVBVYJKW-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- 239000004101 4-Hexylresorcinol Substances 0.000 description 1
- HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 1
- VPTONMHDLLMOOV-UHFFFAOYSA-N 4-[3-[4-(2-methylimidazol-1-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide Chemical compound CC1=NC=CN1C(C=C1)=CC=C1SC1=CC=CC(C2(CCOCC2)C(N)=O)=C1 VPTONMHDLLMOOV-UHFFFAOYSA-N 0.000 description 1
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- DJKNRCWSXSZACF-UHFFFAOYSA-N 4-acetamido-n-tert-butylbenzamide Chemical compound CC(=O)NC1=CC=C(C(=O)NC(C)(C)C)C=C1 DJKNRCWSXSZACF-UHFFFAOYSA-N 0.000 description 1
- JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2r,3r,4s,5r)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- HSBKFSPNDWWPSL-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1C=C[C@@H](CO)O1 HSBKFSPNDWWPSL-CAHLUQPWSA-N 0.000 description 1
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 235000019360 4-hexylresorcinol Nutrition 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- QZHXKQKKEBXYRG-UHFFFAOYSA-N 4-n-(4-aminophenyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=CC=C(N)C=C1 QZHXKQKKEBXYRG-UHFFFAOYSA-N 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- SPLHPRPQTCQRGZ-UHFFFAOYSA-N 5-(2-amino-6-chloropurin-9-yl)pentylboronic acid Chemical compound NC1=NC(Cl)=C2N=CN(CCCCCB(O)O)C2=N1 SPLHPRPQTCQRGZ-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- CVKJAXCQPFOAIN-VXGBXAGGSA-N 5-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1h-imidazole Chemical compound CC(C)(C)CCC#C[C@@H]1C[C@H]1C1=CN=CN1 CVKJAXCQPFOAIN-VXGBXAGGSA-N 0.000 description 1
- KMUWWBNTTNUCDI-UHFFFAOYSA-N 5-amino-1h-imidazo[4,5-d][1,3]oxazin-7-one Chemical compound O=C1OC(N)=NC2=C1N=CN2 KMUWWBNTTNUCDI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- OJFZXRZZXBFEAP-UHFFFAOYSA-N 5-chloro-1,6-dimethylcyclohexa-2,4-dien-1-ol Chemical compound ClC=1C(C(C=CC1)(C)O)C OJFZXRZZXBFEAP-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- ZBXRPLQCPHTHLM-UHFFFAOYSA-N 5-chloro-n-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide;hydrate Chemical compound O.OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl ZBXRPLQCPHTHLM-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- DCDFLGVJWQIRGH-UHFFFAOYSA-N 5-methyl-2-piperazin-4-ium-1-ylbenzenesulfonate Chemical compound OS(=O)(=O)C1=CC(C)=CC=C1N1CCNCC1 DCDFLGVJWQIRGH-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QBFRPGRSZWPABV-UHFFFAOYSA-N 6-fluoro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O QBFRPGRSZWPABV-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- JYRHGXXQSIPDDP-IACUBPJLSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C12([C@H](N)CN(C1)C1=C(C3=C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)C=C1F)OC)CC2 JYRHGXXQSIPDDP-IACUBPJLSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VDBGPMJFHCJMOL-UHFFFAOYSA-N 9-[2-[bis(2,2,2-trifluoroethoxy)phosphorylmethoxy]ethyl]-6-(4-methoxyphenyl)sulfanylpurin-2-amine Chemical compound C1=CC(OC)=CC=C1SC1=NC(N)=NC2=C1N=CN2CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F VDBGPMJFHCJMOL-UHFFFAOYSA-N 0.000 description 1
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 description 1
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- FTQDJVZNPJRVPG-XWEVEMRCSA-N Acetoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C FTQDJVZNPJRVPG-XWEVEMRCSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-M Acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C([O-])=O BSYNRYMUTXBXSQ-UHFFFAOYSA-M 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- XUHBBTKJWIBQMY-MHZLTWQESA-N Anatibant Chemical compound O=C([C@@H]1CCCN1S(=O)(=O)C=1C=CC(Cl)=C(C=1Cl)COC1=CC=CC2=C(C)C=C(N=C21)C)NCCCNC(=O)C1=CC=C(C(N)=N)C=C1 XUHBBTKJWIBQMY-MHZLTWQESA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102100034283 Annexin A5 Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- 241000479811 Aprestes Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- VCCBCXVFGHTDQN-UODBTFMRSA-N BIII-890CL Chemical compound O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 VCCBCXVFGHTDQN-UODBTFMRSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- UZQTXLCTPIDFOX-UHFFFAOYSA-N BrC1=C(C=CC=C1)O.[Bi] Chemical compound BrC1=C(C=CC=C1)O.[Bi] UZQTXLCTPIDFOX-UHFFFAOYSA-N 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- QORQZMBCPRBCAB-UHFFFAOYSA-M Butabarbital sodium Chemical compound [Na+].CCC(C)C1(CC)C(=O)NC([O-])=NC1=O QORQZMBCPRBCAB-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- QKIMIZQJEWOVGF-UHFFFAOYSA-N C(C(C)O)O.C(CCCCCCCCCCCCCCCCC)(=O)OCCCCCCCCCCCCCCCC Chemical compound C(C(C)O)O.C(CCCCCCCCCCCCCCCCC)(=O)OCCCCCCCCCCCCCCCC QKIMIZQJEWOVGF-UHFFFAOYSA-N 0.000 description 1
- ZHAHRWIZTYHZDM-UHFFFAOYSA-N C(CC)(=O)C1=CC=CC=C1.C(C)NCC Chemical compound C(CC)(=O)C1=CC=CC=C1.C(C)NCC ZHAHRWIZTYHZDM-UHFFFAOYSA-N 0.000 description 1
- SAVALVBFHIKAFW-UHFFFAOYSA-N C(CC)[Na].OC1=CC=C(C(=O)O)C=C1 Chemical compound C(CC)[Na].OC1=CC=C(C(=O)O)C=C1 SAVALVBFHIKAFW-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- KNZMXWVWHGTXAB-UHFFFAOYSA-O CCOC(C[N+](C)(C)C)(OCC)S Chemical compound CCOC(C[N+](C)(C)C)(OCC)S KNZMXWVWHGTXAB-UHFFFAOYSA-O 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- DBBYYRWVNDQECM-CDWOPPGASA-N CG-1521 Chemical compound ONC(=O)\C=C\C=C\C=C\C1=CC=CC=C1 DBBYYRWVNDQECM-CDWOPPGASA-N 0.000 description 1
- ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- WRLFSJXJGJBFJQ-WPUCQFJDSA-N Calcifediol monohydrate Chemical compound O.C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C WRLFSJXJGJBFJQ-WPUCQFJDSA-N 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 description 1
- 229940122805 Cathepsin S inhibitor Drugs 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000026368 Cestode infections Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 108010066259 Collagraft Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 235000009046 Convallaria majalis Nutrition 0.000 description 1
- 244000068485 Convallaria majalis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 101710200374 Crotamine Proteins 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical group NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GVOUFPWUYJWQSK-UHFFFAOYSA-N Cyclofenil Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1C=CC(OC(C)=O)=CC=1)=C1CCCCC1 GVOUFPWUYJWQSK-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- KHMVXSQLPUNRCF-UHFFFAOYSA-N DL-Adalin Natural products C1CCC2CC(=O)CC1(CCCCC)N2 KHMVXSQLPUNRCF-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 241000531375 Dexamine Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N Diethylhexyl phthalate Natural products CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- 239000005763 Disodium phosphonate Substances 0.000 description 1
- UVGTXNPVQOQFQW-UHFFFAOYSA-N Disophenol Chemical compound OC1=C(I)C=C([N+]([O-])=O)C=C1I UVGTXNPVQOQFQW-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- NMYAHEULKSYAPP-UHFFFAOYSA-N Eptapirone Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 NMYAHEULKSYAPP-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- UJYGDMFEEDNVBF-UHFFFAOYSA-N Ergocorninine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- 101710134985 Esterase-4 Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 1
- OKGNXSFAYMSVNN-SYAJEJNSSA-L Ferrous gluconate Chemical compound O.O.[Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OKGNXSFAYMSVNN-SYAJEJNSSA-L 0.000 description 1
- 235000007162 Ferula assa foetida Nutrition 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 235000012850 Ferula foetida Nutrition 0.000 description 1
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- PTHLEKANMPKYDB-UHFFFAOYSA-N Flopropione Chemical compound CCC(=O)C1=C(O)C=C(O)C=C1O PTHLEKANMPKYDB-UHFFFAOYSA-N 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- KINWYTAUPKOPCQ-YFKPBYRVSA-N Fudosteine Chemical compound OC(=O)[C@@H](N)CSCCCO KINWYTAUPKOPCQ-YFKPBYRVSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 101710179596 Gene 3 protein Proteins 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXGAGTVDWKQYCX-BQBZGAKWSA-N Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SXGAGTVDWKQYCX-BQBZGAKWSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 239000008961 HMPL-004 Substances 0.000 description 1
- 108010024770 HP 228 Proteins 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- XDKCGKQHVBOOHC-UHFFFAOYSA-N Haloxazolam Chemical compound FC1=CC=CC=C1C1(C2=CC(Br)=CC=C2NC(=O)C2)N2CCO1 XDKCGKQHVBOOHC-UHFFFAOYSA-N 0.000 description 1
- 108010011593 Healos Proteins 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 241000558610 Illicium anisatum Species 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
- YQNFBOJPTAXAKV-OMCISZLKSA-N Iopodic acid Chemical compound CN(C)\C=N\C1=C(I)C=C(I)C(CCC(O)=O)=C1I YQNFBOJPTAXAKV-OMCISZLKSA-N 0.000 description 1
- 101800001026 Irisin Proteins 0.000 description 1
- 102400001216 Irisin Human genes 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- RMSWMRJVUJSDGN-GOSISDBHSA-N Israpafant Chemical compound C1=CC(CC(C)C)=CC=C1CCC1=CC(C(=N[C@H](C)C2=NN=C(C)N22)C=3C(=CC=CC=3)Cl)=C2S1 RMSWMRJVUJSDGN-GOSISDBHSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 108010070919 LJP 1082 Proteins 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- SFIHQZFZMWZOJV-UHFFFAOYSA-N Linolsaeure-amid Natural products CCCCCC=CCC=CCCCCCCCC(N)=O SFIHQZFZMWZOJV-UHFFFAOYSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- VPHPQNGOVQYUMG-UHFFFAOYSA-N Liranaftate Chemical compound COC1=CC=CC(N(C)C(=S)OC=2C=C3CCCCC3=CC=2)=N1 VPHPQNGOVQYUMG-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010048179 Lypressin Proteins 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 1
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- HUNIPYLVUPMFCZ-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-(4-methoxyphenoxy)acetamide Chemical compound CCN(CC)CCNC(=O)COC1=CC=C(OC)C=C1 HUNIPYLVUPMFCZ-UHFFFAOYSA-N 0.000 description 1
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- LZMATGARSSLFMQ-UHFFFAOYSA-N N-isopropylurea Natural products CC(C)NC(N)=O LZMATGARSSLFMQ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DMBHHRLKUKUOEG-UHFFFAOYSA-N N-phenyl aniline Natural products C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- CKMOQBVBEGCJGW-LLIZZRELSA-L OC1=CC=C(C=C1C(=O)O[Na])\N=N\C1=CC=C(C=C1)C(=O)NCCC(=O)O[Na] Chemical compound OC1=CC=C(C=C1C(=O)O[Na])\N=N\C1=CC=C(C=C1)C(=O)NCCC(=O)O[Na] CKMOQBVBEGCJGW-LLIZZRELSA-L 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZAKBUDMIDDEMKO-UHFFFAOYSA-L P(OC(O)OP([O-])=O)([O-])=O.[Na+].[Na+] Chemical compound P(OC(O)OP([O-])=O)([O-])=O.[Na+].[Na+] ZAKBUDMIDDEMKO-UHFFFAOYSA-L 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- RUEYKHOTFAUFKS-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].C(CCCCCCCCCCCCCCCCC)(=O)OCCCCCCCCCCCCCCCC.[Na+].[Na+] Chemical compound S(=O)(=O)([O-])[O-].C(CCCCCCCCCCCCCCCCC)(=O)OCCCCCCCCCCCCCCCC.[Na+].[Na+] RUEYKHOTFAUFKS-UHFFFAOYSA-L 0.000 description 1
- RFPYNXNCMZETNE-UHFFFAOYSA-M S(=S)(=S)[O-].[Na+] Chemical compound S(=S)(=S)[O-].[Na+] RFPYNXNCMZETNE-UHFFFAOYSA-M 0.000 description 1
- VDUOWIXOXCLENI-UHFFFAOYSA-N S1(C=CC=C1)=O.[Cl] Chemical compound S1(C=CC=C1)=O.[Cl] VDUOWIXOXCLENI-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N Secbutobarbitone Natural products CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UNZIDPIPYUMVPA-UHFFFAOYSA-M Sulpyrine Chemical compound O.[Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 UNZIDPIPYUMVPA-UHFFFAOYSA-M 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- XEEPVFFWNATEGX-IUHNQTRMSA-N Tazettadiol Natural products C1=C(CO)C([C@]23[C@H](O)CN(C)[C@H]2C[C@@H](C=C3)OC)=CC2=C1OCO2 XEEPVFFWNATEGX-IUHNQTRMSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- BGHCVCJVXZWKCC-UHFFFAOYSA-N Tetradecane Natural products CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical group [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- ZWTVVWUOTJRXKM-UHFFFAOYSA-N Tonapofylline Chemical compound C1CC(CCC(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 ZWTVVWUOTJRXKM-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- PPORNUWQIKUROY-AINMIYBESA-N [(2r,3s,4r,5r,6r)-2-[(2r,3s,4r,5s,6s)-2-[(3s)-3-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-4-[[(3r,4s,5s)-6-[[(2s)-1-[2-[(4r)-4-[4-[(4-amino-4-iminobutyl)carbamoyl]-1,3-thiazol-2-yl] Chemical compound O([C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC(C)[C@H](NC(=O)C=1C(=C(N)N=C(N=1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)C)C(=O)N[C@H](CCO)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCC(N)=N)C(C)(C)O)[C@H]1O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]1O PPORNUWQIKUROY-AINMIYBESA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- YDQDJLTYVZAOQX-GOMYTPFNSA-N [(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C1 YDQDJLTYVZAOQX-GOMYTPFNSA-N 0.000 description 1
- XAEMHHAVNYDWEO-CVEVMTCXSA-N [1-[(4e,9e,12e)-hexadeca-4,9,12-trienoyl]oxy-3-[(6e,10e,12e)-hexadeca-6,10,12-trienoyl]oxypropan-2-yl] 2-(trimethylazaniumyl)ethyl phosphate;(2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3- Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1.CCC\C=C\C\C=C\CCC\C=C\CCC(=O)OCC(OP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCC\C=C\CC\C=C\C=C\CCC XAEMHHAVNYDWEO-CVEVMTCXSA-N 0.000 description 1
- FQBCODHKOPSNSZ-UHFFFAOYSA-N [1-amino-3-(dimethylamino)-1-(hydroxy-oxido-oxoniumylidene-$l^{5}-phosphanyl)propyl]-oxoniophosphinate Chemical compound CN(C)CCC(N)(P(O)(O)=O)P(O)(O)=O FQBCODHKOPSNSZ-UHFFFAOYSA-N 0.000 description 1
- YDBCQZCJDPGBBE-BVYOMHTDSA-N [2-(4-methoxyphenyl)-2-oxoethyl] (2z,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound C1=CC(OC)=CC=C1C(=O)COC(=O)\C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C YDBCQZCJDPGBBE-BVYOMHTDSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- PZDPVSFZTKORSP-OAHLLOKOSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-[[(3r)-3-aminobutyl]amino]butyl]carbamate Chemical compound C[C@@H](N)CCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N PZDPVSFZTKORSP-OAHLLOKOSA-N 0.000 description 1
- IRWPWCJSDJOZPM-UHFFFAOYSA-N [4-(acetyloxymethyl)-5-hydroxy-6-methylpyridin-3-yl]methyl acetate Chemical compound CC(=O)OCC1=CN=C(C)C(O)=C1COC(C)=O IRWPWCJSDJOZPM-UHFFFAOYSA-N 0.000 description 1
- ANZIOUQAFBXNHU-UHFFFAOYSA-N [4-[2-(diaminomethylidene)hydrazinyl]phenyl]iminothiourea Chemical compound NC(N)=NNC1=CC=C(N=NC(N)=S)C=C1 ANZIOUQAFBXNHU-UHFFFAOYSA-N 0.000 description 1
- RKFMOTBTFHXWCM-UHFFFAOYSA-M [AlH2]O Chemical compound [AlH2]O RKFMOTBTFHXWCM-UHFFFAOYSA-M 0.000 description 1
- MPLNGQBULSHWQW-IDDKEARESA-M [Br-].C[N+]1(CC(=O)c2ccc(cc2)c3ccccc3)[C@@H]4CC[C@H]1C[C@H](C4)OC(=O)[C@H](CO)c5ccccc5 Chemical compound [Br-].C[N+]1(CC(=O)c2ccc(cc2)c3ccccc3)[C@@H]4CC[C@H]1C[C@H](C4)OC(=O)[C@H](CO)c5ccccc5 MPLNGQBULSHWQW-IDDKEARESA-M 0.000 description 1
- DGRGTXJEIOUBJA-UHFFFAOYSA-N [Ca].CCC(=O)OC(C)=O Chemical compound [Ca].CCC(=O)OC(C)=O DGRGTXJEIOUBJA-UHFFFAOYSA-N 0.000 description 1
- NVAMEOLKYITAOX-UHFFFAOYSA-N [ClH]1(OCC=C1)=O Chemical compound [ClH]1(OCC=C1)=O NVAMEOLKYITAOX-UHFFFAOYSA-N 0.000 description 1
- ZALMZWWJQXBYQA-UHFFFAOYSA-N [N].[Cl] Chemical compound [N].[Cl] ZALMZWWJQXBYQA-UHFFFAOYSA-N 0.000 description 1
- GIEAQDPIWWODTH-UHFFFAOYSA-N [Na].[Na].[Na].[Ca] Chemical compound [Na].[Na].[Na].[Ca] GIEAQDPIWWODTH-UHFFFAOYSA-N 0.000 description 1
- PETPLWOCZICIRG-UHFFFAOYSA-L [O-]S(CCS([O-])(=O)=O)(=O)=O.[Na+].[Na+].[Na+] Chemical compound [O-]S(CCS([O-])(=O)=O)(=O)=O.[Na+].[Na+].[Na+] PETPLWOCZICIRG-UHFFFAOYSA-L 0.000 description 1
- XDVMCVGTDUKDHL-UHFFFAOYSA-N [amino(2-azaniumylethylsulfanyl)methylidene]azanium;dibromide Chemical compound Br.Br.NCCSC(N)=N XDVMCVGTDUKDHL-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 229960001171 acetohydroxamic acid Drugs 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 229960004871 acetoxolone Drugs 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- HJCUTNIGJHJGCF-UHFFFAOYSA-N acridan acid Natural products C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 description 1
- 229950003218 actarit Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OOUACICUAVTCEC-LZHWUUGESA-N aezs-108 Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OOUACICUAVTCEC-LZHWUUGESA-N 0.000 description 1
- 229960002629 agomelatine Drugs 0.000 description 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- XWYBFXIUISNTQG-VKMGZQQJSA-N alfadolone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 XWYBFXIUISNTQG-VKMGZQQJSA-N 0.000 description 1
- 229950008709 alfadolone Drugs 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 108010088666 alfimeprase Proteins 0.000 description 1
- 229950002789 alfimeprase Drugs 0.000 description 1
- UMJHTFHIQDEGKB-UHFFFAOYSA-N alibendol Chemical compound COC1=CC(CC=C)=CC(C(=O)NCCO)=C1O UMJHTFHIQDEGKB-UHFFFAOYSA-N 0.000 description 1
- 229960001122 alibendol Drugs 0.000 description 1
- 229950011466 alicaforsen Drugs 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229950001297 altinicline Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- GTQLIPQFXVKRKJ-UNSMHXHVSA-N altropane Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\I)[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-UNSMHXHVSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 229940009861 aluminum chloride hexahydrate Drugs 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- QFIGQGUHYKRFAI-UHFFFAOYSA-K aluminum;trichlorate Chemical compound [Al+3].[O-]Cl(=O)=O.[O-]Cl(=O)=O.[O-]Cl(=O)=O QFIGQGUHYKRFAI-UHFFFAOYSA-K 0.000 description 1
- ZPFXAOWNKLFJDN-UHFFFAOYSA-N alverine Chemical compound C=1C=CC=CC=1CCCN(CC)CCCC1=CC=CC=C1 ZPFXAOWNKLFJDN-UHFFFAOYSA-N 0.000 description 1
- 229960000845 alverine Drugs 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- 229950001163 amelubant Drugs 0.000 description 1
- 229940099544 americaine Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960001441 aminoacridine Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229960004567 aminohippuric acid Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 150000005010 aminoquinolines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229950010999 amiprilose Drugs 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940090948 ammonium benzoate Drugs 0.000 description 1
- 229940063284 ammonium salicylate Drugs 0.000 description 1
- 229960001444 amodiaquine Drugs 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 229950001104 anhydrovinblastine Drugs 0.000 description 1
- XRCFXMGQEVUZFC-UHFFFAOYSA-N anisindione Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O XRCFXMGQEVUZFC-UHFFFAOYSA-N 0.000 description 1
- 229960002138 anisindione Drugs 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- TZIQWQARHPGHIG-UHFFFAOYSA-N anthrarobin Chemical compound C1=CC=CC2=CC3=C(O)C(O)=CC=C3C(O)=C21 TZIQWQARHPGHIG-UHFFFAOYSA-N 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- BZHNHDOWFCBZNK-UHFFFAOYSA-N antimony lithium Chemical compound [Li].[Sb] BZHNHDOWFCBZNK-UHFFFAOYSA-N 0.000 description 1
- 229940026189 antimony potassium tartrate Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 229960004957 aprindine Drugs 0.000 description 1
- NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 description 1
- 229960005397 arbekacin Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- VJWWIRSVNSXUAC-UHFFFAOYSA-N arsinic acid Chemical compound O[AsH2]=O VJWWIRSVNSXUAC-UHFFFAOYSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- MDJRZSNPHZEMJH-MTMZYOSNSA-N artisone acetate Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 MDJRZSNPHZEMJH-MTMZYOSNSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229960001862 atracurium Drugs 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- IBBHWKYSKAODEW-UHFFFAOYSA-M azane mercury(1+) chloride Chemical compound [Cl-].N.[Hg+] IBBHWKYSKAODEW-UHFFFAOYSA-M 0.000 description 1
- XOYADKJBFVROKY-UHFFFAOYSA-N azane;phenoxybenzene Chemical compound N.C=1C=CC=CC=1OC1=CC=CC=C1 XOYADKJBFVROKY-UHFFFAOYSA-N 0.000 description 1
- 229960004904 azanidazole Drugs 0.000 description 1
- LHIALLMPKJMSIQ-NSCUHMNNSA-N azanidazole Chemical compound C1=C([N+]([O-])=O)N(C)C(\C=C\C=2N=C(N)N=CC=2)=N1 LHIALLMPKJMSIQ-NSCUHMNNSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- VVUYEFBRTFASAH-UHFFFAOYSA-N bamifylline Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CCN(CCO)CC)C=1CC1=CC=CC=C1 VVUYEFBRTFASAH-UHFFFAOYSA-N 0.000 description 1
- 229960005176 bamifylline Drugs 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 229940092690 barium sulfate Drugs 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- 229960002507 benperidol Drugs 0.000 description 1
- 229960001871 benproperine Drugs 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- AIZFEOPQVZBNGH-UHFFFAOYSA-N bentazepam Chemical compound C1=2C=3CCCCC=3SC=2NC(=O)CN=C1C1=CC=CC=C1 AIZFEOPQVZBNGH-UHFFFAOYSA-N 0.000 description 1
- 229950001957 bentazepam Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940022880 bentoquatam Drugs 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KXNWPJLDKSLKSB-UHFFFAOYSA-N benzenesulfonic acid;1-[8-(2,4-dichlorophenyl)-2-methylquinolin-4-yl]-3,6-dihydro-2h-pyridine-4-carboxamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C=12C=CC=C(C=3C(=CC(Cl)=CC=3)Cl)C2=NC(C)=CC=1N1CCC(C(N)=O)=CC1 KXNWPJLDKSLKSB-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960004001 benznidazole Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- JSZILQVIPPROJI-UHFFFAOYSA-N benzquinamide Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(C(=O)N(CC)CC)C(OC(C)=O)C2 JSZILQVIPPROJI-UHFFFAOYSA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- YYMVPVZYUYQSJE-UHFFFAOYSA-N benzyl-[2-(2,6-dimethylanilino)-2-oxoethyl]-diethylazanium;benzoate;hydrate Chemical compound O.[O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C YYMVPVZYUYQSJE-UHFFFAOYSA-N 0.000 description 1
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- QFFGVLORLPOAEC-SNVBAGLBSA-N besifloxacin Chemical compound C1[C@H](N)CCCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QFFGVLORLPOAEC-SNVBAGLBSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- LLUJWFHAQXWJOF-UHFFFAOYSA-N betazole Chemical compound NCCC1=CC=N[N]1 LLUJWFHAQXWJOF-UHFFFAOYSA-N 0.000 description 1
- 229960002114 betazole Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229940069715 bicisate Drugs 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 description 1
- 229950004495 binifibrate Drugs 0.000 description 1
- 229950005661 binodenoson Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- YCNCIZWAGQTWBI-UHFFFAOYSA-N biriperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC2CC(C3=CC=CC=C3N3)=C3CN2CC1 YCNCIZWAGQTWBI-UHFFFAOYSA-N 0.000 description 1
- 229950001988 biriperone Drugs 0.000 description 1
- 229940104825 bismuth aluminate Drugs 0.000 description 1
- FSAJRXGMUISOIW-UHFFFAOYSA-N bismuth sodium Chemical compound [Na].[Bi] FSAJRXGMUISOIW-UHFFFAOYSA-N 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- XXCBNHDMGIZPQF-UHFFFAOYSA-L bismuth(2+);5-carboxy-3-hydroxybenzene-1,2-diolate;hydrate Chemical compound O.OC1=CC(C(=O)O)=CC2=C1O[Bi]O2 XXCBNHDMGIZPQF-UHFFFAOYSA-L 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- OMWQUXGVXQELIX-UHFFFAOYSA-N bitoscanate Chemical compound S=C=NC1=CC=C(N=C=S)C=C1 OMWQUXGVXQELIX-UHFFFAOYSA-N 0.000 description 1
- 229950002418 bitoscanate Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 1
- 229950009342 brazikumab Drugs 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- NUNIWXHYABYXKF-UHFFFAOYSA-N bromazine Chemical compound C=1C=C(Br)C=CC=1C(OCCN(C)C)C1=CC=CC=C1 NUNIWXHYABYXKF-UHFFFAOYSA-N 0.000 description 1
- 229960003166 bromazine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229950005228 bromoform Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- ZGJHIFYEQJEUKA-UHFFFAOYSA-N buclosamide Chemical compound CCCCNC(=O)C1=CC=C(Cl)C=C1O ZGJHIFYEQJEUKA-UHFFFAOYSA-N 0.000 description 1
- 229950000430 buclosamide Drugs 0.000 description 1
- 229960001415 buflomedil Drugs 0.000 description 1
- 229960003354 bumadizone Drugs 0.000 description 1
- FLWFHHFTIRLFPV-UHFFFAOYSA-N bumadizone Chemical compound C=1C=CC=CC=1N(C(=O)C(C(O)=O)CCCC)NC1=CC=CC=C1 FLWFHHFTIRLFPV-UHFFFAOYSA-N 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 229960002467 bunazosin Drugs 0.000 description 1
- 229950004443 bunolol Drugs 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229940015694 butabarbital Drugs 0.000 description 1
- 229960003369 butacaine Drugs 0.000 description 1
- HKPHPIREJKHECO-UHFFFAOYSA-N butachlor Chemical compound CCCCOCN(C(=O)CCl)C1=C(CC)C=CC=C1CC HKPHPIREJKHECO-UHFFFAOYSA-N 0.000 description 1
- HZIYHIRJHYIRQO-UHFFFAOYSA-N butazolamide Chemical compound CCCC(=O)NC1=NN=C(S(N)(=O)=O)S1 HZIYHIRJHYIRQO-UHFFFAOYSA-N 0.000 description 1
- 229950000426 butazolamide Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- UULSXYSSHHRCQK-UHFFFAOYSA-N butibufen Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 description 1
- 229960002973 butibufen Drugs 0.000 description 1
- GVNYSERWAKVROD-UHFFFAOYSA-N butidrine Chemical compound C1CCCC2=CC(C(O)CNC(C)CC)=CC=C21 GVNYSERWAKVROD-UHFFFAOYSA-N 0.000 description 1
- 229950003097 butidrine Drugs 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- OPFRMDSDETYVHC-UHFFFAOYSA-L cadmium(2+);2-carboxyphenolate Chemical compound [Cd+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O OPFRMDSDETYVHC-UHFFFAOYSA-L 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- FVPXUCYMFDVPAL-UHFFFAOYSA-L calcium 2-iododocosanoate Chemical compound [Ca++].CCCCCCCCCCCCCCCCCCCCC(I)C([O-])=O.CCCCCCCCCCCCCCCCCCCCC(I)C([O-])=O FVPXUCYMFDVPAL-UHFFFAOYSA-L 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 229960001436 calcium saccharate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- XDVNRYBLLJRCFU-BTVCFUMJSA-N calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound [Ca].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDVNRYBLLJRCFU-BTVCFUMJSA-N 0.000 description 1
- LNMAXKMUGYXKPJ-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 LNMAXKMUGYXKPJ-UHFFFAOYSA-L 0.000 description 1
- XDYFLIAWYWUSMI-UHFFFAOYSA-L calcium;2,2-dihydroxypropanedioate Chemical compound [Ca+2].[O-]C(=O)C(O)(O)C([O-])=O XDYFLIAWYWUSMI-UHFFFAOYSA-L 0.000 description 1
- DUWUEIXQQZTELD-UHFFFAOYSA-L calcium;2-iodooctadecanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCC(I)C([O-])=O.CCCCCCCCCCCCCCCCC(I)C([O-])=O DUWUEIXQQZTELD-UHFFFAOYSA-L 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 229950008808 caldaret Drugs 0.000 description 1
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229950011546 carabersat Drugs 0.000 description 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- ITMSAWKLJVGBIT-UHFFFAOYSA-N carbocloral Chemical compound CCOC(=O)NC(O)C(Cl)(Cl)Cl ITMSAWKLJVGBIT-UHFFFAOYSA-N 0.000 description 1
- 229950003854 carbocloral Drugs 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical group SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960003395 carboprost Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 229950009357 cargutocin Drugs 0.000 description 1
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
- 229950008393 cariporide Drugs 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- AFSOIHMEOKEZJF-UHFFFAOYSA-N carmoxirole Chemical compound C12=CC(C(=O)O)=CC=C2NC=C1CCCCN(CC=1)CCC=1C1=CC=CC=C1 AFSOIHMEOKEZJF-UHFFFAOYSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229940033631 carrageenan sodium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- 229960002142 cefditoren pivoxil Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229940093528 cetearyl ethylhexanoate Drugs 0.000 description 1
- 229940081620 ceteth-2 Drugs 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 229940115464 ceteth-23 Drugs 0.000 description 1
- GOAZMLKQUGCOPO-UHFFFAOYSA-N cetoxime Chemical compound C=1C=CC=CC=1N(CC(/N)=N/O)CC1=CC=CC=C1 GOAZMLKQUGCOPO-UHFFFAOYSA-N 0.000 description 1
- 229950011200 cetoxime Drugs 0.000 description 1
- FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
- 229950009533 cetraxate Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 description 1
- 229960001314 cevimeline Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- TUESWZZJYCLFNL-DAFODLJHSA-N chembl1301 Chemical compound C1=CC(C(=N)N)=CC=C1\C=C\C1=CC=C(C(N)=N)C=C1O TUESWZZJYCLFNL-DAFODLJHSA-N 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- XMEVHPAGJVLHIG-DXDJYCPMSA-N chembl1950577 Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-DXDJYCPMSA-N 0.000 description 1
- XSRKBFUVSRRJDX-GGZJQHSXSA-N chembl475786 Chemical compound C(/[C@H]1OC[C@@H](CO1)S[C@H](C)[C@](O)(CN1N=CN=C1)C=1C(=CC(F)=CC=1)F)=C\C=C\C1=CC=C(C#N)C=C1F XSRKBFUVSRRJDX-GGZJQHSXSA-N 0.000 description 1
- NPNSVNGQJGRSNR-UHFFFAOYSA-N chembl73193 Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)O)=C(F)C(N(CC(O)=O)C)=C(F)C=1OC(C=1)=CC=CC=1C1=NCCN1C NPNSVNGQJGRSNR-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- RMXVHZFHSKRNJN-UHFFFAOYSA-N chlorourea Chemical compound NC(=O)NCl RMXVHZFHSKRNJN-UHFFFAOYSA-N 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 229950007046 chlorphentermine Drugs 0.000 description 1
- ISZNZKHCRKXXAU-UHFFFAOYSA-N chlorproguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C(Cl)=C1 ISZNZKHCRKXXAU-UHFFFAOYSA-N 0.000 description 1
- 229950000764 chlorproguanil Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960004788 choline alfoscerate Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001020 ciclobendazole Drugs 0.000 description 1
- OXLKOMYHDYVIDM-UHFFFAOYSA-N ciclobendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1CC1 OXLKOMYHDYVIDM-UHFFFAOYSA-N 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 1
- 229960002099 cilansetron Drugs 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RCUDFXMNPQNBDU-VOTSOKGWSA-N cinepazide Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 RCUDFXMNPQNBDU-VOTSOKGWSA-N 0.000 description 1
- 229960004201 cinepazide Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229950003936 cipralisant Drugs 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- YXSLJKQTIDHPOT-LJCJQEJUSA-N cisatracurium Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1[N@+](CCC(=O)OCCCCCOC(=O)CC[N@+]2(C)[C@@H](C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-LJCJQEJUSA-N 0.000 description 1
- 229960000358 cisatracurium Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229950000333 cizolirtine Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229950002020 clemizole Drugs 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229950008441 clofibric acid Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- TZWKUQDQKPYNLL-UHFFFAOYSA-N cloforex Chemical compound CCOC(=O)NC(C)(C)CC1=CC=C(Cl)C=C1 TZWKUQDQKPYNLL-UHFFFAOYSA-N 0.000 description 1
- 229950008294 cloforex Drugs 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- BXVOHUQQUBSHLD-XCTBDMBQSA-N clomocycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(=C(/O)NCO)/C(=O)[C@@]4(O)C(=O)C3=C(O)C2=C1O BXVOHUQQUBSHLD-XCTBDMBQSA-N 0.000 description 1
- 229960004094 clomocycline Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- 229960002544 cloperastine Drugs 0.000 description 1
- HXCXASJHZQXCKK-UHFFFAOYSA-N clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 description 1
- 229950000649 clortermine Drugs 0.000 description 1
- 229960001481 clostebol Drugs 0.000 description 1
- KCZCIYZKSLLNNH-FBPKJDBXSA-N clostebol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1Cl KCZCIYZKSLLNNH-FBPKJDBXSA-N 0.000 description 1
- 229960003864 clotiapine Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- OTGAHJPFNKQGAE-UHFFFAOYSA-N cresatin Chemical compound CC(=O)OC1=CC=CC(C)=C1 OTGAHJPFNKQGAE-UHFFFAOYSA-N 0.000 description 1
- 229960000862 cresatin Drugs 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229950005056 crobenetine Drugs 0.000 description 1
- PEFQQQGFYPMQLH-WFQFKEFWSA-N crotamin Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CC=4NC=NC=4)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C=CC(O)=CC=4)CSSC[C@@H](C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=CC=C1 PEFQQQGFYPMQLH-WFQFKEFWSA-N 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 229960004138 cyclobarbital Drugs 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- 229960003263 cyclopentamine Drugs 0.000 description 1
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical compound CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- HKUCYAHWPVLPFN-UHFFFAOYSA-N dacemazine Chemical compound C1=CC=C2N(C(=O)CN(C)C)C3=CC=CC=C3SC2=C1 HKUCYAHWPVLPFN-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 1
- 229960005217 dapoxetine Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960001610 denatonium benzoate Drugs 0.000 description 1
- FPTOUQZVCUIPHY-UHFFFAOYSA-N denaverine Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC(CC)CC)C1=CC=CC=C1 FPTOUQZVCUIPHY-UHFFFAOYSA-N 0.000 description 1
- 229960003392 denaverine Drugs 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 229950003851 desomorphine Drugs 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- NFHRQQKPEBFUJK-HSZRJFAPSA-N devazepide Chemical compound O=C([C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)N=1)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 NFHRQQKPEBFUJK-HSZRJFAPSA-N 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960003428 dexibuprofen Drugs 0.000 description 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- WMUHBTATSZQNJG-TWOHWVPZSA-N dfa iv Chemical compound C([C@H]1O[C@@](OC2)([C@H]([C@@H]1O)O)CO)O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H]2O1 WMUHBTATSZQNJG-TWOHWVPZSA-N 0.000 description 1
- WMUHBTATSZQNJG-UHFFFAOYSA-N di-D-fructose anhydride IV Natural products C1OC(CO)(C(C2O)O)OC2COC2(CO)C(O)C(O)C1O2 WMUHBTATSZQNJG-UHFFFAOYSA-N 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Chemical group 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- 229960000493 dibrompropamidine Drugs 0.000 description 1
- GMJFVGRUYJHMCO-UHFFFAOYSA-N dibrompropamidine Chemical compound BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br GMJFVGRUYJHMCO-UHFFFAOYSA-N 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- GCFPPDBNEBHYGT-UHFFFAOYSA-N dichlorophenarsine Chemical compound NC1=CC([As](Cl)Cl)=CC=C1O GCFPPDBNEBHYGT-UHFFFAOYSA-N 0.000 description 1
- 229950006869 dichlorophenarsine Drugs 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- 229960005493 difenoxin Drugs 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 229950001733 difloxacin Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 1
- 229960002877 dihydralazine Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- LUZRJRNZXALNLM-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 LUZRJRNZXALNLM-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 229960000465 dihydrotachysterol Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229950010007 dimantine Drugs 0.000 description 1
- NAPSCFZYZVSQHF-UHFFFAOYSA-N dimantine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 description 1
- 229950004655 dimepheptanol Drugs 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000010300 dimethyl dicarbonate Nutrition 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 229960001342 dinoprost Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229910000285 diosmectite Inorganic materials 0.000 description 1
- 229940106018 diosmectite Drugs 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- WBTCZEPSIIFINA-MSFWTACDSA-J dipotassium;antimony(3+);(2r,3r)-2,3-dioxidobutanedioate;trihydrate Chemical compound O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O.[O-]C(=O)[C@H]([O-])[C@@H]([O-])C([O-])=O WBTCZEPSIIFINA-MSFWTACDSA-J 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- LWYLQNWMSGFCOZ-UHFFFAOYSA-L disodium 2,6-bis(propan-2-yl)phenoxymethyl phosphate Chemical compound [Na+].[Na+].CC(C)C1=CC=CC(C(C)C)=C1OCOP([O-])([O-])=O LWYLQNWMSGFCOZ-UHFFFAOYSA-L 0.000 description 1
- ZJBLQBHLLQNTDA-UHFFFAOYSA-L disodium butanedioate dodecane-1-sulfonic acid Chemical compound C(CCC(=O)[O-])(=O)[O-].[Na+].C(CCCCCCCCCCC)S(=O)(=O)O.[Na+] ZJBLQBHLLQNTDA-UHFFFAOYSA-L 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 229940079896 disodium hydrogen citrate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 description 1
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 description 1
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 1
- IIRVGTWONXBBAW-UHFFFAOYSA-M disodium;dioxido(oxo)phosphanium Chemical compound [Na+].[Na+].[O-][P+]([O-])=O IIRVGTWONXBBAW-UHFFFAOYSA-M 0.000 description 1
- BJTHMUJCKBTCFR-UHFFFAOYSA-L disodium;ethane-1,2-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCS([O-])(=O)=O BJTHMUJCKBTCFR-UHFFFAOYSA-L 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960005067 ditazole Drugs 0.000 description 1
- UUCMDZWCRNZCOY-UHFFFAOYSA-N ditazole Chemical compound O1C(N(CCO)CCO)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UUCMDZWCRNZCOY-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940048879 dl tartaric acid Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- TWFQJFPTTMIETC-UHFFFAOYSA-N dodecan-1-amine;hydron;chloride Chemical compound [Cl-].CCCCCCCCCCCC[NH3+] TWFQJFPTTMIETC-UHFFFAOYSA-N 0.000 description 1
- BXWAIGKJAVEJDQ-UHFFFAOYSA-N dodecanoic acid;tetradecanoic acid Chemical compound CCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O BXWAIGKJAVEJDQ-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- HBRNMIYLJIXXEE-UHFFFAOYSA-N dodecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCN HBRNMIYLJIXXEE-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 229950010759 domitroban Drugs 0.000 description 1
- PWTCIBWRMQFJBC-ZEMKZVSASA-N domitroban Chemical compound N([C@H]1[C@H]2CC[C@H](C2)[C@@H]1C\C=C/CCCC(=O)O)S(=O)(=O)C1=CC=CC=C1 PWTCIBWRMQFJBC-ZEMKZVSASA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- SOHCKWZVTCTQBG-UHFFFAOYSA-N donitriptan Chemical compound C1=C2C(CCN)=CNC2=CC=C1OCC(=O)N(CC1)CCN1C1=CC=C(C#N)C=C1 SOHCKWZVTCTQBG-UHFFFAOYSA-N 0.000 description 1
- 229950010344 donitriptan Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960001857 dopexamine Drugs 0.000 description 1
- RYBJORHCUPVNMB-UHFFFAOYSA-N dopexamine Chemical compound C1=C(O)C(O)=CC=C1CCNCCCCCCNCCC1=CC=CC=C1 RYBJORHCUPVNMB-UHFFFAOYSA-N 0.000 description 1
- 229960002955 doxapram Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960004483 doxofylline Drugs 0.000 description 1
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 1
- 229960002084 dronedarone Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 1
- 229960002065 drotaverine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 229960004913 dydrogesterone Drugs 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960003062 eberconazole Drugs 0.000 description 1
- 229950002377 ebrotidine Drugs 0.000 description 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 1
- IWCWQNVIUXZOMJ-MISYRCLQSA-N ecabet Chemical compound OC(=O)[C@@](C)([C@@H]1CC2)CCC[C@]1(C)C1=C2C=C(C(C)C)C(S(O)(=O)=O)=C1 IWCWQNVIUXZOMJ-MISYRCLQSA-N 0.000 description 1
- 229950003246 ecabet Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229940113960 edetate calcium Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003937 efinaconazole Drugs 0.000 description 1
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- VTAARTQTOOYTES-RGDLXGNYSA-N eglumegad Chemical compound OC(=O)[C@]1(N)CC[C@H]2[C@H](C(O)=O)[C@@H]12 VTAARTQTOOYTES-RGDLXGNYSA-N 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 229950002320 elarofiban Drugs 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- FZEXGDDBXLBRTD-SJSKTVLPSA-N eldecalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@H](O)[C@H](OCCCO)[C@@H](O)C1=C FZEXGDDBXLBRTD-SJSKTVLPSA-N 0.000 description 1
- 229950005556 eldecalcitol Drugs 0.000 description 1
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- MZYVOFLIPYDBGD-MLZQUWKJSA-N enalaprilat dihydrate Chemical compound O.O.C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 MZYVOFLIPYDBGD-MLZQUWKJSA-N 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 229940104788 entyvio Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 229960002565 eperisone Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 description 1
- 229960002457 epicillin Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229950002850 eptapirone Drugs 0.000 description 1
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 description 1
- 229960003262 erdosteine Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UJYGDMFEEDNVBF-OGGGUQDZSA-N ergocornine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-OGGGUQDZSA-N 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- FEMINZOAAWPBPP-RHMAUSBNSA-J eritoran tetrasodium Chemical compound [Na+].[Na+].[Na+].[Na+].O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP([O-])([O-])=O)[C@@H](COC)O1 FEMINZOAAWPBPP-RHMAUSBNSA-J 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- TYQXKHPOXXXCTP-CSLYCKPJSA-N erythromycin A 2'-propanoate Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TYQXKHPOXXXCTP-CSLYCKPJSA-N 0.000 description 1
- 229960004213 erythromycin lactobionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 description 1
- 229960003233 eslicarbazepine acetate Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- XIQVNETUBQGFHX-JOCHJYFZSA-N esoxybutynin Chemical compound C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-JOCHJYFZSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- IRVLBORJKFZWMI-JQWIXIFHSA-N etafedrine Chemical compound CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 IRVLBORJKFZWMI-JQWIXIFHSA-N 0.000 description 1
- 229950002456 etafedrine Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- UVTJKLLUVOTSOB-UHFFFAOYSA-N etaqualone Chemical compound CCC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C UVTJKLLUVOTSOB-UHFFFAOYSA-N 0.000 description 1
- 229950010472 etaqualone Drugs 0.000 description 1
- JYRBQCWXZNDERM-XIRDDKMYSA-N etazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(CC)[C@@H](CC)[C@H]1N(C)CC2 JYRBQCWXZNDERM-XIRDDKMYSA-N 0.000 description 1
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 description 1
- 229960001588 ethacridine Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000569 ethoheptazine Drugs 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- RZQNBTMGBODDSK-UWVGGRQHSA-N ethyl (2r)-2-[2-[[(2r)-1-ethoxy-1-oxo-3-sulfanylpropan-2-yl]amino]ethylamino]-3-sulfanylpropanoate Chemical compound CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC RZQNBTMGBODDSK-UWVGGRQHSA-N 0.000 description 1
- SYKQOFCBFHMCJV-UHFFFAOYSA-N ethyl 2-cyano-3-phenylpropanoate Chemical compound CCOC(=O)C(C#N)CC1=CC=CC=C1 SYKQOFCBFHMCJV-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- SBVYURPQULDJTI-UHFFFAOYSA-N ethyl n-[amino-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]methylidene]carbamate Chemical compound C1=CC(C(=N)NC(=O)OCC)=CC=C1OCC1=CC=CC(COC=2C=CC(=CC=2)C(C)(C)C=2C=CC(O)=CC=2)=C1 SBVYURPQULDJTI-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960003817 etifoxine Drugs 0.000 description 1
- IBYCYJFUEJQSMK-UHFFFAOYSA-N etifoxine Chemical compound O1C(NCC)=NC2=CC=C(Cl)C=C2C1(C)C1=CC=CC=C1 IBYCYJFUEJQSMK-UHFFFAOYSA-N 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 229960002941 etonogestrel Drugs 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960004514 etozolin Drugs 0.000 description 1
- ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 description 1
- 229950004912 etrolizumab Drugs 0.000 description 1
- ZXUMUPVQYAFTLF-UHFFFAOYSA-N etryptamine Chemical compound C1=CC=C2C(CC(N)CC)=CNC2=C1 ZXUMUPVQYAFTLF-UHFFFAOYSA-N 0.000 description 1
- 229950005957 etryptamine Drugs 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229950005203 fasidotril Drugs 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001938 fencamfamin Drugs 0.000 description 1
- IKFBPFGUINLYQI-UHFFFAOYSA-N fencamfamin Chemical compound CCNC1C(C2)CCC2C1C1=CC=CC=C1 IKFBPFGUINLYQI-UHFFFAOYSA-N 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- UBAJTZKNDCEGKL-UHFFFAOYSA-N fenoverine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C(=O)CN1CCN(CC=2C=C3OCOC3=CC=2)CC1 UBAJTZKNDCEGKL-UHFFFAOYSA-N 0.000 description 1
- 229960001966 fenoverine Drugs 0.000 description 1
- GFYSWQDCHLWRMQ-UHFFFAOYSA-N fenoxazoline Chemical compound CC(C)C1=CC=CC=C1OCC1=NCCN1 GFYSWQDCHLWRMQ-UHFFFAOYSA-N 0.000 description 1
- 229960004970 fenoxazoline Drugs 0.000 description 1
- IQUFSXIQAFPIMR-UHFFFAOYSA-N fenproporex Chemical compound N#CCCNC(C)CC1=CC=CC=C1 IQUFSXIQAFPIMR-UHFFFAOYSA-N 0.000 description 1
- 229960005231 fenproporex Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229950002909 fentonium bromide Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- WAAPEIZFCHNLKK-PELKAZGASA-N fidarestat Chemical compound C([C@@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-PELKAZGASA-N 0.000 description 1
- 229950007256 fidarestat Drugs 0.000 description 1
- 229950004964 fiduxosin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 1
- 229960002053 flibanserin Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002889 fludeoxyglucose (18f) Drugs 0.000 description 1
- 229960004930 fludiazepam Drugs 0.000 description 1
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960005298 fluindione Drugs 0.000 description 1
- NASXCEITKQITLD-UHFFFAOYSA-N fluindione Chemical compound C1=CC(F)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NASXCEITKQITLD-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960000702 flumequine Drugs 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229950008319 flutropium bromide Drugs 0.000 description 1
- FNUZASGZEHGWQM-RJRMRWARSA-M flutropium bromide Chemical compound C[N@+](CCF)([C@H](CC1)C2)[C@@H]1C[C@H]2OC(C(C1=CC=CC=C1)(C1=CC=CC=C1)O)=O.[Br-] FNUZASGZEHGWQM-RJRMRWARSA-M 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229960000693 fosphenytoin Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
- 229950006783 fudosteine Drugs 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000003008 fumonisin Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- TUWCZRFHNIOVTC-UHFFFAOYSA-N fuzapladib Chemical compound CCS(=O)(=O)NC1=NC=C(C(F)(F)F)C=C1NC(=O)C1CCCCC1 TUWCZRFHNIOVTC-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 229950004346 gaboxadol Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 229950006567 ganaxolone Drugs 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- SDIFKXLSGXCGEN-WJUBNSBASA-L gantacurium chloride Chemical compound [Cl-].[Cl-].C1([C@H]2C3=CC(OC)=C(OC)C=C3CC[N@+]2(C)CCCOC(=O)/C=C(\Cl)C(=O)OCCC[N@@+]2(CCC=3C=C(C(=CC=3[C@H]2CC=2C=C(OC)C(OC)=C(OC)C=2)OC)OC)C)=CC(OC)=C(OC)C(OC)=C1 SDIFKXLSGXCGEN-WJUBNSBASA-L 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229960004761 gestrinone Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940074052 glyceryl isostearate Drugs 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940116338 glyceryl ricinoleate Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- AZMMUMQYPBKXHS-UHFFFAOYSA-N gold sodium Chemical compound [Na].[Au] AZMMUMQYPBKXHS-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 229950000958 halofenate Drugs 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229950002502 haloxazolam Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 description 1
- SLKWROUNLHVIIQ-UHFFFAOYSA-N hexachlorocyclohexa-2,5-dien-1-one Chemical compound ClC1=C(Cl)C(Cl)(Cl)C(Cl)=C(Cl)C1=O SLKWROUNLHVIIQ-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Chemical group SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- NYQCKFLLTCINSJ-UHFFFAOYSA-N hydron;3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1h-pyridazin-6-one;chloride Chemical compound Cl.N1C(=O)CCC(C=2C=CC(NC=3C=CN=CC=3)=CC=2)=N1 NYQCKFLLTCINSJ-UHFFFAOYSA-N 0.000 description 1
- NXNSCUZKMVYAJQ-UHFFFAOYSA-N hydron;9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(CCCNC(C)C)(C(N)=O)C3=CC=CC=C3C2=C1 NXNSCUZKMVYAJQ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- QZQSENRWYLQIPC-JPVHLGFFSA-N hydroxyestrone diacetate Chemical compound C1CC2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@@H](OC(=O)C)C(=O)[C@@]1(C)CC2 QZQSENRWYLQIPC-JPVHLGFFSA-N 0.000 description 1
- 229960003398 hydroxyestrone diacetate Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- WTJBNMUWRKPFRS-UHFFFAOYSA-N hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 description 1
- 229950008496 hydroxypethidine Drugs 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 229950005911 hydroxystilbamidine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- NFMHSPWHNQRFNR-UHFFFAOYSA-N hyponitrous acid Chemical compound ON=NO NFMHSPWHNQRFNR-UHFFFAOYSA-N 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- FVRWRGBTEHAPDI-UHFFFAOYSA-N ibuprofen guaiacol ester Chemical compound COC1=CC=CC=C1OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 FVRWRGBTEHAPDI-UHFFFAOYSA-N 0.000 description 1
- 229960004053 ibutilide Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229950003909 iguratimod Drugs 0.000 description 1
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 description 1
- 229950008491 ilaprazole Drugs 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- XJYNBZQTAZDMHZ-UHFFFAOYSA-N imidacrine Chemical compound O.Cl.Cl.O=C1C2=CC(O)=CC=C2N2C=NC3=CC=C(NCCN(CC)CC)C1=C32 XJYNBZQTAZDMHZ-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960003441 imipramine oxide Drugs 0.000 description 1
- QZIQORUGXBPDSU-UHFFFAOYSA-N imipramine oxide Chemical compound C1CC2=CC=CC=C2N(CCC[N+](C)([O-])C)C2=CC=CC=C21 QZIQORUGXBPDSU-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- WXEMWBBXVXHEPU-XNPJUPKFSA-L imisopasem manganese Chemical compound Cl[Mn]Cl.N([C@@H]1CCCC[C@H]1NC1)CCN[C@@H]2CCCC[C@H]2NCC2=CC=CC1=N2 WXEMWBBXVXHEPU-XNPJUPKFSA-L 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- MGSPDRWOUCPKNZ-UHFFFAOYSA-N imolamine Chemical compound O1C(=N)N(CCN(CC)CC)C(C=2C=CC=CC=2)=N1 MGSPDRWOUCPKNZ-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- MNLULKBKWKTZPE-UHFFFAOYSA-N indantadol Chemical compound C1=CC=C2CC(NCC(=O)N)CC2=C1 MNLULKBKWKTZPE-UHFFFAOYSA-N 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 description 1
- 229950007467 indisetron Drugs 0.000 description 1
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 description 1
- 229960003422 indobufen Drugs 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- VJOVAKSZILJDBB-UHFFFAOYSA-N iodol Chemical compound IC=1NC(I)=C(I)C=1I VJOVAKSZILJDBB-UHFFFAOYSA-N 0.000 description 1
- 229950000077 iodol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229960002979 iopanoic acid Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- 229960005490 ipidacrine Drugs 0.000 description 1
- 229940029409 ipodate Drugs 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 108010084684 iron protein succinylate Proteins 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 229960000798 isepamicin Drugs 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- 229960003046 isometheptene Drugs 0.000 description 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 description 1
- 229950000248 isonixin Drugs 0.000 description 1
- WJDDCFNFNAHLAF-UHFFFAOYSA-N isonixin Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC=CNC1=O WJDDCFNFNAHLAF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229950005222 israpafant Drugs 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 229950007654 itasetron Drugs 0.000 description 1
- 229950003818 itolizumab Drugs 0.000 description 1
- 229960005302 itopride Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229950001743 itriglumide Drugs 0.000 description 1
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 description 1
- 229960003825 ivabradine Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- KCWGETCFOVJEPI-UHFFFAOYSA-N jtv-519 Chemical compound C1C2=CC(OC)=CC=C2SCCN1C(=O)CCN(CC1)CCC1CC1=CC=CC=C1 KCWGETCFOVJEPI-UHFFFAOYSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 229960004423 ketazolam Drugs 0.000 description 1
- PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010075606 kynostatin 272 Proteins 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960001159 lactitol monohydrate Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229950010163 lanoconazole Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 1
- 229960001633 lanthanum carbonate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229940057905 laureth-3 Drugs 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- 229950005862 lazabemide Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108010030727 lens intermediate filament proteins Proteins 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
- 229960000692 levosimendan Drugs 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- RRHJHSBDJDZUGL-UHFFFAOYSA-N lidamidine Chemical compound CN=C(N)NC(=O)NC1=C(C)C=CC=C1C RRHJHSBDJDZUGL-UHFFFAOYSA-N 0.000 description 1
- 229960005045 lidamidine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 description 1
- 229950009365 limaprost Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- SFIHQZFZMWZOJV-HZJYTTRNSA-N linoleamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(N)=O SFIHQZFZMWZOJV-HZJYTTRNSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229950010148 liranaftate Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 229960004305 lodoxamide Drugs 0.000 description 1
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 lofentanil Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229950007692 lomerizine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- KXVSBTJVTUVNPM-UKPNQBOSSA-N loperamide oxide Chemical compound C1([C@]2(O)CC[N@@+](CC2)([O-])CCC(C(=O)N(C)C)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C(Cl)C=C1 KXVSBTJVTUVNPM-UKPNQBOSSA-N 0.000 description 1
- 229960003954 loperamide oxide Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- 229950010501 lotrafiban Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 1
- 229960000345 lubiprostone Drugs 0.000 description 1
- FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
- 229950005239 lucanthone Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- RKHCTAKUYDTFHE-QMMMGPOBSA-N ly-156,735 Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2[C@@H](C)CNC(C)=O RKHCTAKUYDTFHE-QMMMGPOBSA-N 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 108700003825 lysine(6)-doxorubicin LHRH Proteins 0.000 description 1
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 description 1
- 229950001846 mabuprofen Drugs 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- YUZJJFWCXJDFOQ-UHFFFAOYSA-K manganese(3+);2-methoxy-6-[2-[(3-methoxy-2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;chloride Chemical compound [Cl-].[Mn+3].COC1=CC=CC(C=NCCN=CC=2C(=C(OC)C=CC=2)[O-])=C1[O-] YUZJJFWCXJDFOQ-UHFFFAOYSA-K 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- KJFBVJALEQWJBS-XUXIUFHCSA-N maribavir Chemical compound CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O KJFBVJALEQWJBS-XUXIUFHCSA-N 0.000 description 1
- 229960003762 maribavir Drugs 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
- 229960002137 melagatran Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- 229960000906 mephenytoin Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229940075610 mercuric cyanide Drugs 0.000 description 1
- PCWIWQHAGMGLFA-CVBJKYQLSA-L mercury(2+);(z)-octadec-9-enoate Chemical compound [Hg+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O PCWIWQHAGMGLFA-CVBJKYQLSA-L 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- YXVZOBVWVRFPTE-UHFFFAOYSA-N metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 description 1
- 229950006180 metapramine Drugs 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
- 229950009131 metazocine Drugs 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- IORZNYNSOYOQJI-UHFFFAOYSA-N methanesulfonic acid;2-piperidin-1-ylethanol Chemical compound CS(O)(=O)=O.OCCN1CCCCC1 IORZNYNSOYOQJI-UHFFFAOYSA-N 0.000 description 1
- VRWLBMGRSLQKSU-UHFFFAOYSA-N methanol;pyridine Chemical compound OC.C1=CC=NC=C1 VRWLBMGRSLQKSU-UHFFFAOYSA-N 0.000 description 1
- PYWBJEDBESDHNP-UHFFFAOYSA-N methestrol Chemical compound C=1C=C(O)C(C)=CC=1C(CC)C(CC)C1=CC=C(O)C(C)=C1 PYWBJEDBESDHNP-UHFFFAOYSA-N 0.000 description 1
- MMHHPKCJJIFLBQ-QFIPXVFZSA-N methyl (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoate Chemical compound N([C@@H](CC=1C=CC(=CC=1)N1C(C2=CC(=CC=C2N(C)C1=O)N(C)C)=O)C(=O)OC)C(=O)C1=C(Cl)C=CC=C1Cl MMHHPKCJJIFLBQ-QFIPXVFZSA-N 0.000 description 1
- FLEVIENZILQUKB-DMJMAAGCSA-N methyl 4-[3-[6-amino-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CCC3CCC(CC3)C(=O)OC)=NC(N)=C2N=C1 FLEVIENZILQUKB-DMJMAAGCSA-N 0.000 description 1
- KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 1
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960002238 methylpentynol Drugs 0.000 description 1
- QXLPXWSKPNOQLE-UHFFFAOYSA-N methylpentynol Chemical compound CCC(C)(O)C#C QXLPXWSKPNOQLE-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- XGZOMURMPLSSKQ-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N(CCO)CCO XGZOMURMPLSSKQ-UHFFFAOYSA-N 0.000 description 1
- ARGDYOIRHYLIMT-UHFFFAOYSA-N n,n-dichloro-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(Cl)Cl)C=C1 ARGDYOIRHYLIMT-UHFFFAOYSA-N 0.000 description 1
- DCMJBKFKXGPPMT-OAHLLOKOSA-N n,n-dimethyl-2-[(r)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C1([C@H](OCCN(C)C)C=2C=CC=CC=2)=CC=NN1C DCMJBKFKXGPPMT-OAHLLOKOSA-N 0.000 description 1
- RQTZMTMTBWAQAI-UHFFFAOYSA-N n,n-dimethyl-2-[5-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-3-yl]ethanamine Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C1=CCN(C)CC1 RQTZMTMTBWAQAI-UHFFFAOYSA-N 0.000 description 1
- FSDOTMQXIKBFKJ-UHFFFAOYSA-N n-(2,5-dichloropyridin-3-yl)-8-methoxyquinoline-5-carboxamide Chemical compound C12=CC=CN=C2C(OC)=CC=C1C(=O)NC1=CC(Cl)=CN=C1Cl FSDOTMQXIKBFKJ-UHFFFAOYSA-N 0.000 description 1
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- OCKHRKSTDPOHEN-BQYQJAHWSA-N n-(4-methoxyphenyl)sulfonyl-n-[2-[(e)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C)=O)C1=CC=CC=C1\C=C\C1=CC=[N+]([O-])C=C1 OCKHRKSTDPOHEN-BQYQJAHWSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IHDRUIHIJWCTIY-JOCHJYFZSA-N n-[(2r)-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(C)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 IHDRUIHIJWCTIY-JOCHJYFZSA-N 0.000 description 1
- BPLYVSYSBPLDOA-GYOJGHLZSA-N n-[(2r,3r)-1,3-dihydroxyoctadecan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-GYOJGHLZSA-N 0.000 description 1
- RHJLQMVZXQKJKB-FPHSVDBKSA-N n-[(2s)-1-[[(e,3s)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)N[C@H](C(=O)N[C@@H](CCC=1C=CC=CC=1)\C=C\S(=O)(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 RHJLQMVZXQKJKB-FPHSVDBKSA-N 0.000 description 1
- RCLXAPJEFHPYEG-ZWKOTPCHSA-N n-[(3r,4s)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide Chemical compound N([C@@H]1[C@@H](O)C(C)(C)OC2=CC=C(C=C21)C(=O)C)C(=O)C1=CC=C(F)C=C1 RCLXAPJEFHPYEG-ZWKOTPCHSA-N 0.000 description 1
- LZGACSIEPSVAQK-UHFFFAOYSA-N n-[2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)naphthalen-1-yl]acetamide Chemical compound C1=CC=C2C(NC(=O)C)=C(C(O)(C(F)(F)F)C(F)(F)F)C=CC2=C1 LZGACSIEPSVAQK-UHFFFAOYSA-N 0.000 description 1
- KWQWWUXRGIIBAS-UHFFFAOYSA-N n-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 KWQWWUXRGIIBAS-UHFFFAOYSA-N 0.000 description 1
- AGWYFDPFBGWOSR-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]octadecanamide;2,3-dihydroxypropyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO.CCCCCCCCCCCCCCCCCC(=O)NCCN(CC)CC AGWYFDPFBGWOSR-UHFFFAOYSA-N 0.000 description 1
- YZHGXYNLMHGNJZ-UHFFFAOYSA-N n-[2-[4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)piperidin-1-yl]ethyl]-1-formylpiperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1CN(C=O)CCC1C(=O)NCCN(CC1)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 YZHGXYNLMHGNJZ-UHFFFAOYSA-N 0.000 description 1
- ZOQHJQODUHVVEV-UHFFFAOYSA-N n-[3-amino-4-[2-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1N ZOQHJQODUHVVEV-UHFFFAOYSA-N 0.000 description 1
- XLLXHGCGAQJLLK-AWEZNQCLSA-N n-[[(5s)-3-[3-fluoro-4-[6-(1-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=NC(=CC=2)C=2N(N=NN=2)C)C(F)=C1 XLLXHGCGAQJLLK-AWEZNQCLSA-N 0.000 description 1
- ZHDORMMHAKXTPT-UHFFFAOYSA-N n-benzoylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=O)C1=CC=CC=C1 ZHDORMMHAKXTPT-UHFFFAOYSA-N 0.000 description 1
- KGXPDNOBLLACKL-BWLGBDCWSA-N n-benzyl-2-[(3z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydron;chloride Chemical compound Cl.C12=CC(F)=CC=C2\C(=C/C=2C=CN=CC=2)C(C)=C1CC(=O)NCC1=CC=CC=C1 KGXPDNOBLLACKL-BWLGBDCWSA-N 0.000 description 1
- NBMBIEOUVBHEBM-UHFFFAOYSA-N n-benzyl-n-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide Chemical compound C12=NC(C=3C=CC=CC=3)=NC=C2N(C)C(=O)N1CC(=O)N(CC)CC1=CC=CC=C1 NBMBIEOUVBHEBM-UHFFFAOYSA-N 0.000 description 1
- QRZLMPANXOGORV-UHFFFAOYSA-N n-cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine Chemical compound N=1C2=CC=CC=C2N2C(C)=CN=C2C=1NC1CCCC1 QRZLMPANXOGORV-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- VQVCFYIDCWPSNE-UHFFFAOYSA-N n-methyl-3-[(2-naphthalen-2-ylacetyl)amino]benzamide Chemical compound CNC(=O)C1=CC=CC(NC(=O)CC=2C=C3C=CC=CC3=CC=2)=C1 VQVCFYIDCWPSNE-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CVRCFLFEGNKMEC-UHFFFAOYSA-N naphthalen-1-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC2=CC=CC=C12 CVRCFLFEGNKMEC-UHFFFAOYSA-N 0.000 description 1
- ZBJVLWIYKOAYQH-UHFFFAOYSA-N naphthalen-2-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=C(C=CC=C2)C2=C1 ZBJVLWIYKOAYQH-UHFFFAOYSA-N 0.000 description 1
- RTXHNOBSQMHTSB-UHFFFAOYSA-N naphthalen-2-yl 2-hydroxypropanoate Chemical compound C1=CC=CC2=CC(OC(=O)C(O)C)=CC=C21 RTXHNOBSQMHTSB-UHFFFAOYSA-N 0.000 description 1
- DWJIJRSTYFPKGD-UHFFFAOYSA-N naphthalen-2-yl benzoate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=O)C1=CC=CC=C1 DWJIJRSTYFPKGD-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960002888 oxitriptan Drugs 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- AFSYRVDDZGJTIL-UHFFFAOYSA-N oxydibutanol Chemical compound CC(O)CCOCCC(C)O AFSYRVDDZGJTIL-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229950005157 peficitinib Drugs 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- HSCXJVOGIGDDMR-UHFFFAOYSA-I pentasodium [oxido(phosphonatooxy)phosphoryl] phosphate hydrate Chemical compound [O-]P([O-])(=O)OP(=O)([O-])OP(=O)([O-])[O-].O.[Na+].[Na+].[Na+].[Na+].[Na+] HSCXJVOGIGDDMR-UHFFFAOYSA-I 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- DAFOCGYVTAOKAJ-UHFFFAOYSA-N phenibut Chemical compound OC(=O)CC(CN)C1=CC=CC=C1 DAFOCGYVTAOKAJ-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- XZGOQALCCBZAKK-UHFFFAOYSA-N piperidine hexahydrate Chemical compound O.O.O.O.O.O.N1CCCCC1 XZGOQALCCBZAKK-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- BFZNCPXNOGIELB-UHFFFAOYSA-N propan-2-yl 10-[5,6-dihexyl-2-(8-oxo-8-propan-2-yloxyoctyl)cyclohex-3-en-1-yl]dec-9-enoate Chemical compound CCCCCCC1C=CC(CCCCCCCC(=O)OC(C)C)C(C=CCCCCCCCC(=O)OC(C)C)C1CCCCCC BFZNCPXNOGIELB-UHFFFAOYSA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- INCUNNRDSKWZKZ-UHFFFAOYSA-N pyridine-2-carboxylic acid;hydrobromide Chemical compound Br.OC(=O)C1=CC=CC=N1 INCUNNRDSKWZKZ-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- SPVXKVOXSXTJOY-UHFFFAOYSA-O selenonium Chemical compound [SeH3+] SPVXKVOXSXTJOY-UHFFFAOYSA-O 0.000 description 1
- SCTZUZTYRMOMKT-UHFFFAOYSA-N senicapoc Chemical compound C=1C=C(F)C=CC=1C(C=1C=CC(F)=CC=1)(C(=O)N)C1=CC=CC=C1 SCTZUZTYRMOMKT-UHFFFAOYSA-N 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- SDUIIRKPTNAXJI-UHFFFAOYSA-M sodium 2-hydroxypropan-2-yl sulfate Chemical compound [Na+].CC(C)(O)OS([O-])(=O)=O SDUIIRKPTNAXJI-UHFFFAOYSA-M 0.000 description 1
- 229940080299 sodium 2-naphthalenesulfonate Drugs 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940045640 sodium aminobenzoate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- JWAALJQUMOTSLS-UHFFFAOYSA-J sodium bis[(2-sulfanylacetyl)oxy]stibanyl 2-sulfanylacetate 2-sulfanylacetate Chemical compound [Na+].[Sb+3].[O-]C(=O)CS.[O-]C(=O)CS.[O-]C(=O)CS.[O-]C(=O)CS JWAALJQUMOTSLS-UHFFFAOYSA-J 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940076133 sodium carbonate monohydrate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080274 sodium cholesteryl sulfate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229960005076 sodium hypochlorite Drugs 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940083599 sodium iodide Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229940001516 sodium nitrate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940075562 sodium phosphate dihydrate Drugs 0.000 description 1
- 229940045919 sodium polymetaphosphate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- FHLZQVLLGNTMTH-UHFFFAOYSA-M sodium pyrrolidin-2-one formate Chemical compound C(=O)[O-].[Na+].N1C(CCC1)=O FHLZQVLLGNTMTH-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- ZBTUYCUNQBRXOR-UHFFFAOYSA-L sodium succinate hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O ZBTUYCUNQBRXOR-UHFFFAOYSA-L 0.000 description 1
- 229940074453 sodium succinate hexahydrate Drugs 0.000 description 1
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ICSAXRANXQSPQP-VUKDEKJYSA-M sodium;(5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound [Na+].S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 ICSAXRANXQSPQP-VUKDEKJYSA-M 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- UWSAIOMORQUEHN-UHFFFAOYSA-L sodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate;iron(5+) Chemical compound [Na+].[Fe+5].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O UWSAIOMORQUEHN-UHFFFAOYSA-L 0.000 description 1
- GKDIMGQSBSDJNC-UHFFFAOYSA-M sodium;2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoate Chemical compound [Na+].C1=CC=C(OC=2C(=CC=CC=2)C([O-])=O)C(CCC)=C1OCCCOC(C(=C1)CC)=CC(O)=C1C1=CC=C(F)C=C1 GKDIMGQSBSDJNC-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- XETSAYZRDCRPJY-UHFFFAOYSA-M sodium;4-aminobenzoate Chemical compound [Na+].NC1=CC=C(C([O-])=O)C=C1 XETSAYZRDCRPJY-UHFFFAOYSA-M 0.000 description 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 1
- LMPVQXVJTZWENW-KPNWGBFJSA-M sodium;[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].C1C=C2C[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 LMPVQXVJTZWENW-KPNWGBFJSA-M 0.000 description 1
- YWAFNFGRBBBSPD-OCMLZEEQSA-M sodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-OCMLZEEQSA-M 0.000 description 1
- RBBWNXJFTBCLKT-UHFFFAOYSA-M sodium;ethanethioate Chemical compound [Na+].CC([S-])=O RBBWNXJFTBCLKT-UHFFFAOYSA-M 0.000 description 1
- YWPOLRBWRRKLMW-UHFFFAOYSA-M sodium;naphthalene-2-sulfonate Chemical compound [Na+].C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 YWPOLRBWRRKLMW-UHFFFAOYSA-M 0.000 description 1
- PANBYUAFMMOFOV-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [Na].OS(O)(=O)=O PANBYUAFMMOFOV-UHFFFAOYSA-N 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940094938 stannous 2-ethylhexanoate Drugs 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 1
- KJVQYDYPDFFJMP-UHFFFAOYSA-N sulfamethylthiazole Chemical compound CC1=CSC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 KJVQYDYPDFFJMP-UHFFFAOYSA-N 0.000 description 1
- 229950005939 sulfamethylthiazole Drugs 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- BVPDYEMZSMSMSB-UHFFFAOYSA-N sulfamoyl acetate Chemical compound CC(=O)OS(N)(=O)=O BVPDYEMZSMSMSB-UHFFFAOYSA-N 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- ZXFRFPSZAKNPQQ-YTWAJWBKSA-N tezampanel Chemical compound C([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)O)CC=1N=NNN=1 ZXFRFPSZAKNPQQ-YTWAJWBKSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000007970 thio esters Chemical group 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- ZHAKYGFJVGCOAE-UHFFFAOYSA-N topixantrone Chemical compound OCCNCCN1N=C2C3=CN=CC=C3C(=O)C3=C2C1=CC=C3NCCN(C)C ZHAKYGFJVGCOAE-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- AMFGTOFWMRQMEM-UHFFFAOYSA-N triazophos Chemical compound N1=C(OP(=S)(OCC)OCC)N=CN1C1=CC=CC=C1 AMFGTOFWMRQMEM-UHFFFAOYSA-N 0.000 description 1
- QKHROXOPRBWBDD-UHFFFAOYSA-N tribromometacresol Chemical compound CC1=C(Br)C=C(Br)C(O)=C1Br QKHROXOPRBWBDD-UHFFFAOYSA-N 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229940057400 trihydroxystearin Drugs 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- GVPDNFYOFKBFEN-UHFFFAOYSA-N trimethyl(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](C)(C)C GVPDNFYOFKBFEN-UHFFFAOYSA-N 0.000 description 1
- 229940113164 trimyristin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- ODHXBMXNKOYIBV-UHFFFAOYSA-N triphenylamine Chemical compound C1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 ODHXBMXNKOYIBV-UHFFFAOYSA-N 0.000 description 1
- NRHFWOJROOQKBK-UHFFFAOYSA-N triphenyltin;hydrate Chemical compound O.C1=CC=CC=C1[Sn](C=1C=CC=CC=1)C1=CC=CC=C1 NRHFWOJROOQKBK-UHFFFAOYSA-N 0.000 description 1
- FYZXEMANQYHCFX-UHFFFAOYSA-K tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [K+].[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O FYZXEMANQYHCFX-UHFFFAOYSA-K 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 description 1
- NCPXQVVMIXIKTN-UHFFFAOYSA-N trisodium;phosphite Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])[O-] NCPXQVVMIXIKTN-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229950008737 vadimezan Drugs 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229950010644 vidofludimus Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本發明特徵為氯硝柳胺(niclosamide)化合物(或其醫藥學上可接受之鹽及/或共晶體，例如氯硝柳胺)，其具有一或多種性質，包括(但不限於)特定純度(例如化學純度大於約99.0%)及特定粒度(例如特定粒度分佈及/或特定粒度範圍及/或比表面積範圍)。在一個態樣中，本文所述之氯硝柳胺化合物(例如氯硝柳胺)可形成適用於經口投與之組合物、劑型(例如單位劑型)及其類似物之一部分。本發明特徵亦為製造及使用其之方法。
Description
本發明之特徵在於具有包括但不限於特定純度(例如，化學純度大於約99.0%)或特定粒度(例如，特定粒度分佈及/或特定粒度範圍及/或比表面積範圍)之一或多種特性的氯硝柳胺(niclosamide)化合物(或其醫藥學上可接受之鹽及/或共晶體，例如氯硝柳胺)。在一個態樣中，本文所述之氯硝柳胺化合物(例如氯硝柳胺)可形成適用於經口投與之組合物、劑型(例如單位劑型)及其類似物之一部分。本發明之特徵亦在於製造及使用其之方法。
潰瘍性結腸炎(UC)及克羅恩氏病(Crohn's disease，CD)為人類之主要慢性發炎性腸病(IBD)。此等病症在本質上為自體免疫的且在不存在感染之情況下發生。IBD影響多達2,000,000美國人(每年增加約15%)且其與不可接受之較高發病率及死亡率相關。IBD亦為美國醫療保健系統之顯著負擔，因為最有效的治療為非常昂貴的生物藥物。
IBD作為由環境刺激、微生物因子及腸道免疫系統之間的複雜相互作用介導之基因敏感個體的不適當免疫反應之結果而出現。IBD之標誌由直接或經由釋放可溶性促炎性介體介導胃腸組織損傷之過度的免疫反應表示。
T細胞為一類浸潤腸道黏膜之免疫細胞，且為IBD中胃腸組織損傷之關鍵驅動因素。此等細胞在腸道黏膜中保持且積聚，因為在IBD之情形下，旨在審查或消除經活化T細胞之正常生理機制為無效的。雖然並未全面闡明IBD中T細胞積聚之確切基礎，但認為胃腸組織內發炎部位處之微生物刺激以及細胞介素環境之慢性活化為重要的。不論此等細胞如何持續，增強腸道黏膜中之T細胞死亡與IBD及藉由殺死腸道中之病原性T細胞而最有效地管理IBD功能之藥物的消退有關(部分)。
儘管不同形式之IBD展現出病理生理學及臨床差異，但用以管理IBD之治療方法共用許多共同要素。IBD之醫療管理在很大程度上係經驗性的，採用消炎劑或免疫抑制藥物。使用柳基偶氮磺胺吡啶及5-胺基柳酸來治療輕度IBD，且若能實現疾病緩解，則作為維持療法。皮質類固醇用於患有中度至重度疾病之患者中。然而，臨床緩解僅可在約60%之患者中實現，且此等患者中僅有約一半在停止治療之後保持緩解。此最後一點為顯著的，因為長期使用皮質類固醇具有嚴重副作用之顯著風險。
免疫抑制藥物亦可用於治療中度至重度IBD病例，通常作為類固醇療法之替代方案。然而，免疫抑制藥物(例如硫唑嘌呤)通常無法確保控制症狀，且治療伴隨有許多禁忌症及嚴重副作用。
通常在治療IBD中展現出最佳功效的藥物為全身性投與(經由注射或輸注)阻斷TNF-α(一種在所有形式IBD (例如UC、CD、移植物抗宿主病、乳糜瀉、醫原性結腸炎(諸如檢查點抑制劑誘發型)等)期間過度產生之促炎性細胞介素)的單株抗體。在IBD之情形下降低TNF-α含量具有兩種結果。第一，作為發炎性細胞介素，TNF-α介導組織損傷。其次，較高含量之TNF-α幫助致病T細胞存活且阻斷TNF-α活性最終引起T細胞死亡。實際上，藉由抗TNF-α藥物(如英利昔單抗(infliximab))誘導細胞死亡可預測患者之臨床改進。
儘管有效，但使用抗TNF-α藥物與包括潛在病原體之再活化、過敏現象、癌症及自體抗體之形成的嚴重全身性副作用相關。一些患者固有地對抗TNF-α藥物具有抗性且隨時間變化，所有展現出反應的患者之幾乎一半出現耐藥性。
根據前述內容，顯而易見，需要相比標準照護更有效、毒性更低、更便宜且更方便地投與之新穎藥物來治療IBD。
氯硝柳胺(5-氯-N-(2-氯-4-硝基苯基)-2-氫苯甲醯胺)為鹵化柳醯胺苯，其屬於一組被稱為驅蟲劑之藥物。驅蟲劑為用於治療蠕蟲感染之藥物。使用具有較低全身性生物可用性及極佳安全概況之氯硝柳胺來治療闊節裂頭絛蟲(broad/fish tapeworm)、短小絛蟲(dwarf tapeworm)及牛肉絛蟲(beef tapeworm)感染。咸信，氯硝柳胺抑制絛蟲(cestode/tapeworm)之粒線體中的氧化磷酸化且刺激腺苷三磷酸酶活性，活體外及活體內兩者殺死絛蟲之頭節及近心骨段(參見Li, Y.等人Cancer Lett
.2014 349
, 8-14)。
經口投與在藥物投與之較佳途徑中，因為此途徑對於患者而言通常為方便且可接受的。在此投與類型中，原料藥通常需要經由至少一個膜吸收。在原料藥為固體口服劑型之一部分的情況下，原料藥之吸收通常在固體口服劑型溶解後發生。以上有時可能對藥物藥物動力學具有相當大的影響且可能造成實際吸收的原料藥之量減少。
本發明之特徵在於具有包括但不限於特定純度(例如，化學純度大於約99.0%)或特定粒度(例如，特定粒度分佈及/或特定粒度範圍及/或比表面積範圍)之一或多種特性的氯硝柳胺化合物(或其醫藥學上可接受之鹽及/或共晶體，例如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)。在一個態樣中，本文所述之氯硝柳胺化合物(例如氯硝柳胺)可形成適用於經口投與之組合物、劑型(例如單位劑型)及其類似物之一部分。有利地且出乎意料地，向個體投與(例如經口投與)本文所述之粒度減小的氯硝柳胺化合物(例如氯硝柳胺)提供個體之相對較高的結腸暴露。因而，本文所述之氯硝柳胺化合物(例如，氯硝柳胺)適用於治療多種胃腸道(「GI」)相關病症，例如發炎性腸病(例如，潰瘍性結腸炎及克羅恩氏病)。本發明之特徵亦在於製造及使用氯硝柳胺化合物之方法。
在一個態樣中，本發明之特徵在於高純度氯硝柳胺化合物或其醫藥學上可接受之鹽。
在另一態樣中，本發明之特徵在於一種高純度氯硝柳胺或其醫藥學上可接受之鹽：
(氯硝柳胺)。
在一些實施例中，高純度氯硝柳胺化合物(例如氯硝柳胺)為適用於例如製備粒度範圍減小(例如藉由量測粒度分佈所確定)之氯硝柳胺化合物(例如氯硝柳胺)的起始物質。
在一個態樣中，本發明之特徵在於粒度減小(例如粒度範圍減小、粒度分佈減小)的氯硝柳胺化合物或其醫藥學上可接受之鹽。
在另一態樣中，本發明之特徵在於粒度減小(例如粒度範圍減小、粒度分佈減小)的氯硝柳胺或其醫藥學上可接受之鹽：
(氯硝柳胺)。
在一個態樣中，本發明之特徵在於粒度減小(例如粒度範圍減小、粒度分佈減小)的高純度氯硝柳胺化合物或其醫藥學上可接受之鹽。
在另一態樣中，本發明之特徵在於粒度減小(例如粒度範圍減小、粒度分佈減小)的高純度氯硝柳胺或其醫藥學上可接受之鹽：
(氯硝柳胺)。
在另一態樣中，本發明之特徵在於一種共晶體，其包括氯硝柳胺化合物(例如，具有本文所述之特性中的任何一或多者的氯硝柳胺)或其醫藥學上可接受之鹽及醫藥學上可接受之共形成物。在一些實施例中，共晶體具有如本文任何地方所述之減小的粒度(例如，對於氯硝柳胺化合物，共晶體本身可減小至具有本文所述之減小的粒度範圍及/或減小的粒度分佈)。
共形成物之非限制性實例包括神經鞘胺醇1-磷酸(S1P)受體調節劑(例如依托西莫德(etrasimod)或奧札莫德(ozanimod))；類固醇消炎劑(例如倍氯米松(beclomethasone)17或布地奈德(budesonide))；非類固醇消炎劑(例如5-ASA)；受體相互作用蛋白質激酶1 (RIPK1)抑制劑(例如GSK2982772)；EP4調節劑(例如KAG-308)；鐸(toll)樣受體(例如TLR4、TLR9)調節劑(例如，JKB-122、庫比莫德(cobitolimod))；詹納斯(Janus)激酶(JAK)抑制劑(例如TD-1473、托法替尼(tofacitinib)、優帕替尼(upadacitinib)、非戈替尼(filgotinib)、PF-06651600及PF-06700841)；羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑(例如BT-11)；磷脂醯膽鹼(例如LT-02)；整合素(例如，α4整合素)調節劑(例如AJM-300 (卡羅格拉斯))；Smad7調節劑(例如蒙格森)；磷酸二酯酶4 (PDE4)調節劑(例如阿普斯特(apremilast))；腫瘤進展基因座2 (TPL2)抑制劑(例如GS-4875)；酪胺酸激酶2 (TYK2)抑制劑(例如BMS-986165、PF-06700841及PF-06826647)；及TEC激酶抑制劑(例如PF-06651600)。
本文所揭示及主張的標的物部分地基於以下發現：可將氯硝柳胺純化至超過現有純度基準之含量，例如含有相對較低量之常見雜質，諸如以下中之一或多者：5-氯-柳酸、2-氯-4硝基-苯胺及水合氯硝柳胺固體形式。在一些實施例中，存在相對較低量之2-氯-4硝基-苯胺(其已知有時展現出突變特性)。
本文所揭示及主張的標的物部分地基於以下驚人發現：減少氯硝柳胺之粒度使得結腸組織中氯硝柳胺的局部暴露顯著增加。舉例而言，發現直腸投與粒度分佈D(0.9)為約5 μm之氯硝柳胺使得結腸組織中之氯硝柳胺的局部濃度比在粒度分佈D(0.9)為約30 μm之氯硝柳胺下得到的濃度高約200倍。
因此，可容易且有效地投與粒度減小的本文所述之氯硝柳胺化合物(例如氯硝柳胺)，使得胃腸道(例如結腸)中之經投與氯硝柳胺化合物(例如氯硝柳胺)的所得局部生物可用性相對較高(例如與經投與氯硝柳胺化合物(例如氯硝柳胺)的所得全身性生物可用性相比)。在所需治療區域(例如胃腸道(例如結腸))局部(非全身性)投與氯硝柳胺化合物(例如氯硝柳胺)顯著降低患者將經歷與一些當前照護標準相關之全身性毒性的可能性。另外且有利地，預期實現胃腸道(例如結腸)中之所需API含量所需的粒度減少的氯硝柳胺化合物(例如氯硝柳胺)之量將低於具有較大粒度之氯硝柳胺化合物(例如氯硝柳胺)所需的量。
因此，在一些實施例中，本文所述之氯硝柳胺化合物(例如氯硝柳胺) (例如粒度減少的氯硝柳胺化合物(例如氯硝柳胺))可使得氯硝柳胺化合物(例如氯硝柳胺)靶向遞送至胃腸道某些區域(例如結腸，例如升結腸及/或橫結腸及/或遠端結腸)。在一些實施例中，向個體投與(例如經口投與)本文所述之氯硝柳胺化合物(例如氯硝柳胺)使得該個體之該胃腸道(例如結腸，例如前述)中的該氯硝柳胺化合物(例如氯硝柳胺)之局部濃度高於該個體之該血漿隔室中的該氯硝柳胺化合物(例如氯硝柳胺)之濃度，藉此，例如更有效地，向胃腸道中的患病組織(例如，前述)提供氯硝柳胺化合物(例如，氯硝柳胺)，且降低與較高全身性氯硝柳胺化合物(例如，氯硝柳胺)暴露相關的風險(例如，毒性)。此外，可潛在地使用本文所述之粒度減小的氯硝柳胺化合物(例如，氯硝柳胺)的較低劑量來實現前述內容。
鑒於上文所敍述之前述優勢及特徵，預期本文所述之氯硝柳胺化合物(例如氯硝柳胺)、方法及組合物在不同患者群體中為功能性的及/或在細胞死亡機制中對阻斷較不敏感。此外，利用傳統小分子(諸如氯硝柳胺)之能力可幫助降低成本且便於患者投與。
在一些實施例中，本文所述之方法及組合物適用於與各種其他治療方案(例如化學療法及/或輻射)的組合療法。在某些實施例中，本文所述之化學實體及方法可用於治療由此等治療方案產生的副作用，例如由化學治療免疫調節劑(例如檢查點抑制劑)誘發之發炎性腸病，其在一些情況下可能極為嚴重。
在某些實施例中，本文所述之方法及組合物適用於與一或多種額外治療劑的組合療法。舉例而言，適用於治療或預防發炎性腸病(IBD) (例如克羅恩氏病、潰瘍性結腸炎)之治療劑。額外治療劑之非限制性實例包括：神經鞘胺醇1-磷酸(S1P)受體調節劑(例如依托西莫德或奧札莫德)；類固醇消炎劑(例如倍氯米松17或布地奈德)；非類固醇消炎劑(例如5-ASA)；受體相互作用蛋白質激酶1 (RIPK1)抑制劑(例如GSK2982772)；EP4調節劑(例如KAG-308)；鐸樣受體(例如TLR4、TLR9)調節劑(例如，JKB-122、庫比莫德)；詹納斯(Janus)激酶(JAK)抑制劑(例如TD-1473、托法替尼、優帕替尼、非戈替尼、PF-06651600及PF-06700841)；羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑(例如BT-11)；磷脂醯膽鹼(例如LT-02)；整合素(例如，α4整合素)調節劑(例如AJM-300 (卡羅格拉斯))；Smad7調節劑(例如蒙格森)；磷酸二酯酶4 (PDE4)調節劑(例如阿普斯特)；腫瘤進展基因座2 (TPL2)抑制劑(例如GS-4875)；酪胺酸激酶2 (TYK2)抑制劑(例如BMS-986165、PF-06700841及PF-06826647)；及TEC激酶抑制劑(例如PF-06651600)。
另外，本文所述之化學實體、方法及組合物亦預期適用於某些抗治療性患者群體，例如對治療抗TNFα療法(例如修美樂、恩博、雷米卡德)或抗整合素療法(例如Entyvio、艾托珠單抗(etrolizumab))或皮質類固醇無反應或具有抗性的患者群體。
在一個態樣中，提供用於誘導個體之(例如消化道及/或胃腸道(GI)中的)一或多個T細胞之細胞死亡的方法。該等方法包括使一或多個T細胞與有效量之氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體接觸；例如粒度減小(例如粒度範圍減小、粒度分佈減小)的本文所述之氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體(例如氯硝柳胺化合物，諸如氯硝柳胺)。在實施例中，氯硝柳胺化合物(諸如氯硝柳胺)具有或進一步具有較高化學純度。
在另一態樣中，提供用於治療患有與個體之(例如消化道及/或胃腸道(GI)處的)不受調節(諸如異常，升高)的一或多種T細胞之募集及/或滯留相關的病狀之該個體的方法。氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如粒度減小(例如粒度範圍減小、粒度分佈減小)的本文所述之氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體(例如氯硝柳胺化合物，諸如氯硝柳胺)。在實施例中，氯硝柳胺化合物(諸如氯硝柳胺)具有或進一步具有較高化學純度。在一些實施例中，該等方法包含經口投與氯硝柳胺化合物。
在一些實施例中，至少一些該等T細胞位於個體之小腸中(例如在小腸之迴腸部分中)。因此，本文所述之方法可用於例如治療發炎性腸病，諸如克羅恩氏病。
在一些實施例中，至少一些該等T細胞位於個體之結腸中。因此，本文所述之方法可用於例如治療發炎性腸病，諸如潰瘍性結腸炎。
在另一態樣中，提供用於治療有需要之個體的以異常發炎反應為特徵之病狀(或其一或多種症狀)的方法(例如自體免疫病症，例如結腸炎，例如自體免疫結腸炎，例如發炎性腸病，例如克羅恩氏病、潰瘍性結腸炎)。該等方法包括向個體投與(例如經口)有效量之氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如粒度減小(例如粒度範圍減小、粒度分佈減小)的本文所述之氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體(例如氯硝柳胺化合物，諸如氯硝柳胺)。在實施例中，氯硝柳胺化合物(諸如氯硝柳胺)具有或進一步具有本文所述之較高化學純度。
在另一態樣中，提供用於治療個體之結腸炎(或其一或多種症狀)的方法。該等方法包括向個體投與有效量之氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如粒度減小(例如粒度範圍減小、粒度分佈減小)的本文所述之氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體(例如氯硝柳胺化合物，諸如氯硝柳胺)。在實施例中，氯硝柳胺化合物(諸如氯硝柳胺)具有或進一步具有本文所述之較高化學純度。
在另一態樣中，提供用於治療自體免疫疾病、癌症、代謝病症、心血管疾病、與微生物(例如病毒或細菌)感染相關之病狀、過敏性疾病、與NF-κB活化及/或發炎性細胞介素產生相關之病狀、藉由水通道蛋白介導之病狀或神經退化性或精神疾病的方法。該等方法包括向個體投與有效量之式(I
)化合物或其醫藥學上可接受之鹽及/或共晶體。在一些實施例中，該等方法包括經口投與式(I
)化合物。在一些實施例中，該等方法包括經直腸(例如經由灌腸)投與式(I)化合物。
實施例可包含以下特徵中之一或多個。
氯硝柳胺化合物(諸如氯硝柳胺)可經口投與。
個體可為人類。
病狀可與個體之胃腸道(GI)處的不受調節(諸如異常或升高)的一或多種T細胞之募集及/或滯留相關。
病狀可與個體之胃腸道(GI)處的不受調節(諸如異常或升高)的一或多種T細胞之活化相關。
病狀可為結腸炎。舉例而言，病狀可為自體免疫結腸炎；病狀可為發炎性腸病(例如潰瘍性結腸炎或克羅恩氏病)。病狀可為醫原性自體免疫結腸炎。
病狀可為由一或多種化學治療劑誘發之結腸炎(例如醫原性自體免疫結腸炎)。
該一或多種化學治療劑中之至少一者可為化學治療免疫調節劑，諸如免疫檢查點抑制劑。該免疫檢查點抑制劑可為靶向選自由以下組成之群的免疫檢查點受體之抑制劑：CTLA-4、PD-1、PD-L1、PD-1-PD-L1、PD-1-PD-L2、介白素-2 (IL-2)、吲哚胺2,3-二加氧酶(IDO)、IL-10、轉型生長因子-β (TGFβ)、T細胞免疫球蛋白及黏蛋白3 (TIM3或HAVCR2)、半乳糖凝集素9-TIM3、磷脂醯絲胺酸-TIM3、淋巴球活化基因3蛋白質(LAG3)、MHC II類-LAG3、4-1BB-4-1BB配位體、OX40-OX40配位體、GITR、GITR配位體-GITR、CD27、CD70-CD27、TNFRSF25、TNFRSF25-TL1A、CD40L、CD40-CD40配位體、HVEM-LIGHT-LTA、HVEM、HVEM-BTLA、HVEM-CD160、HVEM-LIGHT、HVEM-BTLA-CD160、CD80、CD80-PDL-1、PDL2-CD80、CD244、CD48-CD244、CD244、ICOS、ICOS-ICOS配位體、B7-H3、B7-H4、VISTA、TMIGD2、HHLA2-TMIGD2、包括BTNL2之嗜乳脂蛋白、唾液酸結合免疫球蛋白樣凝集素家族(Siglec family)、TIGIT及PVR家族成員、KIR、ILT及LIR、NKG2D及NKG2A、MICA及MICB、CD244、CD28、CD86-CD28、CD86-CTLA、CD80-CD28、CD39、CD73腺苷-CD39-CD73、CXCR4-CXCL12、磷脂醯絲胺酸、TIM3、磷脂醯絲胺酸-TIM3、SIRPA-CD47、VEGF、神經纖毛蛋白、CD160、CD30及CD155。該免疫檢查點抑制劑可選自由以下組成之群：烏瑞魯單抗(Urelumab)、PF‑05082566、MEDI6469、TRX518、瓦里木單抗(Varlilumab)、CP‑870893、派立珠單抗(Pembrolizumab) (PD1)、納武單抗(Nivolumab) (PD1)、阿特珠單抗(Atezolizumab) (先前為MPDL3280A) (PDL1)、MEDI4736 (PD-L1)、阿維魯單抗(Avelumab) (PD-L1)、PDR001 (PD1)、BMS‑986016、MGA271、利瑞路單抗(Lirilumab)、IPH2201、艾瑪圖單抗(Emactuzumab)、INCB024360、高倫替布(Galunisertib)、尤洛庫單抗(Ulocuplumab)、BKT140、巴維昔單抗(Bavituximab)、CC‑90002、貝伐單抗(Bevacizumab)及MNRP1685A，及MGA271。免疫檢查點抑制劑可為靶向CTLA-4之抑制劑。免疫檢查點抑制劑可為抗體。抗體可為伊派利單抗或曲美單抗。免疫檢查點抑制劑可為靶向PD1或PD-L1之抑制劑。免疫檢查點抑制劑可選自納武單抗、蘭布諾單抗(lambroizumab)及BMS-936559。
該病狀可選自由以下組成之群：乳糜瀉、大腸急躁症、黏膜炎、葡萄膜炎、輻射腸炎、類風濕性關節炎、狼瘡、硬皮病、牛皮癬、皮膚T細胞淋巴瘤、急性移植物抗宿主疾病及慢性移植物抗宿主疾病。
該等方法可進一步包括投與一或多種額外治療劑。
舉例而言，適用於治療或預防發炎性腸病(IBD) (例如克羅恩氏病、潰瘍性結腸炎)之治療劑，例如神經鞘胺醇1-磷酸(S1P)受體調節劑(例如依托西莫德或奧札莫德)；類固醇消炎劑(例如倍氯米松17或布地奈德)；非類固醇消炎劑(例如5-ASA)；受體相互作用蛋白質激酶1 (RIPK1)抑制劑(例如GSK2982772)；EP4調節劑(例如KAG-308)；鐸樣受體(例如，TLR4、TLR9)調節劑(例如，JKB-122、庫比莫德)；詹納斯(Janus)激酶(JAK)抑制劑(例如TD-1473、托法替尼、優帕替尼、非戈替尼、PF-06651600及PF-06700841)；羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑(例如BT-11)；磷脂醯膽鹼(例如LT-02)；整合素(例如，α4整合素)調節劑(例如AJM-300 (卡羅格拉斯))；Smad7調節劑(例如蒙格森)；磷酸二酯酶4 (PDE4)調節劑(例如阿普斯特)；腫瘤進展基因座2 (TPL2)抑制劑(例如GS-4875)；酪胺酸激酶2 (TYK2)抑制劑(例如BMS-986165、PF-06700841及PF-06826647)；及TEC激酶抑制劑(例如PF-06651600)。
作為另一實例，一或多種治療劑可為：布地奈德；表皮成長因子；皮質類固醇；環孢黴素(cyclosporine)；柳氮磺胺吡啶；胺基柳酸鹽；6-巰基嘌呤；硫唑嘌呤；甲硝噠唑；脂肪加氧酶抑制劑；美塞拉明(mesalamine)；奧沙拉嗪；巴柳氮；抗氧化劑；凝血脂素抑制劑；IL-1受體拮抗劑；抗IL-1單株抗體；抗-IL-6單株抗體(例如抗IL-6受體抗體及抗IL-6抗體)；生長因子；彈性蛋白酶抑制劑；吡啶基-咪唑化合物；本文所述之TNF拮抗劑；IL-4、IL-10、IL-13及/或TGF.β.細胞介素或其促進劑(例如促效劑抗體)；IL-11；普賴蘇穠、地塞米松或布地奈德之葡萄糖苷酸或聚葡萄糖共軛前驅藥；ICAM-1反義硫代磷酸酯寡去氧核苷酸(ISIS 2302；Isis Pharmaceuticals公司)；可溶互補序列受體1 (TP10；T Cell Sciences公司)；緩釋美沙拉嗪；甲胺喋呤；血小板激活因子(PAF)拮抗劑；環丙沙星；及/或里格卡因。
作為另一實例，一或多種額外治療劑可為治療自體免疫結腸炎之治療劑及/或方案。非限制性實例皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、美塞拉明、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
作為另一實例，一或多種額外治療劑可為用於治療醫原性自體免疫結腸炎之治療劑及/或方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
作為另一實例，一或多種額外治療劑可為用於治療由一或多種化學治療劑誘發之結腸炎的治療劑及/或方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、美塞拉明、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
作為另一實例，一或多種額外治療劑可為用於治療由授受細胞療法治療誘發之結腸炎的治療劑及/或方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
作為另一實例，一或多種額外治療劑可為用於治療與一或多種異體免疫性疾病相關之結腸炎的治療劑及/或方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、柳氮磺胺吡啶及二十碳五烯酸(eicopentaenoic acid)。
作為另一實例，一或多種額外治療劑可為用於治療放射性腸炎之治療劑及/或方案。非限制性實例包括替度魯肽(teduglutide)、阿米福汀、血管收縮素轉化酶(ACE)抑制劑(例如貝那普利、卡托普利、依那普利、福辛普利、賴諾普利、莫西普利、培哚普利、喹那普利、雷米普利及群多普利)、益生菌、補硒、士他汀(例如阿托伐他汀、氟伐他汀、洛伐他汀、普伐他汀、羅素他汀、辛伐他汀及匹伐他汀)、硫糖鋁及維生素E。
作為另一實例，一或多種額外治療劑可為治療膠原性結腸炎之治療劑及/或方案。非限制性實例包括6-巰基嘌呤、硫唑嘌呤(azathaioprine)、次水楊酸鉍(bismuth subsalicate)、齒葉乳香樹提取物(Boswellia serrata extract)、消膽胺、考來替潑、皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、洛哌丁胺、美塞拉明、甲胺喋呤、益生菌及柳氮磺胺吡啶。
作為另一實例，一或多種額外治療劑可為治療淋巴球性結腸炎(lyphocytic colitis)之治療劑及/或方案。非限制性實例包括6-巰基嘌呤、硫唑嘌呤、次水楊酸鉍、消膽胺、考來替潑、皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、洛哌丁胺、美塞拉明、甲胺喋呤及柳氮磺胺吡啶。
作為另一實例，一或多種額外治療劑可為治療顯微鏡結腸炎(microscopic colitis)之治療劑及/或方案。非限制性實例包括6-巰基嘌呤、硫唑嘌呤、次水楊酸鉍、齒葉乳香樹提取物、消膽胺、考來替潑、皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、糞便微生物移植(fecal microbial transplantation)、洛哌丁胺、美塞拉明、甲胺喋呤、益生菌及柳氮磺胺吡啶。
作為另一實例，一或多種額外治療劑可為治療UC之治療劑及/或方案。非限制性實例包括AbGn-168H、ABT-494、ABX464、阿普斯特、PF-00547659、PF-06687234、6-巰基嘌呤、阿達木單抗、硫唑嘌呤、柏替木單抗(bertilimumab)、布拉奇單抗(brazikumab) (MEDI2070)、庫比莫德、聚乙二醇化賽妥珠單抗(Cimzia®)、CP-690,550、皮質類固醇(例如多軸布地奈德(multimax budesonide)、甲基普賴蘇穠)、環孢黴素、E6007、依托西莫德、艾托珠單抗、糞便微生物移植、非洛替尼、古賽庫單抗、戈利木單抗、IL-2、IMU-838、英利昔單抗、基質金屬蛋白酶9 (MMP9)抑制劑(例如GS-5745)、美塞拉明、美塞拉明、密利基單抗(mirikizumab) (LY3074828)、RPC1063、里森基單抗(BI 6555066)、SHP647、柳氮磺胺吡啶、TD-1473、TJ301、替拉珠單抗(MK 3222)、托法替尼、托法替尼、優特克單抗(ustekinumab)、UTTR1147A及維多珠單抗。
作為另一實例，一或多種額外治療劑可為治療克羅恩氏病(CD)之治療劑及/或方案。非限制性實例包括阿達木單抗自體CD34選擇之末梢血液幹細胞移植6-巰基嘌呤、硫唑嘌呤、聚乙二醇化賽妥珠單抗(Cimzia®)、皮質類固醇(例如普賴松)、艾托珠單抗、E6011、糞便微生物移植、非洛替尼、古賽庫單抗、英利昔單抗、IL-2、JAK抑制劑、基質金屬蛋白酶9 (MMP 9)抑制劑(例如GS-5745)、MEDI2070、美塞拉明、甲胺喋呤、那他珠單抗、奧札莫德、RHB-104、利福昔明、里森基單抗、SHP647、柳氮磺胺吡啶、沙立度胺、優帕替尼、V565及維多珠單抗。
作為另一實例，一或多種額外治療劑可為治療IBD之治療劑及/或方案。非限制性實例包括6-巰基嘌呤、AbGn-168H、ABX464、ABT-494、阿達木單抗、AJM300、阿利卡弗森(alicaforsen)、AMG139、安魯金單抗(anrukinzumab)、阿普斯特、ATR-107(PF0530900)、自體CD34選擇之末梢血液幹細胞移植、硫唑嘌呤、柏替木單抗、BI 655066、BMS-936557、聚乙二醇化賽妥珠單抗(Cimzia®)、庫比莫德、皮質類固醇(例如普賴松、甲基普賴蘇穠、普賴松)、CP-690,550、CT-P13、環孢黴素、DIMS0150、E6007、E6011、依托西莫德、艾托珠單抗、糞便微生物移植、非洛替尼、芬戈莫德(fingolimod)、非拉司特(firategrast) (SB-683699) (先前稱為T-0047)、GED0301、GLPG0634、GLPG0974、古賽庫單抗(guselkumab)、戈利木單抗、GSK1399686、HMPL-004(穿心蓮(Andrographis paniculata)提取物)、IMU-838、英利昔單抗(infliximab)、介白素2(IL-2)、傑納斯激酶(Janus kinase) (JAK)抑制劑、拉喹莫德(laquinimod)、馬賽替尼(masitinib) (AB1010)、基質金屬蛋白酶9 (MMP 9)抑制劑(例如GS-5745)、MEDI2070、美塞拉明(mesalamine)、甲胺喋呤、密利基單抗(mirikizumab) (LY3074828)、那他珠單抗(natalizumab)、NNC 0142-0000-0002、NNC0114-0006、奧札莫德、皮非替尼(peficitinib) (JNJ-54781532)、PF-00547659、PF-04236921、PF-06687234、QAX576、RHB-104、利福昔明(rifaximin)、里森基單抗(risankizumab)、RPC1063、SB012、SHP647、柳氮磺胺吡啶、TD-1473、沙立度胺、替拉珠單抗(tildrakizumab) (MK 3222)、TJ301、TNF-Kinoid®、托法替尼、塔羅金單抗(tralokinumab)、TRK-170、優帕替尼、優特克單抗、UTTR1147A、V565、維特立珠單抗(vatelizumab)、VB-201、維多珠單抗(vedolizumab)及維魯迪姆(vidofludimus)。
在一個態樣中，提供一種共晶體，其包括：( i )
氯硝柳胺化合物(諸如氯硝柳胺)或其醫藥學上可接受之鹽及/或水合物；及( ii )
一或多種醫藥學上可接受之共形成物。在一些實施例中，共晶體具有如本文任何地方所述之減小的粒度。在實施例中，共晶體共形成物可包括本文所述之任何共形成物，包括如上文及本文任何地方所述之第二治療劑。
相關申請案之交叉參考
本申請案主張2019年10月18日提出申請的美國臨時申請案第62/923,290號的權益，該臨時申請案以全文引用的方式併入本文中。
定義
為有助於理解本文中所闡述之揭示內容，下文定義多個術語。一般而言，本文所用之命名法及本文所述之有機化學、醫藥化學及藥理學中之實驗室程序係熟知的且常用於此項技術中。除非另外規定，否則本文所用之所有技術及科學術語一般具有與本發明所屬領域之一般熟習此項技術者通常所理解相同之含義。在本說明書通篇及附件中提到的專利、申請案、公開的申請案以及其他出版物各自以全文引用的方式併入本文中。
術語「氯硝柳胺化合物(niclosamide compound)」或「氯硝柳胺化合物(niclosamide compounds)」包括以全文引用之方式併入本文中的WO 2017/040864中所述之氯硝柳胺以及氯硝柳胺類似物。在一些實施例中，氯硝柳胺化合物為氯硝柳胺。
「氯硝柳胺」係指具有以下化學結構之化合物：
。
氯硝柳胺由IUPAC名稱：2'5-二氯-4'-硝基柳醯胺苯及CAS名稱：CAS：5-氯-N-(2-氯-4-硝基苯基)-2-羥基苯甲醯胺已知。氯硝柳胺在20℃下具有約5-8 mg/L之相對較低的水溶性，微溶於乙醚、乙醇及氯仿中，且可溶於丙酮中。在20℃下，乙醇胺鹽溶解於180-280 mg/L之蒸餾水中。
氯硝柳胺可以各種鹽或溶劑化形式獲得。此等包括但不限於由IUPAC名稱5-氯-柳基-(2-氯-4-硝基)苯胺2-胺基乙醇鹽或CAS名稱5-氯-N-(2-氯-4-硝基苯基)-2-羥基苯甲醯胺與2-胺基乙醇(1:1)-參見例如US 2013/0231312已知之乙醇胺鹽；由IUPAC名稱5-氯-柳基-(2-氯-4-硝基)苯胺哌𠯤鹽或CAS名稱5-氯-N-(2-氯-4-硝基苯基)-2-羥基苯甲醯胺與哌𠯤(2:1)已知之哌𠯤鹽；及由IUPAC名稱5-氯-柳基-(2-氯-4-硝基)苯胺單水合物或CAS名稱5-氯-N-(2-氯-4-硝基苯基)-2-羥基苯甲醯胺與單水合物(1:1)已知之氯硝柳胺單水合物。
氯硝柳胺可在多種調配物中獲得，該等調配物包括但不限於BAYER 73®、BAYER 2353®、BAYER 25 648®、BAYLUSCID®、BAYLUSCIDE®、CESTOCID®、CLONITRALID、DICHLOSALE®、FENASAL®、HL 2447®、IOMESAN®、IOMEZAN®、LINTEX®、MANOSIL®、NASEMO®、NICLOSAMID®、PHENASAL®、TREDEMINE®、SULQUI®、VERMITID®、VERMITIN®、YOMESAN®及類似物。
術語「消化道」應理解為包括口腔、咽、食道、胃、小腸(十二指腸、空腸、迴腸)、大腸(盲腸、結腸、直腸)及肛門。
術語「口腔」應理解為包括口腔、咽及食道。
術語「胃腸道(gastrointestinal tract)」或「胃腸道(GI tract)」應理解為包括胃、小腸(十二指腸、空腸、迴腸)、大腸(盲腸、結腸、直腸)及肛門。
如本文所用，關於調配物、組合物或成分之術語「可接受」意謂對正治療之個體的整體健康不具有持續有害作用。
「API」係指活性醫藥成分(例如氯硝柳胺化合物，例如氯硝柳胺)。
如本文所用，術語「有效量」或「治療有效量」係指所投與化學實體(例如，作為線粒體解偶劑展現活性之化合物或其醫藥學上可接受之鹽及/或水合物及/或共晶體；例如，諸如氯硝柳胺之化合物或其醫藥學上可接受之鹽及/或水合物及/或共晶體；例如，諸如氯硝柳胺類似物之化合物或其醫藥學上可接受之鹽及/或水合物及/或共晶體)的足夠量，其將在一定程度上緩解所治療之疾病或病狀的症狀中之一或多者。結果包含減輕及/或緩解疾病之病徵、症狀或病因、或生物系統之任何其他所希望的改變。舉例而言，用於治療用途之「有效量」係使疾病症狀臨床上顯著減輕所需的包含如本文所揭示之化合物之組合物的量。在任何個別情況下的適當「有效」量係使用任何適合技術確定，諸如劑量遞增研究。
術語「賦形劑」或「醫藥學上可接受之賦形劑」意謂醫藥學上可接受之物質、組合物或媒劑，諸如液體或固體填充劑、稀釋劑、載劑、溶劑或囊封物質。在一個實施例中，就以下而言，各組分為「醫藥學上可接受的」：與醫藥調配物之其他成分相容且適用於與人類及動物之組織或器官接觸而無過度毒性、刺激、過敏反應、免疫原性或其他問題或併發症，與合理益處/風險比相稱。參見例如雷明頓 ： 藥學科學及實踐 ( Remington : The Science and Practice of Pharmacy ), 第 21 版 ;
賓夕法尼亞州費城的利平科特威廉姆斯及威爾金斯(Lippincott Williams & Wilkins: Philadelphia, PA), 2005；醫藥賦形劑手冊(Handbook of Pharmaceutical Excipients
),第 6 版
; 羅(Rowe)等人編; 醫藥出版社及美國醫藥協會(The Pharmaceutical Press and the American Pharmaceutical Association): 2009；醫藥添加劑手冊(Handbook of Pharmaceutical Additives
),第 3 版
; 艾什(Ash)及艾什編; 高爾出版公司(Gower Publishing Company): 2007；醫藥預調配及調配(Pharmaceutical Preformulation and Formulation
),第 2 版
; 吉布森(Gibson編); 佛羅里達州波卡拉頓的CRC出版有限責任公司(CRC Press LLC: Boca Raton, FL), 2009。
術語「醫藥學上可接受之鹽」係指這樣一種化合物調配物，該調配物不會對投與其之生物體產生顯著刺激且不會消除該化合物之生物活性及特性。在某些情況下，醫藥上可接受之鹽藉由使本文所述之化合物與諸如鹽酸、氫溴酸、硫酸、硝酸、磷酸、甲磺酸、乙磺酸、對甲苯磺酸、柳酸及其類似物之酸反應獲得。在一些情況下，醫藥學上可接受之鹽藉由使本文所描述之具有酸性基團之化合物與鹼反應以形成鹽或藉由預先確定之其他方法來獲得，該鹽諸如銨鹽；鹼金屬鹽，諸如鈉鹽或鉀鹽；鹼土金屬鹽，諸如鈣鹽或鎂鹽；有機鹼之鹽，諸如二環己胺；N-甲基-D-還原葡糖胺；參(羥基甲基)甲胺及與胺基酸諸如精胺酸、離胺酸的鹽及其類似物。藥理學上可接受之鹽不受特定限制，只要其可用於藥劑即可。本文所述之化合物與鹼形成的鹽的實例包括以下：其與無機鹼，諸如鈉、鉀、鎂、鈣及鋁的鹽；其與有機鹼，諸如甲胺、乙胺及乙醇胺的鹽；其與基礎胺基酸，諸如離胺酸及鳥胺酸的鹽；及銨鹽。鹽可為酸加成鹽，其具體實例為與以下形成之酸加成鹽：礦物酸，諸如鹽酸、氫溴酸、氫碘酸、硫酸、硝酸及磷酸；有機酸，諸如甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、反丁烯二酸、順丁烯二酸、乳酸、蘋果酸、酒石酸、檸檬酸、甲烷磺酸及乙烷磺酸；酸性胺基酸，諸如天冬胺酸及麩胺酸。
術語「醫藥組合物」係指本文所述之化合物與其他化學組分(在本文中通稱為「賦形劑」)諸如載劑、穩定劑、稀釋劑、分散劑、懸浮劑及/或增稠劑之混合物。醫藥組合物有助於將化合物投與至生物體。此項技術中存在多種投與化合物之技術，包括但不限於：經直腸、口服、經靜脈內、氣霧劑、非經腸、經眼、經肺及表面投與。
術語「個體」係指動物，包括但不限於靈長類動物(例如，人類)、猴、牛、豬、綿羊、山羊、馬、狗、貓、兔、大鼠或小鼠。術語「個體」及「患者」在本文中關於例如哺乳動物個體(諸如人類)時可互換使用。
在治療疾病或病症之情況下，術語「治療(Treat/treating/treatment)」意謂包括緩解或消除病症、疾病或病狀或與該病症、疾病或病狀有關之症狀中之一或多者；或減緩疾病、病症或病狀或一或多種其症狀之進展、擴散或惡化。通常，個體由治療劑獲得之有益效應並不會使疾病、病症或病狀完全治癒。
本發明之一或多個實施例的詳情闡述於附圖及以下實施方式中。本發明之其他特徵、目標及優點將自[實施方式]及[圖式]，及自[申請專利範圍]顯而易知。
本發明之特徵在於具有包括但不限於特定純度(例如，化學純度大於約99.0%)及特定粒度(例如，特定粒度分佈及/或特定粒度範圍及/或比表面積範圍)之一或多種特性的氯硝柳胺化合物(或其醫藥學上可接受之鹽及/或共晶體，例如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)。在一個態樣中，本文所述之氯硝柳胺化合物(例如氯硝柳胺)可形成適用於經口投與之組合物、劑型(例如單位劑型)及其類似物之一部分。有利地且出乎意料地，向個體投與(例如經口投與)本文所述之粒度減小的氯硝柳胺化合物(例如氯硝柳胺)提供個體之相對較高的結腸暴露。因而，本文所述之氯硝柳胺化合物(例如，氯硝柳胺)適用於治療多種胃腸道(「GI」)相關病症，例如發炎性腸病(例如，潰瘍性結腸炎及克羅恩氏病)。本發明之特徵亦在於製造及使用氯硝柳胺化合物之方法。
氯硝柳胺化合物 化學純度
在一些實施例中，氯硝柳胺化合物(例如氯硝柳胺)之化學純度大於約99.0%；例如大於約99.5%；或大於約99.7%；或大於約99.8%。
在一些實施例中，氯硝柳胺化合物(例如氯硝柳胺)具有低於約45 ppm之5-氯-柳酸；例如低於約30 ppm之5-氯-柳酸。
在一些實施例中，化合物具有低於約50 ppm之2-氯-4硝基-苯胺。在某些實施例中，化合物具有低於約10 ppm之2-氯-4硝基-苯胺。
在一些實施例中，化合物具有低於約45 ppm之5-氯-柳酸及低於約50 ppm之2-氯-4硝基-苯胺。
在一些實施例中，化合物具有低於約30 ppm之5-氯-柳酸及低於約10 ppm之2-氯-4硝基-苯胺。
在一些實施例中，化合物具有低於約0.05%水。在某些實施例中，該化合物實質上不含水合氯硝柳胺固體形式。作為一個非限制性實例，化合物可為無水氯硝柳胺。
在一些實施例中，純化可根據以下方法進行。將丙酮及粗氯硝柳胺在容器中混合且加熱至回流(約56℃)，直至固體溶解。藉由過濾澄清溶液且轉移至第二容器，加熱至45℃至55℃以溶解固體，冷卻至-5℃至5℃且在此溫度下攪拌至少2小時。過濾固體且用丙酮洗滌。在70℃下真空乾燥固體之後得到結晶的氯硝柳胺。對規格＜1.0%之乾燥固體進行IPC LOD測試。若LOD結果＞1.0%，則乾燥步驟可再重複兩次。亦進行IPC測試以確保起始物質2-氯-4-硝基苯胺之含量＜100 ppm。若2-氯-4-硝基苯胺之含量＞100 ppm，則可進行第二結晶。
在一些實施例中，純度分析可根據以下程序實現。層析：由泵、二極體陣列、偵測器、自動進樣器、自動注射器及管柱冷卻器/加熱器或等效物組成之UPLC系統。管柱：Agilent Poroshell 120 EC-C18管柱，4.6×50 mm，2.7 μm或等效物。管柱溫度：35℃。移動相A：20 mM乙酸銨(pH 5.50)。移動相B：MeOH:ACN (70:30，v/v)。稀釋劑：MeOH:DMSO (70:30，v/v)。
| 時間 (分鐘) | 溶劑A (%) | 溶劑B (%) |
| 0.0 | 75 | 25 |
| 1.0 | 75 | 25 |
| 221.0 | 30 | 70 |
流動速率：1.0 ml/min。注射體積：3.00 μl。製備標準及樣品溶液。氯硝柳胺標準溶液：此溶液之濃度標稱地為0.8 mg/mL。滯留時間：5-氯柳酸(2.9分鐘)；2-氯-4-硝基苯胺(7.0分鐘)；及氯硝柳胺(18.8分鐘)。
粒度
在一些實施例中，化合物具有減小之粒度(例如，如藉由包括但不限於研磨之技術得到)。
在一些實施例中，粒度減小之氯硝柳胺化合物可藉由噴射研磨，例如使用由Sturtevant製造之CMTI設備NGMP-Mill-A，2吋餅狀微磨機來製備；在研磨製程期間使用可撓性容納單元(研磨及文丘里壓力兩者=50 psi；進料速率：96.0公克/小時)。
在前述一些實施例中，化合物之粒度範圍為約0.1 μm至約30 μm。在某些實施例中，化合物之粒度範圍為約0.1 μm至約20 μm。在某些實施例中，化合物之粒度範圍為約0.1 μm至約10 μm。
如本申請案內所用，分散於流體中之粉末或顆粒材料或顆粒的術語「粒度分佈」為用以定義存在的顆粒之相對量，根據大小進行排序的一系列值或數學函數。d(0.1)、d(0.5)及d(0.9)值指示所量測的10%、50%及90%之粒子低於或等於所陳述大小。舉例而言，d(0.1)=0.6、d(0.5)=3.1且d(0.9)=7.3之值意謂10%之粒子低於或等於0.6 μm、50%低於或等於3.1 μm且90%低於或等於7.3 μm。
粒度分佈(PSD)可藉由雷射繞射技術，例如，使用「MALVERN MASTERSIZER 2000」(標準範圍在0.020與2000.0微米之間)，模型「APA 2000」，配備有「Hydro 2000 sm」作為分散單元來確定。代表性程序包括：將約50 mg氯硝柳胺手動分散於25 ml水中；在分散之後，樣品用外部超音波進行音波處理兩分鐘(超音波頻率；37 kHz-Elmasonic S100 (H)-Elma Schmidbauer GmbH，德國)；考慮以下操作條件/機器參數：分散劑：水+3滴泰洛沙泊1.5%；背景量測時間：10秒；量測週期數：3 (以得到平均值)；攪拌速度(分配單位)：1500 rpm。
在一些實施例中，化合物之粒度分佈D(0.9)為約1.0 μm至約15.0 μm。在某些實施例中，化合物之粒度分佈D(0.9)為約1.0 μm至約10.0 μm。在某些實施例中，化合物之粒度分佈D(0.9)為約6.0 μm至約8.0 μm (例如約7.3 μm (例如7.3 μm))。在其他實施例中，化合物之粒度分佈D(0.9)為約2.2 μm至約3.2 μm。
在一些實施例中，化合物之粒度分佈D(0.1)為約0.1 μm至約1.5 μm。在某些實施例中，化合物之粒度分佈D(0.1)為約0.1 μm至約1.0 μm。在某些實施例中，化合物之粒度分佈D(0.1)為約0.3 μm至約0.9 μm。在某些實施例中，化合物之粒度分佈D(0.1)為約0.45 μm至約0.75 μm (例如約0.6 μm (例如0.6 μm))。
在一些實施例中，化合物之粒度分佈D(0.5)為約0.5 μm至約6.0 μm。在某些實施例中，化合物之粒度分佈D(0.5)為約1.0 μm至約4.0 μm。在某些實施例中，化合物之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。在某些其他實施例中，化合物之粒度分佈D(0.5)為約2.5 μm至約3.5 μm (例如約3.1 μm (例如3.1 μm))。
如本文所用，參數D(0.1)係指單個名義篩之篩孔尺寸，使得樣品之所有總粒子的10%通過。因此，D(0.1)= 0.1-1.5 μm意謂用以界定樣品中10%最小粒子的粒度範圍之上限在0.1 μm至1.5 μm之間。因此，10%之總粒子具有不超過D(0.1)之粒度，意謂在此情況下其最大尺寸為0.1 μm至1.5 μm。
如本文所用，參數D(0.5)係指單個名義篩之篩孔尺寸，使得樣品之所有總粒子的50%通過。因此，D(0.5)=0.5-6.0 μm意謂用以界定樣品中名義上一半的粒度範圍之上限在0.5 μm至6.0 μm之間。因此，50%之總粒子具有不超過D(0.5)之粒度，意謂在此情況下其最大尺寸為0.5 μm至6.0 μm。
如本文所用，參數D(0.9)係指單個名義篩之篩孔尺寸，使得樣品之所有總粒子的90%通過，亦即僅保留10%之樣品。因此，D(0.9)=1.0-15.0 μm意謂用以界定樣品中10%最小粒子的粒度範圍之上限在1.0 μm至15.0 μm之間。因此，90%之總粒子具有不超過D(0.9)之粒度，意謂在此情況下其最大尺寸為1.0 μm至15.0 μm。
在一些實施例中，化合物具有低於約0.05%水(例如，如藉由Karl Fisher技術確定)。在某些實施例中，該化合物實質上不含水合氯硝柳胺固體形式。作為一個非限制性實例，化合物可為無水氯硝柳胺。
在一些實施例中，該化合物為結晶的。
在一些實施例中，該化合物之比表面積為約5 m2
/g至約10 m2
/g。
非限制性組合 非限制性組合 [A]
在一些實施例中，化合物之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
在一些實施例中，化合物之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，化合物之粒度分佈D(0.9)為約7.0 μm至約7.5 μm (例如約7.3 μm)、粒度分佈D(0.5)為約2.5 μm至約4.0 μm (例如約3.1 μm)及粒度分佈D(0.1)為約0.45 μm至約0.75 μm (例如約0.6 μm)。
在一些實施例中，化合物之粒度分佈D(0.9)為約7.3 μm、粒度分佈D(0.5)為約3.1 μm及粒度分佈D(0.1)為約0.6 μm。
在一些實施例中，化合物之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
在一些實施例中，該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
在一些實施例中，該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在[A]
之某些實施例中，化合物之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
在[A]
之某些實施例中，化合物之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
在[A]
之某些實施例中，該化合物之化學純度大於約99.5%；或化學純度大於約99.7%；或化學純度大於約99.8%。
在[A]
之某些實施例中，化合物具有低於約45 ppm之5-氯-柳酸；或低於約30 ppm之5-氯-柳酸。
在[A]
之某些實施例中，化合物具有低於約50 ppm之2-氯-4硝基-苯胺；或低於約10 ppm之2-氯-4硝基-苯胺。
在[A]
之某些實施例中，化合物具有低於約45 ppm之5-氯-柳酸及低於約50 ppm之2-氯-4硝基-苯胺；或低於約30 ppm之5-氯-柳酸及低於約10 ppm之2-氯-4硝基-苯胺。
在[A]
之某些實施例中，化合物具有低於約0.05%水。
在[A]
之某些實施例中，該化合物實質上不含水合氯硝柳胺固體形式。
在[A]
之某些實施例中，該化合物為無水氯硝柳胺。
在[A]
之某些實施例中，該化合物為結晶的。
在[A]
之某些實施例中，該化合物之比表面積為約5 m2
/g至約10 m2
/g。
氯硝柳胺化合物之共晶體 概述
在一些實施例中，氯硝柳胺化合物(例如，氯硝柳胺)可呈包括( i )
氯硝柳胺化合物(例如，氯硝柳胺)或其醫藥學上可接受之鹽；及( ii )
一或多種醫藥學上可接受之共形成物的共晶體形式。如本文所用，術語「共晶體」係指在室溫下以化學計量或非化學計量比率由兩種或更多種獨特固體構成之結晶材料，其藉由一或多種非共價相互作用(例如，氫鍵、π堆疊、客體-主體複合及凡得瓦爾相互作用)在晶格中結合在一起。
在一些實施例中，一或多種非共價相互作用中之至少一者為氫鍵。在某些此等實施例中，化學實體為氫鍵供體，且一或多種共形成物中之一者為氫鍵受體。在其他實施例中，化學實體為氫鍵受體，且一或多種共形成物中之一者為氫鍵供體。
本文所述之共晶體可包括晶格中之一或多種溶劑合物(例如水或含有一或多個羥基之有機溶劑，例如C1
-C6
醇或二醇，例如C1
-C6
醇或二醇，例如乙醇或丙二醇)分子。然而，並未進一步包含共形成物(例如，固體共形成物)之化學實體的溶劑合物並不由本發明中所闡述之共晶體定義涵蓋。
在一些實施例中，共晶體包括超過一種共形成物。舉例而言，兩種、三種、四種、五種或更多種共形成物可併入具有化學實體之共晶體中。化學實體與一或多種醫藥學上可接受之共形成物中之每一者的比率可為化學計量或非化學計量的。作為非限制性實例，涵蓋1:1、1:1.5及1:2比率之化學實體:共形成物。
氯硝柳胺化合物(例如氯硝柳胺)及一或多種醫藥學上可接受之共形成物中之每一者可各自獨立地指定為游離形式，或更特定言之，游離酸、游離鹼或兩性離子；鹽，或更具體言之，例如無機鹼加成鹽，諸如鈉鹽、鉀鹽、鋰鹽、鈣鹽、鎂鹽、銨鹽、鋁鹽或有機鹼加成鹽，或無機酸加成鹽，諸如HBr鹽、鹽酸鹽、硫酸鹽、硝酸鹽或磷酸加成鹽，或有機酸加成鹽，諸如乙酸、丙酸、丙酮酸、丙二酸、丁二酸、蘋果酸、順丁烯二酸、反丁烯二酸、酒石酸、檸檬酸、苯甲酸、甲磺酸、乙磺酸、硬脂酸或乳酸加成鹽；游離形式或鹽之無水物或水合物，或更特定言之，例如半水合物、單水合物、二水合物、三水合水、四水合物、五水合物；或游離形式或鹽之溶劑合物。
共形成物
在一些實施例中，一或多種醫藥學上可接受之共形成物中之至少一者可與共晶體中之化學實體形成一或多個氫鍵。在一些實施例中，一或多種醫藥學上可接受之共形成物中之至少一者可接受一或多個來自共晶體中之化學實體的氫鍵。在一些實施例中，一或多種醫藥學上可接受之共形成物中之至少一者可與共晶體中之化學實體形成一或多個氫鍵，且一或多種醫藥學上可接受之共形成物中之至少一者可接受一或多個來自共晶體中之化學實體的氫鍵。
在一些實施例中，一或多種醫藥學上可接受之共形成物中之至少一者包含選自由以下組成之群的一或多個官能基：醚、硫醚、羥基、硫氫基、醛、酮、硫酮、硝酸酯、磷酸酯、硫代磷酸酯、酯、硫酯、硫酸酯、羧酸、膦酸、一元膦酸、磺酸、醯胺基、一級胺、二級胺、氨、三級胺基、sp2胺基、硫代氰酸酯、氰胺、肟、腈、重氮、鹵基烷基、硝基、雜環、雜芳環、環氧化物、過氧化物及氧肟酸。
在某些實施例中，一或多種醫藥學上可接受之共形成物中之每一者獨立地選自乙醯胺、苯甲醯胺、(+/-)-檸檬烯、1-(苯偶氮基)-2-萘胺、1,2,6-己三醇、1,2-二肉豆蔻醯基-sn-丙三氧基-3-(二氧磷基-s-(1-丙三醇))、1,2-二肉豆蔻醯基-sn-丙三氧基-3-磷酸膽鹼、1,2-二油醯基-sn-丙三氧基-3-磷酸膽鹼、1,2-二軟脂醯基-sn-丙三氧基-3-(二氧磷基-外消旋-(1-丙三醇))、1,2-二硬脂醯基-sn-丙三氧基-3-(磷酸基-外消旋-(1-丙三醇))、1,2-二硬脂醯基-sn-丙三氧基-3-磷酸膽鹼、1,5-萘-二磺酸、1-羥基-2-萘甲酸、1-o-甲苯基二胍、2-乙基-1,6-己二醇、4-胺基苯甲酸、4-胺基吡啶、4-胺基柳酸、4-氯苯-磺酸、4-乙氧基苯基脲、7-側氧基-脫氫表雄酮(dhea)、阿拉伯膠、阿拉伯膠漿、阿拉伯膠糖漿、乙醯磺胺酸、乙醯磺胺酸鉀、乙異羥肟酸、丙酮亞硫酸氫鈉、乙醯化羊毛蠟醇、乙醯化單甘油酸酯、乙醯半胱胺酸、乙醯基三丁基檸檬酸鹽、丙烯酸鹽共聚物、丙烯酸-丙烯酸異辛酯共聚物、腺嘌呤、己二酸、丙胺酸、聚合白蛋白、白蛋白膠體、人類白蛋白、白蛋白、褐藻酸、烷基銨磺酸甜菜鹼、烷基芳基磺酸鈉、尿囊素、別嘌呤醇(allopurineol)、烯丙基α-紫羅蘭酮、α-松香醇、α-生育酚、α-生育酚乙酸鹽、胺基苯甲酸鈉、乙酸戊酯、大茴香腦、無水檸檬酸、無水右旋糖、無水乳糖、無水三磷酸鈉、無水檸檬酸三鈉、精胺酸、脫水山梨糖醇三油酸酯(arlacel)、阿魏膠(asafetida)、抗壞血酸、抗壞血酸棕櫚酸酯、天冬醯胺、阿斯巴甜糖、天冬胺酸、抑菌氯化鈉注射、硫酸鋇、苯紮氯銨、苯磺酸、苄索氯銨、十二烷基二甲基苯甲基溴化銨、苯甲酸、乙酸苯甲酯、苄醇、苯甲酸苯甲酯、苯甲氯化物、β-胡蘿蔔素、異萘酚(betanaphthol)、倍糖(betose)、雙巴西肽、次碳酸鉍、次沒食子酸鉍、
酸(boric acid)、溴克利那、十八酸丁酯、丁基化羥基大茴香醚、丁基化羥基甲苯、對羥基苯甲酸丁酯、丁酸、C-11-1-胺基環己烷甲酸、乳酸鹽C12-15烷酯、咖啡鹼、考布曲鈣、卡地胺鈉、鈣塞酸三鈉、鈣立醇鈣、樟腦酸、癸酸、蓋普丹、卡布迪索、羧基聚亞甲基、胭脂紅、巴西棕櫚蠟、棕櫚蠟黃色蠟、角叉菜膠、角叉菜膠鈣、角叉菜膠鹽、角叉菜膠鈉、精製地蠟、鯨蠟硬脂醇醚-12、鯨蠟硬脂醇醚-15、鯨蠟硬脂醇醚-30、十六醇十八醇/鯨蠟硬脂醇醚-20、乙基己酸鯨蠟硬脂酯、鯨蠟醇聚醚-10、鯨蠟醇聚醚-2、鯨蠟醇聚醚-20、鯨蠟醇聚醚-23、鯨蠟硬脂醇、鯨蠟基三甲基銨氯化物、鯨蠟醇、鯨蠟基酯蠟、棕櫚酸十六酯、氯化鯨蠟基吡錠、氯甲酚、氯二甲酚、膽固醇、金黃素、桂皮醛、肉桂酸、檸檬酸鹽、檸檬酸、單水合檸檬酸、克立咪唑、椰油醯胺醚硫酸鹽、椰油胺氧化物、可可甜菜鹼、可可二乙醇醯胺、可可單乙醇醯胺、可可-辛酸鹽、可可-甘油酯、肌酸、肌酐、甲酚、硫酸銅、環己胺磺酸、環甲聚矽氧烷、環甲聚矽氧烷5、半胱胺酸、達方吡啶、癸基甲基亞碸、去氫乙酸、地那銨苯甲酸鹽、去氧膽酸、聚葡萄糖、聚葡萄糖40、葡萄糖結合劑、糊精、右旋糖、右旋糖單水合物、二乙醯化單甘油酸酯、泛影酸、無水磷酸氫二鈉、磷酸氫二鈉、磷酸氫二鈉二水合物、磷酸氫二鈉十二水合物、磷酸氫二鈉七水合物、二丁基鄰苯二甲酸鹽、二丁基癸二酸鹽、鄰苯二甲酸二乙酯、焦碳酸二乙酯、癸二酸二乙酯、二乙胺基乙基硬脂醯胺磷酸酯、二乙二醇單乙醚、二甘醇單甲醚、二乙基己基鄰苯二甲酸酯、己二酸二異丙酯、二亞麻油酸二異丙酯、二異丙基苯并噻唑基-2-次磺醯胺、二甲聚矽氧烷醫學流體360、二甲基異山梨醇、鄰苯二甲酸二甲酯、二甲亞碸、二甲基二(十八烷基)銨膨潤土、二甲基甘胺酸、二甲基矽氧烷/甲基乙烯基矽氧烷共聚物、達諾殺-銨、二丙二醇、椰油兩性二乙酸二鈉、氫檸檬酸二鈉、月桂醇醚磺基丁二酸二鈉、十二基磺基丁二酸二鈉、油醯胺基單乙醇胺磺基丁二酸鹽二鈉、磺基柳酸二鈉、地索苯寧、dl-a350乳酸、dl-乙醯色胺酸、dl-α-生育酚、dl-α-生育酚乙酸酯、dl-二棕櫚醯基磷脂醯甘油、dl-二硬脂醯基磷脂醯膽鹼、dl-麩胺酸、dl-酒石酸、d-甘露糖、dmdm乙內醯脲、多可沙諾、多庫酯鈉、d-核糖、乙二胺四乙酸鈣離子二鈉、依地酸二鈉、乙二胺四乙酸鈉、依地酸、蛋磷脂醯基丙三醇、蛋磷脂、恩磺酸、恩磺酸鈉、表半乳糖、表四環素鹽酸鹽、異抗壞血酸、赤藻糖醇、乙醇胺鹽酸鹽、乙基麥芽糖醇、油酸乙酯、香草酸乙酯、乙基香草醛、乙二胺二鹽酸鹽、羥基硬脂酸乙基己酯、對羥基苯甲酸乙酯、桉油醇、丁香酚、依沙美肟、脂肪酸酯、脂肪酸甘油酯、脂肪酸季戊四醇酯、脂肪酸、脂肪醇檸檬酸酯、脂肪醇、氯化鐵、氧化鐵、四氧化三鐵、反丁烯二酸鐵、氧化亞鐵、螢光素、果糖、反丁烯二酸、反丁烯二醯基二酮哌𠯤、氧化釓、半乳糖二酸、半乳糖、γ環糊精、金雀異黃酮、龍膽酸、龍膽酸乙醇醯胺、龍膽酸乙醇胺、葡庚糖酸鈉、葡糖酸、葡萄糖酸內酯、葡糖胺、葡糖、葡糖醛酸、麩胺酸、鹽酸麩胺酸、麩醯胺酸、戊二酸、麩胱甘肽、辛酸甘油酯、二山崳酸甘油酯、二硬脂酸甘油酯、異硬脂酸甘油酯、月桂酸甘油酯、單硬脂酸甘油酯、油酸甘油酯、棕櫚酸甘油酯、棕櫚基硬脂酸甘油酯、蓖麻油酸甘油酯、硬脂酸甘油酯、硬脂酸甘油酯-月桂醇醚-23、硬脂酸甘油酯/peg硬脂酸酯、硬脂酸甘油酯/peg-100硬脂酸酯、硬脂酸甘油酯/peg-40硬脂酸酯、硬脂酸甘油酯-硬脂醯胺基乙基二乙胺、三油酸甘油酯、甘胺酸、甘胺酸鹽酸鹽、二硬脂酸酯二醇、硬脂酸酯二醇、乙醇酸、甘草素、鹽酸胍、己基間苯二酚、馬尿酸、組胺酸、玻尿酸鈉、皮質醇、對苯二酚、含水-檸檬酸、羥基乙基哌𠯤甲磺酸、羥基硬脂酸羥基二十八烷酯、羥基孕酮己酸酯、羥基丙基β-環糊精、十八酸(hystrene)、山大茴(illicium anisatum)、咪唑、咪唑啶基脲、靛藍二磺酸鈉、碘沙酸、碘非他胺鹽酸鹽、依普黃酮、異白胺酸、異硬脂酸異丙酯、十四烷酸異丙酯、十四烷酸異丙酯-肉豆寇醇、棕櫚酸異丙酯、硬脂酸異丙酯、異硬脂酸、異十八醇、乳酸酯、乳糖醇單水合物、乳糖酸、乳糖、藻酸(landalgine)、羊毛蠟、勞拉氯銨、月桂基胺氧化物、月桂醇醚硫酸酯、十二酸、十二酸二乙醇醯胺、十二酸肉豆蔻酸二乙醇醯胺、十二醯基肌胺酸、十二基乳酸酯、十二基硫酸酯、卵磷脂、白胺酸、左薄荷腦、乙醯丙酸、利多苯寧、l-乳酸鈉、離胺酸、順丁烯二酸、蘋果酸、丙二酸、麥芽糖醇、麥芽糊精、麥芽糖醇、無水麥芽糖、杏仁酸、甘露醇、磺化脂肪醇、甲溴菲寧、中長鏈甘油三酯、亞甲基二膦酸二鈉、亞甲基二膦酸、薄荷醇、間甲酚、甲硫胺酸、柳酸甲酯、硬脂酸甲酯、甲基氯異噻唑啉酮、甲基異噻唑啉酮、對羥基苯甲酸甲酯、對羥基苯甲酸甲鈉、米吡氯銨、單甘油脂及二甘油脂、磷酸二氫鈉、無水磷酸二氫鈉、磷酸二氫鈉二水合物、磷酸二氫鈉單水合物、檸檬酸單甘油酸酯、單甘油酸酯、檸檬酸單鈉、麩胺酸單鈉、檸檬酸單硬脂酯、單硫代甘油、肉豆蔻酸、肉豆寇醇、乳酸肉豆蔻酯、菸鹼醯胺、菸鹼醯胺、菸鹼酸、N-甲基還原葡糖胺、辛酸、油醇醚-20、油醇、油醇油酸酯、乳清酸、草酸、羥亞甲基二膦酸二鈉、氧基喹啉、棕櫚胺氧化物、棕櫚酸、雙羥萘酸、十五內酯、新戊四醇椰油酸酯、噴替酸五鈉、噴替酸鹽鈣離子三鈉、噴替酸、酚、防腐劑、苯氧基乙醇、苯丙胺酸、苯乙醇、磷脂、哌𠯤、哌𠯤六水合物、普魯卡因、產物蠟、脯胺酸、丙烯基乙基愈創木酚、沒食子酸丙酯、碳酸伸丙酯、丙二醇、丙二醇-卵磷脂、丙二醇海藻酸酯、丙二醇二乙酸酯、丙二醇二辛酸酯、丙二醇單月桂酸酯、丙二醇單棕櫚醯硬脂酸酯、丙二醇棕櫚基硬脂酸酯、丙二醇蓖麻油酸酯、丙二醇/重氮利定脲/對羥基苯甲酸甲酯/對羥基苯甲酸丙酯、對羥基苯甲酸丙酯、對羥基苯甲酸丙鈉、對甲苯磺酸、吡哆胺、吡哆醇(4-吡哆酸)、槲皮素、白藜蘆醇、核黃素、鄰磺醯苯甲醯亞胺、鄰磺醯苯甲醯亞胺鈣、鄰磺醯苯甲醯亞胺鈉、無水鄰磺醯苯甲醯亞胺鈉、柳酸、飽和脂肪酸酯、癸二酸、絲胺酸、1,2-乙烷二磺酸鈉、2-萘磺酸鈉、乙酸鈉、無水乙酸鈉、海藻酸鈉、烷基硫酸鈉、鈉矽酸鋁、抗壞血酸鈉、苯甲酸鈉、酸性碳酸鈉、硫酸氫鈉、硫酸氫鈉丙酮、亞硫酸氫鈉、酒石酸氫鈉、酸鈉、酸鈉十水合物、碳酸鈉、碳酸鈉十水合物、碳酸鈉單水合物、鈉羧基甲基β-葡聚糖(ds 065-085)、酪蛋白鈉、纖維素鈉、十六基十八基硫酸鈉、氯酸鈉、氯化鈉、氯化鈉注射、膽固醇基硫酸鈉、檸檬酸鈉、含水檸檬酸鈉、椰油醯基肌胺酸鈉、鈉賽克拉美、脫氧膽酸鈉、二硫磺酸鈉、十二烷基苯磺酸鈉、對羥基苯甲酸乙酯鈉、甲醛合次硫酸氫鈉、葡糖酸鈉、氫氧化鈉、次氯酸鈉、碘化鈉、乳酸鈉、月桂醇醚-2硫酸鈉、月桂醇醚-3硫酸鈉、月桂醇醚-5硫酸鈉、月桂醯基肌胺酸鈉、月桂基硫酸鈉、月桂基磺基乙酸鈉、偏亞硫酸氫鈉、硝酸鈉、油酸鈉、磷酸鈉、磷酸鈉二水合物、亞磷酸鈉、聚丙烯酸鈉、聚丙烯酸鈉(2500000 MW)、聚偏磷酸鈉、丙酸鈉、焦磷酸鈉、吡咯啶酮甲酸鈉、羥基乙酸澱粉鈉、羥基乙酸澱粉鈉a型穀粒、羥基乙酸澱粉鈉a型馬鈴薯、羥基乙酸澱粉鈉B型馬鈴薯、硬脂酸鈉、硬脂醯反丁烯二酸鈉、丁二酸鈉六水合物、硫酸鈉、無水硫酸鈉、硫酸鈉十水合物、亞硫酸鈉、磺基琥珀酸單環烷醇醯胺、酒石酸鈉、硫代乙酸鈉、硫代蘋果酸鈉、硫代硫酸鈉、無水硫代硫酸鈉、三偏磷酸鈉、三聚磷酸鈉、二甲苯磺酸鈉、山梨酸、脫水山梨糖醇、脫水山梨糖醇異硬脂酸酯、脫水山梨糖醇單月桂酸酯、脫水山梨糖醇單油酸酯、脫水山梨糖醇單棕櫚酸酯、脫水山梨糖醇單硬脂酸酯、脫水山梨糖醇倍半油酸酯、脫水山梨糖醇三油酸酯、脫水山梨糖醇三硬脂酸酯、山梨醇、角鯊烷、亞錫2-乙基己酸酯、硬酯基二甲基苄基氯化銨、司拉氯銨水輝石/碳酸伸丙酯、硬脂醯胺基乙基二乙胺、硬脂酸酯、硬脂酸、硬脂酸二乙醇醯胺、硬脂氧基三甲基矽烷、十八烷醇、丁二酸、蔗糖素、蔗糖、蔗糖二硬脂酸酯、蔗糖月桂酸酯、蔗糖棕櫚酸、蔗糖聚酯蔗糖硬脂酸酯、蔗糖糖漿、磺胺醋醯胺鈉、磺基丁醚β-環糊精、塔格糖、酒石酸、三價第三丁基對苯二酚、替曲膦、茶鹼、硫柳汞、蘇胺酸、瑞香草酚、生育酚、托可索侖、黃蓍、三醋精、三磷酸鈉、三磷酸鈉單水合物、甘油三山萮酸酯、三辛酸甘油酯、三鯨蠟硬脂醇聚醚-4磷酸鹽、月桂基硫酸三乙醇胺、檸檬酸三乙酯、三羥基硬脂精、三羊毛醇聚醚-4磷酸鹽、三月桂醇聚醚-4磷酸鹽、三肉豆蔻精、參檸檬酸三鈉二水合物、三鈉羥乙底酸、三硬脂酸甘油酯、三乙醇胺、曲金剛胺、緩血酸胺、色胺酸、泰洛沙泊、酪胺酸、十一碳烯、脲、胺基甲酸酯、熊去氧膽酸、纈胺酸、香草精、維塞胺、左旋抗壞血酸(viscarin)、維生素E、維生素E乙酸酯、維生素K5、木糖醇及硫酸鋅。亦參見美國專利第7,927,613號，其以全文引用的方式併入本文中。其他醫藥學上可接受之共形成物包括在「一般認為安全」(「GRAS」)及/或US FDA「Everything Added to Food in the United States」(「EAFUS」)清單中敍述之彼等共形成物。
在某些實施例中，一或多種醫藥學上可接受之共形成物中之至少一者選自由以下組成之群：咖啡鹼、脲、對-胺基苯甲酸、茶鹼、苯甲酸苯甲酯及菸鹼醯胺。在其他實施例中，一或多種醫藥學上可接受之共形成物為非選自由以下組成之群的共形成物：咖啡鹼、脲、對-胺基苯甲酸、茶鹼、苯甲酸苯甲酯及菸鹼醯胺。在其他實施例中，一或多種醫藥學上可接受之共形成物為非選自由以下組成之群的共形成物：乙醯胺、苯甲醯胺、2-胺基噻唑及異菸肼。在其他實施例中，一或多種醫藥學上可接受之共形成物為胺基酸(例如脯胺酸，例如D-脯胺酸或L-脯胺酸，或外消旋脯胺酸)。在另一實施例中，一或多種醫藥學上可接受之共形成物為5至10 (例如5至9、5至6，或5)員雜芳基，例如含氮雜芳基，例如咪唑。
在某些實施例中，一或多種醫藥學上可接受之共形成物中之至少一者為第二API。在某些此等實施例中，第二API獨立地選自(−)-氨氯地平(amlodipine)、(−)-鹵芬酯(halofenate)、(R)-沙丁胺醇(salbutamol)、(R)-沙丁胺醇、(R,R)-福莫特羅(formoterol)、(S)-多沙唑嗪(doxazosin)、(S)-氟西汀(fluoxetine)、(S)-奧昔布寧(oxybutynin)、1,2-萘醌、17-甲睪酮、17α-羥基孕酮、195mPt-順鉑、柳酸1-萘酯、1-萘胺-4-、1-可可鹼乙酸、1α-羥膽鈣化醇、2,4,6-三溴-間甲酚、2,6-二胺基-2'-丁氧基-3,5'-偶氮吡啶、2-[[[(1r)-2-(1h-咪唑-4-基)-1-甲基乙基]亞胺基]苯基甲基]-苯酚、21-乙醯氧基妊烯醇酮、2-胺基-4-甲吡啶、2-胺基噻唑、2-乙氧基苯甲酸、2-萘酚、苯甲酸2-萘酯、乳酸2-萘酯、柳酸2-萘酯、2-對-胺苯磺醯基(sulfanilyl)苯胺基乙醇、2-硫尿嘧啶、3',3'',5',5''-四-溴酚酞、3-胺基-4-羥基丁酸、3-溴-D-樟腦、3-羥基樟腦、3-O-月桂醯基吡哆醇二乙酸酯、3-十五基兒茶酚、3-
啶醇(quinuclidinol)、4,4'-氧基二-2-丁醇、4,4'-亞磺醯基二苯胺、4-胺基-3-羥基丁酸、4-胺基-3-苯基丁酸、4-胺基柳酸、4-氯-間甲酚、4-己基間苯二酚、4-柳醯基嗎啉、5'-硝基-2'-丙氧基乙醯苯胺、5-胺基乙醯丙酸、5-阿紮胞苷、5-溴柳基-羥肟酸、5F-DF-203、5-FU、5-HT3拮抗劑、6-氮尿苷、6-巰基嘌呤、8-羥基喹啉、9-胺基喜樹鹼、A-151892、A-5021、阿巴卡韋、阿巴哌酮、阿巴瑞克、阿昔單抗、阿貝卡爾、阿貝莫司、阿比特龍、ABLC、ABT-751、AC-5216、阿卡地新、阿坎酸、阿坎酸、阿卡波糖、乙溴菲啉、醋丁洛爾、乙醯卡尼、醋卡溴脲、醋氯芬酸、醋氨苯碸、醋地碸鈉、克醋茶鹼、乙醯穀醯胺、醋谷胺、阿西美辛、醋硝香豆醇、醋丙酸鹽、縮醛、醋胺丁香酚、乙醯胺苯酚、醋氨沙洛、乙醯苯胺、乙醯胂胺、乙醯偶氮胺、乙醯硫胺、醋磺環已脲、乙異羥肟酸、乙醯奮乃靜、乙醯苯、苯乙酮、磺胺苯碸、甘草次酸乙酸酯、醋碘苯酸、乙醯基、乙醯肉鹼、乙醯膽鹼、乙醯膽鹼、乙醯半胱胺酸、乙醯白胺酸、乙醯苯丁醯脲、乙醯基柳酸鹽、乙醯柳酸、阿昔洛韋、阿昔呋喃、阿昔莫司、阿紮司特、阿曲汀、阿克拉黴素、萘二磺酸、烏頭鹼、acranil®、吖啶黃素、吖啶瑣辛、阿伐斯丁、阿伐斯丁、阿肽加定(actagardine)衍生物、阿克他利、ACTH、阿昔洛韋、阿達帕林、ADCON-L、阿丹弗、阿丹弗迪皮夕、腺苷、三磷酸腺苷、ADEPT、阿地唑侖、阿地芬寧、ADL-10-0101、阿屈非尼、腎上腺酮、腎上腺素紅、阿屈高萊、AEOL-10150、雌三醇、AET、AF-2259、氟喹酮、AG-041R、AG-2037、AGN-194310、阿戈美拉汀、ahistan、AHL-157、AIT-034、AIT-202、AJ-9677、AJG-049、阿嗎靈鹼、阿克蘇去氧孕烯、阿拉普利、拉普西爾、阿巴康唑、阿苯達唑、沙丁胺醇、丁硫妥因、阿氯芬酸、阿氯米松、阿庫氯銨、尿囊素羥鋁、醇醛、醛固酮、阿侖膦酸鹽、阿侖膦酸、阿來西定、阿法骨化醇、阿法多龍、阿法沙龍、阿芬太尼、阿非普酶(alfimeprase)、阿夫唑嗪、阿夫唑嗪、阿爾孕酮、阿爾孕酮、海藻膠、阿糖腦苷酶、阿利苯多、阿力克倫、阿利維甲酸、阿立必利、紫草素、阿柯法酮、尿囊素、阿洛巴比妥、安樂普利諾、異硫氰酸烯丙酯、烯丙雌醇、鋁鎂加、阿明洛芬、阿米三嗪、阿莫曲普坦、蘆薈-大黃素、蘆薈素、阿洛司瓊、阿洛夫定、阿洛普令、α-、α-1蛋白酶、阿法羅定、阿吡坦、阿吡必利、阿普唑侖、阿普洛爾、阿沙克肽、ALT-711、阿爾噻嗪(Althiazid)、阿替克林(altinicline)、六甲蜜胺、鋁氯離子六水合物、試鋁靈、鋁乙酸鹽溶液、氯酸鋁、羥基氯化鋁、鋁硫酸鉀、鋁硫酸鈉、鋁硫複、阿爾維林、愛維莫潘、阿昔迪布、ALX-0646、AM-24、AM-36、AM-477、金剛胺、金剛烷胺、安邦宗(ambazon)、安貝氯銨、安立生坦、胺溴素、氨布卡因、安布茶鹼、安布賽德(ambusid)、安布溴銨溴化物、安西奈德、AMD-3100、阿姆地諾西林、阿姆地諾西林酯、安多索韋、阿美本特(amelubant)、苯唑卡因(americaine)、胺甲氧苯嗪、胺芬酸、醯胺福林、脒黴素、阿米福汀、阿米谷胺、阿米卡星、胺氯吡脒(amiloride)、氨吖啶、安咪奈丁、胺硝噻唑、胺基酸製劑、胺基己酸、胺麩精、胺基胍、對胺基馬尿酸、胺美啶、胺戊醯胺、胺茶鹼、胺丙嗪、胺基比林、胺基喹啉、阿米雷司、胺碘酮、胺氯地平、阿米苯唑、胺普立糖、胺磺必利、阿米曲替林、阿米曲替林+氯胺酮、氧阿米替林、胺來呫諾、氨草膠、氨化汞氯離子、銨苯甲酸鹽、銨杏仁酸鹽、銨柳酸鹽、銨戊酸鹽、異戊巴比妥、阿莫卡嗪、阿莫地喹、阿莫羅芬、阿莫斯卡納特(amoscanat)、胺磺洛爾、胺基三苯、阿莫沙平、阿莫西林、阿莫西林+鉀克拉維酸、AMPAlex、安非他命、安非他尼、兩性黴素B、安比西林、安吡昔康、阿普林津、安普那韋、氨吡酮、胺柔比星、安吖啶、哌氨托美丁、阿米洛卡因、AN-152、合成代謝類固醇、阿那孕酮、阿那格雷、阿那曲唑、阿那佐林、安西他濱、安克洛酶、安多司特、雄異噁唑、雄固烯二醇、阿奈可他、大茴香腦、大茴香腦三巰基、生成血管素、血管收縮素、脫水長春花鹼、阿尼芬淨、氨苄哌替啶、茴拉西坦、茴茚二酮、茴香黴素、辛托品、阿尼普酶、安他唑啉、安銻鋰明、蒽三酚、安麴黴素、蒽羅彬、煤質抑制劑、抗血管生成、抗凝血劑、抗抑鬱劑、抗侵襲素、銻鉀酒石酸鹽、銻鈉巰基乙酸鹽、銻巰基乙醯胺銻、抗孕激素、安替比林、安替比林柳酸鹽、抗凝血酶III、抗焦慮劑、AP-521、AP-5280、阿帕西林、阿帕茲醌、阿帕宗、阿樸可特因、阿朴嗎啡、阿朴嗎啡、阿拉可樂定、阿匹坦、阿普林定、阿普比妥、烯丙異丙乙醯脲、抑肽酶、阿替加奈、AQ4N、阿卡文(aquavan)、AR-116081、AR-A2、二十碳四烯酸、阿雷地平、阿貝卡星、阿比朵爾、阿布他明、阿西莫單抗、阿地肝素、檳榔鹼、阿加曲班、精胺酸、Ariflo®、阿立哌唑、阿羅茶鹼、阿羅洛爾、阿撤西丁、三氧化二砷、阿斯凡納明、蒿乙醚、阿替夫林、蒿甲醚、青蒿素、蒿乙醚、青蒿琥酯、阿佐昔芬、AS-3201、ASA、阿斯利多、抗壞血酸、阿塞那平、阿西馬朵林、阿卡波肼(asocarboxazid)、索普瑞尼、乙醛肟、天冬胺酸、三叉蕨素、綿馬素、阿司匹靈、阿司匹靈二吡待摩、阿撲西林、AST-120、阿司咪唑、奧沙那寧、AT-1015、阿他美坦、阿紮那韋、阿替洛爾、阿替洛爾+氯噻酮、阿替洛爾+硝苯地平、阿替韋啶、阿替美唑、阿替莫德二順丁烯二酸鹽、ATL-146e、阿托西汀、阿托伐他汀、阿托西班、阿托喹酮、阿托喹酮+氯胍、阿曲庫銨、阿曲生坦、心房利鈉、苯乳胺、阿托品、奧格門汀、金諾芬、硫代葡萄糖金、阿伐麥布、阿伏苯宗、AWD-12-281、阿紮胞苷、阿紮環醇、阿紮硝唑、阿紮丙酮、偶氮絲胺酸、阿紮司瓊(azasertron)、阿紮他啶、咪唑硫嘌呤、AZD-4282、AZD-6140、壬二酸、氮拉斯汀、阿折地平、疊氮氯黴素、阿度西林、阿齊利特、阿嗪米特、阿奇黴素、阿洛西林、阿佐寒米、安曲南、甘菊藍、巴胺西林、桿菌肽、巴氯芬(baclofen)、黃芩素、巴洛沙星、巴柳氮、班布特羅、巴美生、巴米茶鹼、巴米品、巴比妥、巴尼地平、BAS-118、鹼性氧化鋁、巴斯利昔單抗(baslilximab)、巴馬司他、巴曲酶、Bay-41-2272、Bay-41-8543、BAY-43-9006、BAY-57-1293、巴澤昔芬(bazedoxifen)、BBR-3464、BBR-3576、BBR-3610、BCH-1868、比比林(bebeerine)、苄氯丙醯胺、倍氯米松、貝氟沙通、比凡洛爾、貝美格、苯乃靜、貝那普利、苄環烷、苄達酸、苄氟噻嗪、苯曲安奈德、貝奈克酯、苯氟雷司、苯磷硫胺、苯呋地爾、貝尼地平、貝諾酯、苯惡洛芬、丁氧普魯卡因、苯哌利多、苯丙哌林、苄絲肼、苯他西泮、苯替酪胺、本托奎塔姆(bentoquatam)、苯紮貝特、苯甲烴銨、苯紮隆、苯乍生、苯溴馬隆、苯乙銨、苄替米特、苯二甲烴銨、苯碘達隆、苄硝唑、苯唑卡因、苯佐他明、苯佐那酯、苯佐氯銨、過氧化苯甲醯、苯沙酸鈣、苄非他明、苄哌立隆、苯喹胺、苄噻嗪、苯紮托品、苄達明、苯甲酸苯甲酯、苯甲基氫氯-噻嗪、苯甲基嗎啡、酚乙銨、貝他斯汀、苄普地爾、貝前列素、小蘖鹼、香柑內酯、柏莫洛芬、貝西吡啶、倍他司汀、甜菜鹼、倍他米松、倍他米隆、必妥碘、倍他洛爾、倍他唑、烏拉膽鹼、苄二甲胍、貝托卡因、貝凡洛爾、貝弗甯、貝瑟羅汀、貝齊米特、BG-9928、BIA-2-024、BIA-2-093、BIA-3-202、卡馬風、比阿培南、二苯醚銨、鉍溴酚、比卡魯胺、比西發定、比西酯(bicisate)、雙環、比地索胺、比坦維林、胺醇醋茶鹼、比他舍平、雙法蘭(bifermelane)、戊雙氟酚、聯苯苄唑、比馬前列素、氯吡哌醇、比莫西糖、比尼貝特、比諾狄森(binodenoson)、生物醫學-101 (biomed-10)、生物素、比哌立登、比立哌隆(biriperone)、比爾科達(birlcodar)、吡沙可啶、比生群、雙苯醯硫胺、雙癸喹啉、鉍、鉍、鉍、鋁酸鉍、鉍乙基、鉍鈉、胺三乙酸鉍鈉、次碳酸鉍、次沒食子酸鉍、次硝酸鉍、鉍次柳酸、比索洛爾、比索洛爾+HCTZ、比索洛爾+三氯噻嗪、雙酚沙丁、硫雙二氯酚、比托特羅、雙硫氰苯(bitoscanat)、BL-3875、博萊黴素、布南色林、BMS-184476、BMS-387032、BN-82451、BNP-7787、BO-653、勃雄二醇、勃拉睪酮、勃地酮、波吲洛爾、氯𦯉、柳酸𦯉酯、硼替佐米、波生坦、泊拉得可、腦利鈉、溴烯巴比妥、布索芬新、布喹那、溴苄乙胺、亮綠、溴莫尼定、布林佐胺、溴呋啶、溴莫普林、溴西泮、溴芬酸、溴己新溴化物、溴茚二酮、溴異戊脲、溴麥角環肽、溴-苯海拉明、溴仿、溴必利、溴-柳氯苯胺、溴哌利多、溴苯那敏、溴帕雌烯、溴匹立明、布洛利辛、溴替唑侖、溴長春胺、溴氧喹啉、布羅祖里丁(brozuridine)、馬錢子鹼、布西丁、布西拉明、布新洛爾、布拉地新、安其敏(buclizine)、丁氯柳胺、布可隆、丁吖卡因、布庫洛爾、布地奈德、布地奈德+福莫特羅、布地品、布肼酞嗪、丁苯碘胺、布非洛爾、丁苯羥酸、丁咯地爾、丁雙胍、丁呋洛爾、布瑪迪腙、布美他尼、丁萘夫汀、碘桂酸鈉、布那唑嗪、布尼洛爾、布比卡因、布拉洛爾、丁基原啡因、安非他酮、布拉胺酯、布舍瑞林、丁螺環酮、白消安、白消安、布塔巴比妥、布他卡因、布他西丁、布他拉胺、布他比妥、丁溴比妥、胺苯丁酯、布他米酯、布坦卡因、布他哌嗪、布他維林、布他唑胺、丁酸、布替萘芬、布特薩、布替他酯、丁胺卡因、丁硫妥、布噻嗪、布替布芬、布替君、布托苯定、布康唑、布醯胺、丁非洛爾、布托啡諾、丁托西卡因、布替林、布托溴銨、丁硫基月桂酯、丙酸丁酯(butyrate propio)、甲碘布卓、BVT-5182、BXT-51072、C-1311、卡麥角林、卡麥角林、二甲次胂酸、放線菌素C、卡地姆碘、柳酸鎘、卡屈嗪、卡法米諾、咖啡鹼、骨化二醇、鈣泊三醇、鈣泊三醇、鈣泊三醇+倍氯米松、促鈣三醇、3-硫-2-丙醇-1-磺酸鈣、乙醯基柳酸鈣、溴化乳糖醛酸鈣、碳酸鈣、葡糖酸鈣、甘油磷酸鈣、蛇麻酸鈣、碘二十二烷酸鈣、碘十八酸鈣、乳酸鈣、乙醯丙酸鈣、二羥丙二酸鈣、N-胺甲醯基天冬胺酸鈣、聚卡波非鈣、丙酸鈣、丁二酸鈣、卡爾達雷(caldaret)、卡魯睪酮、卡馬西泮、卡莫司他、樟腦、樟腦酸鹽、樟吡他胺、喜樹鹼、坎地沙坦、坎地沙坦酯、坎沙曲、卡奈替尼、坎利酮、斑蝥素、坎妥珠單抗美登素、卡培他濱、克冠酸、卡普拉林、卡羅單抗、番椒素乳霜、卡普托胺、卡托普利、卡托普利+HCTZ、卡普脲、卡拉博沙(carabersat)、卡拉美芬、卡拉洛爾、碳醯膽鹼、卡馬西平、過氧化尿素、卡巴砷、加保利、卡巴克洛、貝芬替、卡本西林、生胃酮、噴托維林、碳卡賓(carbicarb)、卡比多巴、卡比多巴+左旋多巴-1、甲亢平、卡比沙明、卡波氯醛、羧甲半胱胺酸、四氯化碳、碳酸鹽凝膠、卡鉑、卡前列素、卡前列素、卡波醌、阿達林、卡布比妥、胺磺丁脲、卡布特羅、卡非胺酯、卡哥魯酸、卡古縮宮素、卡茚西林、卡立伯來德、卡立泊來德、肌安寧、卡莫氟、卡莫昔羅、卡莫司汀、肉鹼、卡羅維林、卡羅沙酮、丙醯奮乃靜、卡巴咪嗪、卡洛芬、卡沙蘭、卡替洛爾、卡替卡因、卡柔比星、卡蘆莫南、香芹酚、卡維地洛、香芹酮、美鼠李皮素(cascarillin)、卡泊芬淨、兒茶素、組織蛋白酶K抑制劑、組織蛋白酶S抑制劑、CC-401、CCI-779、CCR5拮抗劑、CDC-394、CDC-801、CEE-03-310、頭孢克洛、頭孢羥胺苄、頭孢胺苄、頭孢胺苄酯、頭孢孟多、頭孢曲秦、頭孢西酮、頭孢唑林、頭孢拉宗、頭孢卡品酯、頭孢克定、頭孢地尼、頭孢托侖酯、頭孢吡肟、頭孢他美、頭孢他美酯、頭孢克肟、頭孢甲肟、頭孢美唑、頭孢米諾、頭孢地秦、頭孢尼西、頭孢哌酮、頭孢哌酮+舒巴坦、頭孢雷特、頭孢噻利、頭孢噻肟、頭孢替坦、頭孢替安、頭孢替安酯、頭孢西丁、頭孢唑蘭、頭孢咪唑、頭孢匹胺、頭孢匹羅、頭孢泊肟、頭孢丙烯、頭孢沙定、頭孢磺啶、頭孢他啶、頭孢特侖、頭孢替唑、頭孢布坦、頭孢唑肟、頭孢唑肟、頭孢曲松、頭孢呋辛、頭孢呋辛醋乙氧、頭孢唑喃、塞內昔布、西戈斯韋、塞利洛爾、纖維素乙基、CEP-1347、CEP-701、頭孢賽曲、吐根酚鹼、頭孢氨苄、頭孢來星、頭孢噻啶、頭孢菌素C、先鋒黴素、吡硫頭孢菌素、頭孢拉定、西立伐他汀、西羅普利、舍托肝素、藍肽、地諾前列酮(cerviprost)、西他氮銨、塞他洛爾、西塞溴銨、喹紅黴素、西替地爾、西替利嗪、西替利嗪、西替利嗪+假麻黃素、西托硫胺、西托肟、西曲酸酯、鯨蠟基三甲基銨、西曲瑞克、十六烷基-銨、十六烷基吡啶、西維美林(cevimeline)、CG-1521、大風子油酸、二羥基膽酸、CHF-3381、氯苯達諾、氯酚嗪、氯醛、苯丁酸氮芥、氨胺-B、氨胺-T、氯胺-氯胺苯醇、氯拉紮尼、氯苄沙明、氯倍他胺、氯環嗪、氯登妥因、氯胍、氯醛已醇、氯己定、氯氮卓、松達氯銨、氯地孕酮、氯汞君、氯美紮酮、氯苄達唑、萘氮芥、氯脒佐定、葉綠素、氯普賴松、氯普魯卡因、氯吡拉敏、氯奎、氯森、氯噻嗪、氯三芳乙烯、氯喔星、氯二甲酚、氯脲菌素、氯苯那敏、氯苯甘油醚、氯芬尼拉明、克立法胺、氯苯安明、氯苯丁胺、氯丙沙嗪、氯丙胍、氯丙胍+氨苯碸、氯丙嗪、氯磺丙脲、氯丙硫葸、氯喹那多、氯四環素、氯噻酮、氯西諾嗪、氯唑沙宗、膽酸、膽鹼、膽茶鹼、L-甘磷酸膽鹼、色酮甲酸、卡波羅孟、柯衣定、CHS-828、CI-1031、CI-1040、西苯唑啉、環索奈德、西氯他寧、環菸酯、環吡酮、環西多明、環孢菌素A、西多福韋、西苯唑啉、西蘭司瓊、西司他汀、西拉普利、西侖吉肽、西尼地平、西洛司特、西洛他唑、西咪替丁、西托溴銨、西那卡塞、辛可尼丁、辛可甯、辛可芬、桂哌酸、桂哌齊特、桂哌齊特、西尼必利、桂美辛、桂麻磺鹼、桂利嗪、西諾西泮、西諾沙星、西諾沙酯、桂溴胺、塞奧羅奈、西潘茶鹼、環丙沙星(cipralisant)、環丙貝特、環丙沙星、環丙沙星+西拉馬多、西沙必利、順式阿曲庫銨、順鉑、西它普蘭、胞磷膽鹼、西替沃酮、檸檬酸鹽、檸檬酸、瓜胺酸、西唑來汀(cizolirtine)、CJ-13610、CKD-602、克拉屈濱(cladribine)、利膽丁酸、克拉黴素、克拉維酸、棒酸二鈉、克拉維酸、氯波必利、氯馬斯汀、克立咪唑(clemizol)、克侖特羅、克侖硫卓、氯維地平、克來夫定、環氯茚酸、環奎二苯酯、克林沙星、克林達黴素、克林達黴素、克林達黴素+維甲酸、克利貝特、克林前列素、氯巴占、氯苄呋醇、氯苄葡甙、氯苯西泮、氯苄苯丙胺、氯苯托品、倍氯松、可洛貝他松、氯苯胺丁醇、氯卡帕明、氯西尼嗪、氯康唑、氯可托龍、氯屈膦酸鹽、氯膦酸、氯法拉濱、氯法齊明、氯非那胺、氯貝丁酯、氯貝酸、鹵卡班、氯福克酚、氯福雷司、氯馬克侖、氯雌酮甲醚、氯美辛、氯美噻唑、氯甲西林、氯米芬、氯米帕明、氯莫環素、可那氮平、可樂定、氯尼他秦、氯硝甘油、氯尼辛、氯吡胺(clopamid)、氯哌噻噸、氯哌斯汀、克羅匹多、氯吡酸、氯潑尼醇、氯拉洛爾、氯氮酸、氯索隆、氯克羅孟、氯茚二酮、氯喘通、鄰氯苯丁胺、氯螺旋嗪、氯睪酮、氯噻平、氯噻西泮、克氯黴唑、克氯黴唑+倍他米松、氯唑西林、氯噁唑侖、氯索睪酮、氯羥喹啉、氯氮平、CMI-392、CMT-3、CNI-1493、CNS-5161、腺苷鈷胺、乙基苯醯芽子鹼、可卡因、可待因、輔因子、秋水仙鹼、考來維侖、考來替蘭、考來替潑、考福辛達羅帕特、考福西利、考萊戈夫(collagraft)、藥西瓜瓤苷、雙醋羥雌酮(colpormon)、考拉西坦、康普瑞汀A-4前藥、化合物B、考尼伐坦共軛物、康奈蒂維納(connettivina)、鈴蘭毒甙、科帕臘芬內特(coparaffinate)、綿羊可的瑞林、皮質酮、皮質酮、可的伐唑、促皮質素、可他寧、可替甯、複方磺胺嘧啶、庫美香豆素、CP-248、CP-461、CPC-211、CPI-1189、CRA-0450、肌肉醇-O-磷酸酯、CRL-5861、克羅奈汀(crobenetine)、氯康唑、色甘酸、色甘酸、克羅丙胺、克羅米通、巴醯乙醯胺、克立他殺(crystacide)、CS-502、CS-758、CS-834、CT-052923、CT-32228、檸檬酸銅、銅克索林、CVT-2584、CX-659S、氰乙醯肼、氰美馬嗪、花青色素、CYC400、環己西林、環己杏仁酸鹽、環佐辛、環沙酮、環絲胺酸、索布瑞醇、環D1抑制劑、賽克利嗪、環巴比妥、環苯達唑、環苯紮平、環丁酸醇、環香豆素、環戊君、環芬尼、氯胍三嗪、環甲卡因、環納洛地德(cycloniumelodide)、環噴他明、環戊噻嗪、環戊巴比妥、環戊通、環磷醯胺、環丙胺、環絲胺酸、環噻嗪、環香草酮、磁麻苷、環絲胺酸、洋薊酸、cyp26抑制劑、塞庚啶、環丙孕酮、半胱胺、囊胞性纖維症劑(cystic fibrosis ther)、阿糖胞苷、D-24851、D-4418、DA-5018、DA-6034、DA-7867、DA-7911、DA-8159、達卡巴嗪、達利珠單抗、放線菌素d、達巴黴素、達福普汀、達福普汀+奎奴普丁、達肝素、達爾卓潘、達那肝素、達那唑、丹蒽醌、丹曲洛林、達哌唑、達匹韋林、達泊西汀、氨苯碸、達托黴素、阿法達貝泊汀、達非那新、道諾黴素、DAX＜ SciClone、DB-67、D-莰佛羧酸、DCF-987、DDT、去氨催產素、丹醇、異喹胍、十甲烯胺、癸氧醯胺、地西他濱、地氯普胺、去鐵酮、去鐵胺、地夫可特、地磷醯胺、地加瑞克、去氫抗壞血酸、去氫依米丁、去氫膽酸、德爾普里+馬尼地平、地拉普利、迪拉韋啶、地馬孕酮、地莫匹醇、地洛西泮、迪魯西明、二甲醯、地美溴銨、地美環素、地美可辛、地美孕酮、地美替林(demexiptilline)、地那維林、樹枝狀聚合物、地尼白介素、地諾帕明、迪諾特寧、去氧膽酸、去氧皮質固酮、地素嗎啡-鏈黴素、去氧腎上腺素、地普奧肽、縮酚酞、地潑托品、地喹銨、德沙拉嗪、地舍平、去鐵胺、地氟烷、地昔帕明、去乙醯毛花苷、地氯雷他定、德舍瑞林、去胺加壓素、去氧孕烯、去氧孕烯+雌二醇、去氧孕烯+炔雌醇(1)、地索嗎啡、地奈德、去羥米松、右旋糖酐、德瓦卡德(devacade)、地塞米松、地塞比諾、右卡多曲、右依法克生、右苄替米特、右布洛芬、右酮洛芬、右氯穀胺、迪美得托咪汀、德克莫西特、右泛醇、右雷佐生、聚葡萄糖-1、聚糖酐、右旋安非他命、右甲嗎喃、右旋嗎拉邁得、右旋丙氧吩、地佐辛、DF-1012、DFA-IV、D-葑酮、D-葡糖醛酸內酯、Diab II、雙醋瑞因、地恩丙胺、雙胺噻唑、地百里碸、泛影酸鹽、安定、亞胺醌、二氮嗪、地貝卡星、二苯西平、雙溴丙脒、狄布卡因、氯醛比林、二氯胺T、二氯松、二氯苯甲基醇、二氯丙醇、二氯酚、二氯苯胂、雙氯非那胺、雙氯芬酸、雙氯芬酸+HA、雙氯西林、雙香豆素、雙香豆素、雙環維林、去羥肌苷、雙脫氧腺甘酸、地多西、雙烯雌酚、地諾孕素、地諾孕素+雌二醇、二乙二酮、二乙嗪、二乙胺、二乙基溴-乙醯胺、二乙碳醯嗪、二乙胺苯丙酮、己烯雌酚、雙苯美林、二苯米唑、地芬諾新、聯苯吡胺、二氟替康、二氟拉松、二氟沙星、氟米松、二氟尼柳、二氟潑尼酯、毛地黃苷、洋地黃毒苷、地高辛、雙己維林、雙肼酞嗪、二氫可待因、醋氫可待酮、二氫麥角隱亭、二氫麥角隱亭、二氫麥角胺、二氫嗎啡、二氫鏈黴素、二氫速留醇、二羥基鋁、地索普明、二異丙基巴拉奧克松、二異丙基胺、地拉齊普、地來洛爾、二氯尼特、地爾硫卓、地美羅酸、二甲弗林、二葡甲胺、二甲嗎喃、茶苯海明、地美沙多、美沙醇、二巰基丙醇、二甲他林、二甲二酮、二甲沙生、二甲茚定、二甲異喹、二甲炔酮、二甲卡因、地美索酯、二甲亞碸、二甲噻丁、二甲福林、地莫拉明、地諾前列酮、閃長岩(diosmectite)、地奧司明、地奧沙屈、嗎苯丁基(dioxaphetyl)、二羥西君、二羥苯酮、二苯馬尼、二苯茚二酮、二苯莎草酮、苯海拉明、地芬尼多、苯乙哌啶、二苯拉林、雙苯他胂、吸附型白喉&破傷風類毒素及非細胞的百日咳疫苗、地匹哌酮、地匹福林、雙嘧達莫、雙嘧達莫、地匹乙酯、安乃近、地誇磷索、地紅黴素、帕米膦酸二鈉、地索苯寧、丙吡胺、地斯的明、二磺法胺、二硫龍、地他唑、碘二噻寧、蒽三酚、二硫卡鈉、二黃原酸、地西拉嗪、DJ-927、DK-507k、DL-乳酸、DMDC、DMXAA、DNA史蒂斯、氫醌磺酸鹽、多巴酚丁胺、多卡巴胺、歐洲紫杉醇、二十二碳六烯酸、二十二醇、多庫酯、多非利特、多拉司瓊甲磺酸鹽、多米奧醇、度米芬、多米曲班、多潘立酮、多奈派齊、多尼曲坦、多巴胺、多培沙明、達馬莫德、多拉噠唑、多尼培南、多佐胺、多佐胺+噻嗎洛爾、多司馬酯、度硫平(dosulepine)、多他利嗪、度琉平、多沙氯銨、多沙普侖、多沙唑嗪、度氟西泮、去氧苯妥英、多塞平、度骨化醇、脫氧氟尿苷、多索茶鹼、小紅莓、多西環素、抗敏安、DPC-817、DPI-3290、DQ-113、六氫芬甯、屈洛昔芬、甲酚曲唑、屈他雄酮、屈大麻酚、決奈達隆、氟哌利多、氫普拉明、羥丙哌𠯤、屈螺酮、屈他維林、羥蒂巴酚、屈惡昔康、屈昔多巴、屈昔多巴、DU-125530、度洛西汀、耐久黴素、硬羥基磷灰石、度他雄胺、DW-1141、DW-286a、DW-471、DX-9065a、DY-9760e、達克羅甯、地屈孕酮、地孟汀(dymanthine)、二羥丙茶鹼、E-1010、E-2101、E2F拮抗劑、E-3620、E-5564、E-5842、E-6259、EAA-90、依巴司汀、依柏康唑、乙溴替丁、依布硒啉、埃那矛寧、依卡派特、依卡倍特、依卡曲爾、脫水芽子鹼、芽子鹼、二乙氧膦醯硫膽鹼、益康唑、依考匹泮、艾克前列素、依克替脲、ED-71、依達拉奉、依達曲沙、乙二胺四乙酸鈣、依地酸二鈉、乙二胺四乙酸鈉、乙二胺四乙酸三鈉、艾多南坦、艾多替德、依度尿苷、依決洛單抗、艾卓酚、依法鋰(efalith)、乙丙昔羅、依法韋侖、乙氟利嗪、二氟甲基鳥胺酸、乙酯黃酮、艾弗醯胺、依福地平、EGIS-7229、埃格蘭梅德(eglumegad)、乙哌侖、依拉非班(elarofiban)、依降鈣素、二十碳五烯酸、依來多辛、依來曲普坦、依高地平、土耳其鞣酸、依利銨、依託拉嗪、艾夫他濱、依沙索南、摁貝素、恩布拉敏、依美斯汀、苯丁乙甲銨、吐根素、乙嘧替氟、EMM-210525、大黃素、依莫法宗、EMR-62203、安卓西他賓、依米氨酯、依那普利、依那普利拉、巴丙甲巴比妥(enallylpropymal)、恩卡胺、恩西拉嗪、恩屈嗪、因法來酸、安氟醚、恩康唑、恩尿嘧啶、ENMD-0995、依諾他濱、烯醇-3-IPA、依諾沙星、依諾肝素、依諾昔酮、甘草次酸、恩前列素、恩拉生坦、恩他卡朋、因提弗、恩維黴素、腎上腺素、依帕司他、拉米夫定、EPC-K1、乙哌立松、依培夫定、麻黃素、依匹西林、表美雌醇、依匹斯汀、依匹唑、表柔比星、環硫雄醇、依普利酮、依利色林、依前列醇、環氧司坦、依普拉酮、愛普列特、依普羅沙坦、依普羅醇、依他匹隆(eptapirone)、依鉑、依斯的明、依他佐辛、埃替非巴肽、馬萘雌酮、馬烯雌酮、ERA-923、厄多司坦、麥角柯寧鹼、麥角異柯寧鹼、甲磺酸二氫麥角鹼、麥角新鹼、麥角固醇、麥角胺、香菇嘌呤、埃羅替尼、厄他培南、四硝酸季四醇酯、紅白金花內酯、紅黴素醋硬脂酸鹽、紅黴素格木鹼、紅黴素依託酸鹽、紅黴素葡庚糖酸鹽、紅黴素乳糖酸鹽、紅黴素丙酸鹽、紅黴素硬脂酸鹽、司丙紅黴素、艾沙拉唑、草酸依西普蘭、馬栗樹皮苷、依色林丁、艾司洛爾、埃索美拉唑、艾司唑侖、酯、雌二醇、雌二醇、雌氮芥、雌三醇、雌激素、雌酮、右佐匹克隆、乙基麻黃鹼、依他苯酮、依他茶鹼、依那西普、依他噠唑、依他喹酮、依特比妥、依沙吖啶、依他尼酸、乙惡二酮、乙胺丁醇、香草二乙胺、酚磺乙胺、乙醇胺、依沙維林、乙氯維諾、乙柳醯胺、乙噻嗪、炔己蟻胺、乙炔基雌二醇、乙炔基雌二醇、乙炔基雌二醇、乙硫異菸胺、炔孕酮、依索庚嗪、乙丙嗪、乙琥胺、乙妥英、依索唑胺、乙苯托品、乙醇、雙香豆素乙酸乙酯、氯乙烷、地布酸乙酯、乙基醚、廿六烷五烯酸乙酯、氯氟卓乙酯、氯氟卓乙酯、乙胺、伸乙基、乙雌烯醇、亞乙基、乙基甲基-噻吩丁烯胺、乙基嗎啡、乙諾那林、炔諾醇、乙炔基胞嘧啶核苷、依替卡因、依替膦酸鹽、依替膦酸、雙苯次甲丁胺、依替福辛、依替福林、乙左多巴、艾潑諾酯、依塞羅酯、依替唑侖、依託度酸、依託羥嗪、依託芬那酯、依託貝特、乙羥茶鹼、益多酯、羥乙茶鹼菸酸酯、依託格魯、依託咪酯、依託多林、依託尼秦、依託孕烯、依託哌酮、依託泊苷、磷酸依託泊苷、依他昔布、乙苯惡啶、依託唑啉、依曲替酯、乙基色胺、乙異丁嗪、尤卡托品、丁香酚、EUK-134、EUK-189、伊凡氏藍、依維莫司、依沙醯胺、依沙美肟、依昔替康、依西美坦、依昔苯酮、依昔舒林、Exosurf®、依澤替米貝、因子IX、因子VIII、因子XIII、法多咪定、法屈唑、氟骨三醇、泛昔洛韋、法莫替丁、氨吡啶、泛鬥沙星、泛托法隆、法羅培南、法羅培南酯、法西多曲、法舒地爾、法劄溴銨溴化物、非巴氨酯、非布丙醇、非布司他、非多托嗪、非巴馬特、聯苯乙酸、非洛地平、苯賴加壓素、非莫西汀、芬貝西林、芬布芬、芬布酯、芬坎法明、芬咖明、芬克洛酸、芬地林、芬度柳、芬乙茶鹼、氟苯丙胺、苯戊醇、非諾貝特、非諾多泮、非諾洛芬、非諾特羅、非諾維林、苯氧唑啉、非諾地爾、非諾唑酮、芬戊二醇、芬哌丙烷、苯維溴銨、氰乙苯丙胺、芬喹唑、非瑞替尼、芬司匹利、芬太尼、芬替酸、芬替克洛、芬替康唑、芬托溴銨溴化物、非普地醇、非普拉宗、乙二胺四乙酸鐵鈉鹽、鐵胺B、鐵膽鹽、葡糖酸鐵、奈米氧化鐵、弗斯特羅定、非索非那定、非博斯特(fibrostat)、非達司他、費度唑嗪(fiduxosin)、非那雄安、芬羅唑(finrozole)、非哌西特、FK-960、夫拉平度、福佛賽、氟卡尼、氟羅沙星、氟辛克生、氟立班絲氨、夫洛非寧、氟氧頭孢、夫洛丙酮、夫洛梯隆、氟司喹南、氟氯西林、氟尿苷、氟星精、氟阿尼酮、氟桂利嗪、氟斯特酮、氟紮可特、氟氯奈德、氟氯西林、氟康唑、氟胞嘧啶、氟達拉賓、氟脫氧葡糖F18、氟地西泮、氟氫可的松、氟芬那酸、氟茚二酮、氟馬西尼、氟美西諾、氟甲喹、氟米松、氟甲噻嗪、氟尼縮松、氟硝西泮、氟諾洛芬、丙酮化氟新龍、膚輕鬆SAL、醋酸氟輕鬆、氟可丁丁基、氟可龍、螢光素、氟苯乙碸、氟米龍、氟沙侖、氟尿嘧啶、氟西汀、氟甲睪酮、氟哌噻噸、氟培龍、氟非那嗪、氟魯匹汀、氟潑尼定乙酸酯、氟普賴蘇穠、氟丙喹宗、氟氫縮松、弗拉西泮、氟比洛芬、氟紅黴素、氟孕酮、六氟二乙酯、氟乙烯醚、氟斯必靈、氟他胺、氟噁唑蘭、氟替卡松、氟托西泮、氟曲馬唑、氟托銨溴化物、氟伐他汀、氟伏沙明、葉酸、醛葉酸、甲吡唑、福米諾苯、福米韋生、福莫卡因、二甲替嗪、方達珀魯、甲醯勃龍、福美司坦、氟甲醯龍、福莫特羅、夫沙那韋、膦甲酸、磷雌酚、福司氟康唑、磷黴素、磷黴素、磷柳酸、福辛普利、磷苯妥英、福莫司汀、呋羅培南、夫羅曲普坦、果糖、果糖-1,6-二磷酸鹽、FTC、FTY-720、福多司坦、氟維司群、富馬吉林(fumagiline)、夫馬菌素、呋喃它酮、夫拉紮勃、呋喃唑酮、呋唑氯銨氯化物、呋喃苯胺酸、呋喃苯胺酸、索銨、呋索銨、梭鏈孢酸、G1、YM生物科學、G25、GABA-A Alpha5、加巴噴丁、加貝酯、加波沙朵、釓貝酸鹽、釓布醇、釓雙胺、釓、釓噴酸、釓特醇、釓弗塞胺、釓塞酸、加蘭他敏、加蘭他敏、加柔比星、加拉明三乙碘化物、五倍子酸、麥芽糖酸鎵、硝酸鎵、加洛帕米、加奈索酮、更昔洛韋、加尼瑞克、更斯的明、更托非班、加雷沙星、加諾司亭、加替沙星、吉法酯、吉非替尼、吉卡賓、吉西他濱(gemcitabine)、吉美前列素、吉非羅齊、吉米沙星、慶大黴素、龍膽紫、龍膽苦苷、龍膽酸、吉培福林、吉哌隆、孕二烯酮、孕二烯酮+乙炔、孕諾酮己酸鹽、孕三烯酮、吉馬替康、吉拉克肽、吉妥辛、GL-406349、格拉非寧、格拉默、格列波脲、格列齊特、格列美脲、格列吡嗪、格列喹酮、格列索脲、格列派特、球蛋白(人類)、葡美辛、葡糖庚酸、葡糖酸、葡糖胺、葡氨苯碸、葡磷醯胺、麩胺酸、戊二醛、格魯米特、格列本脲、格列噻唑、格列丁唑、丙三醇、甘油磷酸鹽、胍基乙酸、二醇柳酸鹽、葡菸腙、格隆溴銨、格列己脲、格列嘧啶、格列平脲、GMDP、金鈉、戈舍瑞林、GPI-1485、GPI-5693、皮膚替代物、格拉司瓊、格帕沙星、灰黃黴素、愈創木酚、哌苯四醚、愈創藍油烴、愈創甘油醚、胍美柳、瓜拉醇磺酸鹽、胍甲環素、胍那苄、胍那決爾、胍乙啶、胍法新、胍諾沙苄、胍生、香膠甾酮、胍立莫司、GW-280430A、GW-320659、GYKI-16084、曲古黴素、哈拉西泮、哈西奈德、鹵貝他索、鹵泛曲林、鹵米松、氟哌啶醇、鹵普賴松、鹵苯炔醚、溴氟丙烷、氟烷、鹵噁唑侖、哈克塞得、HE-2000、希洛斯(healos)、血卟啉、癸菸酯、美多眠、氨甲庚醇、海他西林、羥乙基澱粉、己曲安縮松、六氯酚、海地美銨、己茀銨、六甲銨、己脒定、己丙氨酯、海克西定、己雌酚、己雌酚雙(β-二乙胺基乙基醚)、己巴比妥、海克替啶、六巴比妥鹽、海索苯定、己環銨硫酸甲酯、海索那林、羥乙基澱粉、海克卡因、HF-0299、HGP-2、HGP-6A、海曲司明(hidrosmin)、組織胺、希司咯定、組胺瑞林、HM-101、HMN-214、後馬托品、後莫肯芬、高氯環嗪、胡泮酸、HP-228、石杉鹼A、玻尿酸、羥胺硫蒽酮、氫氰酸、肼酞嗪、白毛莨鹼、白毛茛分鹼、氫氯噻嗪、氫可酮、氫可松胺酯、皮質醇、皮質醇、氫氟噻嗪、氫嗎啡酮、氫化奎尼丁、氫化奎寧、對苯二酚、氫氧化、羥鈷胺素、羥基苯丙胺、羥基氯奎、羥孕酮酯、羥基乙基醚、羥基萘甲酸鹽、羥哌替啶、奧芬氨酯、羥丙基纖維素、羥芪巴脒、羥丁卡因、羥嗪、海蘭G-F 20、羥甲香豆素、茛菪鹼、金絲桃毒、IACFT、伊班膦酸、異波帕胺、異波帕胺、布突默單抗、艾溴利平、異丁司特(ibudilast)、異丁芬酸、布洛芬、布洛芬吡啶甲醇、異丁普生、伊布利特、ICA-17043、伊考糊精、艾達黴素、咪唑克生、IdB-1016、艾地苯醌(idebenone)、IDN-5109、依多西芬(idoxifen)、艾卓肝素、羥乙桂胺、艾芬地爾、異環磷醯胺、艾拉莫德(iguratimod)、艾普拉唑、伊洛馬司他、伊潘立酮、伊洛前列素胺丁三醇、ILX23-7553、加以域、咪達普利、咪唑柳酸鹽、亞胺培南、丙咪嗪、丙咪嗪N-氧化物、咪喹莫特、伊莫拉明、英普他派、英丙舒凡、不活化、依那立松、因卡膦酸鹽、英卡膦酸、吲達品、茚唑啉、吲達帕胺、英地卡胺(indecainid)、茚氯嗪、茚氯嗪、茚心安、茚地那韋、茚地普隆、吲地司瓊、依地蘇蘭、吲哚布芬、吲哚花青綠、吲哚美辛、吲哚洛芬、吲哚拉明、吲哚斯萊(induclem)、英利昔單抗、抑制劑、抑制劑、異丙肌苷、肌醇、肌醇菸酸酯、反向促效劑Mer、碘苄胍、碘苯紮酸、碘比醇、碘絲酸、碘西他酸、碘達胺、碘化物、碘酒、膽影酸、碘克沙醇、碘阿芬酸、氯碘羥喹、碘仿、碘吡啦哈、四碘代吡咯、雙碘喹啉、鹼式沒食子酸(iodosubgallate)、碘非他胺123I、碘甘卡酸、碘海醇、碘美拉酸、碘美普爾、碘帕醇、碘番酸、碘噴托、碘苯酯、碘芬酸、碘普羅胺、碘普羅酸、碘吡醇、碘吡酮、碘他拉、碘曲倫、碘佛醇、碘克沙、碘昔蘭、IP-751、伊匹達克林、IPL-576092、碘泊酸鹽、異菸肼、異丙托銨、異丙托銨、異丙托溴銨、異丙佐羅、依普黃酮、伊普吲哚、異丙菸肼、益普斯酮(ipsapiron)、依貝沙坦、IRFI-042、IRFI-165、虹蟻素、茚達酮、伊立替康、伊洛福芬、山梨醇鐵、伊索拉定、IS-741、伊薩列酮、ISAtx-247、伊波格雷、異帕米星、異米尼爾、對胺基苯甲酸異丁酯、異康唑、異他林、異氟西平(isofloxythepin)、異氟醚、異氟磷、艾索拉朵、異美沙酮、異美汀、異菸肼、異尼辛、異丙美沙嗪、異丙碘銨、異丙醇、異丙基烏諾前列酮、異丙基腎上腺素、異山梨醇、異山梨醇二硝酸鹽、異山梨醇單硝酸鹽、異西噴地、異維甲酸、異戊醯基、伊索克酸、伊索昔康、異克舒令、伊拉地平、伊拉帕泛(israpafant)、ISV-403、伊他司瓊、ITF-282、itopride、伊曲康唑、硝乙胺、伊曲穀胺(itriglumide)、伊妥瑞克、伊伐佈雷定、伊沙匹隆、J-104132、J-107088、J-113397、Janex-1、交沙黴素、JTV-519、K-777、紅藻胺酸、聚苯乙烯磺酸鈣、胰激肽、KB-130015、KCB-328、酮保泰松、氯胺酮、酮色林、凱他唑侖、乙氧二羥丁酮、凱托米酮、酮康唑、酮基布洛芬、酮咯酸、酮咯酸、酮替芬、凱林、活動素、KNI-272、KP-103、KP-157、KP-544、KRN-5500、KT-136、KUL-7211、KW-2170、KW-6002、KW-7158、L-365260、L-5-羥基-色胺酸、L-745337、L-758298、L-826141、拉貝洛爾、拉西地平、乳酸、乳糖醇、乳酮糖、替丁、拉米非班、拉美芙錠、拉莫三嗪、蘭迪洛爾、拉尼西明(lanicemine)、拉尼喹達、拉諾康唑、蘭替普酶、蘭瑞肽、蘭索拉唑、碳酸鑭、拉帕替尼、拉喹莫德、拉索昔芬、拉氧頭孢、拉坦前列素、月桂啶、乙酸勞利銨、指甲花醌、LAX-111、拉紮貝胺、LB-30057、L-半胱胺酸、利非他明、來氟米特、來氟米特、利奧吡咯、侖氨西林、磨菇多糖、來匹盧定、樂卡地平、來立司瓊、來索吡瓊、來普立寧、來托司坦、來曲唑、無色花青素、亮丙立德、亮丙立德乙酸酯、亮丙瑞林、左洛啡烷、左旋咪唑、左色滿卡林、左乙拉西坦、左倍他洛爾、左布諾洛爾、左布比卡因、左卡巴司汀、左旋西替利嗪、左旋多巴、左羥丙哌𠯤、左氧氟沙星、左旋美沙酮乙酸酯、左莫普洛爾、左炔諾孕酮、左法哌酯、左丙氧芬、左啡諾、左西孟旦、左舒必利、左旋甲狀腺素、利沃韋林、來昔決南釤、來昔帕泛、LF-15-0195、LF-16-0687、LGD-1550、LH、LH-RH、來曲唑、利克飛龍、利可替奈、利達膦酸(lidadronate)、利達脒、利多卡因、利多苯寧、利多氟嗪、利馬前列素、林可黴素、林丹、利奈唑胺、亞麻油酸、次亞麻油酸、碘塞羅寧、脂肪酶、脂體-地塞米松、脂體-氟比洛芬、脂質體凝膠HA、利可韋特(LiquiVent)、利拉萘酯、賴諾普利、利索茶鹼(lisofyllin)、麥角乙脲、鋰、檸檬酸鋰、利希普坦、LJP-1082、LLUAlpha、LMP-160、LMP-420、克塞平、洛鉑、山梗菜鹼、氯苯紮利、洛度沙胺、洛芬太尼、洛夫帕明、洛菲西定、氯氟卡班、洛美沙星、洛美利嗪、洛米茶鹼、洛莫司汀、洛那法尼、氯萘帕林、氯那唑酸、氯尼達明、洛哌丁胺、洛哌丁胺氧化物、氯普唑侖、洛普力農(loprinone)、氯碳頭孢、勞拉義明、洛拉他定、勞拉西泮、勞卡尼、氯甲西泮、氯諾昔康、氯沙坦(losartan)、氯替潑諾、洛曲非班(lotrafiban)、洛伐他汀、洛沙平、氯穀胺、洛索洛芬、Lu-35-138、蘆貝魯唑、魯比前列酮、胺甲硫蒽酮、胺甲硫蒽酮、苯芴醇、盧米羅可、勒托替康、鎦德卟啉、LV-216、LX-104、LY-156735、LY-293111、LY-293558、LY-355703、阿樸酸鹽、賴甲環素、利奈孕酮、賴胺酸加壓素、離胺酸乙醯基柳酸鹽、離胺酸柳酸鹽、溶血磷脂、M-40403、馬布洛芬、馬布特羅、巨噬細胞群落刺激因子、MADU、磺胺米隆、馬磷醯胺、鎂加鋁、洋紅I、鎂、碳酸鎂、氯化鎂、檸檬酸鎂、葡糖酸鎂、乳酸鎂、柳酸鎂、馬拉松、馬洛替酯、杏仁酸、杏仁酸異戊基、錳福地吡、馬尼地平、甘露醇氮芥、甘露糖-6-磷酸塩、馬普替林、馬立巴韋、馬立馬司他、馬沙骨化醇、氯苯咪吲哚、馬潑尼酮、MC-5723、MCC-478、MCI-154、乙酸m-甲苯酯、MDAM、MDI-101、MDI-403、MDL-100907、甲苯達唑、甲苯凡林、甲苄咔啉、甲溴菲寧、美布氨酯、美加明、氮芥、氮芥氧化物、美西林、美克利嗪、甲氯環素、甲氯芬那酸、甲氯芬那酸、氯酯醒、甲氯喹酮、半胱甲酯、美達西泮、美地沙明、美屈孕酮、亞甲基二膦酸、甲羥孕酮、甲羥松、甲芬那酸、美芬雷司、美非沙胺、甲氟喹、美夫西特、甲地孕酮、葡甲胺、羥基甲基戊二酸、美拉加群、黑皮素原-4促效劑、美拉胂醇、甲烯雌醇、甲左多巴、甲亞油醯胺、美利曲辛、美洛昔康、美哌隆、美法侖、美盧君、美金剛、MEN-10700、MEN-10755、氫化甲萘醌、甲萘醌、甲萘多昔、孟布酮、美諾立爾、MENT、薄荷醇、戊酸䓝酯、甲氧苯汀、甲基戊炔醇、美帕曲星、麥哌嗪、溴化甲基吡啶酯、嘜啶、美芬新、美芬諾酮、甲苯第三丁胺、美芬妥英、甲苯巴比妥、甲吲洛爾、美雄烷、甲哌卡因、甲哌呫諾、甲普賴松、安寧、甲海蔥次苷、美普他酚、美喹他嗪、汞林鈉、莫魯來、汞溴紅、巰汞林、汞香豆酸、油酸汞、氰氧化汞、美泊地布、美羅培南、汞撒利、巰替肽、美塞拉明、美沙拉嗪、美司鈉、美索噠嗪、美雄諾龍、美睪酮、雌醇甲醚、甲硫芬、美他西泮、美坦西林、美他帕明、間羥異丙腎上腺素、間羥胺、美他佐辛、甲麥角林、二甲雙胍、甲膽鹼、美他環素、美沙酮、美沙呋林、甲基安非他命、美雄醇、美雄酮、甲胺太林、美沙吡林、甲喹酮、甲巴比妥、醋甲唑胺、甲地嗪、烏洛托品、美替諾龍、美雌酚、美替唑啉、二甲氧苯青黴素、甲巰基咪唑、碘甲磺、甲二磺酸、甲硫胺酸、美替沙腙、美西妥拉、美噻噸、美索巴莫、美索比妥、甲胺喋呤、左美丙嗪、美速胺、甲氧沙林、甲氧基肉桂酸酯、甲氧氟烷、甲氧那明、甲氧丙嗪、甲基東莨菪鹼、甲琥胺、甲氯噻嗪、甲基藍、菸鹼酸甲酯、甲基丙基醚、柳酸甲酯、甲基第三丁基醚、甲苄乙氧胺氯化物、甲基溴、甲基鈷維生素、甲基多巴、亞甲基藍、甲基麥角新鹼、甲基己烷醯胺、甲乙哌酮、甲基普賴蘇穠、甲基普賴蘇穠、甲基普賴蘇穠、甲基硫氧嘧啶、甲雌三烯醇酮、甲普龍、美西麥角、甲嗪酸、美替洛爾、甲氧氯普胺、二甲箭毒碘、美托奮乃酯、美托拉宗、美托哌丙嗪、美托酮、美托洛爾、美曲吲哚、甲泛葡胺、甲泛影酸、密特隆、美替拉酮、甲基酪胺酸、美沙唑侖、美克西酮、美西律、美洛西林、MFH-244、米安色林、米貝地爾、米鉑、米卡芬淨、咪康唑、小諾黴素、咪達茶鹼(midaxifyline)、咪達唑侖、麥迪黴素、麥迪黴素乙酸酯、米地司坦、米多君、米哚妥林、米非司酮、米格列醇、美格魯特、米爾膦酸酯、米那普侖、米洛沙星、米利酮、米替福新、米那卜林、二甲胺四環素、米諾膦酸、敏樂定、光神黴素、米氮平、迷索前列醇、米坦西那、米格列奈、二溴甘露醇、丙脒腙、二溴衛矛醇、絲裂黴素、米托坦、米托蒽醌、米托蒽醌、MIV-210、美維庫銨、米伐西醇、咪唑司汀、咪唑立賓、MKC-733、MLN-519、MLN-576、嗎氯貝胺、莫達非尼、莫西普利、莫法羅汀、莫非布宗、莫非吉蘭、黴酚酸的嗎啉基乙基酯(mofetil)、莫苯唑酸、MOL-6131、嗎茚酮、嗎多明、糠酸莫米松、莫那匹爾、莫諾苯宗、單乙醇胺、甘油一月桂酸酯、單萜二醇、孟魯司特(montelukast)、孟替普酶、莫哌隆、莫哌達醇、莫普洛爾、莫雷西嗪、嗎拉宗、莫雷西嗪、嗎啉脒胍、嗎甲吡嗪醯胺、嗎啡鹼、嗎啡鹼-6-葡萄糖苷酸、莫沙帕明、莫沙必利、莫特沙芬、莫維A胺、莫維普利、拉氧頭孢、莫沙斯丁、莫沙維林、莫克雌醇、莫西沙星、百里胺、莫索尼定、M-PGA、MPI-5010、MPI-5020、MPL、MRS-1754、MS-209、MS-275、MS-325、MS-377、莫匹羅星、毒蕈鹼、莫唑胺、MX-1013、黴酚酸酯、黴酚酸、麥羅啡、N-(羥基甲基)-菸鹼醯胺、N,N,N',N'-四乙基酞醯胺、N-[4-[4-(2-甲氧基苯基)-1-哌𠯤基]丁基]萘-2-甲醯胺、N2-甲醯基-磺胺二甲異嘧啶、N4-磺醯基磺胺、N4-β-D-葡糖基磺胺、大麻隆、萘丁美酮、N-乙醯半胱胺酸、N-乙醯基甲硫胺酸、那氟沙星、納多洛爾、萘肟洛爾、萘莫司他、那法瑞林、萘夫西林、萘呋胺、萘呋胺、萘替芬、萘哌地爾、納布啡、萘啶酸、納美芬、納洛芬、納洛酮、納曲酮、NAMI、奈米尼地爾(naminidil)、諾龍、萘二磺乙乳膽、萘唑啉、萘、萘普生、萘普生甜菜鹼、那拉曲普坦、那碎因(鹼)、那可比妥、遊黴素、那格列奈、N-丁基脫氧-野尻黴素、N-丁溴東莨菪鹼溴化物、NC-503、NC-531、NCX-1000、NCX-4016、NCX-456、NCX-950、n-多可沙諾、NE-100、尼阿比妥、奈必洛爾、nebostinel、奈拉西坦、奈達鉑、奈多羅米、奈法唑酮、奈非西坦、奈福泮、負黴素、奈非那韋、奈莫必利、新斯的明、奈帕坦特、奈拉美生、奈立膦酸、黃夾次甙乙、N-乙基苯丙胺、奈替康唑、奈替黴素、奈韋拉平、NGD-98-2、尼阿拉米、尼普拉嗪、尼卡密特、菸拉文、尼卡地平、麥角溴菸酯、菸酸戊四醇酯、氯硝柳胺、菸氯苯丁酯、菸呋糖酯、菸酸環己醇酯、尼可嗎啡、尼可地爾、菸鹼醯胺、菸鹼、菸鹼酸、菸鹼酸苯甲酯、菸醇、硝苯地平、尼非卡蘭、硝苯洛爾、氟尼酸、硝呋太爾、硝呋複林、硝呋齊特、硝呋醛肟、硝呋吡醇、硝呋拉嗪、硝呋莫司、硝呋妥因醇、硝呋肼、NIK-254、可拉明、尼魯胺、尼伐地平、尼美舒利、尼美西泮、尼莫地平、尼莫唑、尼莫司汀、鈮酸鹽、NIP-142、NIP-531、尼匹魯替定、尼普地洛、硝噻噠唑、尼索地平、硝唑尼特、尼替西農、二胺硝吖啶、硝西泮、尼群地平、硝基氟吡洛芬、呋喃妥因、呋喃西林、硝化甘油、梅塔芬、硝基萘普生、硝沙西平、硝羥喹啉、尼沙替丁、尼唑苯酮、NM-3、NM-702、N-甲基麻黃鹼、N-甲基腎上腺素、N-甲基還原葡糖胺、NN-414、NNC-05-1869、諾貝爾、諾加黴素、諾拉曲特、諾米洛爾(nolomirole)、諾匹坦銨、諾美孕酮、諾米芬辛、諾丙磺胺、二乙諾酮、去甲西泮、異腎上腺素、正二氫愈創酸、諾孕曲明、去甲腎上腺素、諾乙雄龍、炔諾酮、羥炔諾酮、去甲苯福林、諾氟沙星、諾孕酮、諾孕酯、炔諾孕酮、諾孕烯酮、去甲左啡諾、去甲美沙酮、甲基諾龍、去甲嗎啡、諾苯唑酮(norphenazone)、諾匹哌酮、去甲偽麻黃鹼、去甲替林、諾乙烯酮、諾斯卡品、新氮芥、新生黴素、諾西替林(noxiptillin)、羥甲基甲硫脲、NS-1209、NS-1231、NS-126、NS-220、NS-2330、NS5A抑制劑、NS-7、NS-8、NSC-330507、NSC-619534、NSC-697726、N-磺胺醯基-3,4-氧基醯胺、NU-6027核苷、NV-07、NVP-SRA880、NW-1029、NXY-059、布酚寧、NZ-314、NZ-419、雙複磷氯化物、OC-108、奧西普隆、奧他苯酮、奧他卡因、奧他莫辛、奧他維林、奧替尼啶、奧托君、章魚胺、奧托硫胺、奧曲肽、辛基、氧氟沙星、歐夾竹桃甙、油酸、奧美沙坦-美度米、鄰碘馬尿酸酯(o-lodohippurate)、奧洛他定、奧帕膦酸、奧沙拉嗪、奧替普拉、OM-294DP、奧馬可、奧馬曲拉、奧美拉唑、奧米西汀、奧莫康唑、奧那司酮、昂丹司瓊、ONO-3403、ONO-4128、ONO-8815 Ly、ONT-093、OPC-14523、OPC-31260、OPC-51803、OPC-6535、奧匹菸肼、類鴉片鎮痛劑、奧匹哌醇、阿卡明、奧拉齊酮(orazipone)、有機物12962、有機物24448、奧利萬星、羅氏鮮、奧美昔芬、奧硝唑、鳥胺酸加壓素、鳥胺酸、奧諾前列素、乳清酸、奧芬那君、俄妥卡因、柳胺酚、奧沙奈坦、奧沙特隆、奧司他韋、OSI-7836、OSI-7904、奧培米芬、奧替溴銨、烏本苷、奧沙西羅、苯唑西林、奧沙氟生、奧沙利鉑、草醯-C、奧沙香豆素、奧沙美他辛(oxametacine)、奧沙尼喹、氧雄龍、奧克太爾、奧普碘銨、奧沙普嗪、奧沙米特、奧沙西泮、奧沙唑侖、奧卡西平、奧昔拉定、異乙諾酮、奧昔卡因、奧昔特隆(oxetoron)、奧昔康唑、奧昔磷酸、氧菸酸、奧拉西坦、氧托銨、奧可萊因(oxolamin)、奧索利酸(oxolinix acid)、氧芬胂、氧烯洛爾、氧苯酮、奧昔布寧、羥苯喹酸、羥考酮、全氟溴烷乳劑、羥甲睪酮、羥甲唑啉、羥次甲氫龍、雙羥甲脲、羥嗎啡酮、奧昔噴地、奧昔哌汀、羥基保泰松、羥苄利明、雙醋酚丁、奧芬溴銨、羥平酮、羥嘌呤醇、氧代鹼(oxytedrine)、氧四環素、奧紮格雷、對(苯甲基磺醯胺基)-苯甲酸、P-100、P-1202、P32/98、PA-824、PACAP 38、紫杉醇、PADRE、帕戈隆、PAI抑制劑、帕林朵(palindore)、帕利珠單抗、帕洛諾司瓊、柏馬溴、撲瘧喹、帕米格雷(pamicogral)、帕米膦酸鹽、對胺基苯甲酸、對氨馬尿酸、對胺基-罌粟鹼、對胺基柳酸、帕納維(panavir)、巴夫龍、帕尼培南、泛硫乙胺、泮托拉唑、泛酸、番木瓜蛋白酶、罌粟鹼、撲熱息痛、對氟噻嗪、三聚乙醛、甲乙雙酮、帕拉米松、瑞尼托林、副甲狀腺荷爾蒙、帕瑞考昔、對乙氧卡因、巴吉林、帕利骨化醇、巴龍黴素、帕羅西汀、對羥苯丙酮、帕沙米特、蒼耳-2、帕秦克隆、帕珠沙星、對溴乙醯苯胺、PC-NSAID、PD-0166285、培西洛星、培氟沙星、派格索曼、石榴鹼、培美曲塞、哌羅來斯、匹莫林、五甲六氯吡啶、PEN-203、培那西林、噴布洛爾、噴昔洛韋、噴沙西林、五氟利多、青黴胺、青黴素G、青黴素G普魯卡因、青黴素N、青黴素O、青黴素V、青哌環素、彭圖斯(penntuss)、新戊四醇、新戊四醇、新戊四醇氯醛、五肽胃泌素、噴他孕酮、電解質複合物、五烴、潘他米丁、戊唑星、噴替酸鹽、噴替酸、噴曲肽、環戊噻吩、己基可可鹼、噴替吉肽、噴替索胺、戊巴比妥、戊雙吡銨、噴托雷司、戊聚糖、噴司他丁、己酮可可鹼、白血生、戊硝醇、戊四唑、培洛黴素、肽、肽、培拉嗪、紫菜黴素、潘氟隆、培磷醯胺、培高利特、哌克昔林、哌氰嗪、哌立福新、紫蘇子醇、哌美他嗪、培哚普利、12-羥-9,10-二碘油酸(periodyl)、哌立索唑、哌拉平、高錳酸、百滅甯、哌羅匹隆、奮乃靜、石油苯精、PH-10、泛喹酮、藥劑(pharmacor)、在研新藥第6362號、在研新藥第4994號、在研新藥第5325號、在研新藥第5972號、在研新藥第6446號、在研新藥第6590號、在研新藥第6656號、在研新藥第6691號、在研新藥第6743號、在研新藥第6748號、霍洛卡因、苯乙醯脲、非那西汀、非那多松、苯烯比妥、苯來美特、雙苯醯草胺、非那佐辛、非那吡啶、苯磺丁脲、苯環己哌啶、苯二甲嗎啉、苯乙肼、苯芥膽甾醇、非沙比妥、非奈西林、苯丁醯脲、苯乙雙胍、芬格魯胺、苯茚胺、苯茚二酮、苯異丙肼、苯吡胺、苯甲惡啉、苯巴比妥、碘芬布酸、菲諾可、辛芬、酚酞、愛格模、酚紅、酚-四氯鄰甲酚磺酞、苯哌利定、酚磺胺噻唑、苯氧苄胺、苯氧丙肼、苯丙氨酯、苯丙香豆醇、苯絲瑞林、苯琥胺、苯丁胺、鄰四碘酚酞、芬托拉明、乙醯基柳酸苯酯、胺基柳酸苯酯、柳酸苯酯、苯基丁氮酮、苯腎上腺素、苯乙醇胺、苯基汞、苯甲比妥、苯丙醇胺、苯丙基-甲胺、苯托沙敏、苯吡氨醇、苯妥英、苯噻妥英、間苯三酚、福爾可定、甲羥苯丙胺、甲醯胺、磷酸鹽、磷酸鹽、磷酸肌酸、磷酸半胱胺、磷酸膽鹼、鄰苯二甲醯基磺胺噻唑、酞磺醋醯、對羥基辛弗林、葉綠醌、毒扁豆鹼、植酸、PI-88、吡貝拉林、哌波色羅、匹西雷司、哌氯定、匹考哌林、苉可硫酸鈉、吡考他胺、哌香豆司特、匹多莫德、哌法寧、吡酮洛芬、匹爾屈嗪、匹魯卡品、鹼乳劑、吡西卡尼、哌美克隆、吡美莫司(pimecrolimus)、匹美茶鹼、匹米前列素、匹米諾定、匹莫苯、哌迷清、吡那地爾、匹維溴胺、匹那西泮、品多洛爾、吡格列酮(pioglitazone)、匹哌環素、匹哌馬嗪、匹泮哌隆、匹哌氮酯、哌保松、哌庫銨、哌庫溴銨、吡哌酸、溴哌噴酯、哌西他嗪、哌拉西林、哌𠯤己二酸酯、二乙哌啶二酮、二苯哌酯、哌苯乙酯(piperilate)、胡椒鹼類似物、哌羅卡因、胡椒醛、吡哌咯生、哌立酮、哌泊溴烷、哌泊舒凡、哌泊噻嗪、哌泊索侖、米拉脫靈、哌普唑啉、吡拉西坦、吡柔比星、吡拉唑酸、吡布特羅、吡諾克辛、哌侖西平、吡咯他尼、吡非尼酮、吡貝地爾、匹多卡因、吡貝特、哌腈米特、吡曲克辛、吡吲哚、吡美諾、吡羅克酮、乙甲吡咯烷替林、吡咯米酸、吡羅昔康、吡羅昔康倍他環糊精、吡羅昔康肉桂酸酯、吡紮地爾、吡洛芬、匹伐他汀、匹伐加賓、特戊醯氧甲基、新戊醯苯醯吖嗪、匹胺西林、匹胺西林/匹美西林、匹夫塞法辛(pivcefalexin)、匹美西林、匹蒽醌、苯噻啶、苯噻啶、PKI-166、對乙氧乳醯苯胺、普拉貝脲、纖維蛋白溶酶原活化劑、甲氧胺喹(plasmocid)、普拉通甯、普勞諾托、PLD-118、PLD-147、普可那利、普卡黴素、對甲苯海明、PMS-601、肺炎鏈球菌、PNU-288034、鬼臼毒素、聚普瑞鋅、泊爾定甲磺醯酯、聚甲酚磺醛、降脂葡胺、聚醚醇、脊髓灰白質炎病毒痘苗、聚-ADPRT抑制劑、聚雌二醇、和茶多酚E、多噻嗪、卟吩姆、泊沙康唑、泊替瑞林、鉀、鉀、鉀、氯化鉀、葡糖酸鉀、對胺基苯甲酸鉀、聚維酮、聚維酮-碘、PP-117、PR-2699、PR-608、普拉洛爾、普拉馬林、磷定、普拉納卡桑(pralnacasan)、普拉克索、普拉西坦、普拉維林、普蘭林肽、普拉莫星、普拉地平、普魯司特、普拉洛芬、普拉睪酮、普拉托沙坦(pratosartan)、普伐他汀、普拉西泮、吡喹酮、哌唑嗪、潑尼卡酯、潑尼氮芥、普賴蘇穠、21-二乙胺基乙酸普賴蘇穠、普賴蘇穠法奈(prednisolone farnesil)、普賴蘇穠鈉、普賴松、普賴蘇穠戊酸酯、潑尼立定、普瑞巴林、妊娠-3α-醇-20-酮、普雷馬林+曲美孕酮、普瑞特羅、普諾地嗪、普尼拉明、藍銅肽、普立地諾、吡芬溴銨、丙胺卡因、伯氨喹、普里米酮、普啉司他、PRO-2000、丙磺舒、普羅布可、普魯卡因胺、普魯卡因、丙卡巴肼、丙卡特羅、丙氯拉嗪、普科噠唑、丙環定、丙環氨酯、普羅地平、普羅黃素、普羅加胺、孕酮、丙谷美辛、丙穀胺、普羅庚嗪、促乳素、普羅林坦、安妥碘、普馬嗪、二甲哌替啶、普美孕酮、普羅雌烯、普魯米近、丙萘洛爾、丙帕他莫、普羅帕酮、丙帕鍺、丙溴比妥、普羅帕脒、丙烷-1,2-二醇、丙泮尼地、普魯本辛、丙美卡因、丙帕硝酯、普羅硝唑、丙戊茶鹼、丙匹西林、丙醯馬嗪、丙酸、丙醯基l-肉鹼、丙哌卡因、丙吡蘭、丙哌維林、丙吡西平、異丙酚、丙氧卡因、丙氧吩、普萘洛爾、環己丙甲胺、丙碘酮、丙基硫氧嘧啶、異丙安替比林、普羅喹宗、原海蔥苷、前列環素、前列腺素E1、前列腺素E2、前列腺素F2α、丙硫硫胺、蛋白質C、丙可可鹼、丙硫噴地、丙噻酯、丙硫異菸胺、丙替嗪酸、原白頭翁素、普羅克洛(protoklol)、原卟啉IX、普羅替林、原尿激酶、普羅沙唑、普塞酯、丙羥巴比、普洛脈寧(proxigermanium)、羥丙茶鹼、普羅紮平、普盧卡必利、普盧利沙星、偽可卡因、假麻黃素、假麻黃素、假麻黃素+曲普利啶、裸蓋菇素、PSK-3841、對胺苯磺醯基-苯甲胺、PT-141、蝶羅呤、嘌呤黴素、PX-12、噻嘧啶、吡嗪醯胺、吡啶酚胺基甲酸酯、吡啶斯的明、吡哆醛5-磷酸酯、吡哆醇、比拉明、乙胺嘧啶、吡諾林、琥珀酸吡多醇酯、吡啶硫酮、吡乙二酮、吡硫醇、鄰苯二酚、連苯三酚、咯萘啶、焦磷酸、吡咯戊酮、火棉膠、吡咯布他明、吡咯卡因、吡咯啉(pyrrolntrin)、雙羥萘酸鹽、誇西泮、槲皮素、喹硫平、喹那西林、奎納克林、喹高利特、喹那普利、喹那普利拉、硫酸喹嘧胺、奎勃龍、奎雌醇、炔雌醚、喹乙唑酮、喹法米特、奎尼丁、奎寧、喹西特、奎紐帕明、奎奴普丁、R-107500、R-667、雷貝拉唑、消旋卡多曲、消旋甲嗎喃、雷諾昔酚、雷替曲塞、雷馬曲班、雷米那酮、雷米普利、拉莫司瓊、拉莫特項目第1097號、雷莫司汀、雷尼替丁、雷尼替丁鉍、雷諾嗪、豹蛙酶、瑞庫溴銨、雷沙吉蘭、阿嗎鹼、拉夫康唑、雷索司特、雷佐生、RC-529、雷巴米特、瑞馬司他、瑞波斯坦(reboxetime)、瑞馬西胺、瑞芬太尼、瑞馬太特(reminetant)、瑞莫必利、倫紮必利、瑞格列奈、瑞派他辛L-離胺酸鹽、樹脂丹寧醇、瑞吡司特、雙環辛巴比妥(reposal)、茶丙特羅、瑞西美托、利新胺、利舍匹林、蛇根素鹼、脂蟾毒配基(resibufogenin)、雷西莫特、間苯二酚、瑞替普酶、瑞替加濱、視黃酸、雷維米德、R-氟比洛芬、ρ(D)免疫劑、ρ激酶抑制劑、利巴韋林、核黃素、核糖黴素、蓖麻油酸、利多格雷、利福布汀、利福拉齊、利福美坦、利福醯胺、立複黴素+甲氧苄啶、利福平、利福黴素SV、利福噴丁、利福昔明、利福昔明乳霜、利馬紮封、利美尼定、利魯唑、金剛乙胺、利馬唑、利美索龍、利米特羅、利莫那班、碘代酚、奧前列素、利塞膦酸鹽、利塞膦酸、利培酮、利坦舍林、利替培南、利托君、利托那韋、利妥昔單抗、雷斯替明、利紮曲普坦、RJR-2403、RNA史蒂斯、Ro-0094889、Ro-61-1790、羅西維林、羅庫溴銨、羅非考昔、羅氟司特、羅他黴素、咯利普蘭、羅利環素、羅莫肽、氯菸貝特、羅匹尼洛、羅比卡因、羅喹美克、羅沙前列醇、羅沙米星、玫瑰紅、羅格列酮、羅索沙新、羅培泊芬、羅素他汀、羅替戈汀、羅曲酸、硝酚胂酸、羅沙替丁、羅昔非班(roxifiban)、洛剋星多、羅紅黴素、RPR-109881A、RPR-130401、R-羅斯維汀、RS-0406、RSR-13、玉紅介芬胺、盧比替康、魯伯斯塔、盧非醯胺、蘆氟沙星、盧帕他定、芸香苷、RWJ-54428、S-0139、S-15535、S-18886、S-34730、S-3578、S-36496、S-36527、S-5751、S-8510、S-8921、沙可美林、沙貝魯唑、S-腺苷甲硫胺酸、沙芬醯胺、醋柳胺、柳氮磺嘧啶、沙丁胺醇、柳苷、鄰羥苄基醇、柳醛胺、柳醛胺O-乙酸、柳醯苯胺、柳酸、柳硫酸、柳菸肼、沙美特羅、雙柳酸酯、沙維林、釤153
Sm、山帕曲拉、山環素、沙康唑、沙丙蝶呤、沙奎那韋、色拉新、沙瑞度坦、沙瑞度坦、沙立佐坦、沙立佐坦、沙格雷酯、沙格雷酯、沙替格雷、沙替格雷、賽特鉑、賽特鉑、沙妥莫單抗、沙妥莫單抗、SB-237376、SB-237376、SB-238039、SB-238039、SB-277011、SB-277011、猩紅、SCH-00013、SCH-00013、Sch-23863、Sch-23863、Sch-57790、Sch-63390、海蔥苷、莨菪鹼、莨菪鹼、莨菪鹼N-氧化物、SCS技術、司骨化醇、塞克硝唑、司可巴比妥、司來吉蘭、硒甲硫胺酸、司美利特、司莫地爾、西奧骨化醇、司匹司他、塞曲司特、舍他康唑、舍他康唑、舍吲哚、舍吲哚、舍曲林、舍曲林、司他比鍀、司他斯汀、司他斯汀、司維拉姆、司維拉姆、七氟烷、七氟烷、SG-210、諾美婷、西卡寧、西地那非、西洛多辛、西前列酮(silprostone)、乳酸銀、苦味酸銀、磺胺嘧啶銀、西美曲特、雙貝特、辛伐他汀、辛卡利特、辛托溴銨、西索米星、西他沙星、西他馬喹(sitamaquine)、西他生坦、西維來司鈉、SJA-6017、SL-65-1498、SLV-306、SLV-308、Sm153雷克斯多南、S-甲基蛋胺酸、SMP-300、SN-38、SNAP-7941、SOA-132、索波度素、索布瑞醇、索布佐生、苯胺砷酸鈉、阿斯凡納明鈉、氯化鈉、地布酸鈉、葉酸鈉、甲醛次硫酸鈉、玻尿酸鈉、碘多啥、亞硝酸鈉、硝普鈉、羥丁酸鈉、酚磺酸鈉、苯丁酸鈉、磷酸鈉、硫酸鈉硫酸普拉睪酮、丙酸鈉、柳酸鈉、十四基硫酸鈉、索法酮、苯丙碸、索非那新、山梨菸酯、山梨醇、索利夫定、索他洛爾、索特瑞醇、二碘酚磺酸、司麩胺酸、司帕沙星、鷹爪豆鹼、SPA-S-843、解痙醚、SPD-754、大觀黴素、SPI-339、螺哌隆、螺普利、螺旋鍺、螺內酯、SR-121463、SR-144190、SR-146131、SR-271425、SR-27897、SR-31747、SR-58611、SS732、SS-750、SSR-149415、SSR-180575、SSR-181507、SSR-591813、SST-101、SSY-726、ST-200、斯塔奇鹼(stachyfilin)、司他黴素、斯坦匹丁(stampidine)、亞錫、錫泊芬(stannsoporfin)、雄諾龍、康力龍、葡萄球菌、STAT4抑制劑、司他夫定、司騰勃龍、司替羅寧(stepronim)、二巰琥珀酸酯、銻波芬、替巴脒、司替戊醇、鏈道酶、鏈黴素、鏈黴素異菸肼、鏈黑菌素、鏈脲菌素、雷奈酸鹽、鍶-89氯化物、二巰丁二酸、丁二醯亞胺、琥珀醯膽鹼、琥珀醯膽鹼、琥珀醯磺胺噻唑、琥珀氨苯碸、琥氯非尼、硫糖鋁、舒芬太尼、舒巴坦、舒巴坦+安比西林、磺苄西林、二苯嗪硫酮、雙異丁硫胺、硫康唑、磺庚甲潑酯、硫索單抗、磺胺苯甲醯、磺胺醋醯胺、磺胺氯噠嗪、磺胺柯定、磺胺西汀、磺胺嘧啶、磺胺戊烯、磺胺二甲氧嗪、磺胺多辛、磺胺乙二唑、磺胺胍、磺胺胍諾、磺胺林、磺胺洛西酸、磺胺甲基嘧啶、磺胺嘧特、磺胺甲嘧啶、磺胺甲二唑、磺胺甲氧甲嘧啶、磺胺甲基異㗁唑、磺胺甲氧吡嗪、磺胺甲氧嗪、磺胺美曲、磺胺米柯定、磺胺噁唑、對胺基苯磺醯胺、對胺基苯磺酸、磺醯脲、磺胺培林、磺胺苯吡唑、磺胺普羅林、磺胺吡啶、磺胺吡啶、磺胺苯胂、硫胂凡納明、柳氮磺胺吡啶、磺胺異噻唑、磺胺均三嗪、磺胺塞唑、磺胺硫脲、硫氧洛爾、苯磺唑酮、舒非侖、磺胺二甲異嘧啶、磺胺異㗁唑、磺溴酞、乙基眠碸、苯磺菸肼、磺酸、眠碸甲烷、磺達嗪、阿地碸、舒林酸、磺酚丁、磺異苯酮、硫馬林、硫馬唑、舒洛地爾、舒泛藍、舒必利、舒他西林、蘇太明、舒托必利、磺托酸、蘇門尼羅(sumanirole)、舒馬曲普坦、SUN-N8075、甲磺司特、舒洛芬、蘇拉明、界面活性劑TA、舒立克隆、琥布宗、SYM-1010、SYM-2081、SYM-2207、三氯異氰尿酸、同步-1253、同步-2190、同步-2869、脫氧腎上腺素、乙酯利血平、T-1095、T-1249、T-3912、T-588、T-67、T-82、TA-2005、TA-2005、TA-993、他莫瑞林、他卡西醇、泰克地那林、他可林、他克莫司、他達拉非、非諾喹、塔呋泊苷、TAK-375、TAK-427、TAK-559、他克澱粉酶、他侖帕奈、酞氨西林、他拉泊芬、他拉斯汀、他布比妥、他林洛爾、他利克索、他爾奈坦、他尼氟酯、他替瑞林、他莫昔芬、他蘇洛辛、坦度螺酮、鞣仿、他前列烯、塔利奎達、TAS-103、他索沙坦、牛膽酸、滔羅定、他紮司特、他紮羅汀、他唑巴坦、他唑巴坦+哌拉西林、TBC-3711、TCH-346、泰比培南、替肟鍀(teboroxime)、泰克代森(tecadenoson)、替卡咪唑、鎝99
Tc、四氯噻嗪、替克洛占、替地沙米、替氟烷、喃氟啶、喃氟啶+尿嘧啶、替加色羅、替考拉寧、替比夫定、替侖西平、泰利黴素、替美司坦、替米沙坦、端粒酶抑制劑、羥基安定、替米維林、替莫普利、替莫西林、替莫泊芬、替莫唑胺、泰妥拉唑、替奈普酶、替尼達普、替尼泊甙、田諾弗、替諾福韋二吡呋酯、替諾尼唑、替諾昔康、細交鏈孢菌酮酸、替普瑞酮、特拉唑嗪、特比萘芬、特布他林、特康唑、特非那定、特麥角脲、特利加壓素、特羅地林、特羅芬那酯、萜二醇、特他洛爾(tertalolol)、第三戊基醇、替格列紮、替米利芬、睪內酯、睪固酮、四酸鹽、四巴比妥、丁苯那嗪、四卡因、四氯乙烯、丁卡因(tetracine)、四環素、四氫唑啉、漢防己鹼、替群妥英、四氫西泮、替曲膦、四氧普林、Tevenel®、替紮他濱、替唑生坦、撒利多胺、西那利定、西尼二胺、可可豆鹼、羥乙茶鹼安妥明、茶鹼、腐絕、氨硫脲、噻吩絲胺酸(thiacymserine)、硫烯比妥、硫胺、硫咪嘌呤、甲碸黴素、硫戊巴比妥、硫西新、硫異丙嗪、噻唑丁炎酮、噻唑碸、硫苯唑林、蒂納馬特(thiemalat)、硫乙拉嗪、硫汞苯磺、硫柳汞、硫巴比妥(thiobarbital)、硫布他比妥、硫柳脲苯胂、硫卡巴胂、硫代秋水仙鹼、甲苯硫酚、硫辛酸、硫代甘油、硫鳥嘌呤、硫瑞格(thioimrag)、硫噴妥、噻替派、醋酸奮乃靜、硫丙拉嗪、硫利達嗪、硫代硫酸鹽、胺碸噻噸、賽奧韋、雙苯乙硫酯、得恩地、桑西胺、托紮啉酮、凝血活酶、菸鹼酸呋酯、賽美他欣、瑞香草酚、胸腺五肽、N-麝香草酚異戊胺甲呋酯、甲狀丙酸(thyropropic acid)、甲狀腺素、硫地醇(tiadenol)、硫加賓、噻美尼定、噻奈普汀、泰必利、噻洛芬酸、噻拉米特、噻唑呋林、泰硼銨(tibezonium)、替勃龍、替卡西林、噻氯匹定、替尼酸、噻苯丙嗎啉、泰格環黴素、替吉莫南、裘波樹鹼、替利定、替利洛爾、替馬考昔(tilmacoxib)、替魯羅酸、特美汀、噻哌溴銨、替米哌隆、噻嗎洛爾、噻唑烷酸、錫乙基艾迪普林、替那唑啉、磺甲硝咪唑、替諾立定、硫卡利特、噻氯香豆素、噻康唑、硫普羅寧、噻托銨、噻克索酮、替培啶、替吡法尼、替拉那韋、替喹溴銨、替拉紮明、替拉曲考、替拉紮特、替羅非班、替瑞醯胺、硫酸鈦、泰澤坦、替可的松、替紮尼定、TLK-199、TLK-286、TNF-β類似物、TNP-470、TO-186、托普黴素、妥卡尼、托莰非、托拉地新、維甲酸維E酯、托屈嗪、托芬那辛、托菲司特、托非索洋、妥拉磺脲、苄唑啉、甲苯磺丁尿、托卡朋、托西拉酯、甲苯磺環脲、托來伐姆、托芬那酸、托林達酯、托利洛爾、托美丁、托萘酯、托洛尼定、胺甲吩噻嗪、托洛沙酮、托哌酮、托普帕敏、托瑞司他、托西林、托特羅定、托伐普坦、托利卡因、托吡酯、拓樸異構酶、拓樸替康、托拉塞米、托徹普、托西他濱(torcitabine)、托瑞米芬、托西邁、托西莫單抗、磺沙星、曲馬多、曲馬唑啉、群多普利、氨甲環酸、曲尼司特、反-視黃酸、反苯環丙胺、曲匹地爾、曲妥珠單抗、曲伏前列素、曲呫諾、曲索羅地、曲唑酮、曲馬卡拉、群勃龍、群孕酮、曲奧舒凡、曲匹布通、曲前列醇(treprostinol)、維甲酸、曲托喹酚、TRH、TRI-50b、三醋精、曲安西龍、曲安西龍、曲安西龍、曲安奈德、胺苯喋啶、三安平、三亞胺醌、三唑侖、三苄糖苷、三溴酚鉍、三氯松、三氯甲噻嗪、三氯氮芥、三氯乙烯、曲比銨、三氯卡班、三氯酚哌𠯤、三氯福司、三氯沙、3-甲色酮(tricromyl)、曲地銨碘、曲恩汀、三乙醇胺、曲他胺、三氟吡拉嗪、三氟哌多、三氟普馬嗪、曲氟尿苷、三氟醋柳酸、三已酸鹽、苯海索、三甲氧唑啉、三甲丁酯、三甲卡因、阿利馬嗪、曲美他嗪、三甲雙酮、三甲噻方、三甲氧苯醯胺、甲氧苄啶、曲美托嗪、曲美沙特、曲莫前列素、曲洛司坦、三甲沙林、曲帕胺、三苯乙醇、曲吡那明、曲普利啶、曲普瑞林、曲硫秦、曲托喹啉、TRK-530、TRK-820、曲氯新鉀、曲磷胺、曲格列酮、醋竹桃黴素、三乙硝胺、曲金剛胺、胺丁三醇、胺丁三醇、緩血酸胺、緩血酸胺、託派古柯鹼、托品因、托品醯胺、托品鹼、特比司瓊、丙大觀黴素、曲司銨、曲伐沙星、曲沙他濱、三羥乙基芸香苷、曲昔匹特、台盼紅、錐蟲胂胺、色胺酸、TSH、TSN-09、TU-2100、異庚胺、殺結核菌素、氯化筒箭毒鹼、妥洛特羅、TV-3326、TY-11223、TY-12533、TYB-3215、泰巴氨酯、泰洛沙泊、泰馬唑啉、酪胺、酪泮酸酯、烏苯美司、烏芬那酯、十一碳烯、烏諾前列酮、UR-8880、尿嘧啶氮芥、消石素-U、烏拉地爾、尿素、烏瑞替派、尿烷、尿苷5'-三磷酸酯、尿抑制素、熊去氧膽酸、熊去氧膽酸、先導細胞(ushercell)、烏紮拉苷、痘苗、白喉痘苗、多價痘苗、發昔洛韋、伐地考昔、戊地胺、戊沙溴銨、纈更昔洛韋、戊諾醯胺、伐馬洛韋、丙戊酸酯、丙戊酸、丙戊醯胺、丙戊塞胺、伐柔比星、纈沙坦、伐司撲達、伐地那非、伐瑞拉迪、水痘病毒、伐尼地平、VEA、維庫溴銨、維吖啶、文拉法辛、維拉必利、維拉帕米、維替泊芬、維司力農、維曲布汀、VF-233、VI-0134、阿糖腺苷、喜保寧、維拉唑酮、維洛沙嗪、維米醇、戊烯比妥、長春鹼、長春布甯、長春蔓胺、長春考酯、長春新鹼、長春地辛、長春氟甯、長春瑞賓、長春西汀、乙烯基醚、乙烯比妥、維喹地爾、霍皮響尾蛇素、維司那定、維生素A、維生素B12、維生素C、維生素D2、維生素D3、維生素K5、產前維生素、VLA-4拮抗劑、VNP-4010M、伏格列波糖、伏立康唑、伏羅唑、VUF-K-8788、華法林、WF-10、WMC-79、創傷癒合基質、WP-170、紮利羅登、紮莫特羅、諾美林、占替諾菸酸鹽、米洛非班、聯苯丁酸、希苯洛爾、異冰片二甲酚、希美加群、西莫普芬、希伯氨、佐爾啡諾、XR-5118、XR-5944、佐爾啡諾、木糖、YH-1885、YM-511、YM-598、育亨賓、YT-146、Z-321、Z-335、紮魯司特、紮西他濱、紮達來特、紮來普隆、紮托洛芬、紮那米韋、紮那哌齊、紮替雷定、ZD-0473、ZD-0947、ZD-6126、ZD-9331、澤布拉恩、澤蘭多帕姆(zelandopam)、折那司他、齊考諾肽、齊多夫定、齊留通、齊美利定、乙酸鋅、醋氨己酸鋅、異丁苯丙酸鋅、對苯酚磺酸鋅、柳酸鋅、淨司他丁、淨司他丁司他美、齊培丙醇、齊拉西酮、佐芬普利、佐芬普利+HCTZ、唑來膦酸、佐利米定、佐米曲普坦、唑吡坦、佐美酸、佐奈派楠(zonampanel)、唑尼泊利(zoniporide)、唑尼沙胺、佐匹克隆、唑泊司他、左柔比星、唑蘇達、佐替平、ZP-123、Z-他莫昔芬、珠氯噻醇、α1-抗胰蛋白酶、α-沒藥醇、α-氯醛糖、α-乙基苯甲基酒精、α-葡糖-1-磷酸酯、α-苯基丁醯胺、α-散道寧、α-松香醇、α-生育酚、β-阿立辛、β-苯亞甲基丁醯胺、β-胡蘿蔔素、β-優卡因、β-丙內酯、β-穀甾醇、γ-胺基丁酸、γ-羥丁酸鹽、γ-次亞麻油酸、δ-胺基乙醯丙酸、ε-乙醯胺基己酸及ε-胺基己酸。亦參見美國專利第7,927,613號，其以全文引用的方式併入本文中。其他醫藥學上可接受之共形成物包括在「一般認為安全」(「GRAS」)及/或US FDA「Everything Added to Food in the United States」(「EAFUS」)清單中敍述之彼等共形成物。
在一些此等實施例中，一或多種醫藥學上可接受之共形成物中之至少一者可為具有如以全文引用之方式併入本文中的美國專利第10,292,951號中所述之化學式(I)、(XVIII)-(XXV)及XXVII (例如式XXIV或XXV)中之任一者的化合物；或以上敍述之化合物中之任一者。在某些此等實施例中，一或多種醫藥學上可接受之共形成物中之至少一者可為具有如以全文引用之方式併入本文中的美國專利第10,292,951號中所述之式(I)、(XVIII)-(XXV)及XXVII (例如式XXIV或XXV；或XXVI)中之任一者的氯硝柳胺類似物；或以上特定敍述之化合物中之任一者。
在一些實施例中，共形成物可為本文所述之任何一或多種額外治療劑。
在一些實施例中，共形成物選自由以下組成之群：神經鞘胺醇1-磷酸(S1P)受體調節劑；類固醇消炎劑；非類固醇消炎劑；受體相互作用蛋白質激酶1 (RIPK1)抑制劑；EP4調節劑；鐸樣受體(例如，TLR4、TLR9)調節劑；詹納斯(Janus)激酶(JAK)抑制劑；羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑；膽鹼磷脂；整合素(例如，α4整合素)調節劑；Smad7調節劑；磷酸二酯酶4 (PDE4)調節劑；腫瘤進展基因座2 (TPL2)抑制劑；酪胺酸激酶2 (TYK2)抑制劑；及TEC激酶抑制劑。
在某些實施例中，該共形成物為神經鞘胺醇1-磷酸(S1P)受體調節劑。
在某些實施例中，該共形成物為依托西莫德或奧札莫德。
在某些實施例中，該共形成物為類固醇消炎劑。作為非限制性實例，該共形成物可為倍氯米松17或布地奈德。
在某些實施例中，該共形成物為非類固醇消炎劑，諸如5-ASA。
在某些實施例中，該共形成物為受體相互作用蛋白質激酶1 (RIPK1)抑制劑，諸如GSK2982772。
在某些實施例中，該共形成物為EP4調節劑，諸如KAG-308。
在某些實施例中，該共形成物為鐸樣受體(例如TLR4、TLR9)調節劑。在某些此等實施例中，該共形成物為TLR4調節劑，諸如JKB-122。在某些實施例中，該共形成物為TLR9調節劑，諸如庫比莫德。
在某些實施例中，該共形成物為詹納斯(Janus)激酶(JAK)抑制劑。在某些此等實施例中，該共形成物選自由以下組成之群：TD-1473、托法替尼、優帕替尼、非戈替尼、PF-06651600及PF-06700841。
在某些實施例中，該共形成物為羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑，諸如BT-11。
在某些實施例中，該共形成物為磷脂醯膽鹼，諸如LT-02。
在某些實施例中，該共形成物為整合素調節劑。在某些此等實施例中，該共形成物為α4整合素調節劑，諸如AJM-300 (卡羅格拉斯)。
在某些實施例中，該共形成物為Smad7反義寡核苷酸，諸如蒙格森。
在某些實施例中，該共形成物為磷酸二酯酶4 (PDE4)調節劑，諸如阿普斯特。
在某些實施例中，該共形成物為腫瘤進展基因座2 (TPL2)抑制劑，諸如GS-4875。
在某些實施例中，該共形成物為酪胺酸激酶2 (TYK2)抑制劑。
在某些此等實施例中，該共形成物為BMS-986165、PF-06700841或PF-06826647。
在某些實施例中，該共形成物為TEC激酶抑制劑，諸如PF-06651600。
非限制性組合
在一些實施例中，共晶體包括( i )
氯硝柳胺；及( ii )
氯硝柳胺之醫藥學上可接受之鹽；或氯硝柳胺類似物之醫藥學上可接受之鹽及/或氯硝柳胺水合物。
在一些實施例中，共晶體包括(i)
氯硝柳胺；及(ii)
第二API。
在一些實施例中，共晶體包括(i)
氯硝柳胺之醫藥學上可接受之鹽；及(ii)
第二API。
在一些實施例中，共晶體包括(i)
氯硝柳胺；及(ii)
第二API。
在一些實施例中，共晶體包括(i)
氯硝柳胺之醫藥學上可接受之鹽；及(ii)
胺基酸(例如脯胺酸，例如D-脯胺酸或L-脯胺酸或外消旋脯胺酸)。
在一些實施例中，共晶體包括(i)
氯硝柳胺；及(ii)
胺基酸(例如脯胺酸，例如D-脯胺酸或L-脯胺酸或外消旋脯胺酸)。
在一些實施例中，共晶體包括(i)
氯硝柳胺之醫藥學上可接受之鹽；及(ii)
5至10 (例如5至9、5至6或5)員雜芳基，例如含氮雜芳基，例如咪唑。
在一些實施例中，共晶體包括(i)
氯硝柳胺；及(ii)
5至10 (例如5至9、5至6或5)員雜芳基，例如含氮雜芳基，例如咪唑。
例如參見Sanphui, P.Cryst. Growth Des
.2012
,12
, 4588; Imramovský, A.Crystals 2012
,2
, 349-361及Grifasi, F.Cryst. Growth Des
.2015
,15
, 4588。
共晶體之氯硝柳胺化合物
在一些實施例中，氯硝柳胺化合物之化學純度可如本文任何地方所定義。
共晶體之粒度
在一些實施例中，對於氯硝柳胺化合物，共晶體可具有如本文任何地方所定義之減少的粒度。
在一些實施例中，粒度減小之共晶體可藉由噴射研磨，例如使用由Sturtevant製造之CMTI設備NGMP-Mill-A，2吋餅狀微磨機來製備。
粒度分佈(PSD)可藉由雷射繞射技術，例如，使用「MALVERN MASTERSIZER 2000」(標準範圍在0.020與2000.0微米之間)，模型「APA 2000」，配備有「Hydro 2000 sm」作為分散單元來確定。
在一些實施例中，共晶體具有減小之粒度範圍。
在一些實施例中，共晶體之粒度範圍為約0.1 μm至約30 μm。在某些實施例中，共晶體之粒度範圍為約0.1 μm至約20 μm。在某些實施例中，共晶體之粒度範圍為約0.1 μm至約10 μm。
在一些實施例中，共晶體之粒度分佈D(0.9)為約1.0 μm至約15.0 μm。在某些實施例中，共晶體之粒度分佈D(0.9)為約1.0 μm至約10.0 μm。在某些實施例中，共晶體之粒度分佈D(0.9)為約6.0 μm至約8.0 μm。在某些實施例中，共晶體之粒度分佈D(0.9)為約2.2 μm至約3.2 μm。
在一些實施例中，共晶體之粒度分佈D(0.1)為約0.1 μm至約1.5 μm。在某些實施例中，共晶體之粒度分佈D(0.1)為約0.1 μm至約1.0 μm。在某些實施例中，共晶體之粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，共晶體之粒度分佈D(0.5)為約0.5 μm至約6.0 μm。在某些實施例中，共晶體之粒度分佈D(0.5)為約1.0 μm至約4.0 μm。在某些實施例中，共晶體之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。在某些實施例中，共晶體之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
在一些實施例中，共晶體之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
在一些實施例中，共晶體之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，共晶體之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
在一些實施例中，氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
在一些實施例中，氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在一些實施例中，氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
在某些前述實施例中，共晶體之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
在某些其他前述實施例中，共晶體之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
醫藥組合物及投與 通用
藉由使化合物生物可用(例如局部生物可用)之任何途徑向有需要之個體投與氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體。在某些實施例中，該途徑為經口投與。
在一些實施例中，將氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)作為醫藥組合物投與，該醫藥組合物包括化學實體及一或多種醫藥學上可接受之賦形劑及視情況本文所述之一或多種其他治療劑。
在一些實施例中，氯硝柳胺化合物可與一或多種習知醫藥賦形劑組合投與。醫藥學上可接受之賦形劑包括但不限於離子交換劑；氧化鋁；硬脂酸鋁；卵磷脂；自乳化藥物遞送系統(SEDDS)，諸如d-α-生育酚聚乙二醇1000琥珀酸酯；以醫藥劑型使用的界面活性劑，諸如Tweens、泊洛沙姆(poloxamer)或其他類似的聚合物遞送基質；血清蛋白，諸如人類血清白蛋白；緩衝物質，諸如磷酸鹽、tris、甘胺酸、山梨酸、山梨酸鉀；飽和植物脂肪酸之偏甘油酯混合物；水、鹽或電解質，諸如硫酸魚精蛋白、磷酸氫二鈉、磷酸氫鉀、氯化鈉；鋅鹽；膠態二氧化矽；三矽酸鎂；聚乙烯吡咯啶酮；纖維素類物質；聚乙二醇；羧甲基纖維素鈉；聚丙烯酸酯；蠟；聚乙烯-聚氧化丙烯嵌段共聚物；及羊毛脂。環糊精諸如α-環糊精、β-環糊精及γ環糊精，或化學改質衍生物諸如羥基烷基環糊精，包括2-羥丙基-β-環糊精及3-羥丙基-β-環糊精，或其他溶解衍生物亦可用於增強本文所述之化合物之遞送。可製備含有在0.005%至100%範圍內的本文所述之化學實體且其餘部分由無毒賦形劑組成的劑型或組合物。所涵蓋之組合物可含有0.001%至100%，在一個實施例中含有0.1%至95%，在另一實施例中含有75%至85%，在另一實施例中含有20%至80%的本文所提供之化學個體。製備此類劑型的實際方法對熟習此項技術者為已知的或將為顯而易見的；舉例而言，參見Remington: The Science and Practice of Pharmacy, 第22版(Pharmaceutical Press, London, UK. 2012)。
在一些實施例中，本文所述之氯硝柳胺化合物或其醫藥組合物可藉由任何所接受之投與途徑向有需要之個體投與。可接受的投藥途徑包括但不限於經頰、皮膚、子宮頸內、竇道內(endosinusial)、氣管內、經腸、硬膜外(epidural)、間質、腹內、動脈內、支氣管內、囊內、腦內、腦池內、冠狀動脈內、皮內、管內、十二指腸內、硬膜內、表皮內、食道內、胃內、齒齦內、迴腸內、淋巴管內、髓內、腦膜內、肌肉內、卵巢內、腹膜內、前列腺內、肺內、竇內(intrasinal)、脊柱內、滑膜內、睪丸內、鞘內、小管內、腫瘤內、子宮內、血管內、靜脈內、經鼻、鼻胃管、經口、非經腸、穿皮(percutaneous)、硬膜外(peridural)、經直腸、呼吸道(吸入)、皮下、舌下、黏膜下、表面、經皮、經黏膜、經氣管、輸尿管、尿道及陰道。
局部投與
在一些實施例中，本文所述之氯硝柳胺化合物或其醫藥組合物適用於局部投與，例如藉助於在特定治療部位(例如消化道、胃腸(「GI」)道(例如結腸))處投與氯硝柳胺化合物或其組合物來局部投與，以便向需要治療之區域(例如口腔；胃腸道(例如結腸)；眼；皮膚；或關節)局部投與化學實體。在某些實施例中，在該局部投與期間發生氯硝柳胺化合物之相對較低全身性暴露。此類組合物之實例包括例如經口投與。
在一些實施例中，本文所述之氯硝柳胺化合物或其醫藥組合物適用於向胃腸道，例如結腸局部投與。在某些實施例中，在投與後，胃腸道中之氯硝柳胺化合物的局部濃度高於血漿隔室中之化學實體的濃度(例如，高約2倍至高約1,000倍；高約2倍至高約900倍；高約2倍至高約800倍；高約2倍至高約700倍；高約2倍至高約500倍；高約2倍至高約400倍；高約2倍至高約300倍；高約2倍至高約200倍；高約2倍至高約100倍；高約2倍至高約50倍，高約5倍至高約1,000倍；高約5倍至高約900倍；高約5倍至高約800倍；高約2倍至高約700倍；高約5倍至高約500倍；高約5倍至高約400倍；高約5倍至高約300倍；高約5倍至高約200倍；高約5倍至高約100倍；高約5倍至高約50倍；高約5倍至高約25倍；高約5倍至高約15倍；例如高約1,000倍、高約900倍、高約800倍、高約700倍、高約600倍、高約500倍、高約400倍、高約300倍、高約200倍、高約100倍、高約50倍、高約25倍、高約20倍、高約15倍、高約10倍、高約5倍)。在某些此等實施例中，使血漿隔室中之化學實體經受首次代謝。
在一些實施例中，本文所述之氯硝柳胺化合物或其醫藥組合物適用於向消化道或胃腸道內之一或多個特定位置，例如結腸局部投與。舉例而言，至少一些氯硝柳胺化合物存在於上胃腸道(例如胃)中；或至少一些氯硝柳胺化合物存在於下胃腸道(例如大腸，例如結腸，例如升結腸及/或橫結腸及/或遠端結腸；或小腸)中。作為另一實例，至少一些氯硝柳胺化合物存在於升結腸及/或橫結腸及/或遠端結腸及/或小腸及/或胃中。該局部投與之方法可包括但不限於經口投與。
在一個態樣中，本文提供一種組合物，其包含如本文任何地方所述之氯硝柳胺化合物或共晶體及一或多種醫藥學上可接受之賦形劑，其中該組合物適用於經口投與。
在一些實施例中，向個體投與單一劑量之該組合物使得該個體之胃腸道(例如結腸)中該氯硝柳胺化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度。
在一些實施例中，向個體投與單一劑量之該組合物使得該個體之胃腸道(例如結腸)中該氯硝柳胺化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度至少約200倍。
在一些實施例中，向個體投與單一劑量之該組合物使得該個體之胃腸道(例如結腸)中該氯硝柳胺化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度至少約300倍。
在一些實施例中，向個體投與單一劑量之該組合物使得該個體之胃腸道(例如結腸)中該氯硝柳胺化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度至少約500倍。
在一些實施例中，向個體投與單一劑量之該組合物使得該個體之胃腸道(例如結腸)中該氯硝柳胺化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度至少約700倍。
在一些實施例中，該個體之胃腸道(例如結腸)中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
在一些實施例中，該個體之胃腸道(例如結腸)中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度至少約100倍，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
在一些實施例中，該個體之胃腸道(例如結腸)中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度至少約100倍，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
在一些實施例中，該第二氯硝柳胺化合物之粒度分佈D(0.9)為約25.0 μm至約65.0 μm。
在一些實施例中，該第二氯硝柳胺化合物之粒度分佈D(0.1)為約4.0 μm至約10.0 μm。
在另一態樣中，本文提供一種包含如本文任何地方所述之組合物的劑型(例如單位劑型)，其中該劑型適用於經口投與。
在一些實施例中，該劑型進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至該升結腸。
在一些實施例中，該劑型進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至該橫結腸。
在一些實施例中，該劑型進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至該遠端結腸。
在一些實施例中，該劑型進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至該小腸。
其他實施例包括在技術方案168-178及/或179-183中之任何一或多者中敍述的實施例。
經口遞送
在其他實施例中，本文所述之化學實體或其醫藥組合物適用於藉助於經口投與而局部遞送至消化道或胃腸道(例如固體或液體劑型)。
用於經口投與之固體劑型包括膠囊劑、錠劑、丸劑、粉劑及粒劑。在此類固體劑型中，化學實體與一或多種醫藥學上可接受之賦形劑混合，諸如檸檬酸鈉或磷酸二鈣及/或以下各者：a)填充劑或增量劑，諸如澱粉、乳糖、蔗糖、葡萄糖、甘露糖醇及矽酸；b)黏合劑，諸如羧甲基纖維素、褐藻酸鹽、明膠、聚乙烯吡咯啶酮、蔗糖及阿拉伯膠；c)保濕劑，諸如甘油；d)崩解劑，諸如瓊脂-瓊脂、碳酸鈣、馬鈴薯或木薯澱粉、褐藻酸、某些矽酸鹽及碳酸鈉；e)溶解延遲劑，諸如石蠟；f)吸收促進劑，諸如四級銨化合物；g)濕潤劑，諸如鯨蠟醇及甘油單硬脂酸酯；h)吸收劑，諸如高嶺土及膨潤土，以及i)潤滑劑，諸如滑石、硬脂酸鈣、硬脂酸鎂、固體聚乙二醇、月桂基硫酸鈉，以及其混合物。在膠囊、錠劑及丸劑之情況下，劑型亦可包括緩衝劑。類似類型之固體組合物亦可用作使用諸如乳糖或牛乳糖以及高分子量聚乙二醇及其類似物之賦形劑之軟填充及硬填充明膠膠囊中的填充劑。
在一個實施例中，組合物將呈單位劑型諸如丸劑或錠劑的形式，且因此，該組合物除含有本文所提供之化學個體以外，亦可含有稀釋劑，諸如乳糖、蔗糖、磷酸二鈣或其類似物；潤滑劑，諸如硬脂酸鎂或其類似物；及黏合劑，諸如澱粉、阿拉伯膠、聚乙烯吡咯啶酮、明膠、纖維素、纖維素衍生物或其類似物。在另一種固體劑型中，粉末、造粒(marume)、溶液或懸浮液(例如，在碳酸伸丙酯、植物油、PEG、泊洛沙姆124或三酸甘油酯中)囊封於膠囊(明膠或纖維素類膠囊)中。亦涵蓋本文提供的一或多種化學實體或額外活性劑物理上分離的單位劑型；例如具有各藥物的顆粒的膠囊(或膠囊中的錠劑)；二層錠劑；二室凝膠帽等。亦涵蓋腸衣或延遲釋放口服劑型。
其他生理學上可接受之化合物包含濕潤劑、乳化劑、分散劑或特別適用於防止微生物生長或作用之防腐劑。各種防腐劑係熟知的且包含例如苯酚及抗壞血酸。
在某些實施例中，賦形劑係無菌的且一般不含不合需要的物質。此等組合物可藉由習知、熟知之滅菌技術來滅菌。對於各種口服劑型賦形劑，諸如錠劑及膠囊，不需要無菌。USP/NF標準通常係足夠的。
在某些實施例中，固體口服劑型可進一步包括在在化學上及/或在結構上使該組合物易於將化學實體遞送至胃部或下胃腸道，例如升結腸及/或橫結腸及/或遠端結腸及/或小腸之一或多種組分。例示性調配技術描述於例如Filipski, K.J.等人, Current Topics in Medicinal Chemistry,2013
, 13, 776-802中，其以全文引用之方式併入本文中。
實例包括上胃腸道靶向技術，例如，Accordion Pill (Intec Pharma)、浮動膠囊及能夠黏附至黏膜壁之物質。
其他實例包括下胃腸道靶向技術。針對靶向腸道中之各個區域，數種腸溶/pH反應性包衣及賦形劑係可用的。基於所需藥物釋放之GI區域來選擇，此等物質通常係經設計以在特定pH範圍下溶解或腐蝕之聚合物。此等物質亦起作用以在活性成分可能刺激上胃腸道之情況下保護酸不穩定藥物免遭胃液或極限暴露破壞(例如，羥丙基甲基纖維素鄰苯二甲酸酯系列、Coateric (聚乙酸乙烯酯鄰苯二甲酸酯)、鄰苯二甲酸乙酸纖維素、乙酸羥丙基甲基纖維素丁二酸酯(hydroxypropyl methylcellulose acetate succinate)、Eudragit系列(甲基丙烯酸-甲基丙烯酸甲酯共聚物)及Marcoat)。其他技術包括對胃腸道中之局部菌群起反應之劑型、控壓式結腸遞送膠囊及脈衝塞囊(Pulsincap)。
用於經口投與之液體劑型包括醫藥學上可接受之乳液、微乳液、溶液、懸浮液、糖漿及酏劑。除了本文所述之化學實體以外，液體劑型亦可含有此項技術中常用之惰性稀釋劑，諸如水或其他溶劑、增溶劑及乳化劑，諸如乙醇、異丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苯甲酯、丙二醇、1,3-丁二醇、二甲基甲醯胺、油(詳言之，棉籽油、花生油、玉米油、胚芽油、橄欖油、蓖麻油及芝麻油)、甘油、四氫糠醇、聚乙二醇及脫水山梨糖醇之脂肪酸酯及其混合物。除惰性稀釋劑以外，經口組合物亦可包括佐劑，諸如濕潤劑、乳化劑及懸浮劑、甜味劑、調味劑及芳香劑。在某些實施例中，該液體劑型為漱口水。在某些實施例中，此類液體口服劑型適用於向消化道或胃腸道，例如消化道，例如口腔局部及表面投與。
其他遞送形式
在一些實施例中，本文所述之化學實體或其醫藥組合物適用於局部及表面投與至眼睛(例如滴眼劑)。眼部組合物可包括但不限於以下任何一或多者：黏稠元(例如，羧甲基纖維素、甘油、聚乙烯吡咯啶酮、聚乙二醇)；穩定劑(例如，普洛尼克(Pluronic) (三嵌段共聚物)、環糊精)；防腐劑(例如，苯紮氯銨(Benzalkonium chloride)、ETDA、SofZia (酸、丙二醇、山梨糖醇以及氯化鋅；愛爾康實驗室有限公司(Alcon Laboratories公司))、Purite (穩定的氧氯複合物；阿勒根有限公司(Allergan公司)))。
在一些實施例中，本文所述之化學實體或其醫藥組合物適用於局部及表面投與至皮膚(例如軟膏及乳膏)。軟膏係通常基於石蠟脂或其他石油衍生物之半固體製劑。含有所選活性劑之乳膏通常係黏稠液體或半固體乳液，常常為水包油或油包水的。乳膏基質通常係水可洗的，且含有油相、乳化劑及水相。油相，有時亦稱作「內部」相，一般包含石蠟脂及脂肪醇諸如十六醇或十八醇；儘管不必需，但水相之體積通常超過油相，且一般含有保濕劑。乳膏調配物中之乳化劑一般係非離子、陰離子、陽離子或兩性界面活性劑。與其他載劑或媒劑相同，軟膏基質應為惰性、穩定、無刺激性且不致敏的。
劑量
劑量可取決於患者需求、所治療病狀的嚴重程度及所採用之特定化合物而變化。針對特定情況之適當劑量可由熟習醫學技術者來確定。總日劑量可分成多份且在一天內按多份投與或藉由提供連續遞送之方式投與。
在一些實施例中，氯硝柳胺化合物以約0.01 mg/Kg至約200 mg/Kg之劑量投與(例如約0.01 mg/Kg至約150 mg/Kg；約0.01 mg/Kg至約100 mg/Kg；約0.01 mg/Kg至約50 mg/Kg；約0.01 mg/Kg至約10 mg/Kg；約0.01 mg/Kg至約5 mg/Kg；約0. 1 mg/Kg至約200 mg/Kg；約0. 1 mg/Kg至約150 mg/Kg；約0. 1 mg/Kg至約100 mg/Kg；約0.1 mg/Kg至約50 mg/Kg；約0. 1 mg/Kg至約10 mg/Kg；約0. 1 mg/Kg至約5 mg/Kg)。
在某些實施例中，氯硝柳胺化合物以約15 mg/Kg至約100 mg/Kg之劑量投與(例如約15 mg/Kg至約90 mg/Kg、約20 mg/Kg至約100 mg/Kg；約20 mg/Kg至約90 mg/Kg；約20 mg/Kg至約80 mg/Kg；約30 mg/Kg至約90 mg/Kg；約30 mg/Kg至約80 mg/Kg；約35 mg/Kg至約75 mg/Kg；約10 mg/Kg至約50 mg/Kg；約15 mg/Kg至約45 mg/Kg；例如約35 mg/Kg或約75 mg/Kg)。在其他實施例中，化學實體以以下之劑量投與：約0.1 mg/Kg至約10 mg/Kg (例如約0.1 mg/Kg至約5 mg/Kg；約1 mg/Kg至約10 mg/Kg；約1 mg/Kg至約5 mg/Kg)。
在一些實施例中，調配物包括約0.5 mg至約2500 mg (例如，約0.5 mg至約2000 mg、約0.5 mg至約1000 mg、約0.5 mg至約750 mg、約0.5 mg至約600 mg、約0.5 mg至約500 mg、約0.5 mg至約400 mg、約0.5 mg至約300 mg、約0.5 mg至約200 mg；例如約5 mg至約2500 mg、約5 mg至約2000 mg、約5 mg至約1000 mg；約5 mg至約750 mg；約5 mg至約600 mg；約5 mg至約500 mg；約5 mg至約400 mg；約5 mg至約300 mg；約5 mg至約200 mg；例如約50 mg至約2000 mg、約50 mg至約1000 mg、約50 mg至約750 mg、約50 mg至約600 mg、約50 mg至約500 mg、約50 mg至約400 mg、約50 mg至約300 mg、約50 mg至約200 mg；例如約100 mg至約2500 mg、約100 mg至約2000 mg、約100 mg至約1000 mg、約100 mg至約750 mg、約100 mg至約700 mg、約100 mg至約600 mg、約100 mg至約500 mg、約100 mg至約400 mg、約100 mg至約300 mg、約100 mg至約200 mg；例如約150 mg至約2500 mg、約150 mg至約2000 mg、約150 mg至約1000 mg、約150 mg至約750 mg、約150 mg至約700 mg、約150 mg至約600 mg、約150 mg至約500 mg、約150 mg至約400 mg、約150 mg至約300 mg、約150 mg至約200 mg；例如約150 mg至約500 mg；例如約300 mg至約2500 mg、約300 mg至約2000 mg、約300 mg至約1000 mg、約300 mg至約750 mg、約300 mg至約700 mg、約300 mg至約600 mg；例如約400 mg至約2500 mg、約400 mg至約2000 mg、約400 mg至約1000 mg、約400 mg至約750 mg、約400 mg至約700 mg、約400 mg至約600、約400 mg至約500 mg；例如150 mg或450 mg)之氯硝柳胺化合物。
在某些實施例中，調配物包括約50 mg至約250 mg (例如約100 mg至約200；例如約150 mg)氯硝柳胺化合物。在某些實施例中，該等劑量適用於藉由直腸投與(例如藉由灌腸)投與的調配物。
在某些實施例中，灌腸調配物包括約350 mg至約550 mg (例如約400 mg至約500；例如約450 mg)之氯硝柳胺化合物。在某些實施例中，該等劑量適用於藉由直腸投與(例如藉由灌腸)投與的調配物。
前述劑量可以天為基礎(例如，以每天單次劑量；或以每天兩次或更多次分次劑量；或兩次或更多次劑量；例如每天兩次劑量、每天三次劑量)或不以天為基礎(例如，隔日、每兩天、每三天、每週一次、每週兩次、每兩週一次或每月一次)投與。在某些實施例中，劑量可投與約1週、約2週、約3週、約4週、約5週、約6週、約7週、約8週、約3個月、約6個月、約1年或更久。舉例而言，液體載劑中之化學實體的劑量(例如，約2.5 mg/mL或約7.5 mg/mL)可以天為基礎每天兩次投與約6週。在某些此等實施例中，化學實體為氯硝柳胺，或其醫藥學上可接受之鹽及/或水合物及/或共晶體。舉例而言，液體載劑中之約2.5 mg/mL或約7.5 mg/mL的氯硝柳胺可以天為基礎每天兩次投與約6週。代表性液體載劑包括例如先前結合組分( ii )
所述之彼等液體載劑。
在一些實施例中，調配物包括約500 mg至約2500 mg (例如，約600 mg至約1800 mg、約700 mg至約1700 mg、約800 mg至約1600 mg、約900 mg至約1500 mg、約1000 mg至約1400 mg、約1100 mg至約1300 mg，例如約1200 mg。在某些實施例中，該等劑量適用於藉由經口投與(例如，藉由錠劑或丸劑)投與之調配物。
在某些實施例中，調配物包括約100 mg至約700 mg (例如，約200 mg至約600 mg；例如，約300 mg至約500 mg；例如，約350 mg至約450 mg；例如，約400 mg)氯硝柳胺化合物。在某些實施例中，該等劑量適用於藉由經口投與(例如，藉由錠劑或丸劑)投與之調配物。
前述劑量可以天為基礎(例如，以每天單次劑量；或以每天兩次或更多次分次劑量；或兩次或更多次劑量；例如每天兩次劑量；或每天三次劑量；或每天四次劑量；或每天五次劑量；例如每天三次劑量)或不以天為基礎(例如，隔日、每兩天、每三天、每週一次、每週兩次、每兩週一次或每月一次)投與。在某些實施例中，劑量可投與約1週、約2週、約3週、約4週、約5週、約6週、約7週、約8週、約3個月、約6個月、約1年或更久，例如2週。
在某些實施例中，調配物包括約100 mg至約700 mg (例如，約200 mg至約600 mg；例如，約300 mg至約500 mg；例如，約350 mg至約450 mg；例如，約400 mg)之氯硝柳胺化合物，且前述劑量以天為基礎投與。在某些實施例中，前述劑量以每天單次劑量形式投與(例如持續14天)。在某些實施例中，該等劑量適用於藉由經口投與(例如，藉由錠劑或丸劑)投與之調配物。
在一些實施例中，調配物包括約500 mg至約2500 mg (例如，約600 mg至約1800 mg、約700 mg至約1700 mg、約800 mg至約1600 mg、約900 mg至約1500 mg、約1000 mg至約1400 mg、約1100 mg至約1300 mg，例如約1200 mg。在某些實施例中，前述劑量以天為基礎投與。在某些實施例中，前述劑量以每天兩次或更多次分次劑量；或兩次或更多次劑量；例如每天兩次劑量；或每天三次劑量；或每天四次劑量；或每天五次劑量；例如每天三次劑量)；例如持續14天。在某些實施例中，該等劑量適用於藉由經口投與(例如，藉由錠劑或丸劑)投與之調配物。在某些實施例中，前述劑量以每天兩次或更多次分次劑量；例如每天三次劑量；例如每天三次400 mg劑量；例如持續14天。
治療方法
在一些實施例中，提供用於誘導個體之(例如消化道及/或胃腸道(GI)、皮膚、眼睛或關節中的)一或多個T細胞之細胞死亡的方法。該等方法包括使一或多個T細胞與有效量之如本文中任何地方所定義之氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體接觸。在某些實施例中，該等方法基本上由或由上文此段落中所述之接觸步驟組成。
在一些實施例中，提供用於治療患有與個體之(例如消化道及/或胃腸道(GI)處的)不受調節(諸如異常，升高)的一或多種T細胞之募集及/或滯留相關的病狀之該個體的方法。該等方法包括使一或多個T細胞與有效量之如本文中任何地方所定義之氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體接觸。在某些實施例中，該等方法基本上由或由上文此段落中所述之接觸步驟組成。
在一些實施例中，提供用於治療患有與個體之(例如消化道及/或胃腸道(GI)，例如結腸中的)不受調節(諸如異常，升高)的一或多種T細胞之活化相關的病狀之該個體的方法。該等方法包括使一或多個經活化T細胞與有效量之共晶體接觸，該共晶體包含本文任何地方所定義之( i )
氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽)；及( ii )
一或多種醫藥學上可接受之共形成物。在某些實施例中，該等方法基本上由或由上文此段落中所述之接觸步驟組成。
在一些實施例中，誘導一或多個T細胞之細胞死亡包括以下路徑中之一或多者：計劃性細胞死亡、壞死性凋亡、細胞凋亡、壞死、細胞焦亡、鐵死亡、失巢凋亡、有絲分裂障礙、副凋亡、焦壞死(Pyronecrosis)、內吞死亡、中性粒細胞胞外陷阱死亡(Netosis)、依賴性細胞死亡、自噬性細胞死亡、RGD：可調控的細胞死亡、非凋亡性計劃性細胞死亡、凋亡蛋白酶非依賴性計劃性細胞死亡誘導一或多種T細胞之壞死或細胞凋亡，例如一或多種T細胞之壞死或細胞凋亡。在某些實施例中，有效量為足以誘導一或多種T細胞中之至少一者的細胞死亡(例如藉由上文所述之路徑中之任何一或多者，例如一或多種T細胞之壞死或細胞凋亡)的量。
在一些實施例中，一或多種T細胞包括一或多種經活化T細胞，例如一或多種經活化T細胞獨立地選自由以下組成之群：
CD45+CD3+TCRαβ+CD62L-；
CD45+CD3+ TCRαβ+CD62L-CCR7-；
CD45+CD3+ TCRαβ+CD62L-CD69+；
CD45+CD3+ TCRαβ+CD62L-CD69+PD-1+；
CD45+CD3+TCRαβ+CD62L-CTLA4+；
CD45+CD3+ TCRαβ+CD62L-PD-1++CTLA4+；
CD45+CD3+TCRγδ+CD62L-；
CD45+CD3+TCRγδ+CD62L-CCR7-；
CD45+CD3+TCRγδ+CD62L-CD69+；
CD45+CD3+ TCRγδ+CD62L-CD69+PD-1+；
CD45+CD3+CD62L-TCRγδ+CTLA4+；及
CD45+CD3+ TCRγδ+CD62L-PD-1++CTLA4+。
在某些實施例中，有效量為足以誘導一或多種經活化T細胞中之至少一者的細胞死亡(例如藉由上文所述之路徑中之任何一或多者，例如一或多種經活化T細胞之壞死或細胞凋亡)的量。
在一些實施例中，一或多種T細胞存在於腸上皮內及/或固有層內及/或派伊爾氏淋巴集結(Peyer's patch，PP)內及/或GALT (腸相關淋巴組織)內及/或腸黏膜內及/或腸黏膜下層及/或腸肌層內及/或腸漿膜內。
在一些實施例中，一或多種T細胞包含一或多種腸向性(gut tropic) T細胞。在某些實施例中，該一或多種腸向性T細胞中之每一者獨立地表現一或多種腸歸巢受體(gut-homing receptor)，該一或多種腸歸巢受體選自由以下組成之群：
(CD3+CCR9+；
CD3+α4+或CD3+β7+；
CD3+α4+ β7+；
CD3+β1+；
CD3+α4+ β1+；
CD3+LFA1；
CD3+CCR4+；及
CD3+CCR10+。
在一些實施例中，提供用於治療有需要之個體的以異常發炎反應為特徵之病狀(或其一或多種症狀)的方法(例如自體免疫病症，例如結腸炎，例如自體免疫結腸炎，例如發炎性腸病，例如克羅恩氏病、潰瘍性結腸炎)。該等方法包括向個體投與有效量之如本文中任何地方所定義之化學實體(例如，氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)。在某些實施例中，該等方法基本上由或由上文此段落中所述之投與步驟組成。
在一些實施例中，提供用於治療有需要之個體的以異常發炎反應為特徵之病狀(或其一或多種症狀)的方法(例如自體免疫病症，例如結腸炎，例如自體免疫結腸炎，例如發炎性腸病，例如克羅恩氏病、潰瘍性結腸炎)。該等方法包括向個體局部及表面投與有效量之如本文中任何地方所定義之化學實體(例如，氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)。在某些實施例中，該等方法基本上由或由上文此段落中所述之投與步驟組成。
在某些此等實施例中，該病狀為自體免疫疾病。自體免疫疾病之非限制性實例包括：關節炎(包括類風濕性關節炎、青少年類風濕性關節炎、骨關節炎、牛皮癬性關節炎)、多發性硬化症、重症肌無力、全身性紅斑狼瘡、自體免疫甲狀腺炎(例如橋本氏甲狀腺炎(Hashimoto's thyroiditis))、皮膚炎(包括異位性皮膚炎及濕疹性皮膚炎)、牛皮癬、休格連氏症候群(包括繼發於休格連氏症候群之乾眼症)、斑禿、由於節肢動物叮咬反應而引起之過敏性反應、克羅恩氏病、口瘡潰瘍、虹膜炎、結膜炎、角膜結膜炎、潰瘍性結腸炎、哮喘、過敏性哮喘、皮膚紅斑狼瘡、硬皮病、陰道炎、直腸炎、藥物疹、麻風逆轉反應、麻瘋結節性紅斑、自體免疫性葡萄膜炎、過敏性腦脊髓炎、急性壞死性出血性腦病、特發性兩側進行性感覺神經性聽覺損失、再生不全性貧血、純紅血球性貧血、特發性血小板減少症、多軟骨炎、韋格納氏肉芽腫病、慢性活性肝炎、史蒂文斯-約翰遜症候群(Stevens-Johnson syndrome)、特發性脂肪瀉(idiopathic sprue)、扁平苔癬、克羅恩氏病、格雷夫斯眼病(Graves ophthalmopathy)、類肉瘤病、原發性膽汁性肝硬化、後部葡萄膜炎及肺間質纖維化。
在一些實施例中，提供用於治療個體之結腸炎，例如自體免疫結腸炎，例如發炎性腸病；例如克羅恩氏病或潰瘍性結腸炎(或其一或多種症狀)的方法。該等方法包括向個體投與有效量之如本文中任何地方所定義之化學實體(例如，氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)。在某些實施例中，該等方法基本上由或由上文此段落中所述之投與步驟組成。
在一些實施例中，提供用於治療個體之選自由以下組成之群的病狀(或其一或多種症狀)的方法：乳糜瀉、大腸急躁症、黏膜炎、葡萄膜炎、膠原性結腸炎、淋巴球性結腸炎、顯微鏡結腸炎、輻射腸炎、類風濕性關節炎、狼瘡、硬皮病、牛皮癬、皮膚T細胞淋巴瘤、急性移植物抗宿主疾病及慢性移植物抗宿主疾病。該等方法包括向個體投與有效量之如本文中任何地方所定義之化學實體(例如，氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)。在某些實施例中，該等方法基本上由或由上文此段落中所述之投與步驟組成。
在一些實施例中，該病狀為結腸炎，例如自體免疫結腸炎。舉例而言，自體免疫結腸炎可為發炎性腸病。發炎性腸病可為克羅恩氏病。發炎性腸病可為潰瘍性結腸炎。結腸炎(例如，自體免疫結腸炎)可為醫原性自體免疫結腸炎，例如由一或多種化學治療劑誘發之結腸炎、由授受細胞療法治療誘發之結腸炎、與一或多種異體免疫性疾病(諸如移植物抗宿主疾病，例如急性移植物抗宿主疾病及慢性移植物抗宿主疾病)相關之結腸炎。在其他實施例中，醫原性自體免疫結腸炎可由艱難梭菌(Clostridium difficile
)感染引起，其為工業化世界中院內腹瀉及結腸炎之主要原因，且通常發生在服用廣泛抗生素之個體中。結腸炎可為膠原結腸炎、淋巴球性結腸炎或顯微鏡結腸炎。
在某些此等實施例中，該病狀為自體免疫疾病。在某些實施例中，病狀為自體免疫結腸炎，例如發炎性腸病(例如克羅恩氏病或潰瘍性結腸炎)。在某些實施例中，病狀為克羅恩氏病、自體免疫性結腸炎、醫原性自體免疫性結腸炎、潰瘍性結腸炎、由一或多種化學治療劑誘發之結腸炎、由過繼細胞療法治療誘發之結腸炎、與一或多種異體免疫性疾病(諸如移植物抗宿主疾病，例如急性移植物抗宿主疾病及慢性移植物抗宿主疾病)相關之結腸炎、放射性腸炎、膠原性結腸炎、淋巴細胞性結腸炎、顯微鏡結腸炎及放射性腸炎。
在某些此等實施例中，該病狀為異體免疫性疾病(諸如移植物抗宿主疾病，例如急性移植物抗宿主疾病及慢性移植物抗宿主疾病)、乳糜瀉、腸激躁症候群、類風濕性關節炎、狼瘡、硬皮病、牛皮癬、皮膚T細胞淋巴瘤、葡萄膜炎及黏膜炎(例如口腔黏膜炎、食道黏膜炎或腸黏膜炎)。
在某些實施例中，病狀為自體免疫結腸炎。
在某些此等實施例中，自體免疫結腸炎由一或多種化學治療劑誘發，例如化學治療免疫調節劑，例如免疫檢查點抑制劑。在某些此等實施例中，該免疫檢查點抑制劑靶向選自由以下組成之群的免疫檢查點受體：CTLA-4、PD-1、PD-L1、PD-1-PD-L1、PD-1-PD-L2、介白素-2 (IL-2)、吲哚胺2,3-二加氧酶(IDO)、IL-10、轉型生長因子-β (TGFβ)、T細胞免疫球蛋白及黏蛋白3 (TIM3或HAVCR2)、半乳糖凝集素9-TIM3、磷脂醯絲胺酸-TIM3、淋巴球活化基因3蛋白質(LAG3)、MHC II類-LAG3、4-1BB-4-1BB配位體、OX40-OX40配位體、GITR、GITR配位體-GITR、CD27、CD70-CD27、TNFRSF25、TNFRSF25-TL1A、CD40L、CD40-CD40配位體、HVEM-LIGHT-LTA、HVEM、HVEM-BTLA、HVEM-CD160、HVEM-LIGHT、HVEM-BTLA-CD160、CD80、CD80-PDL-1、PDL2-CD80、CD244、CD48-CD244、CD244、ICOS、ICOS-ICOS配位體、B7-H3、B7-H4、VISTA、TMIGD2、HHLA2-TMIGD2、包括BTNL2之嗜乳脂蛋白、唾液酸結合免疫球蛋白樣凝集素家族、TIGIT及PVR家族成員、KIR、ILT及LIR、NKG2D及NKG2A、MICA及MICB、CD244、CD28、CD86-CD28、CD86-CTLA、CD80-CD28、CD39、CD73腺苷-CD39-CD73、CXCR4-CXCL12、磷脂醯絲胺酸、TIM3、磷脂醯絲胺酸-TIM3、SIRPA-CD47、VEGF、神經纖毛蛋白、CD160、CD30及CD155；例如CTLA-4或PD1或PD-L1)。參見例如Postow, M.J. Clin. Oncol
.2015
,33
, 1。
在某些此等實施例中，該免疫檢查點抑制劑選自由以下組成之群：烏瑞魯單抗、PF‑05082566、MEDI6469、TRX518、瓦里木單抗、CP‑870893、派立珠單抗(PD1)、納武單抗(PD1)、阿特珠單抗(先前為MPDL3280A) (PDL1)、MEDI4736 (PD-L1)、阿維魯單抗(PD-L1)、PDR001 (PD1)、BMS‑986016、MGA271、利瑞路單抗、IPH2201、艾瑪圖單抗、INCB024360、高倫替布、尤洛庫單抗、BKT140、巴維昔單抗、CC‑90002、貝伐單抗及MNRP1685A，及MGA271。
在某些此等實施例中，免疫檢查點抑制劑靶向CTLA-4，例如抗體，例如伊派利單抗或曲美單抗。
在某些此等實施例中，免疫檢查點抑制劑靶向PD1或PD-L1，例如納武單抗、蘭布諾單抗或BMS-936559。
在某些實施例中，該病狀為黏膜炎，又稱為口炎，其可由單獨或組合之化學療法或放射療法以及由暴露於放射療法環境外部之放射引起之損傷而發生。當單獨或組合使用時可誘發黏膜炎之化學治療劑包括但不限於鉑、順鉑、卡鉑、奧沙利鉑、甲基二(氯乙基)胺、環磷醯胺、苯丁酸氮芥、硫唑嘌呤、巰基嘌呤、長春新鹼、長春鹼、長春瑞賓、長春地辛、依託泊苷及替尼泊甙、太平洋紫杉醇、多西他賽、伊立替康、拓朴替康、安吖啶、依託泊苷、磷酸依託泊苷、替尼泊甙、5-氟尿嘧啶、甲醯四氫葉酸(leucovorin)、甲胺喋呤、吉西他濱、紫杉烷、甲醯四氫葉酸、絲裂黴素C、喃氟啶-尿嘧啶(tegafur-uracil)、艾達黴素、氟達拉濱(fludarabine)、米托蒽醌、異環磷醯胺及小紅莓。額外藥劑包含哺乳動物雷帕黴素目標蛋白(mammalian target of rapamycin，mTOR)之抑制劑，包括但不限於雷帕黴素、依維莫司(everolimus)、坦羅莫司(temsirolimus)及地磷莫司(deforolimus)。
在某些實施例中，該病狀為葡萄膜炎，其為葡萄膜之炎症(例如前葡萄膜炎，例如虹膜睫狀體炎或虹膜炎；中間葡萄膜炎(又稱為睫狀體扁平部炎)；後葡萄膜炎；或脈絡膜視網膜炎，例如全葡萄膜炎)。
在一些實施例中，該病狀為癌症。癌症之非限制性實例包括：多發性骨髓瘤、白血病(HTLV-1依賴性、紅白血病、急性骨髓性白血病(AML)、慢性骨髓性白血病(CML)及大顆粒淋巴細胞白血病(LGL)、淋巴瘤(EBV相關/伯基特氏、蕈樣黴菌病、皮膚T細胞淋巴瘤、非霍奇金氏淋巴瘤(NHL)、多形性大細胞淋巴瘤(ALCL)、乳癌、三陰性乳癌、頭頸癌、黑素瘤、卵巢癌、肺癌、胰臟癌、前列腺癌、肉瘤、骨肉瘤、卡波西氏肉瘤、尤文氏肉瘤、肝細胞癌、神經膠質瘤、神經母細胞瘤、星形細胞瘤、大腸直腸癌、威姆氏腫瘤、腎癌、膀胱癌、子宮內膜癌、子宮頸癌、食道癌、皮膚鱗狀細胞癌、基底細胞癌及轉移性癌症。
在一些實施例中，該病狀為代謝病症。如本文所用，術語「代謝病症」係指由個體之異常代謝(亦即，為重要過程及活動提供能量的活細胞之化學變化)引起或表徵之病症、疾病或病狀。代謝病症包括與異常熱生成或異常脂肪細胞(例如棕色或白色脂肪細胞)含量或功能相關之疾病、病症或病狀。代謝病症之特徵可在於PGC-1活性之誤調(例如下調或上調)。代謝病症可不利地影響細胞功能，諸如細胞增殖、生長、分化或遷移、細胞穩態調節、細胞間或細胞內通信；組織功能，諸如肝功能、腎功能或脂肪細胞功能；生物體中全身性反應，諸如激素反應(例如胰島素反應)。代謝病症之實例包括肥胖、糖尿病、暴食、內分泌異常、三酸甘油酯儲存病、巴迪特-別鐸症候群(Bardet-Biedl syndrome)、勞倫斯-莫因症候群(Lawrence-Moon syndrome)、普拉德-拉伯哈特-威利症候群(Prader-Labhart-Willi syndrome)、食慾不振及惡病體質。代謝病症之非限制性實例包括肥胖症、代謝症候群、胰島素抗性、血脂異常(例如糖尿病異常)、高脂質血症、高血壓、糖尿病(例如2型糖尿病、1型糖尿病、兒童糖尿病)、高血糖症、痛風、LADA、膳食性高血糖症、高脂蛋白血症、小/大白蛋白尿、葡萄糖耐量異常(IGT)、空腹葡萄糖異常(IFG)、肝葡萄糖產生增加、高胰島素血症、非酒精性脂肪肝病(NAFD)、非酒精性脂肪變性肝炎(NASH)、腎病、視網膜病、神經病及糖尿病併發症(包括心血管病、心血管病症、脂質代謝之病症、神經退化性及精神病症、眼內壓失調(包括青光眼)、動脈粥樣硬化、高血壓、冠心病、膽囊疾病、腎病變、視網膜病變或糖尿病性潰瘍)。
在一些實施例中，該病狀為心血管疾病，諸如心肌梗塞及心臟肥大。心血管疾病可進一步包括冠心病(包括心臟病發作及心絞痛或胸痛)；中風；鬱血性心臟衰竭；高血壓(例如，肺動脈高血壓)、高血壓；心臟衰竭；風濕性發熱/風濕性心臟病；先天性心血管缺陷；心律不齊(心律病症)；動脈、小動脈及毛細血管疾病(包括動脈粥樣硬化及川崎病(Kawasaki disease))；細菌心內膜炎；心肌病；心臟瓣膜病；肺部循環疾病；靜脈及淋巴管疾病；及循環系統之其他疾病。在某些實施例中，本文之方法中的一或多者對心臟中之梗塞癒合、增加血管生成及/或減弱肥厚性反應產生有利作用。
在一些實施例中，該病狀為與微生物感染(例如病毒、細菌、真菌及/或寄生蟲感染)相關之病狀。非限制性實例包括：結核(例如肺結核、非肺結核(諸如淋巴腺結核、生殖-泌尿結核、骨骼及關節結核、腦膜炎結核)及栗粒性結核)、炭疽熱、膿腫、尋常痤瘡、放線菌病、哮喘、桿菌痢疾(bacilliary dysentry)、細菌性結膜炎、細菌性角膜炎、細菌性陰道炎、肉毒、布路里潰瘍(Buruli ulcer)、骨骼及關節感染、支氣管炎(急性或慢性)、布氏桿菌病、燒傷、貓抓熱、蜂窩組織炎、軟下疳、膽管炎、膽囊炎、皮膚白喉、囊腫性纖維化、囊性纖維化、膀胱炎、彌漫性泛細支氣管炎、白喉、齲齒、上呼吸道疾病、濕疹、積膿症(empymea)、心內膜炎、子宮內膜炎、腸發熱、腸炎、附睪炎、會厭炎、下肢丹毒(erysipelis)、丹毒、類丹毒、紅癬、眼睛感染、疔瘡(furuncles)、加德納菌(gardnerella vaginitis)、胃腸道感染(腸胃炎)、生殖器感染、齒齦炎、淋病、性病肉芽腫、哈佛希爾熱、燒傷感染、牙科手術後的感染、口腔感染、假肢相關的感染、腹部膿腫、軍團病、麻風、鉤端螺旋體病、李氏菌病、肝膿腫、萊姆病、性病淋巴肉芽腫、乳房炎、乳突炎、腦膜炎及神經系統感染、足菌病、奴卡菌病(例如足菌腫)、非特異性尿道炎、眼炎(例如新生兒眼炎)、骨髓炎、耳炎(例如外耳炎及中耳炎)、睪丸炎、胰臟炎、甲溝炎、盆腔腹膜炎、腹膜炎、腹膜炎及闌尾炎、咽炎、窩織炎、品他病、鼠疫、肋膜積液、肺炎、手術後傷口感染、手術後氣性壞疽、前列腺炎、偽-膜性結腸炎、鸚鵡病、肺氣腫、腎盂腎炎、膿皮病(例如膿皰)、Q熱、鼠叮咬熱、網狀細胞增多、蓖麻毒素中毒、里德耳病、沙門氏桿菌病、輸卵管炎、感染性關節炎、感染性感染、敗血症、鼻竇炎、皮膚感染(例如皮膚肉芽腫、膿皰、毛囊炎及癤瘡)、梅毒、全身感染、扁桃腺炎、中毒性休克症候群、沙眼、土拉菌病、傷寒、斑疹傷寒(例如流行性斑疹傷寒、鼠斑疹傷寒、恙蟲病及斑疹熱)、尿道炎、傷口感染、雅司病、麴黴病、念珠菌病(例如口咽念珠菌病、陰道念珠菌病或龜頭炎)、隱球菌病、黃癬、組織漿菌病、擦疹、白黴菌病、癬(例如體癬、頭癬、股癬、足癬及甲癬)、甲癬、變色糠疹、癬及孢子絲菌病；或感染MSSA、MRSA、表皮葡萄球菌(Staph. epidermidis)、無乳鏈球菌(Strept. agalactiae)、生膿鏈球菌(Strept. pyogenes)、大腸桿菌(Escherichia coli)、肺炎克雷伯氏菌(Klebs. pneumoniae)、產酸克雷伯氏菌(Klebs. oxytoca)、奇異變形桿菌(Pr. mirabilis)、瑞氏變形桿菌(Pr. rettgeri)、普通變形桿菌(Pr. vulgaris)、流感嗜血桿菌(Haemophilis injluenzae)、糞腸球菌(Enterococcus faecalis)及屎腸球菌(Enterococcus faecium)。非限制性實例亦包括由例如以下之感染引起的DNA及RNA病毒性疾病：正黏液病毒(A型及B型流感病毒)、副黏病毒(呼吸道融合病毒(RSV)、亞急性硬化性全腦炎(SSPE)病毒)麻疹及副流感3型)、疱疹病毒(HSV-1、HSV-2、HHV-6、HHV-7、HHV-8、埃-巴二氏病毒(EBV)、巨細胞病毒(HCMV)及水痘帶狀疱疹病毒(VZV))、反轉錄病毒(HIV-1、HIV-2、HTLV-1、HTLV-2)、蟲媒病毒及疫病毒(黃熱病病毒(YFV)、C型肝炎病毒(HCV)、登革熱病毒、牛病毒性腹瀉病毒(BVDV)、趨肝性病毒(hepa-totrophic virus) (A型肝炎病毒(HAV)、B型肝炎病毒(HBV)、HCV、肝炎D病毒(HDV)、肝炎E病毒(HEV)、G型肝炎病毒(HGV)、克里米亞-岡果出血熱病毒(CCHF)、崩芽病毒(Punta Toro病毒，東非瑞夫特河谷羊熱病病毒(RVFV)及白蛉熱-西西里病毒)、漢他病毒、卡拉帕魯病毒)、人體乳頭瘤病毒、腦炎病毒(拉克魯絲病毒)、阿瑞娜病毒(胡寧及塔卡里伯病毒)、呼腸孤病毒、水泡性口炎病毒、鼻病毒(rhinbviruses)、腸病毒(脊髓灰質炎病毒、柯沙奇病毒、腦心肌炎病毒(EMC))、拉沙熱病毒、披衣病毒(辛德比及莖狀森林病毒)及痘病毒。其他非限制性實例包括真菌感染，諸如假比酵母(Candida
)、申克氏胞絲菌(Sporothrix schenkii
)、組織漿菌(Histoplasma
)、副球孢子菌(Paracoccidiodes
)、麴菌屬等；或寄生蟲感染，諸如利什曼原蟲、瘧疾、棘阿米巴、絛蟲等。
在一些實施例中，該病狀為過敏性疾病。非限制性實例包括風疹、食物過敏、過敏性休克、嗜伊紅白血球增多症候群、哮喘、過敏性鼻炎、過敏性結膜炎及異位性皮膚炎。
在一些實施例中，該病狀為與NF-κB活化及/或發炎性細胞介素產生相關的病狀。非限制性實例包括自體免疫疾病，諸如慢性風濕、骨關節炎、全身性紅斑狼瘡、全身性硬皮病、多發性肌炎、肖格倫症候群、血管炎症候群、抗磷脂症候群、斯蒂爾氏病、白塞氏病、結節性動脈周圍炎、潰瘍性結腸炎、克羅恩氏病、活動性慢性肝炎、絲球體腎炎及慢性腎炎、慢性胰臟炎、痛風、動脈粥樣硬化、多發性硬化、動脈硬化、內皮肥大、牛皮癬、牛皮癬性關節炎、接觸性皮炎、異位性皮膚炎、過敏性疾病諸如花粉症、哮喘、支氣管炎、間隙性肺炎、肺病(包含肉芽腫、慢性阻塞性肺病、慢性肺血栓栓塞)、發炎性結腸炎、胰島素抗性、肥胖、糖尿病及其併發症(腎病、視網膜病、神經病、高胰島素血症、動脈硬化、高血壓、外圍血管阻塞等)、包含異常血管增殖之疾病(諸如高血脂病)、視網膜病及肺炎、阿耳滋海默症、腦脊髓炎、急性肝炎、慢性肝炎、藥物誘發之毒性肝病、酒精性肝炎、病毒性肝炎、黃疸、肝硬化、肝機能不全、心房黏液瘤、卡斯爾曼症候群(Caslemann's syndrome)、腎小球膜腎炎、腎癌、肺癌、肝癌、乳癌、子宮癌、胰臟癌、其他實體癌症、肉瘤、骨肉瘤、癌症之轉移性侵入、炎性灶惡變(carceration of inflanimatory focus)、癌性惡病質、癌轉移、白血病(諸如急性骨髓母細胞白血病)、多發性骨髓瘤、雷芮氏淋巴瘤、惡性淋巴瘤、出現癌症之制癌抗性、病灶惡變(諸如病毒性肝炎及肝硬化)、結腸息肉惡變、腦腫瘤、神經腫瘤、內毒素休克、敗血症、細胞術(cytome)、加洛病毒性肺炎、巨細胞病毒視網膜病、腺病毒冷、腺病毒發熱、腺病毒眼炎、結膜炎、AIDS、葡萄膜炎、由感染其他細菌、病毒及真菌引起之疾病或併發症、手術後之併發症(諸如廣泛性發炎症狀)、經皮輸卵管冠狀動脈塑形手術後再狹窄、血管閉塞開口後再灌注病症(諸如缺血再灌注病症)、心臟、肝臟、腎臟或其類似者之器官移植排斥反應及灌注病症、瘙癢、食慾不振、不適、慢性疲勞症候群及其類似者。
在一些實施例中，該病狀為藉由水通道蛋白介導之病狀，例如水不平衡之疾病或病狀。非限制性實例包括：腦或脊髓之水腫(例如，腦水腫，例如由於頭部創傷而產生的腦水腫)、缺血性中風、神經膠質瘤、腦膜炎、急性高山病、癲癇性癲癇發作、感染、代謝障礙、缺氧(包括一般性全身缺氧及由於心跳驟停引起的缺氧)、水中毒、肝衰竭、肝腦病、糖尿病酮酸中毒、膿腫、驚厥、庫賈氏病、狼瘡性腦炎或創傷性中樞神經系統過程(例如神經手術、內血管凝塊移除、脊椎抽液、動脈瘤修復或大腦深度刺激或例如由脊髓損傷(例如脊髓受壓)所致之脊髓水腫或由微重力及/或輻射暴露所致之腦及/或光學神經水腫；視網膜水腫；低鈉血症過量流體保留，例如心衰竭(HF)、肝硬化、腎病病症或不當抗激素分泌之症候群(SIADH)；癲癇症、視網膜缺血或與眼內壓及/或組織水合異常相關之眼部其他疾病、心肌缺血、心肌缺血/再灌注損傷、心肌梗塞、心肌缺氧、充血性心臟衰竭、敗血症或視神經脊髓炎；及偏頭痛。
在一些實施例中，該病狀為神經退化性或精神疾病。神經退化性或精神疾病之非限制性實例包括：肌肉萎縮性側索硬化、帕金森氏病、阿耳滋海默症、神經元死亡、認知功能受損、抑鬱、焦慮、進食障礙、食慾調節、偏頭痛、癲癇及對化學物質成癮。
在一些實施例中，該病狀為勃起功能障礙(男性或女性)、肌病、肌肉組織損耗、肌肉萎縮、肌肉代謝、骨質疏鬆或減緩線性生長。在一些實施例中，該病狀為全身性硬化症。
本發明涵蓋單藥療法方案以及組合療法方案兩者。
在一些實施例中，單藥療法包括向個體投與(例如表面及局部)有效量之如本文任何地方所定義之化學實體(例如氯硝柳胺化合物或其醫藥學上可接受之鹽及/或共晶體；例如化合物，諸如氯硝柳胺或其醫藥學上可接受之鹽及/或共晶體)，但不包括投與其他治療劑(例如，以全文引用之方式併入本文中的美國專利8,148,328中所揭示之活性化合物，例如肽)。
在一些實施例中，本文所述之方法可進一步包括投與第二治療劑或方案。
在某些實施例中，第二治療劑或療程在與化學實體接觸或投與化學實體之前(例如，約一小時前、或約6小時前、或約12小時前、或約24小時前、或約48小時前、或約1週前、或約1個月前)向個體投與。
在其他實施例中，第二治療劑或方案在與化學實體接觸或投與化學實體大約相同的時間向個體投與。藉助於實例，第二治療劑或方案及化學實體以同一劑型同時提供至個體。作為另一實例，第二治療劑或方案及化學個體以獨立劑型並行地提供給個體。
在再其他實施例中，第二治療劑或方案在與化學實體接觸或投與該化學實體之後(例如在約一小時之後、或在約6小時之後、或在約12小時之後、或在約24小時之後、或在約48小時之後、或在約1週之後、或在約1個月之後)向個體投與。
在某些實施例中，第二治療劑為化學治療免疫調節劑，例如免疫檢查點抑制劑，其可如本文任何地方所定義。在其他實施例中，第二治療劑或方案為一或多種在胃腸道中局部起作用之消炎劑或免疫調節劑。在其他實施例中，第二治療劑或方案為5-ASA (及相關遞送系統)、反義抗SMAD7、經口調配之抗TNF、抗整合素、柳氮磺胺吡啶、巴柳氮、類固醇、硫唑嘌呤及甲胺喋呤。在其他實施例中，第二治療劑或方案為輻射或手術。
在某些實施例中，第二治療劑為鉑、順鉑、卡鉑、奧沙利鉑、甲基二(氯乙基)胺、環磷醯胺、苯丁酸氮芥、硫唑嘌呤、巰基嘌呤、長春新鹼、長春鹼、長春瑞賓、長春地辛、依託泊苷及替尼泊甙、太平洋紫杉醇、多西他賽、伊立替康、拓朴替康、安吖啶、依託泊苷、磷酸依託泊苷、替尼泊甙、5-氟尿嘧啶、甲醯四氫葉酸、甲胺喋呤、吉西他濱、紫杉烷、甲醯四氫葉酸、絲裂黴素C、喃氟啶-尿嘧啶、艾達黴素、氟達拉濱、米托蒽醌、異環磷醯胺及小紅莓。額外藥劑包含哺乳動物雷帕黴素目標蛋白(mammalian target of rapamycin，mTOR)之抑制劑，包括但不限於雷帕黴素、依維莫司、坦羅莫司及地磷莫司。
組合療法
在一些實施例中，本文所述之方法及組合物適用於與各種其他治療方案(例如化學療法及/或輻射)的組合療法。在某些實施例中，本文所述之化學實體及方法可用於治療由此等治療方案產生的副作用，例如由化學治療免疫調節劑(例如檢查點抑制劑)誘發之發炎性腸病，其在一些情況下可能極為嚴重。
在一些實施例中，本文所述之方法及組合物適用於與一或多種額外治療劑之組合療法。
在某些實施例中，一或多種額外治療劑在與化學實體接觸或投與該化學實體之前(例如，約一小時之前，或約6小時之前，或約12小時之前，或約24小時之前，或約48小時之前，或約1週之前，或約1個月之前)向個體投與。
在其他實施例中，一或多種額外治療劑在與化學實體接觸或投與該化學實體約相同的時間向個體投與。藉助於實例，第二治療劑或方案及化學實體以同一劑型同時提供至個體。作為另一實例，第二治療劑或方案及化學個體以獨立劑型並行地提供給個體。
在再其他實施例中，一或多種額外治療劑在與化學實體接觸或投與該化學實體之後(例如，在約一小時之後、或在約6小時之後、或在約12小時之後、或在約24小時之後、或在約48小時之後、或在約1週之後、或在約1個月之後)向個體投與。
作為另一實例，一或多種治療劑可為：布地奈德；表皮成長因子；皮質類固醇；環孢黴素；柳氮磺胺吡啶；胺基柳酸鹽；6-巰基嘌呤；硫唑嘌呤；甲硝噠唑；脂肪加氧酶抑制劑；美塞拉明；奧沙拉嗪；巴柳氮；抗氧化劑；凝血脂素抑制劑；IL-1受體拮抗劑；抗IL-1單株抗體；抗-IL-6單株抗體(例如抗IL-6受體抗體及抗IL-6抗體)；生長因子；彈性蛋白酶抑制劑；吡啶基-咪唑化合物；本文所述之TNF拮抗劑；IL-4、IL-10、IL-13及/或TGF.β.細胞介素或其促進劑(例如促效劑抗體)；IL-11；普賴蘇穠、地塞米松或布地奈德之葡萄糖苷酸或聚葡萄糖共軛前驅藥；ICAM-1反義硫代磷酸酯寡去氧核苷酸(ISIS 2302；Isis Pharmaceuticals公司)；可溶互補序列受體1 (TP10；T Cell Sciences公司)；緩釋美沙拉嗪；甲胺喋呤；血小板激活因子(PAF)拮抗劑；環丙沙星；及/或里格卡因。
在一些實施例中，本文所述之方法及組合物適用於與一或多種用於治療或預防發炎性腸病(IBS) (例如克羅恩氏病、潰瘍性結腸炎)之其他治療劑的組合療法。額外治療劑之非限制性實例包括：神經鞘胺醇1-磷酸(S1P)受體調節劑(例如依托西莫德或奧札莫德)；類固醇消炎劑(例如倍氯米松17或布地奈德)；非類固醇消炎劑(例如5-ASA)；受體相互作用蛋白質激酶1 (RIPK1)抑制劑(例如GSK2982772)；EP4調節劑(例如KAG-308)；鐸樣受體(例如，TLR4、TLR9)調節劑(例如，JKB-122、庫比莫德)；詹納斯(Janus)激酶(JAK)抑制劑(例如TD-1473、托法替尼、優帕替尼、非戈替尼、PF-06651600及PF-06700841)；羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑(例如BT-11)；磷脂醯膽鹼(例如LT-02)；整合素(例如，α4整合素)調節劑(例如AJM-300 (卡羅格拉斯))；Smad7調節劑(例如蒙格森)；磷酸二酯酶4 (PDE4)調節劑(例如阿普斯特)；腫瘤進展基因座2 (TPL2)抑制劑(例如GS-4875)；酪胺酸激酶2 (TYK2)抑制劑(例如BMS-986165、PF-06700841及PF-06826647)；及TEC激酶抑制劑(例如PF-06651600)。
在一些實施例中，一或多種額外治療劑選自用於治療類風濕性關節炎之藥劑/方案。非限制性實例包括非類固醇消炎藥(NSAID；例如布洛芬及萘普生)、皮質類固醇(例如普賴松)、疾病調整抗風濕藥物(DMARD；例如甲胺喋呤(Trexall®、Otrexup®、Rasuvo®、Rheumatrex®)、來氟米特(Arava®)、羥基氯奎(氯奎寧)、PF-06650833、艾拉莫德、托法替尼(Xeljanz®)、ABBV-599、伊沃替尼及柳氮磺胺吡啶(Azulfidine®))及生物療法(例如阿巴西普(Orencia®)、阿達木單抗(Humira®)、阿那白滯素(Kineret®)、賽妥珠單抗(Cimzia®)、依那西普(Enbrel®)、戈利木單抗(Simponi®)、英利昔單抗(Remicade®)、利妥昔單抗(Rituxan®)、托西利單抗(Actemra®)、沃巴利單抗、賽瑞單抗(Kevzara®)、塞庫金單抗、ABP 501、CHS-0214、ABC-3373及托西利單抗(ACTEMRA®))。
在一些實施例中，一或多種額外治療劑選自用於治療狼瘡之藥劑/方案。非限制性實例包括類固醇、表面免疫調節劑(例如他克莫司(tacrolimus)軟膏(Protopic®)及吡美莫司乳膏(Elidel®))、沙立度胺(Thalomid®)、非類固醇消炎藥(NSAID；例如布洛芬及萘普生)、抗瘧疾藥(例如羥基氯喹(氯奎寧))、皮質類固醇(例如普賴松)及免疫調節劑(例如伊沃替尼、伊伯度胺(iberdomide)、伏環孢素(voclosporin)、賽尼莫德(cenerimod)、硫唑嘌呤(Imuran®)、環磷醯胺(Cytoxan®、Neosar®、Endoxan®)及環孢黴素(Neoral、Sandimmune®、Gengraf®)及黴酚酸嗎啉乙酯(mycophenolate mofetil))巴瑞替尼(baricitinb)、艾拉莫德、非洛替尼(filogotinib)、GS-9876、雷帕黴素及PF-06650833)，及生物製品(例如貝利單抗(belimumab) (Benlysta®)、阿尼弗洛單抗(anifrolumab)、普雷魯單抗(prezalumab)、MEDI0700、奧比珠單抗(obinutuzumab)、沃巴利單抗、盧利珠單抗(lulizumab)、阿塞西普、PF-06823859及魯普佐(lupizor)、利妥昔單抗、BT063、BI655064、BIIB059、阿地白介素(Proleukin®)、達皮羅珠單抗(dapirolizumab)、艾拉泰德(edratide)、IFN-α-金諾德(kinoid)、OMS721、RC18、RSLV-132、賽拉珠單抗(theralizumab)、XmAb5871及優特克單抗(Stelara®))。舉例而言，全身性紅斑狼瘡之非限制性治療包括非類固醇消炎藥(NSAID；例如布洛芬及萘普生)、抗瘧疾藥(例如羥基氯喹(氯奎寧))、皮質類固醇(例如普賴松)及免疫調節劑(例如伊伯度胺、伏環孢素、硫唑嘌呤(Imuran®)、環磷醯胺(Cytoxan®、Neosar®、Endoxan®)及環孢黴素(Neoral、Sandimmune®、Gengraf®)及黴酚酸嗎啉乙酯、巴瑞替尼、非洛替尼及PF-06650833)、及生物製品(例如貝利單抗(Benlysta®)、阿尼弗洛單抗、普雷魯單抗、MEDI0700、沃巴利單抗、盧利珠單抗、阿塞西普、PF-06823859、魯普佐、利妥昔單抗、BT063、BI655064、BIIB059、阿地白介素(Proleukin®)、達皮羅珠單抗、艾拉泰德、IFN-α-金諾德、RC18、RSLV-132、賽拉珠單抗、XmAb5871及優特克單抗(Stelara®))。作為另一實例，皮膚狼瘡之治療的非限制性實例包括類固醇、免疫調節劑(例如他克莫司軟膏(Protopic®)及吡美莫司乳膏(Elidel®))、GS-9876、非洛替尼及沙立度胺(Thalomid®)。亦可投與用於治療藥物誘發之狼瘡及/或新生兒狼瘡的藥劑及方案。
在一些實施例中，一或多種額外治療劑選自用於治療IBD之藥劑/方案。非限制性實例包括6-巰基嘌呤、AbGn-168H、ABX464、ABT-494、阿達木單抗、AJM300、阿利卡弗森、AMG139、安魯金單抗、阿普斯特、ATR-107(PF0530900)、自體CD34選擇之末梢血液幹細胞移植、硫唑嘌呤、柏替木單抗、BI 655066、BMS-936557、聚乙二醇化賽妥珠單抗(Cimzia®)、庫比莫德、皮質類固醇(例如普賴松、甲基普賴蘇穠、普賴松)、CP-690,550、CT-P13、環孢黴素、DIMS0150、E6007、E6011、依托西莫德、艾托珠單抗、糞便微生物移植、非洛替尼、芬戈莫德、非拉司特(SB-683699) (先前稱為T-0047)、GED0301、GLPG0634、GLPG0974、古賽庫單抗、戈利木單抗、GSK1399686、HMPL-004(穿心蓮提取物)、IMU-838、英利昔單抗、介白素2(IL-2)、傑納斯激酶(Janus kinase) (JAK)抑制劑、拉喹莫德、馬賽替尼(AB1010)、基質金屬蛋白酶9 (MMP 9)抑制劑(例如GS-5745)、MEDI2070、美塞拉明、甲胺喋呤、密利基單抗(LY3074828)、那他珠單抗、NNC 0142-0000-0002、NNC0114-0006、奧札莫德、皮非替尼(JNJ-54781532)、PF-00547659、PF-04236921、PF-06687234、QAX576、RHB-104、利福昔明、里森基單抗、RPC1063、SB012、SHP647、柳氮磺胺吡啶、TD-1473、沙立度胺、替拉珠單抗(MK 3222)、TJ301、TNF-Kinoid®、托法替尼、塔羅金單抗、TRK-170、優帕替尼、優特克單抗、UTTR1147A、V565、維特立珠單抗、VB-201、維多珠單抗及維魯迪姆。
在一些實施例中，一或多種額外治療劑選自用於治療大腸急躁症之藥劑/方案。非限制性實例包括阿洛司瓊(alosetron)、膽酸螯合劑(例如消膽胺(cholestyramine)、考來替潑(colestipol)、考來維侖(colesevelam))、氯離子通道活化劑(例如魯比前列酮(lubiprostone))、經包覆之薄荷油膠囊、地昔帕明(desipramine)、雙環維林(dicyclomine)、依巴司汀(ebastine)、艾沙度林(eluxadoline)、法尼醇X受體促效劑(例如奧貝膽酸(obeticholic acid))、糞便微生物群移植、氟西汀(fluoxetine)、加巴噴丁(gabapentin)、鳥苷酸環化酶-C促效劑(例如利那洛肽(linaclotide)、普卡那肽(plecanatide))、艾波度坦(ibodutant)、丙咪嗪(imipramine)、JCM-16021、洛哌丁胺(loperamide)、魯比前列酮、去甲替林(nortriptyline)、昂丹司瓊(ondansetron)、阿片類藥物、帕羅西汀(paroxetine)、吡那韋(pinaverium)、聚乙二醇、普瑞巴林(pregabalin)、益生菌、拉莫司瓊(ramosetron)、利福昔明(rifaximin)及坦潘諾爾(tanpanor)。
在一些實施例中，一或多種額外治療劑選自用於治療硬皮病之藥劑/方案。非限制性實例包括非類固醇消炎藥(NSAID；例如布洛芬及萘普生)、皮質類固醇(例如普賴松)、免疫調節劑(例如硫唑嘌呤、甲胺喋呤(Trexall®、Otrexup®、Rasuvo®、Rheumatrex®)、環磷醯胺(Cytoxan®、Neosar®、Endoxan®)及環孢黴素(Neoral®、Sandimmune®、Gengraf®)、抗胸腺細胞球蛋白、黴酚酸嗎啉乙酯、靜脈內免疫球蛋白、利妥昔單抗、西羅莫司(sirolimus)及阿法賽特(alefacept))、鈣通道阻斷劑(例如硝苯地平(nifedipine))、α阻斷劑、血清素受體拮抗劑、血管收縮素II受體抑制劑、他汀類(statins)、局部硝酸鹽、伊洛前列素(iloprost)、磷酸二酯酶5抑制劑(例如西地那非(sildenafil))、波生坦(bosentan)、四環素抗生素、內皮素受體拮抗劑、前列腺素類及酪胺酸激酶抑制劑(例如伊馬替尼(imatinib)、尼羅替尼(nilotinib)及達沙替尼(dasatinib))。
在一些實施例中，一或多種額外治療劑選自用於治療克羅恩氏病(CD)之藥劑/方案。非限制性實例包括阿達木單抗自體CD34選擇之末梢血液幹細胞移植6-巰基嘌呤、硫唑嘌呤、聚乙二醇化賽妥珠單抗(Cimzia®)、皮質類固醇(例如普賴松)、艾托珠單抗、E6011、糞便微生物移植、非洛替尼、古賽庫單抗、英利昔單抗、IL-2、JAK抑制劑、基質金屬蛋白酶9 (MMP 9)抑制劑(例如GS-5745)、MEDI2070、美塞拉明、甲胺喋呤、那他珠單抗、奧札莫德、RHB-104、利福昔明、里森基單抗、SHP647、柳氮磺胺吡啶、沙立度胺、優帕替尼、V565及維多珠單抗。
在一些實施例中，一或多種額外治療劑選自用於治療UC之藥劑/方案。非限制性實例包括AbGn-168H、ABT-494、ABX464、阿普斯特、PF-00547659、PF-06687234、6-巰基嘌呤、阿達木單抗、硫唑嘌呤、柏替木單抗、布拉奇單抗(MEDI2070)、庫比莫德、聚乙二醇化賽妥珠單抗(Cimzia®)、CP-690,550、皮質類固醇(例如多軸布地奈德、甲基普賴蘇穠)、環孢黴素、E6007、依托西莫德、艾托珠單抗、糞便微生物移植、非洛替尼、古賽庫單抗、戈利木單抗、IL-2、IMU-838、英利昔單抗、基質金屬蛋白酶9 (MMP9)抑制劑(例如GS-5745)、美塞拉明、美塞拉明、密利基單抗(LY3074828)、RPC1063、里森基單抗(BI 6555066)、SHP647、柳氮磺胺吡啶、TD-1473、TJ301、替拉珠單抗(MK 3222)、托法替尼、托法替尼、優特克單抗、UTTR1147A及維多珠單抗。
在一些實施例中，一或多種額外治療劑選自用於治療自體免疫結腸炎之藥劑/方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、美塞拉明、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
在一些實施例中，一或多種額外治療劑選自用於治療醫原性自體免疫結腸炎之藥劑/方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
在一些實施例中，一或多種額外治療劑選自用於治療由一或多種化學治療劑誘發之結腸炎的藥劑/方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、美塞拉明、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
在一些實施例中，一或多種額外治療劑選自由授受細胞療法治療誘發之結腸炎的藥劑/方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、苯乙哌啶/阿托品、英利昔單抗、洛哌丁胺、TIP60抑制劑(參見例如美國專利申請公開案第2012/0202848號)及維多珠單抗。
在一些實施例中，一或多種額外治療劑選自用於治療與一或多種異體免疫性疾病相關之結腸炎的藥劑/方案。非限制性實例包括皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、柳氮磺胺吡啶及二十碳五烯酸。
在一些實施例中，一或多種額外治療劑選自用於治療放射性腸炎之藥劑/方案。非限制性實例包括替度魯肽、阿米福汀、血管收縮素轉化酶(ACE)抑制劑(例如貝那普利、卡托普利、依那普利、福辛普利、賴諾普利、莫西普利、培哚普利、喹那普利、雷米普利及群多普利)、益生菌、補硒、士他汀(例如阿托伐他汀、氟伐他汀、洛伐他汀、普伐他汀、羅素他汀、辛伐他汀及匹伐他汀)、硫糖鋁及維生素E。
在一些實施例中，一或多種額外治療劑選自用於治療膠原性結腸炎之藥劑/方案。非限制性實例包括6-巰基嘌呤、硫唑嘌呤、次水楊酸鉍、齒葉乳香樹提取物、消膽胺、考來替潑、皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、洛哌丁胺、美塞拉明、甲胺喋呤、益生菌及柳氮磺胺吡啶。
在一些實施例中，一或多種額外治療劑選自用於治療淋巴球性結腸炎之藥劑/方案。非限制性實例包括6-巰基嘌呤、硫唑嘌呤、次水楊酸鉍、消膽胺、考來替潑、皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、洛哌丁胺、美塞拉明、甲胺喋呤及柳氮磺胺吡啶。
在一些實施例中，一或多種額外治療劑選自用於治療顯微鏡結腸炎之藥劑/方案。非限制性實例包括6-巰基嘌呤、硫唑嘌呤、次水楊酸鉍、齒葉乳香樹提取物、消膽胺、考來替潑、皮質類固醇(例如布地奈德、普賴松、普賴蘇穠、倍氯米松二丙酸鹽)、糞便微生物移植、洛哌丁胺、美塞拉明、甲胺喋呤、益生菌及柳氮磺胺吡啶。
在一些實施例中，一或多種額外治療劑選自用於治療異體免疫性疾病之藥劑/方案。非限制性實例包含子宮內血小板輸注、靜脈內免疫球蛋白、母體使用類固醇、阿巴西普、阿侖單抗、α1-抗胰蛋白酶、AMG592、抗胸腺細胞球蛋白、巴瑞替尼、巴利昔單抗、硼替佐米、本妥昔單抗、大麻二酚、皮質類固醇(例如甲基普賴松、普賴松)、環孢黴素、達西珠單抗(dacilzumab)、去纖苷(defribrotide)、地尼白介素(denileukin diftitox)、格拉吉伯(glasdegib)、依魯替尼(ibrutinib)、IL-2、英利昔單抗、伊他替尼(itacitinib)、LBH589、馬拉維若(maraviroc)、黴酚酸嗎啉乙酯、那他珠單抗、內胡利珠單抗(neihulizumab)、噴司他丁、佩沃塔特(pevonedistat)、光生物調節、光除去法、盧佐替尼、西羅莫司、索尼得吉(sonidegib)、他克莫司、托西利單抗及維莫德吉。
在一些實施例中，一或多種額外治療劑選自用於治療多發性硬化症(MS)之藥劑/方案。非限制性實例包括阿侖單抗(Lemtrada®)、ALKS 8700、胺氯吡脒、ATX-MS-1467、硫唑嘌呤、巴氯芬(Lioresal®)、β干擾素(例如IFN-β-1a、IFN-β-1b)、克拉屈濱、皮質類固醇(例如甲基普賴蘇穠)、達利珠單抗、反丁烯二酸二甲酯(Tecfidera®)、芬戈莫德(Gilenya®)、氟西汀、乙酸格拉替美(glatiramer acetate) (Copaxone®)、羥基氯喹、異丁司特、艾地苯醌、拉喹莫德、類脂酸、氯沙坦、馬賽替尼、MD1003(生物素)、米托蒽醌、孟魯司特、那他珠單抗(Tysabri®)、NeuroVaxTM
、奧克珠單抗(ocrelizumab)、奧伐木單抗、吡格列酮及RPC1063。
在一些實施例中，一或多種額外治療劑選自用於治療移植物抗宿主疾病之藥劑/方案。非限制性實例包括阿巴西普、阿侖單抗、α1-抗胰蛋白酶、AMG592、抗胸腺細胞球蛋白、巴瑞替尼、巴利昔單抗、硼替佐米、本妥昔單抗、大麻二酚、皮質類固醇(例如甲基普賴松、普賴松)、環孢黴素、達西珠單抗、去纖苷、地尼白介素、格拉吉伯、依魯替尼、IL-2、英利昔單抗、伊他替尼、LBH589、馬拉維若、黴酚酸嗎啉乙酯、那他珠單抗、內胡利珠單抗、噴司他丁、佩沃塔特、光生物調節、光除去法、盧佐替尼、西羅莫司、索尼得吉、他克莫司、托西利單抗及維莫德吉。
在一些實施例中，一或多種額外治療劑選自用於治療急性移植物抗宿主疾病之藥劑/方案。非限制性實例包括阿倫單抗、α-1抗胰蛋白酶、抗胸腺細胞球蛋白、巴利昔單抗、貝倫妥單抗、皮質類固醇(例如甲基普賴松、普賴松)、環孢黴素、達西魯單抗、去纖苷、地尼白介素、依魯替尼、英利昔單抗、伊他替尼、LBH589、黴酚酸嗎啉乙酯、那他珠單抗、內胡利珠單抗、噴司他丁、光除去法、盧利替尼、西羅莫司、他克莫司及托西利單抗。
在一些實施例中，一或多種額外治療劑選自用於治療慢性移植物抗宿主疾病之藥劑/方案。非限制性實例包括阿巴西普、阿侖單抗、AMG592、抗胸腺細胞球蛋白、巴利昔單抗、硼替佐米、皮質類固醇(例如甲基普賴松、普賴松)、環孢黴素、達西魯單抗、地尼白介素、格拉吉伯、依魯替尼、IL-2、加以域、英利昔單抗、黴酚酸嗎啉乙酯、噴司他丁、光生物調節、光除去法、盧利替尼、西羅莫司、索尼得吉、他克莫司、托西利單抗及維莫德吉。
在一些實施例中，一或多種額外治療劑選自用於治療乳糜瀉之藥劑/方案。非限制性實例包括AMG 714、AMY01、黑麴黴脯胺醯基內切蛋白酶、BL-7010、CALY-002、GBR 830、Hu-Mik-Beta-1、IMGX003、KumaMax、拉瑞唑來乙酸酯、Nexvan2®、胰脂肪酶、TIMP-GLIA、維多珠單抗及ZED1227。
在一些實施例中，一或多種額外治療劑選自用於治療牛皮癬之藥劑/方案。非限制性實例包括表面用皮質類固醇、表面用克里博羅(crisaborole)/AN2728、表面用SNA-120、表面用SAN021、表面用他匹那羅(tapinarof)、表面用托卡非尼(tocafinib)、表面用IDP-118、表面用M518101、表面用鈣泊三醇(calcipotriene)及二丙酸倍他米松(例如MC2-01乳膏及Taclonex®)、表面用P-3073、表面用LEO 90100(Enstilar®)、表面用二丙酸倍他米松(Sernivo®)、丙酸鹵貝他索(halobetasol propionate) (Ultravate®)、維生素D類似物(例如鈣泊三醇(Dovonex®)及促鈣三醇(calcitriol) (Vectical®))、蒽三酚(anthralin) (例如Dritho-scalp®及Dritho-crème®)、表面用類視黃素(例如他紮羅汀(tazarotene) (例如Tazorac®及Avage®))、鈣調神經磷酸酶抑制劑(例如他克莫司(Prograf®)及吡美莫司(Elidel®))、柳酸、煤焦油、增濕劑、光照療法(例如暴露於日光、UVB光照療法、窄帶UVB光照療法、戈克曼療法(Goeckerman therapy)、補骨脂素(psoralen)加紫外光A(PUVA)療法及準分子雷射)、類視黃素(例如阿曲汀(acitretin) (Soriatane®))、甲胺喋呤(Trexall®、Otrexup®、Rasuvo®、Rheumatrex®)、Apo805K1、巴瑞替尼、FP187、KD025、皮瑞索(prurisol)、VTP-43742、XP23829、ZPL-389、CF101(吡地諾松(piclidenoson))、LAS41008、VPD-737(瑟羅匹坦(serlopitant))、優帕替尼(ABT-494)、阿普斯特(aprmilast)、托法替尼、環孢黴素(Neoral®、Sandimmune®、Gengraf®)、生物製品(例如依那西普(Enbrel®)、依那西普-szzs(Elrezi®)、英利昔單抗(Remicade®)、阿達木單抗(Humira®)、阿達木單抗-adbm(Cyltezo®)、優特克單抗(Stelara®)、戈利木單抗(Simponi®)、阿普斯特(Otezla®)、塞庫金單抗(Cosentyx®)、聚乙二醇化賽妥珠單抗、塞庫金單抗、替拉珠單抗-asmn、英利昔單抗-dyyb、阿巴西普、伊科奇單抗(ixekizumab) (Taltz®)、ABP 710、BCD-057、BI695501、比美克單抗(bimekizumab) (UCB4940)、CHS-1420、GP2017、古賽庫單抗(CNTO 1959)、HD203、M923、MSB11022、密利基單抗(LY3074828)、PF-06410293、PF-06438179、里森基單抗(BI655066)、SB2、SB4、SB5、siliq(布羅達單抗(brodalumab))、奈米路單抗(namilumab) (MT203、替拉珠單抗(tildrakizumab) (MK-3222)及伊科奇單抗(ixekizumab) (Taltz®))、硫鳥嘌呤及羥基脲(例如Droxia®及Hydrea®)。
在一些實施例中，一或多種額外治療劑選自用於治療皮膚T細胞淋巴瘤之藥劑/方案。非限制性實例包括光電療法(例如暴露於日光、UVB光照療法、窄帶UVB光照療法、戈克曼療法、補骨脂素加紫外光A(PUVA)療法及準分子雷射)、體外光除去法、放射線療法(例如點狀放射及全身電子束療法)、幹細胞移植、皮質類固醇、咪喹莫特(imiquimod)、貝沙羅汀凝膠(bexarotene gel)、表面用雙氯乙基硝基脲、甲氮芥凝膠、伏立諾他(vorinostat) (Zolinza®)、羅米地辛(romidepsin) (Istodax®)、普拉曲沙(pralatrexate) (Folotyn®)生物製品(例如阿侖單抗(Campath®)、本妥昔單抗(SGN-35)、莫格利珠單抗(mogamulizumab)及IPH4102)。
在一些實施例中，一或多種額外治療劑選自用於治療葡萄膜炎之藥劑/方案。非限制性實例包括皮質類固醇(例如玻璃體內曲安奈德可注射懸浮液)、抗生素、抗病毒劑(例如阿昔洛韋)、地塞米松、免疫調節劑(例如他克莫司、來氟米特、環磷醯胺(Cytoxan®、Neosar®、Endoxan®)及環孢黴素(Neoral®、Sandimmune®、Gengraf®)、苯丁酸氮芥、硫唑嘌呤、甲胺喋呤及黴酚酸嗎啉乙酯)、生物療法(例如英利昔單抗(Remicade®)、阿達木單抗(Humira®)、依那西普(Enbrel®)、戈利木單抗(Simponi®)、賽妥珠單抗(Cimzia®)、利妥昔單抗(Rituxan®)、阿巴西普(Orencia®)、巴利昔單抗(Simulect®)、阿那白滯素(Kineret®)、康納單抗(Ilaris®)、gevokixumab (XOMA052)、托西利單抗(Actemra®)、阿侖單抗(Campath®)、艾法珠單抗(Raptiva®)、LFG316、西羅莫司(Santen®)、阿巴西普、賽瑞單抗(Kevzara®)及達利珠單抗(Zenapax®))、細胞毒素藥物、手術植入物(例如膚輕鬆插入物)及玻璃體切除術。
在一些實施例中，一或多種額外治療劑選自用於治療黏膜炎之藥劑/方案。非限制性實例包括AG013、SGX942 (dusquetide)、阿米福汀(Ethyol®)、超低溫療法、cepacol lonzenges、辣椒鹼錠劑、黏膜黏附劑(例如MuGard®)口服苯海拉明(例如Benadry® elixir)、口服bioadherents(例如聚乙烯吡咯啶酮-玻尿酸鈉凝膠(Gelclair®))、口服潤滑劑(例如Oral Balance®)、caphosol、德國甘菊漱口水、食用葡萄植物外泌體、抗菌漱口水(例如氯己定葡糖酸鹽(例如Peridex®或Periogard®)、表面疼痛舒解劑(例如利多卡因、苯唑卡因、達克羅寧鹽酸鹽、昔羅卡因(例如黏稠昔羅卡因2%)及Ulcerease® (0.6%酚))、皮質類固醇(例如普賴松)、止痛劑(例如布洛芬、萘普生、乙醯胺苯酚及類鴉片)、GC4419、帕利夫明(角質細胞成長因子；Kepivance®)、ATL-104、clonidine lauriad、IZN-6N4、SGX942、雷巴米特、奈匹德明、可溶β-1,3/1,6葡聚糖、P276、LP-0004-09、CR-3294、ALD-518、IZN-6N4、槲皮素、包含歐洲越橘提取物、博落回生物鹼及狹葉紫花馬蘭菊提取物之顆粒(例如SAMITAL®)及腸胃混合物(止胃酸劑，諸如氫氧化鋁及氫氧化鎂(例如Maalox)、抗真菌(例如耐絲菌素)及鎮痛劑(例如颶風液體))。舉例而言，口腔黏膜炎治療之非限制性實例包含AG013、阿米福汀(Ethyol®)、冷凍療法、西帕科耳口含錠、黏膜黏附劑(例如MuGard®)口服苯海拉明(例如Benadry®酏劑)、口服生物黏附劑(例如聚乙烯吡咯啶酮-玻尿酸鈉凝膠(Gelclair®))、口服潤滑劑(例如口服Balance®)、卡非索、德國甘菊漱口水、可食用葡萄植物胞外體、消毒用漱口水(例如葡糖酸氯己定(例如Peridex®或Periogard®)、表面用疼痛舒解劑(例如利多卡因、苯唑卡因、鹽酸達克羅甯、昔羅卡因(例如黏性昔羅卡因2%)及Ulcerease®(0.6%苯酚))、皮質類固醇(例如普賴松)、止痛劑(例如布洛芬、萘普生、乙醯胺苯酚及阿片類藥物)、GC4419、帕利夫明(角質細胞生長因子；Kepivance®)、ATL-104、可樂定羅瑞德、IZN-6N4、SGX942、雷巴米特、奈匹德明、可溶性β-1,3/1,6葡聚糖、P276、LP-0004-09、CR-3294、ALD-518、IZN-6N4、槲皮素及胃腸用混合液(減酸劑，諸如氫氧化鋁及氫氧化鎂(例如Maalox)、抗真菌劑(例如耐絲菌素)及鎮痛劑(例如颶風液))。作為另一實例，食道黏膜炎治療之非限制性實例包含昔羅卡因(例如黏性昔羅卡因凝膠2%)。作為另一實例，腸黏膜炎治療、調節腸黏膜炎之治療及腸黏膜炎病徵及症狀之治療包含胃腸用混合液(減酸劑，諸如氫氧化鋁及氫氧化鎂(例如Maalox)、抗真菌劑(例如耐絲菌素)及鎮痛劑(例如颶風液))。
在某些實施例中，一或多種額外治療劑為化學治療免疫調節劑，例如免疫檢查點抑制劑，其可如本文任何地方所定義。在其他實施例中，第二治療劑或方案為一或多種在胃腸道中局部起作用之消炎劑或免疫調節劑。在其他實施例中，第二治療劑或方案為5-ASA (及相關遞送系統)、反義抗SMAD7、經口調配之抗TNF、抗整合素、柳氮磺胺吡啶、巴柳氮、類固醇、硫唑嘌呤及甲胺喋呤。在其他實施例中，第二治療劑或方案為輻射或手術。
在某些實施例中，一或多種額外治療劑為鉑、順鉑、卡鉑、奧沙利鉑、甲基二(氯乙基)胺、環磷醯胺、苯丁酸氮芥、硫唑嘌呤、巰基嘌呤、長春新鹼、長春鹼、長春瑞賓、長春地辛、依託泊苷及替尼泊甙、太平洋紫杉醇、多西他賽、伊立替康、拓朴替康、安吖啶、依託泊苷、磷酸依託泊苷、替尼泊甙、5-氟尿嘧啶、甲醯四氫葉酸、甲胺喋呤、吉西他濱、紫杉烷、甲醯四氫葉酸、絲裂黴素C、喃氟啶-尿嘧啶、艾達黴素、氟達拉濱、米托蒽醌、異環磷醯胺及小紅莓。額外藥劑包含哺乳動物雷帕黴素目標蛋白(mammalian target of rapamycin，mTOR)之抑制劑，包括但不限於雷帕黴素、依維莫司、坦羅莫司及地磷莫司。
在某些實施例中，一或多種額外治療劑可選自上文所述之治療劑(參見美國專利7,927,613，其以全文引用之方式併入本文中)。
在某些實施例中，一或多種額外治療劑可選自一般(子一般且特定言之)在WO 2004/006906；WO 2006/120178；US 2009/0062396；WO 2012/143377；WO 2012/068274；美國專利7,132,546；美國專利7,989,498及美國專利8,263,857中之任何一或多者中所揭示之化合物：其各者以全文引用的方式併入本文中。
在某些實施例中，一或多種額外治療劑可為驅蟲劑，其選自硝唑尼特、氯氰碘柳胺、撲蟯靈(pyrvinium pamoate)及鹽黴素。參見例如Senkowski, W.等人Mol. Cancer Ther
.2015
,14
, 1504。
在一些實施例中，本文所述之方法進一步包括鑑別需要此類治療之個體(例如患者)的步驟(例如藉助於切片檢查、內視鏡檢法或所屬領域中已知之其他習知方法)。
在一些實施例中，本文所述之化學實體、方法及組合物可投與至某些耐治療性患者群體，例如對抗TNFα療法(例如修美樂、恩博、雷米卡德、辛脂、戈利木單抗、恩博、黃嘌呤衍生物，例如己酮可可鹼及安非他酮；(R)-DOI、TCB-2、LSD及LA-SS-Az)之治療無反應或具有抗性的患者群體。在某些實施例中，患者正在進行及/或已進行抗TNFα療法(例如修美樂、恩博、雷米卡德、辛脂、戈利木單抗、恩博、黃嘌呤衍生物，例如己酮可可鹼及安非他酮；(R)-DOI、TCB-2、LSD及LA-SS-Az)之治療。
為了進一步說明本發明，包括以下實例。當然，實例不應解釋為專門限制本發明。此等實例在申請專利範圍之範疇內的變化處於熟習此項技術者之眼界內，且視為屬於如本文描述及主張的本發明範疇內。讀者將認識到，熟悉本發明且熟習此項技術之熟練技術人員不需詳盡實例即能夠製備及使用本發明。
實例 實例 1 . 粒度對結腸暴露量之影響
進行實驗：(1)粒度分佈D(0.9)為約30微米之未經研磨的氯硝柳胺API，及(2)約5微米之粒度減小的噴射研磨(微米尺寸化，在下文稱為「經研磨」)的氯硝柳胺。將此等氯硝柳胺製劑調配成懸浮液。用單次劑量之指定劑量的此等氯硝柳胺懸浮液處理兔。給藥後，在指定時間點得到血液樣品及直腸黏膜樣品。
結果概述：
相比於給藥1小時之後的血漿濃度3.93 ng/ml (stdev 1.37)，未經研磨氯硝柳胺(7.5 mg)之直腸投與產生22.55 ng/ml (stdev 14.49)之平均結腸組織氯硝柳胺濃度。此差異意謂在1小時時，氯硝柳胺之結腸組織濃度超過血漿濃度之5倍。
相比於1小時(在此實驗中量測的氯硝柳胺之最大血漿濃度時間點)時的氯硝柳胺血漿濃度6.576 (stdev 4.50)，經研磨氯硝柳胺(7.5 mg)之直腸投與使得在給藥之後1小時平均結腸組織氯硝柳胺濃度為5030 ng/ml (stdev 367)。此差異意謂氯硝柳胺之結腸組織濃度大於最大量測血漿濃度之750倍。
相比於1小時(在此實驗中量測的氯硝柳胺之最大血漿濃度時間點)時的氯硝柳胺血漿濃度20.24 (stdev 21.00)，經研磨氯硝柳胺(22.5 mg)之直腸投與使得平均結腸組織氯硝柳胺濃度為6090 ng/ml (stdev 2828)。此差異意謂氯硝柳胺之結腸組織濃度大於最大量測血漿濃度之300倍。
相比於給藥1小時之後未經研磨氯硝柳胺之直腸投與產生22.55 ng/ml (stdev 14.49)之平均結腸組織氯硝柳胺濃度，經研磨氯硝柳胺(7.5 mg)產生5030 ng/ml (stdev 367)之平均結腸濃度。此差異意謂用經研磨材料調配的氯硝柳胺之結腸組織濃度大於用未經研磨材料調配的氯硝柳胺之結腸組織濃度之200倍。
已描述多個本發明之多個實施例。儘管如此，應理解可在不背離本發明的精神及範疇的情況下進行各種修改。因此，其他實施例係在以下申請專利範圍之範疇內。
Claims (222)
- 一種高純度氯硝柳胺(niclosamide)化合物，或其醫藥學上可接受之鹽。
- 如請求項1之化合物，其中該化合物具有下式：(氯硝柳胺)。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.5%。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.7%。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.8%。
- 如請求項1或2之化合物，其中該化合物具有低於約45 ppm之5-氯-柳酸。
- 如請求項1或2之化合物，其中該化合物具有低於約30 ppm之5-氯-柳酸。
- 如請求項1或2之化合物，其中該化合物具有低於約50 ppm之2-氯-4硝基-苯胺。
- 如請求項1或2之化合物，其中該化合物具有低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項1或2之化合物，其中該化合物具有低於約45 ppm之5-氯-柳酸及低於約50 ppm之2-氯-4硝基-苯胺。
- 如請求項1或2之化合物，其中該化合物具有低於約30 ppm之5-氯-柳酸及低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項1或2之化合物，其中該化合物具有低於約0.05%水。
- 如請求項1或2之化合物，其中該化合物實質上不含水合氯硝柳胺固體形式。
- 如請求項1或2之化合物，其中該化合物為無水氯硝柳胺。
- 如請求項1或2之化合物，其中該化合物為結晶的。
- 如請求項1或2之化合物，其中該化合物具有減小的粒度範圍。
- 如請求項1或2之化合物，其中該化合物之粒度範圍為約0.1 μm至約30 μm。
- 如請求項1或2之化合物，其中該化合物之粒度範圍為約0.1 μm至約20 μm。
- 如請求項1或2之化合物，其中該化合物之粒度範圍為約0.1 μm至約10 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約1.0 μm至約15.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約1.0 μm至約10.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約6.0 μm至約8.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約2.2 μm至約3.2 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.1)為約0.1 μm至約1.5 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.5)為約0.5 μm至約6.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.5)為約1.0 μm至約4.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項1或2之化合物，其中該化合物之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項1或2之化合物，其中該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項32之化合物，其中該化合物之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
- 如請求項32之化合物，其中該化合物之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
- 如請求項32之化合物，其中該化合物之化學純度大於約99.5%；或化學純度大於約99.7%；或化學純度大於約99.8%。
- 如請求項32之化合物，其中該化合物具有低於約45 ppm之5-氯-柳酸；或低於約30 ppm之5-氯-柳酸。
- 如請求項32之化合物，其中該化合物具有低於約50 ppm之2-氯-4硝基-苯胺；或低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項32之化合物，其中該化合物具有低於約45 ppm之5-氯-柳酸及低於約50 ppm之2-氯-4硝基-苯胺；或低於約30 ppm之5-氯-柳酸及低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項32之化合物，其中該化合物具有低於約0.05%水。
- 如請求項32之化合物，其中該化合物實質上不含水合氯硝柳胺固體形式。
- 如請求項32之化合物，其中該化合物為無水氯硝柳胺。
- 如請求項32之化合物，其中該化合物為結晶的。
- 如請求項1或2之化合物，其中該化合物之比表面積為約5 m2 /g至約10 m2 /g。
- 一種組合物，其包含如請求項1至51中任一項之氯硝柳胺化合物及一或多種醫藥學上可接受之賦形劑，其中該組合物適用於經口投與。
- 如請求項52之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道(GI tract)中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室(plasma compartment)中該化合物之濃度。
- 如請求項52或53之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約200倍。
- 如請求項52或53之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約300倍。
- 如請求項52或53之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約500倍。
- 如請求項52或53之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約700倍。
- 如請求項52或53之組合物，其中該個體之胃腸道中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
- 如請求項52或53之組合物，其中該個體之胃腸道中的該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度至少約100倍，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
- 如請求項52或53之組合物，其中該個體之胃腸道中的該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度至少約100倍，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
- 如請求項52或53之組合物，其中該第二氯硝柳胺化合物之粒度分佈D(0.9)為約25.0 μm至約65.0 μm。
- 如請求項52或53之組合物，其中該第二氯硝柳胺化合物之粒度分佈D(0.1)為約4.0 μm至約10.0 μm。
- 一種包含如請求項52至62中任一項之組合物的劑型(例如單位劑型)，其中該劑型適用於經口投與。
- 如請求項63之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至升結腸。
- 如請求項63或64之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至橫結腸。
- 如請求項63或64之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至遠端結腸。
- 如請求項63或64之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至小腸。
- 一種粒度減小的氯硝柳胺化合物，或其醫藥學上可接受之鹽。
- 如請求項68之化合物，其中該化合物具有下式：(氯硝柳胺)。
- 如請求項68或69之化合物，其中該化合物之粒度範圍為約0.1 μm至約30 μm。
- 如請求項68或69之化合物，其中該化合物之粒度範圍為約0.1 μm至約20 μm。
- 如請求項68或69之化合物，其中該化合物之粒度範圍為約0.1 μm至約10 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約1.0 μm至約15.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約1.0 μm至約10.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約6.0 μm至約8.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約2.2 μm至約3.2 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.1)為約0.1 μm至約1.5 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.5)為約0.5 μm至約6.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.5)為約1.0 μm至約4.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項68或69之化合物，其中該化合物之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項68或69之化合物，其中該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項68或69之化合物，其中該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項68或69之化合物，其中該化合物之化學純度大於約99.0%、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項68或69之化合物，其中該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項68或69之化合物，其中該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項68或69之化合物，其中該化合物之化學純度大於約99.0%、粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項84之化合物，其中該化合物之粒度分佈D(0.5)為約2.5 μm至約3.5 μm；或其中該化合物之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
- 如請求項52或53之組合物或如請求項63或64之劑型，其包含如請求項68至94中任一項之化合物。
- 一種共晶體，其包含氯硝柳胺化合物或其醫藥學上可接受之鹽及醫藥學上可接受之共形成物(coformer)。
- 如請求項95之共晶體，其中該氯硝柳胺化合物具有下式：(氯硝柳胺)。
- 如請求項95或96之共晶體，其中該共形成物選自由以下組成之群：神經鞘胺醇1-磷酸(S1P)受體調節劑；類固醇消炎劑；非類固醇消炎劑；受體相互作用蛋白質激酶1 (RIPK1)抑制劑；EP4調節劑；鐸(toll)樣受體(例如TLR4、TLR9)調節劑；詹納斯(Janus)激酶(JAK)抑制劑；羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑；磷脂醯膽鹼；整合素(例如α4整合素)調節劑；Smad7調節劑；磷酸二酯酶4 (PDE4)調節劑；腫瘤進展基因座2 (TPL2)抑制劑；酪胺酸激酶2 (TYK2)抑制劑；及TEC激酶抑制劑。
- 如請求項95或96之共晶體，其中該共形成物為神經鞘胺醇1-磷酸(S1P)受體調節劑。
- 如請求項95或96之共晶體，其中該共形成物為依托西莫德(etrasimod)或奧札莫德(ozanimod)。
- 如請求項95或96之共晶體，其中該共形成物為類固醇消炎劑。
- 如請求項95或96之共晶體，其中該共形成物為倍氯米松(beclomethasone) 17或布地奈德(budesonide)。
- 如請求項95或96之共晶體，其中該共形成物為非類固醇消炎劑，諸如5-ASA。
- 如請求項95或96之共晶體，其中該共形成物為受體相互作用蛋白質激酶1 (RIPK1)抑制劑，諸如GSK2982772。
- 如請求項95或96之共晶體，其中該共形成物為EP4調節劑，諸如KAG-308。
- 如請求項95或96之共晶體，其中該共形成物為鐸樣受體(例如TLR4、TLR9)調節劑。
- 如請求項95或96之共晶體，其中該共形成物為TLR4調節劑，諸如JKB-122。
- 如請求項95或96之共晶體，其中該共形成物為TLR9調節劑，諸如庫比莫德(cobitolimod)。
- 如請求項95或96之共晶體，其中該共形成物為詹納斯(Janus)激酶(JAK)抑制劑。
- 如請求項95或96之共晶體，其中該共形成物選自由以下組成之群：TD-1473、托法替尼(tofacitinib)、優帕替尼(upadacitinib)、非戈替尼(filgotinib)、PF-06651600及PF-06700841。
- 如請求項95或96之共晶體，其中該共形成物為羊毛硫胺酸合成酶C樣2 (LANCL2)調節劑，諸如BT-11。
- 如請求項95或96之共晶體，其中該共形成物為磷脂醯膽鹼，諸如LT-02。
- 如請求項95或96之共晶體，其中該共形成物為整合素調節劑。
- 如請求項95或96之共晶體，其中該共形成物為α4整合素調節劑，諸如AJM-300 (卡羅格拉斯(carotegrast))。
- 如請求項95或96之共晶體，其中該共形成物為Smad7反義寡核苷酸，諸如蒙格森(mongersen)。
- 如請求項95或96之共晶體，其中該共形成物為磷酸二酯酶4 (PDE4)調節劑，諸如阿普斯特(apremilast)。
- 如請求項95或96之共晶體，其中該共形成物為腫瘤進展基因座2 (TPL2)抑制劑，諸如GS-4875。
- 如請求項95或96之共晶體，其中該共形成物為酪胺酸激酶2 (TYK2)抑制劑。
- 如請求項95或96之共晶體，其中該共形成物為BMS-986165、PF-06700841或PF-06826647。
- 如請求項95或96之共晶體，其中該共形成物為TEC激酶抑制劑，諸如PF-06651600。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.5%。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.7%。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.8%。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約45 ppm之5-氯-柳酸。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約30 ppm之5-氯-柳酸。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約50 ppm之2-氯-4硝基-苯胺。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約45 ppm之5-氯-柳酸及低於約50 ppm之2-氯-4硝基-苯胺。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約30 ppm之5-氯-柳酸及低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物具有低於約0.05%水。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物實質上不含水合氯硝柳胺固體形式。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物為無水氯硝柳胺。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物為結晶的。
- 如請求項95或96之共晶體，其中該共晶體具有減小的粒度範圍。
- 如請求項95或96之共晶體，其中該共晶體之粒度範圍為約0.1 μm至約30 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度範圍為約0.1 μm至約20 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度範圍為約0.1 μm至約10 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約1.0 μm至約15.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約1.0 μm至約10.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約6.0 μm至約8.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約2.2 μm至約3.2 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.1)為約0.1 μm至約1.5 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.5)為約0.5 μm至約6.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.5)為約1.0 μm至約4.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項95或96之共晶體，其中該共晶體之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約1.0 μm至約10.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.1 μm至約1.0 μm。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約6.0 μm至約8.0 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項95或96之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.0%；且該共晶體之粒度範圍為約0.1 μm至約30 μm、粒度分佈D(0.9)為約2.2 μm至約3.2 μm、粒度分佈D(0.5)為約1.0 μm至約4.0 μm，及粒度分佈D(0.1)為約0.3 μm至約0.9 μm。
- 如請求項149之共晶體，其中該共晶體之粒度分佈D(0.5)為約2.5 μm至約3.5 μm。
- 如請求項149之共晶體，其中該共晶體之粒度分佈D(0.5)為約1.0 μm至約2.0 μm。
- 如請求項149之共晶體，其中該氯硝柳胺化合物之化學純度大於約99.5%；或化學純度大於約99.7%；或化學純度大於約99.8%。
- 如請求項149之共晶體，其中該氯硝柳胺化合物具有低於約45 ppm之5-氯-柳酸；或低於約30 ppm之5-氯-柳酸。
- 如請求項149之共晶體，其中該氯硝柳胺化合物具有低於約50 ppm之2-氯-4硝基-苯胺；或低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項149之共晶體，其中該氯硝柳胺化合物具有低於約45 ppm之5-氯-柳酸及低於約50 ppm之2-氯-4硝基-苯胺；或低於約30 ppm之5-氯-柳酸及低於約10 ppm之2-氯-4硝基-苯胺。
- 如請求項149之共晶體，其中該氯硝柳胺化合物具有低於約0.05%水。
- 如請求項149之共晶體，其中該氯硝柳胺化合物實質上不含水合氯硝柳胺固體形式。
- 如請求項149之共晶體，其中該氯硝柳胺化合物為無水氯硝柳胺；及/或其中該氯硝柳胺化合物為結晶的。
- 如請求項149之共晶體，其中該氯硝柳胺化合物之比表面積為約5 m2 /g至約10 m2 /g。
- 一種組合物，其包含如請求項95至167中任一項之共晶體及一或多種醫藥學上可接受之賦形劑，其中該組合物適用於經口投與。
- 如請求項168之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度。
- 如請求項168或169之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約200倍。
- 如請求項168或169之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約300倍。
- 如請求項168或169之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約500倍。
- 如請求項168或169之組合物，其中向個體投與單一劑量之該組合物使得該個體之胃腸道中該氯硝柳胺化合物之局部濃度高於該個體之血漿隔室中該化合物之濃度至少約700倍。
- 如請求項168或169之組合物，其中該個體之胃腸道中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
- 如請求項168或169之組合物，其中該個體之胃腸道中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度至少約100倍，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
- 如請求項168或169之組合物，其中該個體之胃腸道中該氯硝柳胺化合物的局部濃度高於藉由經口投與單一劑量之包含第二氯硝柳胺化合物的第二組合物產生的局部濃度至少約100倍，其中該第二氯硝柳胺化合物之粒度高於該氯硝柳胺化合物。
- 如請求項168或169之組合物，其中該第二氯硝柳胺化合物之粒度分佈D(0.9)為約25.0 μm至約65.0 μm。
- 如請求項168或169之組合物，其中該第二氯硝柳胺化合物之粒度分佈D(0.1)為約4.0 μm至約10.0 μm。
- 一種包含如請求項168至178中任一項之組合物的劑型(例如單位劑型)，其中該劑型適用於經口投與。
- 如請求項179之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至升結腸。
- 如請求項179或180之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至橫結腸。
- 如請求項179或180之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至遠端結腸。
- 如請求項179或180之劑型，其進一步包含一或多種組分，該一或多種組分在化學上及/或在結構上使該劑型易於將該化合物遞送至小腸。
- 一種如請求項1至51及68至94中任一項之氯硝柳胺化合物或其醫藥學上可接受之鹽、如請求項52至62及168至178中任一項之組合物、如請求項63至67及179至183中任一項之劑型或如請求項95至167中任一項之共晶體之用途，其用於製造用以治療患有與個體之胃腸道(GI)的不受調節(諸如異常或升高)的一或多種T細胞之募集及/或滯留相關病狀之個體的藥劑。
- 一種如請求項1至51及68至94中任一項之氯硝柳胺化合物或其醫藥學上可接受之鹽、如請求項52至62及168至178中任一項之組合物、如請求項63至67及179至183中任一項之劑型或如請求項95至167中任一項之共晶體之用途，其用於製造用以治療患有與個體之胃腸道(GI)中不受調節(諸如異常或升高)的一或多種T細胞之活化相關病狀之個體的藥劑。
- 一種如請求項1至51及68至94中任一項之氯硝柳胺化合物或其醫藥學上可接受之鹽、如請求項52至62及168至178中任一項之組合物、如請求項63至67及179至183中任一項之劑型或如請求項95至167中任一項之共晶體之用途，其用於製造用以治療有需要個體之結腸炎的藥劑。
- 如請求項186之用途，其中該藥劑適用於局部遞送至消化道或胃腸道。
- 如請求項187之用途，其中該藥劑進一步包含一或多種在化學上及/或在結構上使該藥劑易於將該氯硝柳胺化合物或其醫藥學上可接受之鹽遞送至下胃腸道的組分。
- 如請求項187之用途，其中該藥劑進一步包含一或多種在化學上及/或在結構上使該藥劑易於將該氯硝柳胺化合物或其醫藥學上可接受之鹽遞送至升結腸及/或橫結腸及/或遠端結腸的組分。
- 如請求項188之用途，其中該藥劑係藉由錠劑、丸劑或漱口水投與。
- 如請求項186之用途，其中在投與該藥劑時，胃腸道中之該氯硝柳胺或其醫藥學上可接受之鹽的局部濃度高於該血漿隔室中該藥劑的濃度。
- 如請求項191之用途，其中在投與該藥劑時，胃腸道中之該藥劑的局部濃度高於該血漿隔室中該氯硝柳胺或其醫藥學上可接受之鹽的濃度約5倍。
- 如請求項191之用途，其中該血漿隔室中之該氯硝柳胺或其醫藥學上可接受之鹽經首次代謝。
- 如請求項186之用途，其中至少一些該藥劑存在於下胃腸道中。
- 如請求項192之用途，其中至少一些該藥劑存在於結腸中。
- 如請求項193之用途，其中至少一些該藥劑存在於升結腸中。
- 如請求項193之用途，其中至少一些該藥劑存在於橫結腸中。
- 如請求項193之用途，其中至少一些該藥劑存在於遠端結腸中。
- 如請求項186之用途，其中該個體為人類。
- 如請求項186之用途，其中該結腸炎為自體免疫結腸炎。
- 如請求項200之用途，其中該自體免疫結腸炎為發炎性腸病。
- 如請求項201之用途，其中該發炎性腸病為潰瘍性結腸炎。
- 如請求項201之用途，其中該發炎性腸病為克羅恩氏病(Crohn's disease)。
- 如請求項200之用途，其中該自體免疫結腸炎為醫原性自體免疫結腸炎。
- 如請求項204之用途，其中該醫原性自體免疫結腸炎為由一或多種化學治療劑誘發之結腸炎。
- 如請求項205之用途，其中該一或多種化學治療劑中之至少一者為化學治療免疫調節劑。
- 如請求項206之用途，其中該化學治療免疫調節劑為免疫檢查點抑制劑。
- 如請求項207之用途，其中該免疫檢查點抑制劑靶向選自由以下組成之群的免疫檢查點受體：CTLA-4、PD-1、PD-L1、PD-1-PD-L1、PD-1-PD-L2、介白素-2 (IL-2)、吲哚胺2,3-二加氧酶(IDO)、IL-10、轉型生長因子-β (TGFβ)、T細胞免疫球蛋白及黏蛋白3 (TIM3或HAVCR2)、半乳糖凝集素(Galectin) 9-TIM3、磷脂醯絲胺酸-TIM3、淋巴球活化基因3蛋白質(LAG3)、MHC II類-LAG3、4-1BB-4-1BB配位體、OX40-OX40配位體、GITR、GITR配位體-GITR、CD27、CD70-CD27、TNFRSF25、TNFRSF25-TL1A、CD40L、CD40-CD40配位體、HVEM-LIGHT-LTA、HVEM、HVEM-BTLA、HVEM-CD160、HVEM-LIGHT、HVEM-BTLA-CD160、CD80、CD80-PDL-1、PDL2-CD80、CD244、CD48-CD244、CD244、ICOS、ICOS-ICOS配位體、B7-H3、B7-H4、VISTA、TMIGD2、HHLA2-TMIGD2、包括BTNL2之嗜乳脂蛋白(Butyrophilins)、唾液酸結合免疫球蛋白樣凝集素家族(Siglec family)、TIGIT及PVR家族成員、KIR、ILT及LIR、NKG2D及NKG2A、MICA及MICB、CD244、CD28、CD86-CD28、CD86-CTLA、CD80-CD28、CD39、CD73腺苷-CD39-CD73、CXCR4-CXCL12、磷脂醯絲胺酸、TIM3、磷脂醯絲胺酸-TIM3、SIRPA-CD47、VEGF、神經纖毛蛋白(Neuropilin)、CD160、CD30及CD155。
- 如請求項208之用途，其中該免疫檢查點抑制劑選自由以下組成之群：烏瑞魯單抗(Urelumab)、PF‑05082566、MEDI6469、TRX518、瓦里魯單抗(Varlilumab)、CP‑870893、派立珠單抗(Pembrolizumab) (PD1)、納武單抗(Nivolumab) (PD1)、阿特珠單抗(Atezolizumab) (先前為MPDL3280A) (PDL1)、MEDI4736 (PD-L1)、阿維魯單抗(Avelumab) (PD-L1)、PDR001 (PD1)、BMS‑986016、MGA271、利瑞路單抗(Lirilumab)、IPH2201、艾瑪圖單抗(Emactuzumab)、INCB024360、高倫替布(Galunisertib)、尤洛庫單抗(Ulocuplumab)、BKT140、巴維昔單抗(Bavituximab)、CC‑90002、貝伐單抗(Bevacizumab)及MNRP 1685A，及MGA271。
- 如請求項208之用途，其中該免疫檢查點抑制劑靶向CTLA-4。
- 如請求項210之用途，其中該免疫檢查點抑制劑為抗體。
- 如請求項211之用途，其中該抗體為伊派利單抗(ipilimumab)或曲美單抗(tremelimumab)。
- 如請求項208之用途，其中該免疫檢查點抑制劑靶向PD1或PD-L1。
- 如請求項213之用途，其中該免疫檢查點抑制劑選自納武單抗、蘭布諾單抗(lambroizumab)及BMS-936559。
- 如請求項186至214中任一項之用途，其中該藥劑係經口投與。
- 如請求項69之化合物，其中該化合物之化學純度大於約99.5%；或化學純度大於約99.7%；或化學純度大於約99.8%。
- 如請求項69之化合物，其中該化合物之比表面積為約5 m2 /g至約10 m2 /g。
- 一種醫藥組合物，其包含如請求項69之化合物及一或多種醫藥學上可接受之賦形劑。
- 如請求項218之組合物，其中該組合物適用於經口投與。
- 如請求項218之組合物，其中該組合物適用於藉由吸入投與。
- 如請求項69之化合物，其中向個體投與單一劑量之該化合物使得該個體之胃腸道中該化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度至少約300倍。
- 如請求項69之化合物，其中向個體投與單一劑量之該化合物使得該個體之結腸組織中該化合物之局部濃度高於該個體之該血漿隔室中該化合物之濃度至少約300倍。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923290P | 2019-10-18 | 2019-10-18 | |
| US62/923,290 | 2019-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202128610A true TW202128610A (zh) | 2021-08-01 |
Family
ID=75492817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109136022A TW202128610A (zh) | 2019-10-18 | 2020-10-16 | 醫藥調配物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210114973A1 (zh) |
| EP (1) | EP4045480A4 (zh) |
| JP (1) | JP2022553934A (zh) |
| KR (1) | KR20240039083A (zh) |
| CN (1) | CN117597327A (zh) |
| AR (1) | AR122323A1 (zh) |
| CA (1) | CA3157861A1 (zh) |
| TW (1) | TW202128610A (zh) |
| WO (1) | WO2021076922A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768937A (zh) * | 2021-11-15 | 2021-12-10 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| US11724985B2 (en) | 2020-05-19 | 2023-08-15 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA032899B1 (ru) | 2014-09-12 | 2019-07-31 | Юнион Терапьютикс А/С | Применение галогенированных салициланилидов в качестве антибактериальных средств |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| PE20181295A1 (es) | 2015-09-01 | 2018-08-07 | First Wave Bio Inc | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| US20230107927A1 (en) * | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| US11045434B1 (en) | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
| GB202301306D0 (en) * | 2023-01-30 | 2023-03-15 | Ucl Business Ltd | Treatment of granulomatous disease |
| CN117466786A (zh) * | 2023-12-25 | 2024-01-30 | 湖南一格制药有限公司 | 盐酸戊乙奎醚杂质及其制备方法 |
| CN118649135B (zh) * | 2024-07-18 | 2024-12-10 | 广东药科大学 | 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法 |
| CN119431243A (zh) * | 2025-01-09 | 2025-02-14 | 万邦德制药集团有限公司 | 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2557615C2 (de) * | 1975-12-20 | 1985-08-14 | Bayer Ag, 5090 Leverkusen | Neue Niclosamid-Suspensionsformulierungen |
| NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
| AU2003249244A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| CN1546919A (zh) * | 2003-07-13 | 2004-11-17 | 叶声羽 | 桑拿浴房 |
| CN1626506A (zh) * | 2004-08-10 | 2005-06-15 | 李志良 | 高纯度、高收率氯硝柳胺的制备 |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| CN103751854B (zh) * | 2014-01-20 | 2015-08-26 | 瞿介明 | 抗菌医用导管 |
| EP3168211A1 (en) * | 2015-11-10 | 2017-05-17 | Westfälische Wilhelms-Universität Münster | Pharmaceutical co-crystals of niclosamide |
-
2020
- 2020-04-07 US US16/842,695 patent/US20210114973A1/en not_active Abandoned
- 2020-10-16 JP JP2022522825A patent/JP2022553934A/ja active Pending
- 2020-10-16 WO PCT/US2020/056027 patent/WO2021076922A1/en active Application Filing
- 2020-10-16 CN CN202080088987.0A patent/CN117597327A/zh active Pending
- 2020-10-16 EP EP20877454.7A patent/EP4045480A4/en active Pending
- 2020-10-16 CA CA3157861A patent/CA3157861A1/en active Pending
- 2020-10-16 TW TW109136022A patent/TW202128610A/zh unknown
- 2020-10-16 KR KR1020227016634A patent/KR20240039083A/ko active Pending
- 2020-10-19 AR ARP200102884A patent/AR122323A1/es not_active Application Discontinuation
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724985B2 (en) | 2020-05-19 | 2023-08-15 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11746088B2 (en) | 2020-05-19 | 2023-09-05 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11834410B2 (en) | 2020-05-19 | 2023-12-05 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11958807B2 (en) | 2020-05-19 | 2024-04-16 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12110272B2 (en) | 2020-05-19 | 2024-10-08 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN113768937A (zh) * | 2021-11-15 | 2021-12-10 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3157861A1 (en) | 2021-04-22 |
| KR20240039083A (ko) | 2024-03-26 |
| US20210114973A1 (en) | 2021-04-22 |
| WO2021076922A1 (en) | 2021-04-22 |
| EP4045480A1 (en) | 2022-08-24 |
| AR122323A1 (es) | 2022-08-31 |
| EP4045480A4 (en) | 2023-11-22 |
| JP2022553934A (ja) | 2022-12-27 |
| CN117597327A (zh) | 2024-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202128610A (zh) | 醫藥調配物 | |
| JP7189983B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
| US11564896B2 (en) | Methods of treatment | |
| US20230190684A1 (en) | Methods of treating covid-19 with a niclosamide compound | |
| US20230102999A1 (en) | Deuterated niclosamide |